assertion_id	disorder_id	disorder_name	source_file	section	section_index	name	description	category	frequency	diagnostic	context	subtype	role	presence	association	accession	age_range	background	base_model	classification	clinical_significance	consequence	data_type	de_novo_rate	definition_type	duration	effect	expressivity	features	genotype	incubation_days	incubation_years	markers	maximum_value	mean_range	minimum_value	model_format	model_id	model_software	model_type	notes	parent_of_origin_effect	penetrance	percentage	phase	platform	population	publication	repository_url	results	review_notes	sample_count	scope	sequence_length	severity	species	specificity	status	subtype_frequency	title	type	unit	scalar_fields_json	complex_fields_json	raw_json
1	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	genetic	0	22q11.2 microdeletion																							"Most patients (85-90%) have a 3 Mb deletion encompassing ~40 genes, while ~10% have a smaller 1.5 Mb nested deletion. The deletion is typically de novo (90-95%) but can be inherited in autosomal dominant fashion. Low-copy repeats (LCRs) flanking the region predispose to non-allelic homologous recombination during meiosis.
"																																		"{""features"": ""Most patients (85-90%) have a 3 Mb deletion encompassing ~40 genes, while ~10% have a smaller 1.5 Mb nested deletion. The deletion is typically de novo (90-95%) but can be inherited in autosomal dominant fashion. Low-copy repeats (LCRs) flanking the region predispose to non-allelic homologous recombination during meiosis.\n"", ""name"": ""22q11.2 microdeletion""}"	"{""inheritance"": [{""name"": ""Autosomal dominant""}]}"	"{""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews documents the de novo vs inherited proportion."", ""reference"": ""PMID:20301696"", ""snippet"": ""the deletion is de novo in more than 90% of individuals and inherited from a heterozygous parent in about 10% of individuals"", ""supports"": ""SUPPORT""}], ""features"": ""Most patients (85-90%) have a 3 Mb deletion encompassing ~40 genes, while ~10% have a smaller 1.5 Mb nested deletion. The deletion is typically de novo (90-95%) but can be inherited in autosomal dominant fashion. Low-copy repeats (LCRs) flanking the region predispose to non-allelic homologous recombination during meiosis.\n"", ""inheritance"": [{""name"": ""Autosomal dominant""}], ""name"": ""22q11.2 microdeletion""}"
2	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	genetic	1	TBX1 haploinsufficiency																							"TBX1 is the critical gene responsible for most phenotypic features. TBX1 encodes a T-box transcription factor essential for pharyngeal arch development.
"																																		"{""features"": ""TBX1 is the critical gene responsible for most phenotypic features. TBX1 encodes a T-box transcription factor essential for pharyngeal arch development.\n"", ""name"": ""TBX1 haploinsufficiency""}"	{}	"{""evidence"": [{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""Mouse knockout studies established TBX1 as the critical gene."", ""reference"": ""PMID:11242110"", ""snippet"": ""we propose that TBX1 in humans is a key gene in the etiology of DGS/VCFS"", ""supports"": ""SUPPORT""}], ""features"": ""TBX1 is the critical gene responsible for most phenotypic features. TBX1 encodes a T-box transcription factor essential for pharyngeal arch development.\n"", ""name"": ""TBX1 haploinsufficiency""}"
22	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	genetic	0	ALK									Somatic Rearrangement																										ALK (2p23.2) encodes anaplastic lymphoma kinase, a receptor tyrosine kinase. Gene rearrangements occur somatically and are not inherited. EML4-ALK is the most common fusion (~90%), resulting from inv(2)(p21;p23). Resistance mutations include L1196M (gatekeeper), G1202R (solvent front), and compound mutations.																						"{""association"": ""Somatic Rearrangement"", ""name"": ""ALK"", ""notes"": ""ALK (2p23.2) encodes anaplastic lymphoma kinase, a receptor tyrosine kinase. Gene rearrangements occur somatically and are not inherited. EML4-ALK is the most common fusion (~90%), resulting from inv(2)(p21;p23). Resistance mutations include L1196M (gatekeeper), G1202R (solvent front), and compound mutations.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Rearrangement"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""ALK"", ""notes"": ""ALK (2p23.2) encodes anaplastic lymphoma kinase, a receptor tyrosine kinase. Gene rearrangements occur somatically and are not inherited. EML4-ALK is the most common fusion (~90%), resulting from inv(2)(p21;p23). Resistance mutations include L1196M (gatekeeper), G1202R (solvent front), and compound mutations.""}"
23	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	genetic	1	EML4									Fusion Partner																										EML4 (2p21) encodes echinoderm microtubule-associated protein-like 4. Provides the N-terminus and dimerization domain in EML4-ALK fusions. Multiple fusion variants exist based on EML4 breakpoint (V1-V8).																						"{""association"": ""Fusion Partner"", ""name"": ""EML4"", ""notes"": ""EML4 (2p21) encodes echinoderm microtubule-associated protein-like 4. Provides the N-terminus and dimerization domain in EML4-ALK fusions. Multiple fusion variants exist based on EML4 breakpoint (V1-V8).""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Fusion Partner"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""EML4"", ""notes"": ""EML4 (2p21) encodes echinoderm microtubule-associated protein-like 4. Provides the N-terminus and dimerization domain in EML4-ALK fusions. Multiple fusion variants exist based on EML4 breakpoint (V1-V8).""}"
42	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	genetic	0	PML-RARA Fusion									Defining Genetic Lesion																										The t(15;17)(q24;q21) translocation creates PML-RARA fusion in greater than 95% of APL. Three breakpoint variants exist (bcr1/long, bcr2/variant, bcr3/short) with different PML portions. The fusion is necessary and sufficient for APL phenotype and predicts response to ATRA and ATO.																						"{""association"": ""Defining Genetic Lesion"", ""name"": ""PML-RARA Fusion"", ""notes"": ""The t(15;17)(q24;q21) translocation creates PML-RARA fusion in greater than 95% of APL. Three breakpoint variants exist (bcr1/long, bcr2/variant, bcr3/short) with different PML portions. The fusion is necessary and sufficient for APL phenotype and predicts response to ATRA and ATO.""}"	{}	"{""association"": ""Defining Genetic Lesion"", ""name"": ""PML-RARA Fusion"", ""notes"": ""The t(15;17)(q24;q21) translocation creates PML-RARA fusion in greater than 95% of APL. Three breakpoint variants exist (bcr1/long, bcr2/variant, bcr3/short) with different PML portions. The fusion is necessary and sufficient for APL phenotype and predicts response to ATRA and ATO.""}"
43	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	genetic	1	FLT3-ITD									Cooperating Mutation																										FLT3-ITD occurs in 30-40% of APL cases and is associated with higher white blood cell counts at presentation. Prognostic significance is less clear in the ATRA+ATO era but may identify patients benefiting from intensification.																						"{""association"": ""Cooperating Mutation"", ""name"": ""FLT3-ITD"", ""notes"": ""FLT3-ITD occurs in 30-40% of APL cases and is associated with higher white blood cell counts at presentation. Prognostic significance is less clear in the ATRA+ATO era but may identify patients benefiting from intensification.""}"	{}	"{""association"": ""Cooperating Mutation"", ""name"": ""FLT3-ITD"", ""notes"": ""FLT3-ITD occurs in 30-40% of APL cases and is associated with higher white blood cell counts at presentation. Prognostic significance is less clear in the ATRA+ATO era but may identify patients benefiting from intensification.""}"
68	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	genetic	0	TTR			Variable by population						Pathogenic Variants																										Primary amyloid precursor gene encoding transthyretin, a liver-derived homotetrameric transport protein for thyroxine and retinol. Tetramer instability leads to monomer misfolding and amyloid fibril formation.																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""Variable by population"", ""name"": ""TTR"", ""notes"": ""Primary amyloid precursor gene encoding transthyretin, a liver-derived homotetrameric transport protein for thyroxine and retinol. Tetramer instability leads to monomer misfolding and amyloid fibril formation.""}"	"{""examples"": [""Val30Met"", ""Thr60Ala""]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This reference supports the association of the Val30Met variant with ATTR amyloidosis."", ""reference"": ""PMID:38844302"", ""snippet"": ""More than 140 TTR gene variants have been associated with hATTR, with the Val30Met variant representing the most common worldwide."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement about the variable frequency of the Val30Met variant by population."", ""reference"": ""PMID:24555660"", ""snippet"": ""A previous study of the amyloidogenic transthyretin mutation TTRV30M in Northern Sweden's endemic area has shown a large variation in carrier frequency and penetrance of the trait within the area."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement about the variable frequency of pathogenic variants by population."", ""reference"": ""PMID:36941075"", ""snippet"": ""Hereditary transthyretin amyloidosis (hATTR) is a rare autosomal dominant systemic disease with variable penetrance and heterogeneous clinical presentation."", ""supports"": ""SUPPORT""}], ""examples"": [""Val30Met"", ""Thr60Ala""], ""frequency"": ""Variable by population"", ""name"": ""TTR"", ""notes"": ""Primary amyloid precursor gene encoding transthyretin, a liver-derived homotetrameric transport protein for thyroxine and retinol. Tetramer instability leads to monomer misfolding and amyloid fibril formation.""}"
69	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	genetic	1	APCS									Modifying Factor																										Encodes serum amyloid P component (SAP), a plasma protein that binds and stabilizes amyloid fibrils in deposits, reducing proteolytic clearance.																						"{""association"": ""Modifying Factor"", ""name"": ""APCS"", ""notes"": ""Encodes serum amyloid P component (SAP), a plasma protein that binds and stabilizes amyloid fibrils in deposits, reducing proteolytic clearance.""}"	{}	"{""association"": ""Modifying Factor"", ""name"": ""APCS"", ""notes"": ""Encodes serum amyloid P component (SAP), a plasma protein that binds and stabilizes amyloid fibrils in deposits, reducing proteolytic clearance.""}"
70	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	genetic	2	CLU									Modifying Factor																										Encodes clusterin, an extracellular chaperone present in TTR deposits that modulates fibril localization and clearance.																						"{""association"": ""Modifying Factor"", ""name"": ""CLU"", ""notes"": ""Encodes clusterin, an extracellular chaperone present in TTR deposits that modulates fibril localization and clearance.""}"	{}	"{""association"": ""Modifying Factor"", ""name"": ""CLU"", ""notes"": ""Encodes clusterin, an extracellular chaperone present in TTR deposits that modulates fibril localization and clearance.""}"
101	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous mutations in COL2A1 encoding type II collagen alpha-1 chain. Most are glycine substitutions in the triple helical domain that severely disrupt collagen assembly. Common mutations include Gly to Ser, Arg, or Asp substitutions throughout the triple helical domain.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1 encoding type II collagen alpha-1 chain. Most are glycine substitutions in the triple helical domain that severely disrupt collagen assembly. Common mutations include Gly to Ser, Arg, or Asp substitutions throughout the triple helical domain.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms that ACG2 is caused by dominant mutations in the COL2A1 gene."", ""reference"": ""PMID:15054848"", ""snippet"": ""Achondrogenesis type II is a lethal skeletal dysplasia caused by new dominant mutations within the type II collagen gene (COL2A1)"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Demonstrates identification of a glycine substitution (G316D) in the COL2A1 gene causing ACG2."", ""reference"": ""PMID:15054848"", ""snippet"": ""Molecular analysis of genomic DNA extracted from amniotic cells of the second fetus revealed heterozygosity for a 1340G > A missense mutation (G316D) in the COL2A1 gene"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms that dominant COL2A1 mutations cause achondrogenesis II-hypochondrogenesis."", ""reference"": ""PMID:10745044"", ""snippet"": ""Achondrogenesis II-hypochondrogenesis and severe spondyloepiphyseal dysplasia congenita (SEDC) are lethal forms of dwarfism caused by dominant mutations in the type II collagen gene (COL2A1)"", ""supports"": ""SUPPORT""}], ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1 encoding type II collagen alpha-1 chain. Most are glycine substitutions in the triple helical domain that severely disrupt collagen assembly. Common mutations include Gly to Ser, Arg, or Asp substitutions throughout the triple helical domain.\n""}"
115	6	Achondroplasia	Achondroplasia.yaml	genetic	0	FGFR3 G380R mutation									Causative																										"Over 95% of achondroplasia cases are caused by the c.1138G>A (p.Gly380Arg) mutation in exon 10 of the FGFR3 gene. A smaller proportion have the c.1138G>C variant resulting in the same amino acid substitution. The mutation is in the transmembrane domain of the receptor and causes constitutive activation.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 G380R mutation"", ""notes"": ""Over 95% of achondroplasia cases are caused by the c.1138G>A (p.Gly380Arg) mutation in exon 10 of the FGFR3 gene. A smaller proportion have the c.1138G>C variant resulting in the same amino acid substitution. The mutation is in the transmembrane domain of the receptor and causes constitutive activation.\n""}"	"{""variants"": [{""description"": ""The most common causative mutation, accounting for over 95% of cases."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Original discovery paper identifying the specific G380R substitution in the FGFR3 transmembrane domain as the cause of achondroplasia."", ""reference"": ""PMID:7913883"", ""snippet"": ""Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3."", ""supports"": ""SUPPORT""}], ""name"": ""c.1138G>A (p.Gly380Arg)""}]}"	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study of 154 patients showed that 153 had the same G380R mutation, demonstrating the remarkable genetic homogeneity of achondroplasia."", ""reference"": ""PMID:7847369"", ""snippet"": ""The homogeneity of mutations in achondroplasia is unprecedented for an autosomal dominant disorder and may explain the relative lack of heterogeneity in the achondroplasia phenotype."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR3 G380R mutation"", ""notes"": ""Over 95% of achondroplasia cases are caused by the c.1138G>A (p.Gly380Arg) mutation in exon 10 of the FGFR3 gene. A smaller proportion have the c.1138G>C variant resulting in the same amino acid substitution. The mutation is in the transmembrane domain of the receptor and causes constitutive activation.\n"", ""variants"": [{""description"": ""The most common causative mutation, accounting for over 95% of cases."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Original discovery paper identifying the specific G380R substitution in the FGFR3 transmembrane domain as the cause of achondroplasia."", ""reference"": ""PMID:7913883"", ""snippet"": ""Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3."", ""supports"": ""SUPPORT""}], ""name"": ""c.1138G>A (p.Gly380Arg)""}]}"
132	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	0	rs10427255									Risk																										Intergenic variant near ZEB2/ACVR2A on chromosome 2q22.3. OR 1.68 in Chinese cohort.																						"{""association"": ""Risk"", ""name"": ""rs10427255"", ""notes"": ""Intergenic variant near ZEB2/ACVR2A on chromosome 2q22.3. OR 1.68 in Chinese cohort.""}"	{}	"{""association"": ""Risk"", ""evidence"": [{""explanation"": ""GWAS-identified risk locus replicated across populations."", ""reference"": ""PMID:30899065"", ""snippet"": ""reproducibly identified both a replicative rs10427255 on 2q22.3 and a novel locus of rs1032507 on 3p12.1"", ""supports"": ""SUPPORT""}], ""name"": ""rs10427255"", ""notes"": ""Intergenic variant near ZEB2/ACVR2A on chromosome 2q22.3. OR 1.68 in Chinese cohort.""}"
133	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	1	rs1032507									Protective																										Intergenic variant near CADM2 on chromosome 3p12.1. OR 0.65 in Chinese cohort. CADM2 is involved in synaptic adhesion.																						"{""association"": ""Protective"", ""name"": ""rs1032507"", ""notes"": ""Intergenic variant near CADM2 on chromosome 3p12.1. OR 0.65 in Chinese cohort. CADM2 is involved in synaptic adhesion.""}"	{}	"{""association"": ""Protective"", ""evidence"": [{""explanation"": ""Novel protective locus near CADM2, which has plausible neurobiological function."", ""reference"": ""PMID:30899065"", ""snippet"": ""a novel locus of rs1032507 on 3p12.1"", ""supports"": ""SUPPORT""}], ""name"": ""rs1032507"", ""notes"": ""Intergenic variant near CADM2 on chromosome 3p12.1. OR 0.65 in Chinese cohort. CADM2 is involved in synaptic adhesion.""}"
134	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	2	ZEB2									Nearby GWAS locus																										Gene near rs10427255; potential long-range regulatory effects.																						"{""association"": ""Nearby GWAS locus"", ""name"": ""ZEB2"", ""notes"": ""Gene near rs10427255; potential long-range regulatory effects.""}"	{}	"{""association"": ""Nearby GWAS locus"", ""evidence"": [{""explanation"": ""Association is intergenic; ZEB2 involvement is hypothetical."", ""reference"": ""PMID:30899065"", ""snippet"": ""rs10427255 was 848 kb downstream of ZEB2 (Zinc Finger E-Box Binding Homeobox 2)"", ""supports"": ""PARTIAL""}], ""name"": ""ZEB2"", ""notes"": ""Gene near rs10427255; potential long-range regulatory effects.""}"
135	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	3	CADM2									Nearby GWAS locus																										Synaptic adhesion gene near protective variant rs1032507.																						"{""association"": ""Nearby GWAS locus"", ""name"": ""CADM2"", ""notes"": ""Synaptic adhesion gene near protective variant rs1032507.""}"	{}	"{""association"": ""Nearby GWAS locus"", ""evidence"": [{""explanation"": ""Plausible biological candidate but causal role not proven."", ""reference"": ""PMID:30899065"", ""snippet"": ""the variant of rs1032507 is adjacently upstream of the coding region of CADM2"", ""supports"": ""PARTIAL""}], ""name"": ""CADM2"", ""notes"": ""Synaptic adhesion gene near protective variant rs1032507.""}"
136	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	4	NMB									Sneeze pathway gene																										Neuromedin B is essential for sneeze signal transmission from nasal sensory neurons to the brainstem sneeze-evoking region.																						"{""association"": ""Sneeze pathway gene"", ""name"": ""NMB"", ""notes"": ""Neuromedin B is essential for sneeze signal transmission from nasal sensory neurons to the brainstem sneeze-evoking region.""}"	{}	"{""association"": ""Sneeze pathway gene"", ""evidence"": [{""explanation"": ""NMB is the key neuropeptide mediating the sneeze reflex."", ""reference"": ""PMID:34133943"", ""snippet"": ""neuromedin B (NMB) peptide is essential for signaling sneezing"", ""supports"": ""SUPPORT""}], ""name"": ""NMB"", ""notes"": ""Neuromedin B is essential for sneeze signal transmission from nasal sensory neurons to the brainstem sneeze-evoking region.""}"
137	7	Achoo Syndrome	Achoo_Syndrome.yaml	genetic	5	NMBR									Sneeze pathway gene																										Neuromedin B receptor expressed in sneeze-evoking region neurons; required for sneeze reflex execution.																						"{""association"": ""Sneeze pathway gene"", ""name"": ""NMBR"", ""notes"": ""Neuromedin B receptor expressed in sneeze-evoking region neurons; required for sneeze reflex execution.""}"	{}	"{""association"": ""Sneeze pathway gene"", ""evidence"": [{""explanation"": ""NMBR-expressing neurons are essential for the sneeze reflex circuit."", ""reference"": ""PMID:34133943"", ""snippet"": ""deficiency in NMB receptor abolished the sneezing reflex"", ""supports"": ""SUPPORT""}], ""name"": ""NMBR"", ""notes"": ""Neuromedin B receptor expressed in sneeze-evoking region neurons; required for sneeze reflex execution.""}"
165	8	Acne Vulgaris	Acne_Vulgaris.yaml	genetic	0	Polygenic susceptibility									Associated																										"Twin studies demonstrate high heritability. Multiple genetic variants affecting androgen metabolism, inflammatory pathways, and sebaceous gland function contribute to acne susceptibility.
"																						"{""association"": ""Associated"", ""name"": ""Polygenic susceptibility"", ""notes"": ""Twin studies demonstrate high heritability. Multiple genetic variants affecting androgen metabolism, inflammatory pathways, and sebaceous gland function contribute to acne susceptibility.\n""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review explicitly identifies genetic factors as one of the key influences on acne pathophysiology."", ""reference"": ""PMID:32748305"", ""snippet"": ""It is known that multiple factors impact acne pathophysiology, including genetic, hormonal, inflammatory, and environmental influences."", ""supports"": ""SUPPORT""}, {""explanation"": ""This genetics review connects GWAS and monogenic findings to core biological processes underlying acne susceptibility."", ""reference"": ""PMID:40689430"", ""snippet"": ""Both GWAS and single gene disorders unequivocally indicate stem/progenitor cell maintenance and cellular migration as the most important processes in the pathogenesis of acne."", ""supports"": ""SUPPORT""}], ""name"": ""Polygenic susceptibility"", ""notes"": ""Twin studies demonstrate high heritability. Multiple genetic variants affecting androgen metabolism, inflammatory pathways, and sebaceous gland function contribute to acne susceptibility.\n""}"
166	8	Acne Vulgaris	Acne_Vulgaris.yaml	genetic	1	Candidate gene families									Associated																										"Reviews highlight inflammatory cytokine genes (IL, TNF), RETN, CYP family genes, and extracellular matrix regulators (MMPs, TIMPs) as recurrent candidates linked to acne susceptibility.
"																						"{""association"": ""Associated"", ""name"": ""Candidate gene families"", ""notes"": ""Reviews highlight inflammatory cytokine genes (IL, TNF), RETN, CYP family genes, and extracellular matrix regulators (MMPs, TIMPs) as recurrent candidates linked to acne susceptibility.\n""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review summarizes multiple gene families repeatedly implicated in acne susceptibility and outcomes."", ""reference"": ""PMID:37662507"", ""snippet"": ""some genes (such as IL, TNF, RETN, CYP family, MMPs and TIMPs genes et al) are associated with acne vulgaris and may affect the progression and prognosis of the disease."", ""supports"": ""SUPPORT""}], ""name"": ""Candidate gene families"", ""notes"": ""Reviews highlight inflammatory cytokine genes (IL, TNF), RETN, CYP family genes, and extracellular matrix regulators (MMPs, TIMPs) as recurrent candidates linked to acne susceptibility.\n""}"
167	8	Acne Vulgaris	Acne_Vulgaris.yaml	genetic	2	RETN-420C>G and IL6-572G>C polymorphisms									Associated																										"Case-control data in a Chinese cohort link RETN-420G and IL6-572C alleles to increased acne susceptibility and severity.
"																						"{""association"": ""Associated"", ""name"": ""RETN-420C>G and IL6-572G>C polymorphisms"", ""notes"": ""Case-control data in a Chinese cohort link RETN-420G and IL6-572C alleles to increased acne susceptibility and severity.\n""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This study reports RETN-420 and IL6-572 risk alleles associated with acne susceptibility."", ""reference"": ""PMID:35279931"", ""snippet"": ""There is a strong correlation between RETN-420 and IL6-572 polymorphisms and acne susceptibility; the RETN-420G and IL6-572C alleles increase the risk of acne development."", ""supports"": ""SUPPORT""}], ""name"": ""RETN-420C>G and IL6-572G>C polymorphisms"", ""notes"": ""Case-control data in a Chinese cohort link RETN-420G and IL6-572C alleles to increased acne susceptibility and severity.\n""}"
168	8	Acne Vulgaris	Acne_Vulgaris.yaml	genetic	3	TNFR2 M196R and TLR2 Arg753Gln polymorphisms									Associated																										"Risk alleles in TNFR2 and TLR2 are enriched in moderate-to-severe acne subgroups, supporting an inflammatory genetic contribution.
"																						"{""association"": ""Associated"", ""name"": ""TNFR2 M196R and TLR2 Arg753Gln polymorphisms"", ""notes"": ""Risk alleles in TNFR2 and TLR2 are enriched in moderate-to-severe acne subgroups, supporting an inflammatory genetic contribution.\n""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This study links TNFR2 and TLR2 risk alleles to acne susceptibility in a Chinese Han cohort."", ""reference"": ""PMID:20861605"", ""snippet"": ""The 196R allele of TNFR2 M196R as well as the 753Gln allele of TLR2 Arg753Gln are risk factors for acne vulgaris in Chinese Han patients, further supporting the contribution of inflammatory cytokines to the pathogenesis of acne."", ""supports"": ""SUPPORT""}], ""name"": ""TNFR2 M196R and TLR2 Arg753Gln polymorphisms"", ""notes"": ""Risk alleles in TNFR2 and TLR2 are enriched in moderate-to-severe acne subgroups, supporting an inflammatory genetic contribution.\n""}"
208	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	0	CD4									Host receptor for HIV entry																										Primary receptor for HIV gp120 binding, essential for viral entry into target cells. CD4-positive T cells are the primary target cells depleted in AIDS progression.																						"{""association"": ""Host receptor for HIV entry"", ""name"": ""CD4"", ""notes"": ""Primary receptor for HIV gp120 binding, essential for viral entry into target cells. CD4-positive T cells are the primary target cells depleted in AIDS progression.""}"	{}	"{""association"": ""Host receptor for HIV entry"", ""name"": ""CD4"", ""notes"": ""Primary receptor for HIV gp120 binding, essential for viral entry into target cells. CD4-positive T cells are the primary target cells depleted in AIDS progression.""}"
209	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	1	CCR5									Host co-receptor for HIV entry																										Chemokine receptor serving as primary co-receptor for R5-tropic HIV strains. CCR5-delta32 mutation confers resistance to HIV infection.																						"{""association"": ""Host co-receptor for HIV entry"", ""name"": ""CCR5"", ""notes"": ""Chemokine receptor serving as primary co-receptor for R5-tropic HIV strains. CCR5-delta32 mutation confers resistance to HIV infection.""}"	{}	"{""association"": ""Host co-receptor for HIV entry"", ""name"": ""CCR5"", ""notes"": ""Chemokine receptor serving as primary co-receptor for R5-tropic HIV strains. CCR5-delta32 mutation confers resistance to HIV infection.""}"
210	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	2	CXCR4									Host co-receptor for HIV entry																										Chemokine receptor serving as co-receptor for X4-tropic HIV strains. Tropism shift from CCR5 to CXCR4 often occurs in disease progression.																						"{""association"": ""Host co-receptor for HIV entry"", ""name"": ""CXCR4"", ""notes"": ""Chemokine receptor serving as co-receptor for X4-tropic HIV strains. Tropism shift from CCR5 to CXCR4 often occurs in disease progression.""}"	{}	"{""association"": ""Host co-receptor for HIV entry"", ""name"": ""CXCR4"", ""notes"": ""Chemokine receptor serving as co-receptor for X4-tropic HIV strains. Tropism shift from CCR5 to CXCR4 often occurs in disease progression.""}"
211	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	3	APOBEC3G									Host antiviral restriction factor																										Cytidine deaminase that restricts HIV replication by hypermutating viral DNA. Counteracted by HIV Vif protein.																						"{""association"": ""Host antiviral restriction factor"", ""name"": ""APOBEC3G"", ""notes"": ""Cytidine deaminase that restricts HIV replication by hypermutating viral DNA. Counteracted by HIV Vif protein.""}"	{}	"{""association"": ""Host antiviral restriction factor"", ""name"": ""APOBEC3G"", ""notes"": ""Cytidine deaminase that restricts HIV replication by hypermutating viral DNA. Counteracted by HIV Vif protein.""}"
212	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	4	SAMHD1									Host antiviral restriction factor																										Deoxynucleoside triphosphate triphosphohydrolase that depletes dNTP pools and restricts HIV reverse transcription in myeloid cells and resting T cells.																						"{""association"": ""Host antiviral restriction factor"", ""name"": ""SAMHD1"", ""notes"": ""Deoxynucleoside triphosphate triphosphohydrolase that depletes dNTP pools and restricts HIV reverse transcription in myeloid cells and resting T cells.""}"	{}	"{""association"": ""Host antiviral restriction factor"", ""name"": ""SAMHD1"", ""notes"": ""Deoxynucleoside triphosphate triphosphohydrolase that depletes dNTP pools and restricts HIV reverse transcription in myeloid cells and resting T cells.""}"
213	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	5	TRIM5									Host antiviral restriction factor																										E3 ubiquitin ligase that restricts HIV through premature uncoating of viral capsid. Displays species-specific antiviral activity.																						"{""association"": ""Host antiviral restriction factor"", ""name"": ""TRIM5"", ""notes"": ""E3 ubiquitin ligase that restricts HIV through premature uncoating of viral capsid. Displays species-specific antiviral activity.""}"	{}	"{""association"": ""Host antiviral restriction factor"", ""name"": ""TRIM5"", ""notes"": ""E3 ubiquitin ligase that restricts HIV through premature uncoating of viral capsid. Displays species-specific antiviral activity.""}"
214	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	6	BST2									Host antiviral restriction factor (tetherin)																										Interferon-induced protein that tethers budding virions to cell surface, preventing viral release. Counteracted by HIV Vpu protein.																						"{""association"": ""Host antiviral restriction factor (tetherin)"", ""name"": ""BST2"", ""notes"": ""Interferon-induced protein that tethers budding virions to cell surface, preventing viral release. Counteracted by HIV Vpu protein.""}"	{}	"{""association"": ""Host antiviral restriction factor (tetherin)"", ""name"": ""BST2"", ""notes"": ""Interferon-induced protein that tethers budding virions to cell surface, preventing viral release. Counteracted by HIV Vpu protein.""}"
215	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	genetic	7	SERINC5									Host antiviral restriction factor																										Multipass transmembrane protein incorporated into virions that impairs infectivity. Counteracted by HIV Nef protein.																						"{""association"": ""Host antiviral restriction factor"", ""name"": ""SERINC5"", ""notes"": ""Multipass transmembrane protein incorporated into virions that impairs infectivity. Counteracted by HIV Nef protein.""}"	{}	"{""association"": ""Host antiviral restriction factor"", ""name"": ""SERINC5"", ""notes"": ""Multipass transmembrane protein incorporated into virions that impairs infectivity. Counteracted by HIV Nef protein.""}"
244	10	Addison's Disease	Addisons_Disease.yaml	genetic	0	CYP21A2 (21-hydroxylase)									Major adrenal autoantigen; autoantibodies target this enzyme																										Target of autoantibodies and autoreactive T cells in autoimmune Addison's disease																						"{""association"": ""Major adrenal autoantigen; autoantibodies target this enzyme"", ""name"": ""CYP21A2 (21-hydroxylase)"", ""notes"": ""Target of autoantibodies and autoreactive T cells in autoimmune Addison's disease""}"	{}	"{""association"": ""Major adrenal autoantigen; autoantibodies target this enzyme"", ""evidence"": [{""explanation"": ""This study demonstrates that 21-hydroxylase is the major autoantigen in autoimmune Addison's disease."", ""reference"": ""PMID:34665570"", ""snippet"": ""The most common cause of primary adrenal failure (Addison's disease) in the Western world is autoimmunity characterized by autoantibodies against the steroidogenic enzyme 21-hydroxylase (CYP21A2, 21OH)"", ""supports"": ""SUPPORT""}], ""name"": ""CYP21A2 (21-hydroxylase)"", ""notes"": ""Target of autoantibodies and autoreactive T cells in autoimmune Addison's disease""}"
245	10	Addison's Disease	Addisons_Disease.yaml	genetic	1	AIRE									Autoimmune Polyendocrine Syndrome Type 1 (APS-1) is a known genetic cause																										Biallelic loss-of-function mutations cause breakdown of central tolerance in thymus																						"{""association"": ""Autoimmune Polyendocrine Syndrome Type 1 (APS-1) is a known genetic cause"", ""name"": ""AIRE"", ""notes"": ""Biallelic loss-of-function mutations cause breakdown of central tolerance in thymus""}"	{}	"{""association"": ""Autoimmune Polyendocrine Syndrome Type 1 (APS-1) is a known genetic cause"", ""evidence"": [{""explanation"": ""The literature clearly states that APS1, which includes Addison's disease, is caused by mutations in the AIRE gene."", ""reference"": ""PMID:33717087"", ""snippet"": ""The autoimmune polyglandular syndrome type 1 (APS1) is caused by pathogenic variants of the autoimmune regulator (AIRE) gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""APS1 is listed among the genetic causes of adrenal insufficiency, which is directly related to Addison's disease."", ""reference"": ""PMID:25667374"", ""snippet"": ""The genetic mutations associated with several familial causes of adrenal insufficiency have now been identified... autoimmune polyglandular syndrome type 1."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identifies specific mutations in the AIRE gene associated with APS1, which includes Addison's disease."", ""reference"": ""PMID:24988226"", ""snippet"": ""Autoimmune polyglandular syndrome type 1 (APS-1, OMIM 240300) is a rare autosomal recessive disorder... We identified a novel homozygous mutation in the splice site acceptor (SSA) of intron 5 (c.653-1G>A) in two siblings with different clinical outcomes of APS-1."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that APS1 is caused by mutations in the AIRE gene, supporting the association with Addison's disease."", ""reference"": ""PMID:22344197"", ""snippet"": ""Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disorder caused by mutations in the autoimmune regulator (AIRE) gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""The high prevalence of AIRE gene mutations in APS1 patients supports the genetic link to Addison's disease."", ""reference"": ""PMID:24014553"", ""snippet"": ""Of the patients with APS1, 96% were revealed to have AIRE gene mutations."", ""supports"": ""SUPPORT""}], ""name"": ""AIRE"", ""notes"": ""Biallelic loss-of-function mutations cause breakdown of central tolerance in thymus""}"
246	10	Addison's Disease	Addisons_Disease.yaml	genetic	2	HLA-DR3-DQ2 and HLA-DR4-DQ8									HLA class II haplotypes strongly increase risk																										Polygenic susceptibility; altered peptide presentation to CD4+ T cells (HLA-DRB1, HLA-DQA1, HLA-DQB1)																						"{""association"": ""HLA class II haplotypes strongly increase risk"", ""name"": ""HLA-DR3-DQ2 and HLA-DR4-DQ8"", ""notes"": ""Polygenic susceptibility; altered peptide presentation to CD4+ T cells (HLA-DRB1, HLA-DQA1, HLA-DQB1)""}"	{}	"{""association"": ""HLA class II haplotypes strongly increase risk"", ""evidence"": [{""explanation"": ""This study demonstrates that HLA-DR3-DQ2 and DR4-DQ8 haplotypes are major susceptibility markers for Addison's disease."", ""reference"": ""PMID:12392510"", ""snippet"": ""Susceptibility to Addison's disease is influenced by the genes around MICA and D6S273 for both the HLA DR3-DQ2 and DR4-DQ8 haplotypes"", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DR3-DQ2 and HLA-DR4-DQ8"", ""notes"": ""Polygenic susceptibility; altered peptide presentation to CD4+ T cells (HLA-DRB1, HLA-DQA1, HLA-DQB1)""}"
247	10	Addison's Disease	Addisons_Disease.yaml	genetic	3	CTLA4									Immune checkpoint regulator; risk variants reduce T-cell inhibition																										Target of immune checkpoint inhibitor drugs that can precipitate autoimmune adrenalitis																						"{""association"": ""Immune checkpoint regulator; risk variants reduce T-cell inhibition"", ""name"": ""CTLA4"", ""notes"": ""Target of immune checkpoint inhibitor drugs that can precipitate autoimmune adrenalitis""}"	{}	"{""association"": ""Immune checkpoint regulator; risk variants reduce T-cell inhibition"", ""evidence"": [{""explanation"": ""This study demonstrates that CTLA4 variants are a genetic susceptibility locus for autoimmune Addison's disease."", ""reference"": ""PMID:26204230"", ""snippet"": ""The G-allele of SNP rs231775 in CTLA-4 is associated with AAD in Norwegian patients (odds ratio (OR)=1.35 (confidence interval (CI) 1.10-1.66), P=0.004)"", ""supports"": ""SUPPORT""}], ""name"": ""CTLA4"", ""notes"": ""Target of immune checkpoint inhibitor drugs that can precipitate autoimmune adrenalitis""}"
248	10	Addison's Disease	Addisons_Disease.yaml	genetic	4	PTPN22									Tyrosine phosphatase modulating T-cell receptor signaling																										Risk alleles perturb T-cell selection and activation																						"{""association"": ""Tyrosine phosphatase modulating T-cell receptor signaling"", ""name"": ""PTPN22"", ""notes"": ""Risk alleles perturb T-cell selection and activation""}"	{}	"{""association"": ""Tyrosine phosphatase modulating T-cell receptor signaling"", ""evidence"": [{""explanation"": ""This study demonstrates that PTPN22 1858T-allele is associated with autoimmune Addison's disease susceptibility."", ""reference"": ""PMID:18301444"", ""snippet"": ""the 1858T-allele is a PTPN22 genetic susceptibility factor for autoimmune AD"", ""supports"": ""SUPPORT""}], ""name"": ""PTPN22"", ""notes"": ""Risk alleles perturb T-cell selection and activation""}"
249	10	Addison's Disease	Addisons_Disease.yaml	genetic	5	BACH2									Transcription factor controlling B- and T-cell differentiation																										Variants associated with autoimmunity and Addison's disease susceptibility																						"{""association"": ""Transcription factor controlling B- and T-cell differentiation"", ""name"": ""BACH2"", ""notes"": ""Variants associated with autoimmunity and Addison's disease susceptibility""}"	{}	"{""association"": ""Transcription factor controlling B- and T-cell differentiation"", ""name"": ""BACH2"", ""notes"": ""Variants associated with autoimmunity and Addison's disease susceptibility""}"
250	10	Addison's Disease	Addisons_Disease.yaml	genetic	6	CLEC16A									GWAS-implicated locus linked to antigen presentation and autophagy																										Contributes to polygenic autoimmune susceptibility																						"{""association"": ""GWAS-implicated locus linked to antigen presentation and autophagy"", ""name"": ""CLEC16A"", ""notes"": ""Contributes to polygenic autoimmune susceptibility""}"	{}	"{""association"": ""GWAS-implicated locus linked to antigen presentation and autophagy"", ""name"": ""CLEC16A"", ""notes"": ""Contributes to polygenic autoimmune susceptibility""}"
251	10	Addison's Disease	Addisons_Disease.yaml	genetic	7	NLRP1									Inflammasome component; variants implicate inflammatory pathways																										May modulate adrenal inflammation in autoimmune context																						"{""association"": ""Inflammasome component; variants implicate inflammatory pathways"", ""name"": ""NLRP1"", ""notes"": ""May modulate adrenal inflammation in autoimmune context""}"	{}	"{""association"": ""Inflammasome component; variants implicate inflammatory pathways"", ""name"": ""NLRP1"", ""notes"": ""May modulate adrenal inflammation in autoimmune context""}"
252	10	Addison's Disease	Addisons_Disease.yaml	genetic	8	CIITA									Master regulator of MHC class II expression																										Variation can alter antigen presentation and autoimmunity risk																						"{""association"": ""Master regulator of MHC class II expression"", ""name"": ""CIITA"", ""notes"": ""Variation can alter antigen presentation and autoimmunity risk""}"	{}	"{""association"": ""Master regulator of MHC class II expression"", ""name"": ""CIITA"", ""notes"": ""Variation can alter antigen presentation and autoimmunity risk""}"
253	10	Addison's Disease	Addisons_Disease.yaml	genetic	9	STAT4									Transcription factor promoting Th1 differentiation																										Implicated in directing Th1-biased responses in autoimmune Addison's disease																						"{""association"": ""Transcription factor promoting Th1 differentiation"", ""name"": ""STAT4"", ""notes"": ""Implicated in directing Th1-biased responses in autoimmune Addison's disease""}"	{}	"{""association"": ""Transcription factor promoting Th1 differentiation"", ""name"": ""STAT4"", ""notes"": ""Implicated in directing Th1-biased responses in autoimmune Addison's disease""}"
280	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	genetic	0	HTLV-1 Tax									Viral Oncogene																										Tax is the major HTLV-1 transforming protein. Activates NF-kappaB, CREB, and AP-1 pathways; induces genomic instability; inhibits DNA repair; and dysregulates cell cycle. Tax expression is often lost in established ATLL due to promoter methylation, suggesting its role is primarily in early transformation.																						"{""association"": ""Viral Oncogene"", ""name"": ""HTLV-1 Tax"", ""notes"": ""Tax is the major HTLV-1 transforming protein. Activates NF-kappaB, CREB, and AP-1 pathways; induces genomic instability; inhibits DNA repair; and dysregulates cell cycle. Tax expression is often lost in established ATLL due to promoter methylation, suggesting its role is primarily in early transformation.""}"	{}	"{""association"": ""Viral Oncogene"", ""name"": ""HTLV-1 Tax"", ""notes"": ""Tax is the major HTLV-1 transforming protein. Activates NF-kappaB, CREB, and AP-1 pathways; induces genomic instability; inhibits DNA repair; and dysregulates cell cycle. Tax expression is often lost in established ATLL due to promoter methylation, suggesting its role is primarily in early transformation.""}"
281	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	genetic	1	HTLV-1 HBZ									Viral Oncogene																										HBZ (HTLV-1 basic leucine zipper factor) is expressed from the antisense strand and maintained in all ATLL cells. Promotes T-cell proliferation and regulatory T-cell phenotype. Contributes to transformation independently of Tax.																						"{""association"": ""Viral Oncogene"", ""name"": ""HTLV-1 HBZ"", ""notes"": ""HBZ (HTLV-1 basic leucine zipper factor) is expressed from the antisense strand and maintained in all ATLL cells. Promotes T-cell proliferation and regulatory T-cell phenotype. Contributes to transformation independently of Tax.""}"	{}	"{""association"": ""Viral Oncogene"", ""name"": ""HTLV-1 HBZ"", ""notes"": ""HBZ (HTLV-1 basic leucine zipper factor) is expressed from the antisense strand and maintained in all ATLL cells. Promotes T-cell proliferation and regulatory T-cell phenotype. Contributes to transformation independently of Tax.""}"
282	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	genetic	2	TP53									Somatic Mutation																										TP53 mutations occur in approximately 20-40% of aggressive ATLL and are associated with poor prognosis. More common in acute than indolent forms.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 20-40% of aggressive ATLL and are associated with poor prognosis. More common in acute than indolent forms.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 20-40% of aggressive ATLL and are associated with poor prognosis. More common in acute than indolent forms.""}"
283	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	genetic	3	CCR4									Gain of Function Mutation																										CCR4 mutations occur in approximately 25% of cases and result in receptor stabilization and enhanced signaling. Target of mogamulizumab therapy.																						"{""association"": ""Gain of Function Mutation"", ""name"": ""CCR4"", ""notes"": ""CCR4 mutations occur in approximately 25% of cases and result in receptor stabilization and enhanced signaling. Target of mogamulizumab therapy.""}"	{}	"{""association"": ""Gain of Function Mutation"", ""name"": ""CCR4"", ""notes"": ""CCR4 mutations occur in approximately 25% of cases and result in receptor stabilization and enhanced signaling. Target of mogamulizumab therapy.""}"
310	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	genetic	0	TP53									Somatic Mutation (R249S)																										The TP53 R249S mutation is the molecular signature of aflatoxin-related HCC, found in approximately 50% of HCCs in high-exposure regions but <5% in low-exposure areas. Results from AFB1-epoxide adduct formation at the third position of codon 249 causing G>T transversion. This mutation inactivates p53 tumor suppressor function.																						"{""association"": ""Somatic Mutation (R249S)"", ""name"": ""TP53"", ""notes"": ""The TP53 R249S mutation is the molecular signature of aflatoxin-related HCC, found in approximately 50% of HCCs in high-exposure regions but <5% in low-exposure areas. Results from AFB1-epoxide adduct formation at the third position of codon 249 causing G>T transversion. This mutation inactivates p53 tumor suppressor function.""}"	{}	"{""association"": ""Somatic Mutation (R249S)"", ""name"": ""TP53"", ""notes"": ""The TP53 R249S mutation is the molecular signature of aflatoxin-related HCC, found in approximately 50% of HCCs in high-exposure regions but <5% in low-exposure areas. Results from AFB1-epoxide adduct formation at the third position of codon 249 causing G>T transversion. This mutation inactivates p53 tumor suppressor function.""}"
311	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	genetic	1	CTNNB1									Somatic Mutation																										CTNNB1 (beta-catenin) activating mutations occur in approximately 20-30% of HCCs and activate Wnt signaling, promoting proliferation.																						"{""association"": ""Somatic Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 (beta-catenin) activating mutations occur in approximately 20-30% of HCCs and activate Wnt signaling, promoting proliferation.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 (beta-catenin) activating mutations occur in approximately 20-30% of HCCs and activate Wnt signaling, promoting proliferation.""}"
312	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	genetic	2	TERT Promoter									Somatic Mutation																										TERT promoter mutations occur in approximately 50% of HCCs, activating telomerase and enabling immortalization. Often an early event in hepatocarcinogenesis.																						"{""association"": ""Somatic Mutation"", ""name"": ""TERT Promoter"", ""notes"": ""TERT promoter mutations occur in approximately 50% of HCCs, activating telomerase and enabling immortalization. Often an early event in hepatocarcinogenesis.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TERT Promoter"", ""notes"": ""TERT promoter mutations occur in approximately 50% of HCCs, activating telomerase and enabling immortalization. Often an early event in hepatocarcinogenesis.""}"
340	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	genetic	0	CFH									Risk Factor																										Complement factor H, Y402H variant																						"{""association"": ""Risk Factor"", ""name"": ""CFH"", ""notes"": ""Complement factor H, Y402H variant""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CFH"", ""notes"": ""Complement factor H, Y402H variant""}"
341	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	genetic	1	ARMS2/HTRA1									Risk Factor																										10q26 locus																						"{""association"": ""Risk Factor"", ""name"": ""ARMS2/HTRA1"", ""notes"": ""10q26 locus""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ARMS2/HTRA1"", ""notes"": ""10q26 locus""}"
342	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	genetic	2	C3									Risk Factor																										Complement component 3																						"{""association"": ""Risk Factor"", ""name"": ""C3"", ""notes"": ""Complement component 3""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""C3"", ""notes"": ""Complement component 3""}"
343	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	genetic	3	CFB									Risk Factor																										Complement factor B																						"{""association"": ""Risk Factor"", ""name"": ""CFB"", ""notes"": ""Complement factor B""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CFB"", ""notes"": ""Complement factor B""}"
410	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	0	APP						Mendelian (Early-Onset)			Genetic Mutation																																																"{""association"": ""Genetic Mutation"", ""name"": ""APP"", ""subtype"": ""Mendelian (Early-Onset)""}"	{}	"{""association"": ""Genetic Mutation"", ""evidence"": [{""explanation"": ""This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease."", ""reference"": ""PMID:1365885"", ""snippet"": ""Four mutations involving amino acid substitutions in exons 16 and 17 of the amyloid precursor protein (APP) gene, have been identified which co-segregate with the disease in some families multiply affected by early onset Alzheimer's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the role of APP gene mutations in causing early-onset Alzheimer's disease."", ""reference"": ""PMID:33789815"", ""snippet"": ""This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-beta/tau pathology."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease."", ""reference"": ""PMID:36306459"", ""snippet"": ""Numerous mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been identified for EOAD, but they can only account for a small proportion of EOAD cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease."", ""reference"": ""PMID:31623876"", ""snippet"": ""In this study, a novel mutation in APP gene, Val669Leu ('Seoul APP'), was reported in a Korean female patient with Alzheimer's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease."", ""reference"": ""PMID:26243569"", ""snippet"": ""It is thought that this risk is conferred by the presence of three copies of the gene encoding amyloid precursor protein (APP)--an Alzheimer disease risk factor."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease."", ""reference"": ""PMID:22727994"", ""snippet"": ""APP mutations cause Alzheimer disease (AD) with virtually complete penetrance."", ""supports"": ""SUPPORT""}], ""name"": ""APP"", ""subtype"": ""Mendelian (Early-Onset)""}"
411	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	1	PSEN1						Mendelian (Early-Onset)			Genetic Mutation																																																"{""association"": ""Genetic Mutation"", ""name"": ""PSEN1"", ""subtype"": ""Mendelian (Early-Onset)""}"	{}	"{""association"": ""Genetic Mutation"", ""evidence"": [{""explanation"": ""The study reports a novel PSEN1 mutation associated with early-onset Alzheimer's disease, supporting the genetic association."", ""reference"": ""PMID:31296348"", ""snippet"": ""Presenilin 1 (PSEN1) gene mutations are the major known genetic cause of early-onset Alzheimer's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms that PSEN1 is one of the genes associated with early-onset Alzheimer's disease."", ""reference"": ""PMID:35487021"", ""snippet"": ""At present, three early-onset AD genes (APP, PSEN1, PSEN2) and one late-onset AD susceptibility gene apolipoprotein E (APOE) have been determined."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses a large cohort with a specific PSEN1 mutation associated with early-onset Alzheimer's disease, reinforcing the genetic link."", ""reference"": ""PMID:36951251"", ""snippet"": ""A genetic association study was conducted to examine ADAD AAO in 340 individuals with the PSEN1 E280A mutation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses early-onset Alzheimer's disease and mentions PSEN1 mutations, supporting the genetic association."", ""reference"": ""PMID:36641620"", ""snippet"": ""Early-onset AD represents about 5.5% of the total cases and occurs in patients under age 65. The EOAD progresses more aggressively and has a shorter life expectancy due to a greater pathogenic load."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights the occurrence of early-onset Alzheimer's disease and mentions PSEN1 mutations, supporting the genetic link."", ""reference"": ""PMID:35430993"", ""snippet"": ""Early-onset Alzheimer's disease (EOAD) is commonly diagnosed with an onset age of earlier than 65 years and accounts for 5-10% of all Alzheimer's disease (AD) cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms that PSEN1 mutations are a frequent cause of early-onset Alzheimer's disease."", ""reference"": ""PMID:30549411"", ""snippet"": ""The gene mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the frequent causes of AD."", ""supports"": ""SUPPORT""}], ""name"": ""PSEN1"", ""subtype"": ""Mendelian (Early-Onset)""}"
412	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	2	PSEN2						Mendelian (Early-Onset)			Genetic Mutation																																																"{""association"": ""Genetic Mutation"", ""name"": ""PSEN2"", ""subtype"": ""Mendelian (Early-Onset)""}"	{}	"{""association"": ""Genetic Mutation"", ""evidence"": [{""explanation"": ""The reference confirms that PSEN2 mutations are among the causative factors for early-onset Alzheimer's disease."", ""reference"": ""PMID:35491795"", ""snippet"": ""The established causative mutations in the APP, PSEN1, and PSEN2 can explain less than 1%, Alzheimer''s disease (AD) patients. Of the identified variants, the PSEN2 mutations are even less common."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the association of PSEN2 with early-onset Alzheimer's disease, although it notes that such cases are rare."", ""reference"": ""PMID:36701017"", ""snippet"": ""Early-onset AD (EOAD) was defined as AD occurring before age 65. Although it has a high genetic risk, EOAD due to PSEN2 variation is very rare."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference explicitly states that early-onset familial Alzheimer's disease can be caused by PSEN2 mutations."", ""reference"": ""PMID:32741831"", ""snippet"": ""Early-onset familial Alzheimer disease (EOFAD) is caused by heterozygous variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP genes."", ""supports"": ""SUPPORT""}], ""name"": ""PSEN2"", ""subtype"": ""Mendelian (Early-Onset)""}"
413	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	3	APOE						Complex (Late-Onset)			Risk Factor																										APOE4 allele is the major genetic risk factor for late-onset Alzheimer's disease, modulating lipid metabolism, microglial states, and A handling.																						"{""association"": ""Risk Factor"", ""name"": ""APOE"", ""notes"": ""APOE4 allele is the major genetic risk factor for late-onset Alzheimer's disease, modulating lipid metabolism, microglial states, and A handling."", ""subtype"": ""Complex (Late-Onset)""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""APOE"", ""notes"": ""APOE4 allele is the major genetic risk factor for late-onset Alzheimer's disease, modulating lipid metabolism, microglial states, and A handling."", ""subtype"": ""Complex (Late-Onset)""}"
414	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	4	TREM2						Complex (Late-Onset)			Risk Factor																										Microglial receptor that influences disease-associated microglial phenotypes, phagocytosis, and immune responses to A pathology.																						"{""association"": ""Risk Factor"", ""name"": ""TREM2"", ""notes"": ""Microglial receptor that influences disease-associated microglial phenotypes, phagocytosis, and immune responses to A pathology."", ""subtype"": ""Complex (Late-Onset)""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TREM2"", ""notes"": ""Microglial receptor that influences disease-associated microglial phenotypes, phagocytosis, and immune responses to A pathology."", ""subtype"": ""Complex (Late-Onset)""}"
415	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	5	NLRP3									Genetic Variant																										Encodes the NLRP3 inflammasome sensor in microglia that drives IL-1 production, pyroptosis, and neuroinflammation in response to A and tau aggregates.																						"{""association"": ""Genetic Variant"", ""name"": ""NLRP3"", ""notes"": ""Encodes the NLRP3 inflammasome sensor in microglia that drives IL-1 production, pyroptosis, and neuroinflammation in response to A and tau aggregates.""}"	{}	"{""association"": ""Genetic Variant"", ""name"": ""NLRP3"", ""notes"": ""Encodes the NLRP3 inflammasome sensor in microglia that drives IL-1 production, pyroptosis, and neuroinflammation in response to A and tau aggregates.""}"
416	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	6	PYCARD									Genetic Variant																										Encodes ASC (apoptosis-associated speck-like protein containing a CARD), the inflammasome adaptor required for NLRP3 signaling and IL-1 maturation.																						"{""association"": ""Genetic Variant"", ""name"": ""PYCARD"", ""notes"": ""Encodes ASC (apoptosis-associated speck-like protein containing a CARD), the inflammasome adaptor required for NLRP3 signaling and IL-1 maturation.""}"	{}	"{""association"": ""Genetic Variant"", ""name"": ""PYCARD"", ""notes"": ""Encodes ASC (apoptosis-associated speck-like protein containing a CARD), the inflammasome adaptor required for NLRP3 signaling and IL-1 maturation.""}"
417	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	genetic	7	LRP1									Genetic Variant																										Low-density lipoprotein receptor-related protein 1, mediates A clearance across the blood-brain barrier. Variants and reduced expression impair A efflux.																						"{""association"": ""Genetic Variant"", ""name"": ""LRP1"", ""notes"": ""Low-density lipoprotein receptor-related protein 1, mediates A clearance across the blood-brain barrier. Variants and reduced expression impair A efflux.""}"	{}	"{""association"": ""Genetic Variant"", ""name"": ""LRP1"", ""notes"": ""Low-density lipoprotein receptor-related protein 1, mediates A clearance across the blood-brain barrier. Variants and reduced expression impair A efflux.""}"
442	18	Alopecia Areata	Alopecia_Areata.yaml	genetic	0	HLA-DRB1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"
443	18	Alopecia Areata	Alopecia_Areata.yaml	genetic	1	CTLA4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CTLA4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CTLA4""}"
444	18	Alopecia Areata	Alopecia_Areata.yaml	genetic	2	IL2RA									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL2RA""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL2RA""}"
445	18	Alopecia Areata	Alopecia_Areata.yaml	genetic	3	PTPN22									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""PTPN22""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PTPN22""}"
479	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	genetic	0	PAX3-FOXO1 Fusion									Somatic Fusion Oncogene																										The t(2;13)(q35;q14) translocation creates the PAX3-FOXO1 fusion in approximately 55% of cases. This is the most aggressive molecular subtype.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""PAX3-FOXO1 Fusion"", ""notes"": ""The t(2;13)(q35;q14) translocation creates the PAX3-FOXO1 fusion in approximately 55% of cases. This is the most aggressive molecular subtype.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""PAX3-FOXO1 Fusion"", ""notes"": ""The t(2;13)(q35;q14) translocation creates the PAX3-FOXO1 fusion in approximately 55% of cases. This is the most aggressive molecular subtype.""}"
480	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	genetic	1	PAX7-FOXO1 Fusion									Somatic Fusion Oncogene																										The t(1;13)(p36;q14) translocation creates the PAX7-FOXO1 fusion in approximately 22% of cases. Associated with better prognosis than PAX3-FOXO1.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""PAX7-FOXO1 Fusion"", ""notes"": ""The t(1;13)(p36;q14) translocation creates the PAX7-FOXO1 fusion in approximately 22% of cases. Associated with better prognosis than PAX3-FOXO1.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""PAX7-FOXO1 Fusion"", ""notes"": ""The t(1;13)(p36;q14) translocation creates the PAX7-FOXO1 fusion in approximately 22% of cases. Associated with better prognosis than PAX3-FOXO1.""}"
481	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	genetic	2	MYCN Amplification									Secondary Genetic Event																										MYCN amplification occurs in a subset of fusion-positive ARMS and is associated with worse prognosis.																						"{""association"": ""Secondary Genetic Event"", ""name"": ""MYCN Amplification"", ""notes"": ""MYCN amplification occurs in a subset of fusion-positive ARMS and is associated with worse prognosis.""}"	{}	"{""association"": ""Secondary Genetic Event"", ""name"": ""MYCN Amplification"", ""notes"": ""MYCN amplification occurs in a subset of fusion-positive ARMS and is associated with worse prognosis.""}"
496	21	Alzheimer's Disease	Alzheimers_Disease.yaml	genetic	0	APP									Mutations cause early-onset autosomal dominant Alzheimer disease																										Amyloid precursor protein gene; mutations increase production of aggregation-prone A peptides, triggering pathological cascade. Accounts for 10-15% of autosomal dominant early-onset AD cases.																						"{""association"": ""Mutations cause early-onset autosomal dominant Alzheimer disease"", ""name"": ""APP"", ""notes"": ""Amyloid precursor protein gene; mutations increase production of aggregation-prone A peptides, triggering pathological cascade. Accounts for 10-15% of autosomal dominant early-onset AD cases.""}"	{}	"{""association"": ""Mutations cause early-onset autosomal dominant Alzheimer disease"", ""evidence"": [{""explanation"": ""This confirms that APP mutations cause autosomal dominant early-onset Alzheimer's disease."", ""reference"": ""PMID:28002825"", ""snippet"": ""Extremely rare variants in the APP, PSEN1, or PSEN2 genes, or duplications of the APP gene cause autosomal dominant forms, generally with complete penetrance by the age of 65 years."", ""supports"": ""SUPPORT""}], ""name"": ""APP"", ""notes"": ""Amyloid precursor protein gene; mutations increase production of aggregation-prone A peptides, triggering pathological cascade. Accounts for 10-15% of autosomal dominant early-onset AD cases.""}"
497	21	Alzheimer's Disease	Alzheimers_Disease.yaml	genetic	1	PSEN1									Most common cause of early-onset autosomal dominant Alzheimer disease																										Presenilin 1 gene; encodes component of -secretase complex. Mutations alter APP processing to increase A42/A40 ratio. Over 300 pathogenic mutations identified; accounts for 30-70% of autosomal dominant early-onset AD cases.																						"{""association"": ""Most common cause of early-onset autosomal dominant Alzheimer disease"", ""name"": ""PSEN1"", ""notes"": ""Presenilin 1 gene; encodes component of -secretase complex. Mutations alter APP processing to increase A42/A40 ratio. Over 300 pathogenic mutations identified; accounts for 30-70% of autosomal dominant early-onset AD cases.""}"	{}	"{""association"": ""Most common cause of early-onset autosomal dominant Alzheimer disease"", ""evidence"": [{""explanation"": ""This confirms that PSEN1 mutations cause autosomal dominant early-onset Alzheimer's disease with high penetrance."", ""reference"": ""PMID:28002825"", ""snippet"": ""Extremely rare variants in the APP, PSEN1, or PSEN2 genes, or duplications of the APP gene cause autosomal dominant forms, generally with complete penetrance by the age of 65 years."", ""supports"": ""SUPPORT""}], ""name"": ""PSEN1"", ""notes"": ""Presenilin 1 gene; encodes component of -secretase complex. Mutations alter APP processing to increase A42/A40 ratio. Over 300 pathogenic mutations identified; accounts for 30-70% of autosomal dominant early-onset AD cases.""}"
498	21	Alzheimer's Disease	Alzheimers_Disease.yaml	genetic	2	PSEN2									Rare cause of early-onset autosomal dominant Alzheimer disease																										Presenilin 2 gene; encodes component of -secretase complex. Mutations have similar effects to PSEN1 but account for less than 5% of autosomal dominant early-onset AD cases.																						"{""association"": ""Rare cause of early-onset autosomal dominant Alzheimer disease"", ""name"": ""PSEN2"", ""notes"": ""Presenilin 2 gene; encodes component of -secretase complex. Mutations have similar effects to PSEN1 but account for less than 5% of autosomal dominant early-onset AD cases.""}"	{}	"{""association"": ""Rare cause of early-onset autosomal dominant Alzheimer disease"", ""evidence"": [{""explanation"": ""This confirms that PSEN2 mutations can cause autosomal dominant early-onset Alzheimer's disease."", ""reference"": ""PMID:28002825"", ""snippet"": ""Extremely rare variants in the APP, PSEN1, or PSEN2 genes, or duplications of the APP gene cause autosomal dominant forms, generally with complete penetrance by the age of 65 years."", ""supports"": ""SUPPORT""}], ""name"": ""PSEN2"", ""notes"": ""Presenilin 2 gene; encodes component of -secretase complex. Mutations have similar effects to PSEN1 but account for less than 5% of autosomal dominant early-onset AD cases.""}"
499	21	Alzheimer's Disease	Alzheimers_Disease.yaml	genetic	3	APOE									APOE 4 allele is the strongest genetic risk factor for late-onset Alzheimer disease																										Apolipoprotein E gene; APOE 4 allele dramatically increases risk for late-onset AD. Heterozygous carriers have OR of 4, homozygous carriers have OR of 11-14. The 4 allele affects A clearance, aggregation, and toxicity.																						"{""association"": ""APOE 4 allele is the strongest genetic risk factor for late-onset Alzheimer disease"", ""name"": ""APOE"", ""notes"": ""Apolipoprotein E gene; APOE 4 allele dramatically increases risk for late-onset AD. Heterozygous carriers have OR of 4, homozygous carriers have OR of 11-14. The 4 allele affects A clearance, aggregation, and toxicity.""}"	{}	"{""association"": ""APOE 4 allele is the strongest genetic risk factor for late-onset Alzheimer disease"", ""evidence"": [{""explanation"": ""This demonstrates the substantial genetic risk conferred by the APOE 4 allele for Alzheimer's disease."", ""reference"": ""PMID:28002825"", ""snippet"": ""Among them, the APOE 4 allele is a rare example of a common allele with a large effect size, the ORs ranging from 4 to 11-14 for heterozygous and homozygous carriers, respectively."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights ApoE4 as an important genetic factor influencing Alzheimer's disease pathology and memory loss."", ""reference"": ""PMID:24459411"", ""snippet"": ""The investigation of AD memory loss helps to identify the involved neural structures, such as the default mode network, the influence of epigenetic and genetic factors, such as ApoE4 status, and evolutionary aspects of human cognition."", ""supports"": ""SUPPORT""}], ""name"": ""APOE"", ""notes"": ""Apolipoprotein E gene; APOE 4 allele dramatically increases risk for late-onset AD. Heterozygous carriers have OR of 4, homozygous carriers have OR of 11-14. The 4 allele affects A clearance, aggregation, and toxicity.""}"
522	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	genetic	0	C9orf72 Repeat Expansion									Causative																										Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion																						"{""association"": ""Causative"", ""name"": ""C9orf72 Repeat Expansion"", ""notes"": ""Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS."", ""reference"": ""PMID:21944778"", ""snippet"": ""Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""C9orf72 Repeat Expansion"", ""notes"": ""Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion""}"
523	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	genetic	1	SOD1 Mutations									Causative																										First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases																						"{""association"": ""Causative"", ""name"": ""SOD1 Mutations"", ""notes"": ""First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Original discovery paper identifying SOD1 mutations as a cause of familial ALS."", ""reference"": ""PMID:8446170"", ""snippet"": ""We identified 11 different SOD1 missense mutations in 13 different FALS families."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""SOD1 Mutations"", ""notes"": ""First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases""}"
524	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	genetic	2	TARDBP Mutations									Causative																										Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS																						"{""association"": ""Causative"", ""name"": ""TARDBP Mutations"", ""notes"": ""Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Gene therapy review highlights TARDBP among the most common ALS genes targeted by therapeutic strategies."", ""reference"": ""PMID:35805149"", ""snippet"": ""Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""TARDBP Mutations"", ""notes"": ""Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS""}"
525	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	genetic	3	FUS Mutations									Causative																										RNA-binding protein; mutations cause approximately 5% of familial ALS																						"{""association"": ""Causative"", ""name"": ""FUS Mutations"", ""notes"": ""RNA-binding protein; mutations cause approximately 5% of familial ALS""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Review notes FUS among the four most common ALS genes and discusses gene-targeted therapies."", ""reference"": ""PMID:35805149"", ""snippet"": ""Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""FUS Mutations"", ""notes"": ""RNA-binding protein; mutations cause approximately 5% of familial ALS""}"
526	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	genetic	4	NEK1 Variants									Susceptibility																										Risk variants found in nearly 3% of ALS cases																						"{""association"": ""Susceptibility"", ""name"": ""NEK1 Variants"", ""notes"": ""Risk variants found in nearly 3% of ALS cases""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""Large-scale genetic study identifying NEK1 variants as risk factors for ALS."", ""reference"": ""PMID:27455347"", ""snippet"": ""In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity."", ""supports"": ""SUPPORT""}], ""name"": ""NEK1 Variants"", ""notes"": ""Risk variants found in nearly 3% of ALS cases""}"
559	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	genetic	0	HLA-B27									Strong Risk Factor																										Present in 90-95% of patients																						"{""association"": ""Strong Risk Factor"", ""name"": ""HLA-B27"", ""notes"": ""Present in 90-95% of patients""}"	{}	"{""association"": ""Strong Risk Factor"", ""evidence"": [{""explanation"": ""Evidence confirming HLA-B27 as the strongest genetic risk factor for ankylosing spondylitis."", ""reference"": ""PMID:33692806"", ""snippet"": ""The strongest genetic association is with the allele human leukocyte antigen B27 (HLA-B27) of the Major Histocompatibility Complex-I (MHC-I) gene, located on chromosome 6 (98)."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-B27"", ""notes"": ""Present in 90-95% of patients""}"
560	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	genetic	1	ERAP1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ERAP1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Evidence that ERAP1 genetic variants are associated with ankylosing spondylitis through effects on antigen processing and MHC-I presentation."", ""reference"": ""PMID:33692806"", ""snippet"": ""In particular, single nucleotide polymorphisms (SNPs) in genes coding for aminopeptidases expressed in the endoplasmic reticulum (ER), such as ERAP1 and ERAP2, were identified in the past decade. These proteins trim peptides in the ER so that these molecules get to the right length, usually between 8 and 10 amino acids, to be presented by MHC-I molecules (107)."", ""supports"": ""SUPPORT""}], ""name"": ""ERAP1""}"
561	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	genetic	2	IL23R									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL23R""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Evidence that IL23R variants are associated with ankylosing spondylitis, highlighting the importance of the IL-23/IL-17 pathway."", ""reference"": ""PMID:33692806"", ""snippet"": ""SNPs directly affecting the IL-23/IL-17 axis were described in AS and further stress the importance of this pathway. The most relevant are located in the genes coding for IL-23R and STAT3 and TYK2, which are downstream targets of IL-23 signaling (110, 111)."", ""supports"": ""SUPPORT""}], ""name"": ""IL23R""}"
580	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	genetic	0	HLA-DR7								Positive																																																	"{""name"": ""HLA-DR7"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The reference mentions various HLA-DR associations with antiphospholipid antibodies but does not specifically mention HLA-DR7."", ""reference"": ""PMID:12967526"", ""snippet"": ""Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference does not mention HLA-DR7 in the context of antiphospholipid syndrome."", ""reference"": ""PMID:19758197"", ""snippet"": ""We found that, as reported in the literature, the occurrence of DRB1*03 and DQB1*0201 alleles was higher in SLE patients than in controls, but these alleles were rare in the PAPS+SLE group."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""Although HLA-DR7 is not specifically mentioned, this study discusses HLA-DR associations and could support the association indirectly. However, the mention of HLA-DR7 is more explicitly connected to diabetic retinopathy rather than APS."", ""reference"": ""PMID:7767340"", ""snippet"": ""In conclusion, in PAPS patients from the South of Spain, HLA-DQ7 antigen showed the highest relative risk for PAPS, followed by DRw53."", ""supports"": ""SUPPORT""}, {""explanation"": ""HLA-DR7 is discussed in the context of diabetic retinopathy and not antiphospholipid syndrome."", ""reference"": ""PMID:11886709"", ""snippet"": ""Our results suggest that the presence of HLA-DR7 protects against the development of proliferative disease in the diabetic Mexican population."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""HLA-DR7"", ""presence"": ""Positive""}"
581	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	genetic	1	HLA-DR4								Negative																																																	"{""name"": ""HLA-DR4"", ""presence"": ""Negative""}"	{}	"{""evidence"": [{""explanation"": ""The literature suggests an association between primary antiphospholipid syndrome (PAPS), which is a form of APS, and HLA-DR4, contradicting the claim that HLA-DR4 presence is negative."", ""reference"": ""PMID:7767340"", ""snippet"": ""Univariant analysis showed an association between PAPS and HLA-DQ7 (47% vs 25%l P = 0.3), DR4 (32% vs 16%; P = 0.08) and DQ3 (63% vs 39%; P = 0.04)."", ""supports"": ""REFUTE""}, {""explanation"": ""This reference discusses HLA associations in general terms but does not provide specific evidence about HLA-DR4."", ""reference"": ""PMID:12967526"", ""snippet"": ""Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""HLA-DR4"", ""presence"": ""Negative""}"
604	25	Apert Syndrome	Apert_Syndrome.yaml	genetic	0	FGFR2 Mutations									Causative																										"Two adjacent mutations in FGFR2 exon 7 account for nearly all cases: S252W (c.755C>G) in ~65% and P253R (c.758C>G) in ~32%. Both affect the linker region between Ig-II and Ig-III domains. The S252W mutation is associated with more severe craniofacial features; P253R with more severe syndactyly.
"																						"{""association"": ""Causative"", ""name"": ""FGFR2 Mutations"", ""notes"": ""Two adjacent mutations in FGFR2 exon 7 account for nearly all cases: S252W (c.755C>G) in ~65% and P253R (c.758C>G) in ~32%. Both affect the linker region between Ig-II and Ig-III domains. The S252W mutation is associated with more severe craniofacial features; P253R with more severe syndactyly.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Landmark study identifying S252W and P253R as the causative mutations in 100% of 40 unrelated Apert syndrome cases examined."", ""reference"": ""PMID:7719344"", ""snippet"": ""We have identified specific missense substitutions involving adjacent amino acids (Ser252Trp and Pro253Arg) in the linker between the second and third extracellular immunoglobulin (Ig) domains of fibroblast growth factor receptor 2 (FGFR2) in all 40 unrelated cases of Apert syndrome studied."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR2 Mutations"", ""notes"": ""Two adjacent mutations in FGFR2 exon 7 account for nearly all cases: S252W (c.755C>G) in ~65% and P253R (c.758C>G) in ~32%. Both affect the linker region between Ig-II and Ig-III domains. The S252W mutation is associated with more severe craniofacial features; P253R with more severe syndactyly.\n""}"
623	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	genetic	0	CYP19A1									Causal																										Biallelic loss-of-function mutations in CYP19A1 (HGNC:2594) encoding aromatase enzyme cause complete estrogen deficiency																						"{""association"": ""Causal"", ""name"": ""CYP19A1"", ""notes"": ""Biallelic loss-of-function mutations in CYP19A1 (HGNC:2594) encoding aromatase enzyme cause complete estrogen deficiency""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""This case report confirms that mutations in CYP19A1 encoding aromatase enzyme cause aromatase deficiency."", ""reference"": ""PMID:40321354"", ""snippet"": ""Aromatase deficiency is a rare autosomal recessive condition due to a mutation in the CYP19A1 encoding aromatase enzyme."", ""supports"": ""SUPPORT""}], ""name"": ""CYP19A1"", ""notes"": ""Biallelic loss-of-function mutations in CYP19A1 (HGNC:2594) encoding aromatase enzyme cause complete estrogen deficiency""}"
624	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	genetic	1	ESR1									Modifier																										Estrogen receptor alpha (HGNC:3467) mediates estrogen signaling; signaling is diminished due to low estrogen																						"{""association"": ""Modifier"", ""name"": ""ESR1"", ""notes"": ""Estrogen receptor alpha (HGNC:3467) mediates estrogen signaling; signaling is diminished due to low estrogen""}"	{}	"{""association"": ""Modifier"", ""name"": ""ESR1"", ""notes"": ""Estrogen receptor alpha (HGNC:3467) mediates estrogen signaling; signaling is diminished due to low estrogen""}"
625	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	genetic	2	ESR2									Modifier																										Estrogen receptor beta (HGNC:3468) mediates tissue-specific estrogen responses that are reduced																						"{""association"": ""Modifier"", ""name"": ""ESR2"", ""notes"": ""Estrogen receptor beta (HGNC:3468) mediates tissue-specific estrogen responses that are reduced""}"	{}	"{""association"": ""Modifier"", ""name"": ""ESR2"", ""notes"": ""Estrogen receptor beta (HGNC:3468) mediates tissue-specific estrogen responses that are reduced""}"
626	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	genetic	3	POR									Differential																										POR (HGNC:9208) defects can phenocopy aromatase deficiency by reducing CYP19A1 activity; requires genetic testing to distinguish																						"{""association"": ""Differential"", ""name"": ""POR"", ""notes"": ""POR (HGNC:9208) defects can phenocopy aromatase deficiency by reducing CYP19A1 activity; requires genetic testing to distinguish""}"	{}	"{""association"": ""Differential"", ""name"": ""POR"", ""notes"": ""POR (HGNC:9208) defects can phenocopy aromatase deficiency by reducing CYP19A1 activity; requires genetic testing to distinguish""}"
648	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	genetic	0	AS3MT									Susceptibility Polymorphisms																										Polymorphisms in arsenic (+3 oxidation state) methyltransferase (AS3MT) affect arsenic methylation efficiency. Individuals with lower methylation capacity accumulate more toxic trivalent metabolites and have increased cancer risk.																						"{""association"": ""Susceptibility Polymorphisms"", ""name"": ""AS3MT"", ""notes"": ""Polymorphisms in arsenic (+3 oxidation state) methyltransferase (AS3MT) affect arsenic methylation efficiency. Individuals with lower methylation capacity accumulate more toxic trivalent metabolites and have increased cancer risk.""}"	{}	"{""association"": ""Susceptibility Polymorphisms"", ""name"": ""AS3MT"", ""notes"": ""Polymorphisms in arsenic (+3 oxidation state) methyltransferase (AS3MT) affect arsenic methylation efficiency. Individuals with lower methylation capacity accumulate more toxic trivalent metabolites and have increased cancer risk.""}"
649	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	genetic	1	GSTO1/GSTO2									Susceptibility Polymorphisms																										Glutathione S-transferase omega (GSTO) polymorphisms affect arsenic reduction and detoxification, modifying cancer susceptibility in exposed populations.																						"{""association"": ""Susceptibility Polymorphisms"", ""name"": ""GSTO1/GSTO2"", ""notes"": ""Glutathione S-transferase omega (GSTO) polymorphisms affect arsenic reduction and detoxification, modifying cancer susceptibility in exposed populations.""}"	{}	"{""association"": ""Susceptibility Polymorphisms"", ""name"": ""GSTO1/GSTO2"", ""notes"": ""Glutathione S-transferase omega (GSTO) polymorphisms affect arsenic reduction and detoxification, modifying cancer susceptibility in exposed populations.""}"
650	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	genetic	2	TP53									Somatic Mutation																										TP53 mutations occur in arsenic-related skin and bladder cancers, though mutation spectra differ from UV-induced or smoking-related cancers, reflecting distinct carcinogenic mechanisms.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in arsenic-related skin and bladder cancers, though mutation spectra differ from UV-induced or smoking-related cancers, reflecting distinct carcinogenic mechanisms.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in arsenic-related skin and bladder cancers, though mutation spectra differ from UV-induced or smoking-related cancers, reflecting distinct carcinogenic mechanisms.""}"
684	28	Asthma	Asthma.yaml	genetic	0	IL4									Associated																																																"{""association"": ""Associated"", ""name"": ""IL4""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This meta-analysis found a significant association between IL-4 polymorphisms (C-33T and C-589T) and asthma susceptibility."", ""reference"": ""PMID:23070918"", ""snippet"": ""The results indicated that there were an association between the IL-4 C-33T (P = 0.006) and C-589T (P = 0.04) ... and susceptibility to asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference generally supports the idea of genetic associations in asthma, including those likely involving IL-4."", ""reference"": ""PMID:10073323"", ""snippet"": ""Using both the candidate gene and the positional cloning approaches, there is evidence that predisposing factors, if not the disease itself, are genetically transferred."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study refers to IL-4 receptor-alpha and not IL-4 directly, and its context is specific to occupational asthma caused by diisocyanate exposure."", ""reference"": ""PMID:21325943"", ""snippet"": ""Genotype combinations of IL-4 receptor-alpha and CD14 single nucleotide polymorphisms (SNPs) were significantly associated with diisocyanate asthma."", ""supports"": ""PARTIAL""}], ""name"": ""IL4""}"
685	28	Asthma	Asthma.yaml	genetic	1	IL13									Associated																																																"{""association"": ""Associated"", ""name"": ""IL13""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study provides evidence that the IL13 gene polymorphism A-1512C is significantly associated with asthma."", ""reference"": ""PMID:23996716"", ""snippet"": ""Interleukin-13 (IL-13) is known to be a key regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion and airway hyperresponsiveness... A statistically significant association of the A-1512C polymorphism in IL13 gene was observed with atopy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that IL-13 is involved in allergic lung inflammation which is relevant to asthma, but it primarily discusses IL-13's role in mediating immune responses rather than directly associating IL-13 genetic polymorphisms with asthma."", ""reference"": ""PMID:30539779"", ""snippet"": ""An efficient memory Th2 cell response is dependent on IL-13 produced by ILC2s, causing allergic lung inflammation and elevated serum levels of immunoglobulin E."", ""supports"": ""PARTIAL""}, {""explanation"": ""The review highlights the role of IL-13 in the pathway involved in asthma pathogenesis but does not directly establish a genetic association between IL-13 and asthma."", ""reference"": ""PMID:23380221"", ""snippet"": ""Very recently, a novel population of IL-33-responsive innate immune cells, the type 2 innate lymphoid cells, was found to produce hallmark TH2 cytokines, such as IL-5 and IL-13."", ""supports"": ""PARTIAL""}, {""explanation"": ""The abstract discusses GWAS studies related to asthma but does not specifically mention IL13."", ""reference"": ""PMID:21681015"", ""snippet"": ""Genome-wide association studies of asthma."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""IL13""}"
686	28	Asthma	Asthma.yaml	genetic	2	ADAM33									Associated																																																"{""association"": ""Associated"", ""name"": ""ADAM33""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This study and its findings directly support the statement about the association between the ADAM33 gene and asthma."", ""reference"": ""PMID:26666372"", ""snippet"": ""A disintegrin and metalloproteinase 33 (ADAM33) gene has been considered as an asthma susceptibility gene due to its possible role in airway remodeling, abnormal cell proliferation, and differentiation. Association of this gene with asthma has been reported in several genetic studies on various populations."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study acknowledges the genetic association between ADAM33 and asthma among other genes, further supporting the statement."", ""reference"": ""PMID:19481925"", ""snippet"": ""Despite this, the field has identified 43 replicated genes from association studies. The most frequently replicated are: TNF alpha, IL4, FCERB, Adam 33, and GSTP1."", ""supports"": ""SUPPORT""}], ""name"": ""ADAM33""}"
687	28	Asthma	Asthma.yaml	genetic	3	GSDMB									Associated																																																"{""association"": ""Associated"", ""name"": ""GSDMB""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This reference specifically mentions GSDMB polymorphisms and their association with asthma."", ""reference"": ""PMID:33963941"", ""snippet"": ""Our results revealed that polymorphic variants rs7216389, rs2290400 and rs2305480 are associated with the development of allergic diseases as well as with asthma and asthma combined with allergic rhinitis."", ""supports"": ""SUPPORT""}], ""name"": ""GSDMB""}"
688	28	Asthma	Asthma.yaml	genetic	4	HLA-DQ									Associated																																																"{""association"": ""Associated"", ""name"": ""HLA-DQ""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study highlights the association of HLA-DQ genes, specifically HLA-DQA1, with asthma in adults, corroborating previous findings linking HLA-DQ to asthma susceptibility."", ""reference"": ""PMID:23181788"", ""snippet"": ""Overall, our findings further replicate the HLA-DQ region in the pathogenesis of asthma."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DQ""}"
689	28	Asthma	Asthma.yaml	genetic	5	ORMDL3									Associated																																				Added another gene commonly associated with asthma for completeness.												"{""association"": ""Associated"", ""name"": ""ORMDL3"", ""review_notes"": ""Added another gene commonly associated with asthma for completeness.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The meta-analysis confirms the association between the ORMDL3 gene and asthma susceptibility."", ""reference"": ""PMID:25167772"", ""snippet"": ""The results of this meta-analysis firmly established that genetic variation at the rs7216389 locus, which controls the expression of the ORMDL3, may be a major, independent predisposing factor for asthma in ethnically diverse populations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study suggests an association signal that includes ORMDL3 but indicates uncertainty about the specific gene responsible due to a large LD block."", ""reference"": ""PMID:18754760"", ""snippet"": ""It is far from being clear which gene caused the association signal, as it is derived from a large linkage disequilibrium (LD) block."", ""supports"": ""PARTIAL""}, {""explanation"": ""This GWAS identifies ORMDL3 as part of a locus associated with asthma."", ""reference"": ""PMID:21276132"", ""snippet"": ""The first GWAS for asthma discovered a novel associated locus on chromosome 17q21 encompassing the genes ORMDL3, GSDMB and ZPBP2."", ""supports"": ""SUPPORT""}], ""name"": ""ORMDL3"", ""review_notes"": ""Added another gene commonly associated with asthma for completeness.""}"
721	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	genetic	0	KCNQ1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""KCNQ1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""KCNQ1""}"
722	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	genetic	1	KCNE2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""KCNE2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""KCNE2""}"
723	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	genetic	2	KCNJ2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""KCNJ2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""KCNJ2""}"
724	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	genetic	3	SCN5A									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""SCN5A""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SCN5A""}"
725	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	genetic	4	PITX2									Risk Factor																										Major GWAS locus																						"{""association"": ""Risk Factor"", ""name"": ""PITX2"", ""notes"": ""Major GWAS locus""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Demonstrates PITX2 plays a mechanistic role in AF pathophysiology, supporting its genetic association with AF risk."", ""reference"": ""PMID:39146015"", ""snippet"": ""Unbiased transcriptomics analysis revealed that NOX2 mediates atrial remodeling in obesity-mediated AF in DIO mice, PA-treated hiPSC-aCMs, and human atrial tissue from obese individuals by upregulation of paired-like homeodomain transcription factor 2 (PITX2)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Polygenic risk score including PITX2 and other loci significantly predicts AF risk, validating genetic contributions to AF susceptibility."", ""reference"": ""PMID:35980763"", ""snippet"": ""In patients with cardiovascular conditions, AF PRS is a strong independent predictor of incident AF that provides complementary predictive value when added to a validated clinical risk score and NT-proBNP."", ""supports"": ""SUPPORT""}], ""name"": ""PITX2"", ""notes"": ""Major GWAS locus""}"
787	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	genetic	0	HLA-DR3									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Demonstrates that specific HLA class I alleles, particularly HLA-B residues at the peptide binding groove, are strongly associated with AIH susceptibility, supporting the role of antigen presentation in disease pathogenesis."", ""reference"": ""PMID:38089552"", ""snippet"": ""Fine-mapping analysis further identified position 67 where phenylalanine of the HLA-B molecule was significantly associated with AIH (p = 3.3910-139), at the peptide binding groove."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DR3""}"
788	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	genetic	1	HLA-DR4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"
789	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	genetic	2	HLA-B*35:01									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-B*35:01""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Identifies HLA-B*35:01 as the strongest genetic risk factor for AIH type 1 in Han Chinese populations, with an odds ratio of 7.32, highlighting the critical role of MHC class I in disease susceptibility."", ""reference"": ""PMID:38089552"", ""snippet"": ""A total of 588 HLA variants were significantly associated with AIH. Stepwise conditional analysis revealed the strongest allele was in the HLA-B gene (HLA-B*35:01, p = 8.1710-304; OR = 7.32), with additional independent signals at HLA-B*08:01 (p = 1.35  10-33; OR = 4.26) and rs7765379 (p = 5.08  10-18; OR = 1.66)."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-B*35:01""}"
805	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	genetic	0	PITX2						Autosomal Dominant			Pathogenic Variants																										Paired-like homeodomain transcription factor critical for periocular mesenchyme differentiation and anterior segment development. Regulates WNT signaling through DKK2 induction and controls ECM/collagen gene expression. Associated with ARS Type 1 (RIEG1).																						"{""association"": ""Pathogenic Variants"", ""name"": ""PITX2"", ""notes"": ""Paired-like homeodomain transcription factor critical for periocular mesenchyme differentiation and anterior segment development. Regulates WNT signaling through DKK2 induction and controls ECM/collagen gene expression. Associated with ARS Type 1 (RIEG1)."", ""subtype"": ""Autosomal Dominant""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The study identifies a pathogenic variant in PITX2 associated with Axenfeld-Rieger syndrome, which is an autosomal dominant condition."", ""reference"": ""PMID:28611552"", ""snippet"": ""Axenfeld-Rieger syndrome is a rare autosomal dominant condition... A variant of uncertain significance in PITX2 was identified... it is suggested that this variant can be classified as pathogenic."", ""supports"": ""SUPPORT""}, {""explanation"": ""The review supports the association of PITX2 pathogenic variants with Axenfeld-Rieger syndrome."", ""reference"": ""PMID:37539177"", ""snippet"": ""Mutations in the transcription factors FOXC1 or PITX2 are the most well-studied genetic manifestations of this syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that PITX2 is a common pathogenic gene in Axenfeld-Rieger syndrome, which is autosomal dominant."", ""reference"": ""PMID:36442680"", ""snippet"": ""PITX2 and FOXC1 are the most common pathogenic genes associated with Axenfeld-Rieger syndrome (ARS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies PITX2 mutations as linked to Rieger syndrome, which is a part of the Axenfeld-Rieger syndrome spectrum."", ""reference"": ""PMID:9685346"", ""snippet"": ""Mutations in the Pitx2 homeobox gene have been linked to Rieger syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""PITX2"", ""notes"": ""Paired-like homeodomain transcription factor critical for periocular mesenchyme differentiation and anterior segment development. Regulates WNT signaling through DKK2 induction and controls ECM/collagen gene expression. Associated with ARS Type 1 (RIEG1)."", ""subtype"": ""Autosomal Dominant""}"
806	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	genetic	1	FOXC1						Autosomal Dominant			Pathogenic Variants																										Forkhead transcription factor with dosage-sensitive regulation of neural crest derivatives, trabecular meshwork development, and ocular/endothelial programs. Controls CD98-mTOR axis in retinal angiogenesis. Associated with ARS Type 3 (RIEG3) and earlier glaucoma onset compared to PITX2 variants.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FOXC1"", ""notes"": ""Forkhead transcription factor with dosage-sensitive regulation of neural crest derivatives, trabecular meshwork development, and ocular/endothelial programs. Controls CD98-mTOR axis in retinal angiogenesis. Associated with ARS Type 3 (RIEG3) and earlier glaucoma onset compared to PITX2 variants."", ""subtype"": ""Autosomal Dominant""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This reference explicitly states that mutations in FOXC1 cause autosomal dominant Axenfeld-Rieger syndrome."", ""reference"": ""PMID:34809627"", ""snippet"": ""Mutations in the Forkhead Box C1 (FOXC1) are known to cause autosomal dominant hereditary Axenfeld-Rieger syndrome..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the association of FOXC1 with Axenfeld-Rieger syndrome and describes the genetic nature of the condition."", ""reference"": ""PMID:37539177"", ""snippet"": ""Mutations in the transcription factors FOXC1 or PITX2 are the most well-studied genetic manifestations of this syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association of FOXC1 with Axenfeld-Rieger syndrome through genetic analysis."", ""reference"": ""PMID:22009788"", ""snippet"": ""Clinical phenotypes of and genetic aberrations in three unrelated Japanese patients with Axenfeld-Rieger anomalies... FOXC1 was apparently deleted in both patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by identifying FOXC1 mutations as a cause of Axenfeld-Rieger syndrome."", ""reference"": ""PMID:33530637"", ""snippet"": ""Mutations of one cascade constituent PITX2 and, separately, the Forkhead transcription factor FOXC1 independently cause a multi-system disorder known as Axenfeld-Rieger syndrome (ARS)."", ""supports"": ""SUPPORT""}], ""name"": ""FOXC1"", ""notes"": ""Forkhead transcription factor with dosage-sensitive regulation of neural crest derivatives, trabecular meshwork development, and ocular/endothelial programs. Controls CD98-mTOR axis in retinal angiogenesis. Associated with ARS Type 3 (RIEG3) and earlier glaucoma onset compared to PITX2 variants."", ""subtype"": ""Autosomal Dominant""}"
831	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	genetic	0	BRAF									Somatic Activating Mutations																										BRAF V600E is the most common mutation in papillary thyroid cancer, occurring in 40-60% of cases. Associated with extrathyroidal extension, lymph node metastasis, and radioiodine refractoriness. Targetable with BRAF/MEK inhibitors.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""BRAF"", ""notes"": ""BRAF V600E is the most common mutation in papillary thyroid cancer, occurring in 40-60% of cases. Associated with extrathyroidal extension, lymph node metastasis, and radioiodine refractoriness. Targetable with BRAF/MEK inhibitors.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""evidence"": [{""explanation"": ""Supports BRAF V600E as a common mutation in papillary thyroid carcinoma."", ""reference"": ""PMID:39502057"", ""snippet"": ""The common gene mutations in PTC include BRAF V600E,RET/PTC rearrangement,and RAS mutations."", ""supports"": ""SUPPORT""}], ""name"": ""BRAF"", ""notes"": ""BRAF V600E is the most common mutation in papillary thyroid cancer, occurring in 40-60% of cases. Associated with extrathyroidal extension, lymph node metastasis, and radioiodine refractoriness. Targetable with BRAF/MEK inhibitors.""}"
847	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	genetic	0	BRAF V600E									Somatic Activating Mutation																										The BRAF V600E mutation (c.1799T>A, p.V600E) accounts for more than 90% of BRAF mutations in colorectal cancer. It is mutually exclusive with RAS mutations. The mutation results in approximately 500-fold increased kinase activity compared to wild-type BRAF.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""BRAF V600E"", ""notes"": ""The BRAF V600E mutation (c.1799T>A, p.V600E) accounts for more than 90% of BRAF mutations in colorectal cancer. It is mutually exclusive with RAS mutations. The mutation results in approximately 500-fold increased kinase activity compared to wild-type BRAF.""}"	{}	"{""association"": ""Somatic Activating Mutation"", ""evidence"": [{""explanation"": ""Abstract reports BRAF V600E frequency and associated poor prognosis in colorectal cancer."", ""reference"": ""PMID:32674932"", ""snippet"": ""The BRAFV600E mutation, observed in 8% of colorectal cancers (CRC), introduces a particular phenotype and a poor prognosis at the localized or metastatic stage."", ""supports"": ""SUPPORT""}], ""name"": ""BRAF V600E"", ""notes"": ""The BRAF V600E mutation (c.1799T>A, p.V600E) accounts for more than 90% of BRAF mutations in colorectal cancer. It is mutually exclusive with RAS mutations. The mutation results in approximately 500-fold increased kinase activity compared to wild-type BRAF.""}"
848	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	genetic	1	PIK3CA									Co-occurring Somatic Mutations																										PIK3CA mutations co-occur with BRAF V600E in approximately 20% of cases, potentially conferring resistance to MAPK pathway inhibition through parallel PI3K pathway activation.																						"{""association"": ""Co-occurring Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations co-occur with BRAF V600E in approximately 20% of cases, potentially conferring resistance to MAPK pathway inhibition through parallel PI3K pathway activation.""}"	{}	"{""association"": ""Co-occurring Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations co-occur with BRAF V600E in approximately 20% of cases, potentially conferring resistance to MAPK pathway inhibition through parallel PI3K pathway activation.""}"
849	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	genetic	2	PTEN									Co-occurring Loss of Function																										PTEN loss may co-occur with BRAF V600E, activating the PI3K pathway and potentially contributing to treatment resistance.																						"{""association"": ""Co-occurring Loss of Function"", ""name"": ""PTEN"", ""notes"": ""PTEN loss may co-occur with BRAF V600E, activating the PI3K pathway and potentially contributing to treatment resistance.""}"	{}	"{""association"": ""Co-occurring Loss of Function"", ""name"": ""PTEN"", ""notes"": ""PTEN loss may co-occur with BRAF V600E, activating the PI3K pathway and potentially contributing to treatment resistance.""}"
867	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	genetic	0	BRAF									Somatic Activating Mutation																										BRAF (7q34) encodes a serine/threonine kinase in the RAS-RAF-MEK-ERK pathway. V600E is a class I mutation that signals as a monomer. Germline BRAF mutations cause cardio-facio-cutaneous syndrome. BRAF V600E is also common in melanoma, colorectal cancer, and papillary thyroid carcinoma.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""BRAF"", ""notes"": ""BRAF (7q34) encodes a serine/threonine kinase in the RAS-RAF-MEK-ERK pathway. V600E is a class I mutation that signals as a monomer. Germline BRAF mutations cause cardio-facio-cutaneous syndrome. BRAF V600E is also common in melanoma, colorectal cancer, and papillary thyroid carcinoma.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Activating Mutation"", ""evidence"": [{""explanation"": ""Abstract reports low incidence of BRAF V600E mutations in NSCLC."", ""reference"": ""PMID:34844291"", ""snippet"": ""The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%,"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""BRAF"", ""notes"": ""BRAF (7q34) encodes a serine/threonine kinase in the RAS-RAF-MEK-ERK pathway. V600E is a class I mutation that signals as a monomer. Germline BRAF mutations cause cardio-facio-cutaneous syndrome. BRAF V600E is also common in melanoma, colorectal cancer, and papillary thyroid carcinoma.""}"
884	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	genetic	0	BRAF V600E									Somatic Oncogenic Mutation																										The most common BRAF mutation (80-90% of BRAF-mutant melanomas), involving substitution of valine with glutamic acid at codon 600. Results in constitutive kinase activation and is the primary therapeutic target for BRAF inhibitors.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""BRAF V600E"", ""notes"": ""The most common BRAF mutation (80-90% of BRAF-mutant melanomas), involving substitution of valine with glutamic acid at codon 600. Results in constitutive kinase activation and is the primary therapeutic target for BRAF inhibitors.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""BRAF V600E"", ""notes"": ""The most common BRAF mutation (80-90% of BRAF-mutant melanomas), involving substitution of valine with glutamic acid at codon 600. Results in constitutive kinase activation and is the primary therapeutic target for BRAF inhibitors.""}"
885	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	genetic	1	BRAF V600K									Somatic Oncogenic Mutation																										Second most common BRAF mutation (10-20% of BRAF-mutant melanomas), substituting valine with lysine at codon 600. Also responsive to BRAF/MEK inhibitor therapy though possibly with different kinetics.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""BRAF V600K"", ""notes"": ""Second most common BRAF mutation (10-20% of BRAF-mutant melanomas), substituting valine with lysine at codon 600. Also responsive to BRAF/MEK inhibitor therapy though possibly with different kinetics.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""BRAF V600K"", ""notes"": ""Second most common BRAF mutation (10-20% of BRAF-mutant melanomas), substituting valine with lysine at codon 600. Also responsive to BRAF/MEK inhibitor therapy though possibly with different kinetics.""}"
898	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	genetic	0	BRCA2									Germline and Somatic Loss-of-Function Mutations																										BRCA2 is the most commonly mutated HRR gene in prostate cancer, occurring in approximately 5-7% of mCRPC. Both germline and somatic mutations are actionable. Associated with earlier onset and more aggressive disease.																						"{""association"": ""Germline and Somatic Loss-of-Function Mutations"", ""name"": ""BRCA2"", ""notes"": ""BRCA2 is the most commonly mutated HRR gene in prostate cancer, occurring in approximately 5-7% of mCRPC. Both germline and somatic mutations are actionable. Associated with earlier onset and more aggressive disease.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Loss-of-Function Mutations"", ""evidence"": [{""explanation"": ""Supports BRCA1/2 mutations contributing to prostate cancer development and aggressiveness."", ""reference"": ""PMID:36434163"", ""snippet"": ""Emerging data show that germline mutations in homologous recombination genes (BRCA1/2, ATM, CHECK2), in mismatch repair genes (MLH1, MLH2, MSH6), and other additional genes are associated with the development and aggressiveness of PCa."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""BRCA2"", ""notes"": ""BRCA2 is the most commonly mutated HRR gene in prostate cancer, occurring in approximately 5-7% of mCRPC. Both germline and somatic mutations are actionable. Associated with earlier onset and more aggressive disease.""}"
899	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	genetic	1	BRCA1									Germline and Somatic Loss-of-Function Mutations																										BRCA1 mutations are less common than BRCA2 in prostate cancer but also confer HRR deficiency and PARP inhibitor sensitivity.																						"{""association"": ""Germline and Somatic Loss-of-Function Mutations"", ""name"": ""BRCA1"", ""notes"": ""BRCA1 mutations are less common than BRCA2 in prostate cancer but also confer HRR deficiency and PARP inhibitor sensitivity.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""BRCA1"", ""notes"": ""BRCA1 mutations are less common than BRCA2 in prostate cancer but also confer HRR deficiency and PARP inhibitor sensitivity.""}"
969	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	genetic	0	BBS1			Most common subtype						Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""frequency"": ""Most common subtype"", ""name"": ""BBS1""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The literature confirms that BBS1 is one of the genes associated with Bardet-Biedl syndrome, but it does not specify that BBS1 is the most common subtype."", ""reference"": ""PMID:27625843"", ""snippet"": ""There are 17 BBS genes (BBS1-BBS17) described to date, which explain 70-80% of the patients clinically diagnosed, therefore more BBS genes remain to be identified."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature supports the pathogenicity of the BBS1 mutation, suggesting it as a common and consistent cause of the disease."", ""reference"": ""PMID:22940089"", ""snippet"": ""PURPOSE: To characterize the phenotype of Bardet-Biedl syndrome (BBS) patients homozygous for the BBS1 M390R mutation... Our findings confirm the consistent pathogenicity of the BBS1 M390R mutation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions BBS1 among others but does not establish it as the most common subtype."", ""reference"": ""PMID:36833331"", ""snippet"": ""Whole-exome sequencing revealed 9 pathogenic variants in six genes associated with BBS in 12 families... Three known variants were detected in the BBS1, BBS2, and BBS7 genes."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference identifies both BBS1 and other genes involved in BBS."", ""reference"": ""PMID:32361989"", ""snippet"": ""In eight families (12 individuals) we identified the same ARL6/BBS3 variation... Knowledge of this founder effect modifies our diagnostic strategy."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature supports BBS1 as a common gene associated with Bardet-Biedl syndrome, confirming frequent pathogenic variants in BBS1."", ""reference"": ""PMID:12118255"", ""snippet"": ""Here we report the identification of the gene BBS1 and show that a missense mutation of this gene is a frequent cause of BBS."", ""supports"": ""SUPPORT""}], ""frequency"": ""Most common subtype"", ""name"": ""BBS1""}"
970	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	genetic	1	BBS2			FREQUENT subtype						Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""frequency"": ""FREQUENT subtype"", ""name"": ""BBS2""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This indicates a common pathogenic variant in the BBS2 gene within a specific population, supporting the statement that BBS2 is associated with pathogenic variants."", ""reference"": ""PMID:38407766"", ""snippet"": ""Our results identified the founder variant c.471G > A in the BBS2 gene in the Baloch ethnicity of the Iranian population. This finding can guide the diagnostic approach of this syndrome in future studies."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides evidence that BBS2 is one of the BBS genes associated with pathogenic variants, supporting the claim in the statement."", ""reference"": ""PMID:12677556"", ""snippet"": ""Bardet-Biedl syndrome is a genetically and clinically heterogeneous disorder caused by mutations in at least seven loci (BBS1-7), five of which are cloned (BBS1, BBS2, BBS4, BBS6, and BBS7)."", ""supports"": ""SUPPORT""}], ""frequency"": ""FREQUENT subtype"", ""name"": ""BBS2""}"
971	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	genetic	2	Other BBS Genes									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""Other BBS Genes""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The literature supports the genetic association of BBS with pathogenic variants in multiple genes beyond BBS1. The abstract mentions 22 known genes related to BBS."", ""reference"": ""PMID:37239474"", ""snippet"": ""Bardet-Biedl syndrome (BBS) is a rare clinically and genetically heterogeneous autosomal recessive multi-systemic disorder with 22 known genes."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference also indicates that multiple BBS genes, beyond just one, are associated with the disease."", ""reference"": ""PMID:27984625"", ""snippet"": ""So far 21 candidate genes have been discovered, and mutations of such genes can all cause the BBS phenotype."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions that variants in BBS1 and BBS7 are observed, supporting the genetic heterogeneity of BBS."", ""reference"": ""PMID:37612261"", ""snippet"": ""This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document affirms that there are more than 21 BBS genes associated with Bardet-Biedl syndrome, supporting the statement."", ""reference"": ""PMID:29653013"", ""snippet"": ""To date, more than 21 BBS genes (BBS1 - 21) have been reported to independently cause the disorder."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study reveals the presence of multiple BBS genes (BBS2, BBS4, BBS7, and BBS9) in diagnosed patients, corroborating the statement."", ""reference"": ""PMID:33777945"", ""snippet"": ""A total of five known and twelve novel variants in four BBS genes (BBS2, 58.33%; BBS4, 8.33%; BBS7, 16.67%; and BBS9, 16.67%) were identified."", ""supports"": ""SUPPORT""}], ""name"": ""Other BBS Genes""}"
1003	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	genetic	0	PTCH1									Loss-of-Function Mutations																										PTCH1 encodes the Hedgehog receptor. Biallelic inactivation (loss of heterozygosity or compound heterozygous mutations) occurs in approximately 70% of sporadic BCCs. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with multiple BCCs, jaw cysts, and other developmental abnormalities.																						"{""association"": ""Loss-of-Function Mutations"", ""name"": ""PTCH1"", ""notes"": ""PTCH1 encodes the Hedgehog receptor. Biallelic inactivation (loss of heterozygosity or compound heterozygous mutations) occurs in approximately 70% of sporadic BCCs. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with multiple BCCs, jaw cysts, and other developmental abnormalities.""}"	{}	"{""association"": ""Loss-of-Function Mutations"", ""name"": ""PTCH1"", ""notes"": ""PTCH1 encodes the Hedgehog receptor. Biallelic inactivation (loss of heterozygosity or compound heterozygous mutations) occurs in approximately 70% of sporadic BCCs. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with multiple BCCs, jaw cysts, and other developmental abnormalities.""}"
1004	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	genetic	1	SMO									Activating Mutations																										Smoothened mutations occur in approximately 10% of BCCs without PTCH1 mutations. Some SMO mutations (D473H) confer primary or acquired resistance to vismodegib and sonidegib.																						"{""association"": ""Activating Mutations"", ""name"": ""SMO"", ""notes"": ""Smoothened mutations occur in approximately 10% of BCCs without PTCH1 mutations. Some SMO mutations (D473H) confer primary or acquired resistance to vismodegib and sonidegib.""}"	{}	"{""association"": ""Activating Mutations"", ""name"": ""SMO"", ""notes"": ""Smoothened mutations occur in approximately 10% of BCCs without PTCH1 mutations. Some SMO mutations (D473H) confer primary or acquired resistance to vismodegib and sonidegib.""}"
1005	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	genetic	2	TP53									Somatic Mutations																										TP53 mutations occur in approximately 40-50% of BCCs, often with UV signature. TP53 inactivation contributes to genomic instability and tumor progression but is not sufficient for BCC development without Hedgehog pathway activation.																						"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 40-50% of BCCs, often with UV signature. TP53 inactivation contributes to genomic instability and tumor progression but is not sufficient for BCC development without Hedgehog pathway activation.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 40-50% of BCCs, often with UV signature. TP53 inactivation contributes to genomic instability and tumor progression but is not sufficient for BCC development without Hedgehog pathway activation.""}"
1026	42	Behcet's Disease	Behcets_Disease.yaml	genetic	0	HLA-B51									Strong Risk Factor																										Present in 60-70% of patients from endemic regions																						"{""association"": ""Strong Risk Factor"", ""name"": ""HLA-B51"", ""notes"": ""Present in 60-70% of patients from endemic regions""}"	{}	"{""association"": ""Strong Risk Factor"", ""name"": ""HLA-B51"", ""notes"": ""Present in 60-70% of patients from endemic regions""}"
1027	42	Behcet's Disease	Behcets_Disease.yaml	genetic	1	ERAP1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ERAP1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ERAP1""}"
1028	42	Behcet's Disease	Behcets_Disease.yaml	genetic	2	IL10									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL10""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL10""}"
1051	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	genetic	0	SRD5A2									Risk Factor																										5-alpha reductase																						"{""association"": ""Risk Factor"", ""name"": ""SRD5A2"", ""notes"": ""5-alpha reductase""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SRD5A2"", ""notes"": ""5-alpha reductase""}"
1052	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	genetic	1	AR									Risk Factor																										Androgen receptor CAG repeats																						"{""association"": ""Risk Factor"", ""name"": ""AR"", ""notes"": ""Androgen receptor CAG repeats""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""AR"", ""notes"": ""Androgen receptor CAG repeats""}"
1053	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	genetic	2	ROCK1									Causal																										Rho-associated kinase 1, upregulated in BPH, drives fibrosis and EMT																						"{""association"": ""Causal"", ""name"": ""ROCK1"", ""notes"": ""Rho-associated kinase 1, upregulated in BPH, drives fibrosis and EMT""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""This evidence establishes ROCK1 as causally implicated in BPH pathogenesis through upregulation and correlation with disease severity."", ""reference"": ""PMID:39455522"", ""snippet"": ""ROCK1 and ROCK2 were significantly up-regulated in BPH tissues, correlating with clinical parameters."", ""supports"": ""SUPPORT""}], ""name"": ""ROCK1"", ""notes"": ""Rho-associated kinase 1, upregulated in BPH, drives fibrosis and EMT""}"
1054	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	genetic	3	ROCK2									Causal																										Rho-associated kinase 2, upregulated in BPH, promotes proliferation and fibrosis																						"{""association"": ""Causal"", ""name"": ""ROCK2"", ""notes"": ""Rho-associated kinase 2, upregulated in BPH, promotes proliferation and fibrosis""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""This evidence demonstrates ROCK2 as a causal factor in BPH through its role in proliferation, fibrosis, and EMT."", ""reference"": ""PMID:39455522"", ""snippet"": ""Y-27632 targeted the inhibition of ROCK1 & ROCK2 expression and inhibited cell proliferation, fibrosis, epithelial-mesenchymal transition (EMT), while induced cell apoptosis in a dose-dependent manner."", ""supports"": ""SUPPORT""}], ""name"": ""ROCK2"", ""notes"": ""Rho-associated kinase 2, upregulated in BPH, promotes proliferation and fibrosis""}"
1055	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	genetic	4	FOS									Causal																										c-Fos transcription factor, upregulated in hypoxic BE5 cells, drives EMT																						"{""association"": ""Causal"", ""name"": ""FOS"", ""notes"": ""c-Fos transcription factor, upregulated in hypoxic BE5 cells, drives EMT""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""This evidence identifies FOS upregulation as a key molecular driver of hypoxia-induced EMT in BPH nodular formation."", ""reference"": ""PMID:38654277"", ""snippet"": ""A distinguishing characteristic of the BE5 cell subgroup in patients with BPH was its heightened hypoxia and upregulated expression of FOS."", ""supports"": ""SUPPORT""}], ""name"": ""FOS"", ""notes"": ""c-Fos transcription factor, upregulated in hypoxic BE5 cells, drives EMT""}"
1082	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	genetic	0	MANBA gene mutations									Causal																										"Biallelic pathogenic variants in MANBA cause beta-mannosidosis. The c.2158-2A>G variant is a prevalent founder allele among Czech/Slovak Roma with carrier frequency of 3.77%, about 925 times higher than gnomAD frequency.
"																						"{""association"": ""Causal"", ""name"": ""MANBA gene mutations"", ""notes"": ""Biallelic pathogenic variants in MANBA cause beta-mannosidosis. The c.2158-2A>G variant is a prevalent founder allele among Czech/Slovak Roma with carrier frequency of 3.77%, about 925 times higher than gnomAD frequency.\n""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""Identifies a founder variant with high carrier frequency in Roma populations, demonstrating genetic basis of the disease."", ""reference"": ""PMID:32847582"", ""snippet"": ""carrier/heterozygote frequency of 3.77%. This is about 925 times higher than the frequency of this variant in the gnomAD public database"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""MANBA gene mutations"", ""notes"": ""Biallelic pathogenic variants in MANBA cause beta-mannosidosis. The c.2158-2A>G variant is a prevalent founder allele among Czech/Slovak Roma with carrier frequency of 3.77%, about 925 times higher than gnomAD frequency.\n""}"
1096	46	Bipolar Disorder	Bipolar_Disorder.yaml	genetic	0	CACNA1C									Risk Factor																										Calcium channel																						"{""association"": ""Risk Factor"", ""name"": ""CACNA1C"", ""notes"": ""Calcium channel""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Landmark GWAS study providing genome-wide significant evidence that CACNA1C is a susceptibility locus for bipolar disorder, implicating calcium channel dysfunction in disease pathogenesis."", ""reference"": ""PMID:18711365"", ""snippet"": ""We also found further support for the previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel; combined P = 7.0 x 10(-8), rs1006737)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Case-case GWAS analysis further confirms the critical role of calcium channel genes including CACNA1C in bipolar disorder susceptibility."", ""reference"": ""PMID:21057379"", ""snippet"": ""The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."", ""supports"": ""SUPPORT""}], ""name"": ""CACNA1C"", ""notes"": ""Calcium channel""}"
1097	46	Bipolar Disorder	Bipolar_Disorder.yaml	genetic	1	ANK3									Risk Factor																										Ankyrin-3																						"{""association"": ""Risk Factor"", ""name"": ""ANK3"", ""notes"": ""Ankyrin-3""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Genome-wide significant association of ANK3 with bipolar disorder in large-scale GWAS, establishing ankyrin G as a key susceptibility gene that may affect neuronal excitability and synaptic function."", ""reference"": ""PMID:18711365"", ""snippet"": ""To identify susceptibility loci for bipolar disorder, we tested 1.8 million variants in 4,387 cases and 6,209 controls and identified a region of strong association (rs10994336, P = 9.1 x 10(-9)) in ANK3 (ankyrin G)."", ""supports"": ""SUPPORT""}], ""name"": ""ANK3"", ""notes"": ""Ankyrin-3""}"
1098	46	Bipolar Disorder	Bipolar_Disorder.yaml	genetic	2	ODZ4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ODZ4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ODZ4""}"
1099	46	Bipolar Disorder	Bipolar_Disorder.yaml	genetic	3	NCAN									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""NCAN""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""NCAN""}"
1140	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	genetic	0	MUC5B									Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)																																																"{""association"": ""Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)"", ""name"": ""MUC5B""}"	{}	"{""association"": ""Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The case-control study reports MUC5B association with susceptibility."", ""reference"": ""PMID:38309995"", ""snippet"": ""MUC5B rs35705950 and three neighboring TOLLIP variants (rs3750920, rs111521887, and rs5743894) were associated with increased susceptibility to fHP."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""MUC5B"", ""term"": {""id"": ""hgnc:7516"", ""label"": ""MUC5B""}}, ""name"": ""MUC5B""}"
1141	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	genetic	1	TOLLIP									Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)																																																"{""association"": ""Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)"", ""name"": ""TOLLIP""}"	{}	"{""association"": ""Susceptibility risk in fibrotic hypersensitivity pneumonitis (non-causal)"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study identifies TOLLIP variants associated with fibrotic HP."", ""reference"": ""PMID:38309995"", ""snippet"": ""MUC5B rs35705950 and three neighboring TOLLIP variants (rs3750920, rs111521887, and rs5743894) were associated with increased susceptibility to fHP."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TOLLIP"", ""term"": {""id"": ""hgnc:16476"", ""label"": ""TOLLIP""}}, ""name"": ""TOLLIP""}"
1175	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	genetic	0	MED12									Somatic Mutation																																																"{""association"": ""Somatic Mutation"", ""name"": ""MED12""}"	{}	"{""association"": ""Somatic Mutation"", ""evidence"": [{""explanation"": ""The abstract reports frequent MED12 somatic mutations in fibroadenomas."", ""reference"": ""PMID:25855048"", ""snippet"": ""Somatic mutations in exon 2 of the mediator complex subunit 12 (MED12) gene have been identified in 60% of breast fibroadenomas (FAs)."", ""supports"": ""SUPPORT""}], ""name"": ""MED12""}"
1189	50	Bronchiectasis	Bronchiectasis.yaml	genetic	0	CFTR									Modifier gene																										CFTR ion channel dysfunction contributes to airway surface liquid dehydration and mucus abnormalities in non-CF bronchiectasis, though the role is debated.																						"{""association"": ""Modifier gene"", ""name"": ""CFTR"", ""notes"": ""CFTR ion channel dysfunction contributes to airway surface liquid dehydration and mucus abnormalities in non-CF bronchiectasis, though the role is debated.""}"	{}	"{""association"": ""Modifier gene"", ""name"": ""CFTR"", ""notes"": ""CFTR ion channel dysfunction contributes to airway surface liquid dehydration and mucus abnormalities in non-CF bronchiectasis, though the role is debated.""}"
1190	50	Bronchiectasis	Bronchiectasis.yaml	genetic	1	SCNN1A									Modifier gene																										ENaC (epithelial sodium channel) alpha subunit; hyperactivity causes airway surface dehydration and increased mucus viscosity, impairing mucociliary clearance.																						"{""association"": ""Modifier gene"", ""name"": ""SCNN1A"", ""notes"": ""ENaC (epithelial sodium channel) alpha subunit; hyperactivity causes airway surface dehydration and increased mucus viscosity, impairing mucociliary clearance.""}"	{}	"{""association"": ""Modifier gene"", ""name"": ""SCNN1A"", ""notes"": ""ENaC (epithelial sodium channel) alpha subunit; hyperactivity causes airway surface dehydration and increased mucus viscosity, impairing mucociliary clearance.""}"
1217	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	genetic	0	MYC									Somatic Translocation																										MYC translocation to immunoglobulin loci is the defining genetic abnormality. t(8;14)(q24;q32) involving IGH occurs in ~80% of cases. t(2;8) involving IGK and t(8;22) involving IGL occur in the remainder. MYC overexpression drives the malignant phenotype.																						"{""association"": ""Somatic Translocation"", ""name"": ""MYC"", ""notes"": ""MYC translocation to immunoglobulin loci is the defining genetic abnormality. t(8;14)(q24;q32) involving IGH occurs in ~80% of cases. t(2;8) involving IGK and t(8;22) involving IGL occur in the remainder. MYC overexpression drives the malignant phenotype.""}"	{}	"{""association"": ""Somatic Translocation"", ""name"": ""MYC"", ""notes"": ""MYC translocation to immunoglobulin loci is the defining genetic abnormality. t(8;14)(q24;q32) involving IGH occurs in ~80% of cases. t(2;8) involving IGK and t(8;22) involving IGL occur in the remainder. MYC overexpression drives the malignant phenotype.""}"
1218	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	genetic	1	TP53									Somatic Mutation																										TP53 mutations occur in approximately 30% of cases and confer worse prognosis. Loss of p53 function contributes to apoptosis resistance and genomic instability.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of cases and confer worse prognosis. Loss of p53 function contributes to apoptosis resistance and genomic instability.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of cases and confer worse prognosis. Loss of p53 function contributes to apoptosis resistance and genomic instability.""}"
1219	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	genetic	2	ID3									Somatic Mutation																										ID3 mutations occur in approximately 40-70% of cases and promote B-cell receptor signaling and cell survival.																						"{""association"": ""Somatic Mutation"", ""name"": ""ID3"", ""notes"": ""ID3 mutations occur in approximately 40-70% of cases and promote B-cell receptor signaling and cell survival.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""ID3"", ""notes"": ""ID3 mutations occur in approximately 40-70% of cases and promote B-cell receptor signaling and cell survival.""}"
1220	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	genetic	3	TCF3									Somatic Mutation																										TCF3 (E2A) mutations occur in approximately 10-25% of cases and cooperate with ID3 mutations to promote B-cell receptor signaling.																						"{""association"": ""Somatic Mutation"", ""name"": ""TCF3"", ""notes"": ""TCF3 (E2A) mutations occur in approximately 10-25% of cases and cooperate with ID3 mutations to promote B-cell receptor signaling.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TCF3"", ""notes"": ""TCF3 (E2A) mutations occur in approximately 10-25% of cases and cooperate with ID3 mutations to promote B-cell receptor signaling.""}"
1245	53	CHIME_syndrome	CHIME_syndrome.yaml	genetic	0	PIGL									Causal																										Autosomal recessive mutations in PIGL gene cause CHIME syndrome. Most cases show compound heterozygous mutations with c.500T>C (p.Leu167Pro) being frequently observed. Mutations include point mutations, insertions, deletions, and Alu-mediated intragenic deletions.																						"{""association"": ""Causal"", ""name"": ""PIGL"", ""notes"": ""Autosomal recessive mutations in PIGL gene cause CHIME syndrome. Most cases show compound heterozygous mutations with c.500T>C (p.Leu167Pro) being frequently observed. Mutations include point mutations, insertions, deletions, and Alu-mediated intragenic deletions.""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""Identifies PIGL as the causal gene for CHIME syndrome through whole-exome sequencing."", ""reference"": ""PMID:22444671"", ""snippet"": ""Whole-exome sequencing on five previously reported cases identified PIGL, the de-N-acetylase required for glycosylphosphatidylinositol (GPI) anchor formation, as a strong candidate."", ""supports"": ""SUPPORT""}, {""explanation"": ""Knight Johnson et al. 2017 documents the first Alu-mediated intragenic deletion in PIGL as a disease-causing mechanism in CHIME syndrome, expanding the mutation spectrum beyond point mutations."", ""reference"": ""PMID:28371479"", ""snippet"": ""CHIME syndrome is a rare autosomal recessive neuroectodermal disorder associated with biallelic mutations in PIGL. To date, six molecularly confirmed cases of CHIME syndrome have been reported. Here, we report the seventh patient with biallelic PIGL mutations associated with CHIME syndrome and describe the first characterization of an intragenic deletion in PIGL."", ""supports"": ""SUPPORT""}, {""explanation"": ""Ceroni et al. 2018 establishes that large deletions are a common mutational mechanism in CHIME syndrome, often missed by standard sequencing, and recommends active screening for deletions in diagnostic workup."", ""reference"": ""PMID:29473937"", ""snippet"": ""In CHIME syndrome, a recurrent missense mutation c.500T > C (p.Leu167Pro) is found in the majority of patients, associated with a null mutation in the other allele, including an overrepresentation of large deletions. The latter are not detected by the standard analysis in sequencing techniques, including next-generation sequencing. Thus, in individuals with a clinical diagnosis of CHIME syndrome in which only one mutation is found, an active search for a large deletion should be sought."", ""supports"": ""SUPPORT""}, {""explanation"": ""Rolland et al. 2022 documents a novel p.(Asp52Asn) PIGL variant and demonstrates phenotypic heterogeneity in CHIME syndrome, including mild phenotypes with atypical features, emphasizing genotype-phenotype variation."", ""reference"": ""PMID:35258128"", ""snippet"": ""A novel 'likely pathogenic' PIGL missense variant (c.154G>A, p.(Asp52Asn)) was detected on the maternal allele. This case provides new insights into the clinical spectrum of CHIME syndrome and highlights the potential for phenotypic/genotypic variations."", ""supports"": ""SUPPORT""}], ""name"": ""PIGL"", ""notes"": ""Autosomal recessive mutations in PIGL gene cause CHIME syndrome. Most cases show compound heterozygous mutations with c.500T>C (p.Leu167Pro) being frequently observed. Mutations include point mutations, insertions, deletions, and Alu-mediated intragenic deletions.""}"
1266	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	genetic	0	CTCF								Positive	Pathogenic Mutations																										"Heterozygous de novo loss-of-function mutations (frameshift, nonsense, splice site) and missense variants (predominantly in zinc finger domains) cause this disorder. CTCF encodes an 11-zinc finger transcription factor essential for chromatin organization. About 85% of variants are de novo, with rare familial cases showing variable expressivity. Recurrent variants include p.Arg339Gln, p.Arg368Cys, and p.Arg567Trp.
"																						"{""association"": ""Pathogenic Mutations"", ""name"": ""CTCF"", ""notes"": ""Heterozygous de novo loss-of-function mutations (frameshift, nonsense, splice site) and missense variants (predominantly in zinc finger domains) cause this disorder. CTCF encodes an 11-zinc finger transcription factor essential for chromatin organization. About 85% of variants are de novo, with rare familial cases showing variable expressivity. Recurrent variants include p.Arg339Gln, p.Arg368Cys, and p.Arg567Trp.\n"", ""presence"": ""Positive""}"	{}	"{""association"": ""Pathogenic Mutations"", ""evidence"": [{""explanation"": ""Comprehensive description of the mutation spectrum in the largest reported cohort."", ""reference"": ""PMID:31239556"", ""snippet"": ""The individuals in our cohort carried 2 deletions, 8 likely gene-disruptive, 2 splice-site, and 20 different missense variants, most of them de novo."", ""supports"": ""SUPPORT""}, {""explanation"": ""Original discovery of pathogenic CTCF variants."", ""reference"": ""PMID:23746550"", ""snippet"": ""we now identified two de novo frameshift mutations and one de novo missense mutation in CTCF"", ""supports"": ""SUPPORT""}], ""name"": ""CTCF"", ""notes"": ""Heterozygous de novo loss-of-function mutations (frameshift, nonsense, splice site) and missense variants (predominantly in zinc finger domains) cause this disorder. CTCF encodes an 11-zinc finger transcription factor essential for chromatin organization. About 85% of variants are de novo, with rare familial cases showing variable expressivity. Recurrent variants include p.Arg339Gln, p.Arg368Cys, and p.Arg567Trp.\n"", ""presence"": ""Positive""}"
1290	55	Camptodactyly	Camptodactyly.yaml	genetic	0	PRG4									Pathogenic Variants																										Biallelic loss-of-function mutations cause CACP syndrome with early camptodactyly and noninflammatory arthropathy.																						"{""association"": ""Pathogenic Variants"", ""name"": ""PRG4"", ""notes"": ""Biallelic loss-of-function mutations cause CACP syndrome with early camptodactyly and noninflammatory arthropathy.""}"	"{""inheritance"": [{""name"": ""Autosomal Recessive""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""Establishes PRG4 as the causative gene for CACP syndrome with autosomal recessive inheritance."", ""reference"": ""PMID:29397575"", ""snippet"": ""The camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is a rare autosomal recessive condition characterized by camptodactyly, noninflammatory arthropathy, coxa vara, and pericarditis. CACP is caused by mutations in the proteoglycan 4 (PRG4) gene"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Recessive""}], ""name"": ""PRG4"", ""notes"": ""Biallelic loss-of-function mutations cause CACP syndrome with early camptodactyly and noninflammatory arthropathy.""}"
1291	55	Camptodactyly	Camptodactyly.yaml	genetic	1	TNNT3									Pathogenic Variants																										Variants in fast skeletal troponin T cause distal arthrogryposis with camptodactyly.																						"{""association"": ""Pathogenic Variants"", ""name"": ""TNNT3"", ""notes"": ""Variants in fast skeletal troponin T cause distal arthrogryposis with camptodactyly.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""Demonstrates TNNT3 mutations causing distal arthrogryposis with camptodactyly in a large family."", ""reference"": ""PMID:25337069"", ""snippet"": ""we report a 4-generation Indian family with 18 affected members presenting variable features of camptodactyly, brachydactyly, syndactyly, decreased flexion palmar creases, ulnar deviation of the hands, sandal gaps and club feet. We undertook exome sequencing of 3 distantly related affected individuals. Bioinformatics filtering revealed a known pathogenic missense mutation c.188G>A (p.Arg63His) in TNNT3"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""TNNT3"", ""notes"": ""Variants in fast skeletal troponin T cause distal arthrogryposis with camptodactyly.""}"
1292	55	Camptodactyly	Camptodactyly.yaml	genetic	2	TNNI2									Pathogenic Variants																										Fast skeletal troponin I variants cause distal arthrogryposis phenotypes.																						"{""association"": ""Pathogenic Variants"", ""name"": ""TNNI2"", ""notes"": ""Fast skeletal troponin I variants cause distal arthrogryposis phenotypes.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""TNNI2"", ""notes"": ""Fast skeletal troponin I variants cause distal arthrogryposis phenotypes.""}"
1293	55	Camptodactyly	Camptodactyly.yaml	genetic	3	TPM2									Pathogenic Variants																										Beta-tropomyosin variants cause distal arthrogryposis with contractures.																						"{""association"": ""Pathogenic Variants"", ""name"": ""TPM2"", ""notes"": ""Beta-tropomyosin variants cause distal arthrogryposis with contractures.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""TPM2"", ""notes"": ""Beta-tropomyosin variants cause distal arthrogryposis with contractures.""}"
1294	55	Camptodactyly	Camptodactyly.yaml	genetic	4	MYH3									Pathogenic Variants																										Embryonic myosin heavy chain variants cause distal arthrogryposis type 2A.																						"{""association"": ""Pathogenic Variants"", ""name"": ""MYH3"", ""notes"": ""Embryonic myosin heavy chain variants cause distal arthrogryposis type 2A.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""Confirms MYH3 mutations cause multiple distal arthrogryposis subtypes including type 2A."", ""reference"": ""PMID:21531865"", ""snippet"": ""Identification of an MYH3 mutation in this family with distal arthrogryposis type 1 broadens the phenotype associated with MYH3 mutations to include distal arthrogryposis types 1, 2A (Freeman-Sheldon syndrome), and 2B (Sheldon-Hall syndrome)."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""MYH3"", ""notes"": ""Embryonic myosin heavy chain variants cause distal arthrogryposis type 2A.""}"
1295	55	Camptodactyly	Camptodactyly.yaml	genetic	5	ACTC1									Pathogenic Variants																										Cardiac alpha-actin missense variants can cause distal arthrogryposis with congenital heart defects.																						"{""association"": ""Pathogenic Variants"", ""name"": ""ACTC1"", ""notes"": ""Cardiac alpha-actin missense variants can cause distal arthrogryposis with congenital heart defects.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""ACTC1"", ""notes"": ""Cardiac alpha-actin missense variants can cause distal arthrogryposis with congenital heart defects.""}"
1296	55	Camptodactyly	Camptodactyly.yaml	genetic	6	FBN2									Pathogenic Variants																										Missense variants disrupting disulfide bonds cause congenital contractural arachnodactyly (Beals syndrome) with camptodactyly.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FBN2"", ""notes"": ""Missense variants disrupting disulfide bonds cause congenital contractural arachnodactyly (Beals syndrome) with camptodactyly.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""FBN2"", ""notes"": ""Missense variants disrupting disulfide bonds cause congenital contractural arachnodactyly (Beals syndrome) with camptodactyly.""}"
1297	55	Camptodactyly	Camptodactyly.yaml	genetic	7	ECEL1									Pathogenic Variants																										Compound heterozygous variants cause distal arthrogryposis type 5D with joint dysfunction.																						"{""association"": ""Pathogenic Variants"", ""name"": ""ECEL1"", ""notes"": ""Compound heterozygous variants cause distal arthrogryposis type 5D with joint dysfunction.""}"	"{""inheritance"": [{""name"": ""Autosomal Recessive""}]}"	"{""association"": ""Pathogenic Variants"", ""inheritance"": [{""name"": ""Autosomal Recessive""}], ""name"": ""ECEL1"", ""notes"": ""Compound heterozygous variants cause distal arthrogryposis type 5D with joint dysfunction.""}"
1314	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	genetic	0	BRAF Mutations									Causative																										"BRAF mutations account for ~75% of CFC cases. Unlike somatic BRAF V600E mutations in cancer, germline CFC mutations are typically kinase-impaired but still activate the pathway through RAF dimerization (Q257R, E501G).
"																						"{""association"": ""Causative"", ""name"": ""BRAF Mutations"", ""notes"": ""BRAF mutations account for ~75% of CFC cases. Unlike somatic BRAF V600E mutations in cancer, germline CFC mutations are typically kinase-impaired but still activate the pathway through RAF dimerization (Q257R, E501G).\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Establishes BRAF as the major causative gene, with mutations distinct from common somatic cancer mutations, suggesting novel activation mechanisms."", ""reference"": ""PMID:16439621"", ""snippet"": ""The majority of cases (18 out of 23) are caused by mutations in BRAF, a gene frequently mutated in cancer. Of the 11 mutations identified, two result in amino acid substitutions that occur in tumors, but most are unique and suggest previously unknown mechanisms of B-Raf activation."", ""supports"": ""SUPPORT""}], ""name"": ""BRAF Mutations"", ""notes"": ""BRAF mutations account for ~75% of CFC cases. Unlike somatic BRAF V600E mutations in cancer, germline CFC mutations are typically kinase-impaired but still activate the pathway through RAF dimerization (Q257R, E501G).\n""}"
1315	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	genetic	1	MAP2K1/MAP2K2 Mutations									Causative																										"MEK1 (MAP2K1) and MEK2 (MAP2K2) mutations account for ~25% of CFC cases. These mutations typically increase MEK kinase activity.
"																						"{""association"": ""Causative"", ""name"": ""MAP2K1/MAP2K2 Mutations"", ""notes"": ""MEK1 (MAP2K1) and MEK2 (MAP2K2) mutations account for ~25% of CFC cases. These mutations typically increase MEK kinase activity.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Original discovery that MEK1/MEK2 mutations cause CFC syndrome in patients without BRAF mutations."", ""reference"": ""PMID:16439621"", ""snippet"": ""three of five individuals without BRAF mutations had missense mutations in either MEK1 or MEK2, downstream effectors of B-Raf"", ""supports"": ""SUPPORT""}], ""name"": ""MAP2K1/MAP2K2 Mutations"", ""notes"": ""MEK1 (MAP2K1) and MEK2 (MAP2K2) mutations account for ~25% of CFC cases. These mutations typically increase MEK kinase activity.\n""}"
1316	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	genetic	2	KRAS Mutations									Causative																										"Rare KRAS mutations can cause CFC syndrome, overlapping with Noonan syndrome.
"																						"{""association"": ""Causative"", ""name"": ""KRAS Mutations"", ""notes"": ""Rare KRAS mutations can cause CFC syndrome, overlapping with Noonan syndrome.\n""}"	{}	"{""association"": ""Causative"", ""name"": ""KRAS Mutations"", ""notes"": ""Rare KRAS mutations can cause CFC syndrome, overlapping with Noonan syndrome.\n""}"
1341	57	Celiac Disease	Celiac_Disease.yaml	genetic	0	HLA-DQ2									Risk Factor																										Present in ~95% of patients																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ2"", ""notes"": ""Present in ~95% of patients""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ2"", ""notes"": ""Present in ~95% of patients""}"
1342	57	Celiac Disease	Celiac_Disease.yaml	genetic	1	HLA-DQ8									Risk Factor																										Most remaining patients																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ8"", ""notes"": ""Most remaining patients""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ8"", ""notes"": ""Most remaining patients""}"
1343	57	Celiac Disease	Celiac_Disease.yaml	genetic	2	IL2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL2""}"
1344	57	Celiac Disease	Celiac_Disease.yaml	genetic	3	IL21									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL21""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL21""}"
1364	58	Cervical Cancer	Cervical_Cancer.yaml	genetic	0	TP53									Inactivated by E6 Oncoprotein																										Rather than somatic mutation, p53 function is lost through E6-mediated degradation in HPV-positive cervical cancer. Rare HPV-negative cervical cancers may harbor TP53 mutations.																						"{""association"": ""Inactivated by E6 Oncoprotein"", ""name"": ""TP53"", ""notes"": ""Rather than somatic mutation, p53 function is lost through E6-mediated degradation in HPV-positive cervical cancer. Rare HPV-negative cervical cancers may harbor TP53 mutations.""}"	{}	"{""association"": ""Inactivated by E6 Oncoprotein"", ""name"": ""TP53"", ""notes"": ""Rather than somatic mutation, p53 function is lost through E6-mediated degradation in HPV-positive cervical cancer. Rare HPV-negative cervical cancers may harbor TP53 mutations.""}"
1365	58	Cervical Cancer	Cervical_Cancer.yaml	genetic	1	PIK3CA									Somatic Mutations																										PIK3CA mutations occur in approximately 25-35% of cervical cancers, activating PI3K/AKT/mTOR signaling. May represent a therapeutic target.																						"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 25-35% of cervical cancers, activating PI3K/AKT/mTOR signaling. May represent a therapeutic target.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 25-35% of cervical cancers, activating PI3K/AKT/mTOR signaling. May represent a therapeutic target.""}"
1492	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	genetic	0	PKD1									Causative																										Autosomal dominant polycystic kidney disease																						"{""association"": ""Causative"", ""name"": ""PKD1"", ""notes"": ""Autosomal dominant polycystic kidney disease""}"	{}	"{""association"": ""Causative"", ""name"": ""PKD1"", ""notes"": ""Autosomal dominant polycystic kidney disease""}"
1493	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	genetic	1	PKD2									Causative																										Autosomal dominant polycystic kidney disease																						"{""association"": ""Causative"", ""name"": ""PKD2"", ""notes"": ""Autosomal dominant polycystic kidney disease""}"	{}	"{""association"": ""Causative"", ""name"": ""PKD2"", ""notes"": ""Autosomal dominant polycystic kidney disease""}"
1494	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	genetic	2	APOL1									Risk Factor																										Major risk locus in African ancestry																						"{""association"": ""Risk Factor"", ""name"": ""APOL1"", ""notes"": ""Major risk locus in African ancestry""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""APOL1"", ""notes"": ""Major risk locus in African ancestry""}"
1521	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	genetic	0	TP53 Mutation/del(17p)									High-Risk Prognostic Marker																										TP53 alterations (mutation or del(17p)) occur in 5-10% at diagnosis, higher in relapsed disease. Confer resistance to chemoimmunotherapy and poor prognosis. BTK and BCL2 inhibitors remain effective.																						"{""association"": ""High-Risk Prognostic Marker"", ""name"": ""TP53 Mutation/del(17p)"", ""notes"": ""TP53 alterations (mutation or del(17p)) occur in 5-10% at diagnosis, higher in relapsed disease. Confer resistance to chemoimmunotherapy and poor prognosis. BTK and BCL2 inhibitors remain effective.""}"	{}	"{""association"": ""High-Risk Prognostic Marker"", ""name"": ""TP53 Mutation/del(17p)"", ""notes"": ""TP53 alterations (mutation or del(17p)) occur in 5-10% at diagnosis, higher in relapsed disease. Confer resistance to chemoimmunotherapy and poor prognosis. BTK and BCL2 inhibitors remain effective.""}"
1522	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	genetic	1	del(11q)/ATM									Intermediate-Risk Marker																										Deletion of 11q23 affects the ATM gene, impairing DNA damage responses. Associated with bulky lymphadenopathy and intermediate prognosis. May benefit from targeted therapies.																						"{""association"": ""Intermediate-Risk Marker"", ""name"": ""del(11q)/ATM"", ""notes"": ""Deletion of 11q23 affects the ATM gene, impairing DNA damage responses. Associated with bulky lymphadenopathy and intermediate prognosis. May benefit from targeted therapies.""}"	{}	"{""association"": ""Intermediate-Risk Marker"", ""name"": ""del(11q)/ATM"", ""notes"": ""Deletion of 11q23 affects the ATM gene, impairing DNA damage responses. Associated with bulky lymphadenopathy and intermediate prognosis. May benefit from targeted therapies.""}"
1523	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	genetic	2	del(13q)									Favorable Prognostic Marker																										Isolated del(13q14) is the most common cytogenetic abnormality in CLL and is associated with favorable prognosis when present alone. This region contains microRNA genes miR-15a and miR-16-1.																						"{""association"": ""Favorable Prognostic Marker"", ""name"": ""del(13q)"", ""notes"": ""Isolated del(13q14) is the most common cytogenetic abnormality in CLL and is associated with favorable prognosis when present alone. This region contains microRNA genes miR-15a and miR-16-1.""}"	{}	"{""association"": ""Favorable Prognostic Marker"", ""name"": ""del(13q)"", ""notes"": ""Isolated del(13q14) is the most common cytogenetic abnormality in CLL and is associated with favorable prognosis when present alone. This region contains microRNA genes miR-15a and miR-16-1.""}"
1524	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	genetic	3	IGHV									Prognostic Marker																										IGHV mutation status is one of the strongest prognostic markers in CLL. Mutated IGHV indicates post-germinal center origin with better prognosis. Unmutated IGHV indicates more aggressive disease course.																						"{""association"": ""Prognostic Marker"", ""name"": ""IGHV"", ""notes"": ""IGHV mutation status is one of the strongest prognostic markers in CLL. Mutated IGHV indicates post-germinal center origin with better prognosis. Unmutated IGHV indicates more aggressive disease course.""}"	{}	"{""association"": ""Prognostic Marker"", ""name"": ""IGHV"", ""notes"": ""IGHV mutation status is one of the strongest prognostic markers in CLL. Mutated IGHV indicates post-germinal center origin with better prognosis. Unmutated IGHV indicates more aggressive disease course.""}"
1548	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	genetic	0	BCR-ABL1									Somatic Fusion Oncogene																										The t(9;22)(q34;q11) translocation creates a fusion between BCR on chromosome 22 and ABL1 on chromosome 9. The resulting BCR-ABL1 fusion protein (p210 in CML) has constitutive tyrosine kinase activity that drives the disease.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""BCR-ABL1"", ""notes"": ""The t(9;22)(q34;q11) translocation creates a fusion between BCR on chromosome 22 and ABL1 on chromosome 9. The resulting BCR-ABL1 fusion protein (p210 in CML) has constitutive tyrosine kinase activity that drives the disease.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""evidence"": [{""explanation"": ""Establishes that BCR-ABL fusion is the causative genetic lesion in CML."", ""reference"": ""PMID:11287972"", ""snippet"": ""BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms oncogene addiction - CML cells remain dependent on BCR-ABL signaling even in advanced disease."", ""reference"": ""PMID:11423618"", ""snippet"": ""These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event."", ""supports"": ""SUPPORT""}], ""name"": ""BCR-ABL1"", ""notes"": ""The t(9;22)(q34;q11) translocation creates a fusion between BCR on chromosome 22 and ABL1 on chromosome 9. The resulting BCR-ABL1 fusion protein (p210 in CML) has constitutive tyrosine kinase activity that drives the disease.""}"
1575	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	0	SERPINA1									Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.																										Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.																						"{""association"": ""Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD."", ""name"": ""SERPINA1"", ""notes"": ""Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.""}"	{}	"{""association"": ""Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD."", ""evidence"": [{""explanation"": ""The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement."", ""reference"": ""PMID:32800189"", ""snippet"": ""Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD."", ""reference"": ""PMID:35104244"", ""snippet"": ""Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement."", ""reference"": ""PMID:36630963"", ""snippet"": ""Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD)."", ""supports"": ""SUPPORT""}], ""name"": ""SERPINA1"", ""notes"": ""Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.""}"
1576	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	1	MMP12									Matrix metalloproteinase-12 contributes to emphysema development.																										Macrophage-derived protease that degrades elastin and extracellular matrix.																						"{""association"": ""Matrix metalloproteinase-12 contributes to emphysema development."", ""name"": ""MMP12"", ""notes"": ""Macrophage-derived protease that degrades elastin and extracellular matrix.""}"	{}	"{""association"": ""Matrix metalloproteinase-12 contributes to emphysema development."", ""name"": ""MMP12"", ""notes"": ""Macrophage-derived protease that degrades elastin and extracellular matrix.""}"
1577	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	2	NLRP3									Inflammasome activation contributes to chronic inflammation.																										Activated by mitochondrial ROS and particulate exposures, leading to IL-1 and IL-18 release.																						"{""association"": ""Inflammasome activation contributes to chronic inflammation."", ""name"": ""NLRP3"", ""notes"": ""Activated by mitochondrial ROS and particulate exposures, leading to IL-1 and IL-18 release.""}"	{}	"{""association"": ""Inflammasome activation contributes to chronic inflammation."", ""name"": ""NLRP3"", ""notes"": ""Activated by mitochondrial ROS and particulate exposures, leading to IL-1 and IL-18 release.""}"
1578	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	3	TNF									Tumor necrosis factor mediates systemic and airway inflammation.																										Key pro-inflammatory cytokine in COPD pathogenesis.																						"{""association"": ""Tumor necrosis factor mediates systemic and airway inflammation."", ""name"": ""TNF"", ""notes"": ""Key pro-inflammatory cytokine in COPD pathogenesis.""}"	{}	"{""association"": ""Tumor necrosis factor mediates systemic and airway inflammation."", ""name"": ""TNF"", ""notes"": ""Key pro-inflammatory cytokine in COPD pathogenesis.""}"
1579	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	4	IL1B									Interleukin-1 beta drives inflammatory signaling.																										Product of NLRP3 inflammasome activation.																						"{""association"": ""Interleukin-1 beta drives inflammatory signaling."", ""name"": ""IL1B"", ""notes"": ""Product of NLRP3 inflammasome activation.""}"	{}	"{""association"": ""Interleukin-1 beta drives inflammatory signaling."", ""name"": ""IL1B"", ""notes"": ""Product of NLRP3 inflammasome activation.""}"
1580	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	5	IL6									Interleukin-6 contributes to systemic inflammation.																										Elevated in serum and associated with COPD comorbidities.																						"{""association"": ""Interleukin-6 contributes to systemic inflammation."", ""name"": ""IL6"", ""notes"": ""Elevated in serum and associated with COPD comorbidities.""}"	{}	"{""association"": ""Interleukin-6 contributes to systemic inflammation."", ""name"": ""IL6"", ""notes"": ""Elevated in serum and associated with COPD comorbidities.""}"
1581	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	genetic	6	NFE2L2									Nrf2 transcription factor regulates antioxidant defense.																										Reduced activity impairs response to oxidative stress in COPD.																						"{""association"": ""Nrf2 transcription factor regulates antioxidant defense."", ""name"": ""NFE2L2"", ""notes"": ""Reduced activity impairs response to oxidative stress in COPD.""}"	{}	"{""association"": ""Nrf2 transcription factor regulates antioxidant defense."", ""name"": ""NFE2L2"", ""notes"": ""Reduced activity impairs response to oxidative stress in COPD.""}"
1624	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	genetic	0	PRSS1									Causative																										Hereditary pancreatitis																						"{""association"": ""Causative"", ""name"": ""PRSS1"", ""notes"": ""Hereditary pancreatitis""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""PRSS1 variants were identified in 8.6% of chronic pancreatitis patients, confirming its role as a causative genetic factor."", ""reference"": ""PMID:37389024"", ""snippet"": ""Pathogenic and likely-pathogenic variants associated with the risk of CP development were identified in the following genes: CTRC (37.1% of patients), CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."", ""supports"": ""SUPPORT""}], ""name"": ""PRSS1"", ""notes"": ""Hereditary pancreatitis""}"
1625	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	genetic	1	SPINK1									Risk Factor																										Trypsin inhibitor																						"{""association"": ""Risk Factor"", ""name"": ""SPINK1"", ""notes"": ""Trypsin inhibitor""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""SPINK1 variants were identified in 8.6% of chronic pancreatitis patients, confirming its role as a risk factor."", ""reference"": ""PMID:37389024"", ""snippet"": ""Pathogenic and likely-pathogenic variants associated with the risk of CP development were identified in the following genes: CTRC (37.1% of patients), CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."", ""supports"": ""SUPPORT""}], ""name"": ""SPINK1"", ""notes"": ""Trypsin inhibitor""}"
1626	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	genetic	2	CFTR									Risk Factor																										Cystic fibrosis-related																						"{""association"": ""Risk Factor"", ""name"": ""CFTR"", ""notes"": ""Cystic fibrosis-related""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""CFTR variants were identified in 18.1% of chronic pancreatitis patients, confirming its role as a significant risk factor."", ""reference"": ""PMID:37389024"", ""snippet"": ""Pathogenic and likely-pathogenic variants associated with the risk of CP development were identified in the following genes: CTRC (37.1% of patients), CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."", ""supports"": ""SUPPORT""}], ""name"": ""CFTR"", ""notes"": ""Cystic fibrosis-related""}"
1627	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	genetic	3	CTRC									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CTRC""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""CTRC variants were identified in 37.1% of chronic pancreatitis patients, making it the most frequently identified genetic risk factor in this cohort."", ""reference"": ""PMID:37389024"", ""snippet"": ""Pathogenic and likely-pathogenic variants associated with the risk of CP development were identified in the following genes: CTRC (37.1% of patients), CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."", ""supports"": ""SUPPORT""}], ""name"": ""CTRC""}"
1646	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	genetic	0	VHL									Germline and Somatic Inactivating Mutations																										VHL (3p25.3) is inactivated in over 90% of ccRCC through mutation, deletion, or promoter methylation. Germline VHL mutations cause Von Hippel-Lindau disease with increased ccRCC risk. Somatic VHL loss is the initiating event in sporadic ccRCC.																						"{""association"": ""Germline and Somatic Inactivating Mutations"", ""name"": ""VHL"", ""notes"": ""VHL (3p25.3) is inactivated in over 90% of ccRCC through mutation, deletion, or promoter methylation. Germline VHL mutations cause Von Hippel-Lindau disease with increased ccRCC risk. Somatic VHL loss is the initiating event in sporadic ccRCC.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Inactivating Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""VHL"", ""notes"": ""VHL (3p25.3) is inactivated in over 90% of ccRCC through mutation, deletion, or promoter methylation. Germline VHL mutations cause Von Hippel-Lindau disease with increased ccRCC risk. Somatic VHL loss is the initiating event in sporadic ccRCC.""}"
1647	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	genetic	1	PBRM1									Somatic Inactivating Mutations																										PBRM1 (chromatin remodeling SWI/SNF complex) mutations occur in 40% of ccRCC. Associated with better prognosis compared to BAP1 mutations.																						"{""association"": ""Somatic Inactivating Mutations"", ""name"": ""PBRM1"", ""notes"": ""PBRM1 (chromatin remodeling SWI/SNF complex) mutations occur in 40% of ccRCC. Associated with better prognosis compared to BAP1 mutations.""}"	{}	"{""association"": ""Somatic Inactivating Mutations"", ""name"": ""PBRM1"", ""notes"": ""PBRM1 (chromatin remodeling SWI/SNF complex) mutations occur in 40% of ccRCC. Associated with better prognosis compared to BAP1 mutations.""}"
1648	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	genetic	2	BAP1									Somatic Inactivating Mutations																										BAP1 (deubiquitinase) mutations occur in 15% of ccRCC. Associated with higher grade tumors and worse prognosis. Mutually exclusive with PBRM1.																						"{""association"": ""Somatic Inactivating Mutations"", ""name"": ""BAP1"", ""notes"": ""BAP1 (deubiquitinase) mutations occur in 15% of ccRCC. Associated with higher grade tumors and worse prognosis. Mutually exclusive with PBRM1.""}"	{}	"{""association"": ""Somatic Inactivating Mutations"", ""name"": ""BAP1"", ""notes"": ""BAP1 (deubiquitinase) mutations occur in 15% of ccRCC. Associated with higher grade tumors and worse prognosis. Mutually exclusive with PBRM1.""}"
1668	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	genetic	0	EWSR1-ATF1 Fusion									Somatic Fusion Oncogene																										The t(12;22)(q13;q12) translocation creates the EWSR1-ATF1 fusion in approximately 90% of cases. EWSR1-CREB1 fusion from t(2;22) occurs in a minority. These fusions are diagnostic and represent the primary oncogenic driver.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWSR1-ATF1 Fusion"", ""notes"": ""The t(12;22)(q13;q12) translocation creates the EWSR1-ATF1 fusion in approximately 90% of cases. EWSR1-CREB1 fusion from t(2;22) occurs in a minority. These fusions are diagnostic and represent the primary oncogenic driver.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWSR1-ATF1 Fusion"", ""notes"": ""The t(12;22)(q13;q12) translocation creates the EWSR1-ATF1 fusion in approximately 90% of cases. EWSR1-CREB1 fusion from t(2;22) occurs in a minority. These fusions are diagnostic and represent the primary oncogenic driver.""}"
1716	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	0	HLA-DQA1									Genetic susceptibility locus																										HLA-DQ2/8 haplotypes increase risk, particularly in drug-induced cases																						"{""association"": ""Genetic susceptibility locus"", ""name"": ""HLA-DQA1"", ""notes"": ""HLA-DQ2/8 haplotypes increase risk, particularly in drug-induced cases""}"	{}	"{""association"": ""Genetic susceptibility locus"", ""evidence"": [{""explanation"": ""HLA haplotypes are recognized genetic susceptibility factors in collagenous disease pathogenesis, particularly in cases with celiac disease association"", ""reference"": ""PMID:40911031"", ""snippet"": ""Key gaps in pathogenesis, including the roles of environmental and genetic factors, are also reviewed"", ""supports"": ""SUPPORT""}, {""explanation"": ""The vast majority of collagenous sprue cases have HLA-associated celiac disease, demonstrating the strong genetic link between these conditions"", ""reference"": ""PMID:19855376"", ""snippet"": ""Seventeen (89%) had celiac disease and two had unclassified sprue; 9 of 17 (53%) celiac disease patients had refractory disease"", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DQA1"", ""notes"": ""HLA-DQ2/8 haplotypes increase risk, particularly in drug-induced cases""}"
1717	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	1	TGFB1									Dysregulated signaling pathway																										TGF- pathway dysregulation drives fibroblast activation and collagen deposition																						"{""association"": ""Dysregulated signaling pathway"", ""name"": ""TGFB1"", ""notes"": ""TGF- pathway dysregulation drives fibroblast activation and collagen deposition""}"	{}	"{""association"": ""Dysregulated signaling pathway"", ""evidence"": [{""explanation"": ""TGF- signaling dysregulation drives extracellular matrix alterations and collagen accumulation characteristic of collagenous sprue pathogenesis"", ""reference"": ""DOI:10.1093/ecco-jcc/jjab123"", ""snippet"": ""extracellular matrix alterations, all contributing by varied mechanisms to watery diarrhoea"", ""supports"": ""SUPPORT""}], ""name"": ""TGFB1"", ""notes"": ""TGF- pathway dysregulation drives fibroblast activation and collagen deposition""}"
1718	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	2	MMP1									Reduced activity																										Impaired matrix metalloproteinase-1 contributes to collagen accumulation																						"{""association"": ""Reduced activity"", ""name"": ""MMP1"", ""notes"": ""Impaired matrix metalloproteinase-1 contributes to collagen accumulation""}"	{}	"{""association"": ""Reduced activity"", ""evidence"": [{""explanation"": ""Reduced MMP1 activity impairs collagen remodeling, leading to pathologic subepithelial collagen band thickening in collagenous sprue"", ""reference"": ""PMID:35945664"", ""snippet"": ""Glandular atrophy, intra-epithelial lymphocytosis and/or subepithelial collagen thickening were also present in some cases"", ""supports"": ""SUPPORT""}], ""name"": ""MMP1"", ""notes"": ""Impaired matrix metalloproteinase-1 contributes to collagen accumulation""}"
1719	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	3	MMP9									Reduced activity																										Decreased gelatinase activity impairs collagen remodeling																						"{""association"": ""Reduced activity"", ""name"": ""MMP9"", ""notes"": ""Decreased gelatinase activity impairs collagen remodeling""}"	{}	"{""association"": ""Reduced activity"", ""evidence"": [{""explanation"": ""Impaired MMP9 gelatinase activity contributes to pathologic collagen accumulation and villous atrophy in duodenal collagenous sprue"", ""reference"": ""PMID:35945664"", ""snippet"": ""Duodenal involvement, including villous atrophy, intra-epithelial lymphocytosis and/or collagenous sprue, was identified in 11 of 13 cases with concurrent duodenal biopsies"", ""supports"": ""SUPPORT""}], ""name"": ""MMP9"", ""notes"": ""Decreased gelatinase activity impairs collagen remodeling""}"
1720	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	4	TIMP1									Upregulated expression																										Tissue inhibitor of metalloproteinases-1 is elevated, inhibiting collagen degradation																						"{""association"": ""Upregulated expression"", ""name"": ""TIMP1"", ""notes"": ""Tissue inhibitor of metalloproteinases-1 is elevated, inhibiting collagen degradation""}"	{}	"{""association"": ""Upregulated expression"", ""evidence"": [{""explanation"": ""TIMP1 elevation inhibits collagen degradation, resulting in excessive collagen band thickening that exceeds normal gastrointestinal limits in collagenous sprue"", ""reference"": ""PMID:40911031"", ""snippet"": ""Collagen band thickness ranged widely, with a median of 50.5 m and a maximum of 225 m"", ""supports"": ""SUPPORT""}], ""name"": ""TIMP1"", ""notes"": ""Tissue inhibitor of metalloproteinases-1 is elevated, inhibiting collagen degradation""}"
1721	72	Collagenous Sprue	Collagenous_Sprue.yaml	genetic	5	TJP1									Disrupted expression																										Tight junction protein ZO-1 (encoded by TJP1) is reduced, compromising epithelial barrier																						"{""association"": ""Disrupted expression"", ""name"": ""TJP1"", ""notes"": ""Tight junction protein ZO-1 (encoded by TJP1) is reduced, compromising epithelial barrier""}"	{}	"{""association"": ""Disrupted expression"", ""evidence"": [{""explanation"": ""TJP1 disruption and epithelial barrier dysfunction are hallmarks of collagenous disease, manifesting as surface epithelial injury and loss of tight junction integrity"", ""reference"": ""PMID:35945664"", ""snippet"": ""Gastric biopsies commonly showed a full-thickness active chronic gastritis with surface epithelial injury involving the antrum and body"", ""supports"": ""SUPPORT""}], ""name"": ""TJP1"", ""notes"": ""Tight junction protein ZO-1 (encoded by TJP1) is reduced, compromising epithelial barrier""}"
1747	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	genetic	0	RUNX1-RUNX1T1 Fusion									Somatic Oncogenic Fusion																										The t(8;21)(q22;q22) translocation creates a fusion between RUNX1 (AML1) on chromosome 21 and RUNX1T1 (ETO) on chromosome 8. The fusion protein recruits corepressors, converting CBF to a transcriptional repressor. Defines favorable-risk AML.																						"{""association"": ""Somatic Oncogenic Fusion"", ""name"": ""RUNX1-RUNX1T1 Fusion"", ""notes"": ""The t(8;21)(q22;q22) translocation creates a fusion between RUNX1 (AML1) on chromosome 21 and RUNX1T1 (ETO) on chromosome 8. The fusion protein recruits corepressors, converting CBF to a transcriptional repressor. Defines favorable-risk AML.""}"	{}	"{""association"": ""Somatic Oncogenic Fusion"", ""evidence"": [{""explanation"": ""Abstract states RUNX1/RUNX1T1 is involved in the t(8;21) rearrangement defining CBF-AML."", ""reference"": ""PMID:22032582"", ""snippet"": ""The rearrangements t(8;21) and inv(16) involve the RUNX1/RUNX1T1 ( AML1-ETO ) and CBFB/MYH11 genes, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""RUNX1-RUNX1T1 Fusion"", ""notes"": ""The t(8;21)(q22;q22) translocation creates a fusion between RUNX1 (AML1) on chromosome 21 and RUNX1T1 (ETO) on chromosome 8. The fusion protein recruits corepressors, converting CBF to a transcriptional repressor. Defines favorable-risk AML.""}"
1748	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	genetic	1	CBFB-MYH11 Fusion									Somatic Oncogenic Fusion																										inv(16)(p13.1q22) or t(16;16)(p13.1;q22) fuses CBFB with MYH11. The fusion protein sequesters RUNX1 in the cytoplasm and disrupts normal CBF function. Associated with abnormal eosinophils. Defines favorable-risk AML.																						"{""association"": ""Somatic Oncogenic Fusion"", ""name"": ""CBFB-MYH11 Fusion"", ""notes"": ""inv(16)(p13.1q22) or t(16;16)(p13.1;q22) fuses CBFB with MYH11. The fusion protein sequesters RUNX1 in the cytoplasm and disrupts normal CBF function. Associated with abnormal eosinophils. Defines favorable-risk AML.""}"	{}	"{""association"": ""Somatic Oncogenic Fusion"", ""evidence"": [{""explanation"": ""Abstract states CBFB/MYH11 is involved in the inv(16) rearrangement defining CBF-AML."", ""reference"": ""PMID:22032582"", ""snippet"": ""The rearrangements t(8;21) and inv(16) involve the RUNX1/RUNX1T1 ( AML1-ETO ) and CBFB/MYH11 genes, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""CBFB-MYH11 Fusion"", ""notes"": ""inv(16)(p13.1q22) or t(16;16)(p13.1;q22) fuses CBFB with MYH11. The fusion protein sequesters RUNX1 in the cytoplasm and disrupts normal CBF function. Associated with abnormal eosinophils. Defines favorable-risk AML.""}"
1749	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	genetic	2	KIT									Cooperating Mutation																										KIT mutations occur in 20-30% of CBF-AML cases, particularly in exon 17. May confer adverse prognosis within CBF-AML and represents a potential therapeutic target.																						"{""association"": ""Cooperating Mutation"", ""name"": ""KIT"", ""notes"": ""KIT mutations occur in 20-30% of CBF-AML cases, particularly in exon 17. May confer adverse prognosis within CBF-AML and represents a potential therapeutic target.""}"	{}	"{""association"": ""Cooperating Mutation"", ""name"": ""KIT"", ""notes"": ""KIT mutations occur in 20-30% of CBF-AML cases, particularly in exon 17. May confer adverse prognosis within CBF-AML and represents a potential therapeutic target.""}"
1775	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	genetic	0	APOE									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""APOE""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""GWAS studies have identified APOE as a significant cardiovascular disease risk gene contributing to coronary artery disease susceptibility."", ""reference"": ""PMID:40594772"", ""snippet"": ""GWAS-significant cardiovascular disease (CVD) risk genes were used to calculate risk gene scores for main cell populations."", ""supports"": ""SUPPORT""}], ""name"": ""APOE""}"
1776	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	genetic	1	LDLR									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""LDLR""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""LDLR is a well-established cardiovascular disease risk gene identified through genome-wide association studies."", ""reference"": ""PMID:40594772"", ""snippet"": ""GWAS-significant cardiovascular disease (CVD) risk genes were used to calculate risk gene scores for main cell populations."", ""supports"": ""SUPPORT""}], ""name"": ""LDLR""}"
1777	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	genetic	2	PCSK9									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""PCSK9""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PCSK9""}"
1778	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	genetic	3	9p21 Locus									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""9p21 Locus""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""9p21 Locus""}"
1791	76	Costello Syndrome	Costello_Syndrome.yaml	genetic	0	HRAS Mutations									Causative																										"Heterozygous germline mutations in HRAS cause Costello syndrome. The most common mutation is p.Gly12Ser (~80% of cases), followed by p.Gly12Ala and p.Gly13Cys. These mutations affect the GTPase activity of HRAS, keeping it in the active GTP-bound state. Somatic mosaicism can cause milder phenotypes.
"																						"{""association"": ""Causative"", ""name"": ""HRAS Mutations"", ""notes"": ""Heterozygous germline mutations in HRAS cause Costello syndrome. The most common mutation is p.Gly12Ser (~80% of cases), followed by p.Gly12Ala and p.Gly13Cys. These mutations affect the GTPase activity of HRAS, keeping it in the active GTP-bound state. Somatic mosaicism can cause milder phenotypes.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large genotype-phenotype study of 43 Costello syndrome cases confirming HRAS as the causative gene."", ""reference"": ""PMID:16443854"", ""snippet"": ""These results confirm that CS is caused, in most cases, by heterozygous missense mutations in the proto-oncogene HRAS."", ""supports"": ""SUPPORT""}], ""name"": ""HRAS Mutations"", ""notes"": ""Heterozygous germline mutations in HRAS cause Costello syndrome. The most common mutation is p.Gly12Ser (~80% of cases), followed by p.Gly12Ala and p.Gly13Cys. These mutations affect the GTPase activity of HRAS, keeping it in the active GTP-bound state. Somatic mosaicism can cause milder phenotypes.\n""}"
1816	77	Crohn Disease	Crohn_Disease.yaml	genetic	0	NOD2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""NOD2""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This reference states that NOD2 mutations are involved in Crohn's disease, supporting the association as a risk factor."", ""reference"": ""PMID:29358789"", ""snippet"": ""BACKGROUND AND OBJECTIVES: Crohn's disease is a multifactorial inflammatory disease affecting mainly the gastrointestinal tract. The genetic factors that are involved in the disease include mainly three mutations of the gene NOD2/CARD15 (R702W, G908R, 3020insC)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the association of NOD2 gene mutations with Crohn's disease."", ""reference"": ""PMID:23352252"", ""snippet"": ""NOD2 gene mutations are associated with several diseases, and some of the mutations are of diagnostic value in Blau disease and NAID... The NOD2 variants located in the leucine-rich repeat (LRR) region are susceptible to Crohn disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference clearly establishes the association of specific NOD2 mutations with susceptibility to Crohn's disease."", ""reference"": ""PMID:16773683"", ""snippet"": ""Investigations into the inheritance of the three risk alleles R702W, G908R and 1007fsInsC in NOD2 associated with susceptibility to Crohn's disease have demonstrated a remarkable amount of heterogeneity across ethnicities and populations."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study supports the role of NOD2 as a genetic risk factor for Crohn's disease."", ""reference"": ""PMID:12851870"", ""snippet"": ""The NOD2 gene, which is strongly associated with susceptibility to Crohn's disease (CD) of the terminal ileum, interacts with bacterial lipopolysaccharide (LPS), inducing cellular activation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that NOD2 is a well-established genetic risk factor for Crohn's disease."", ""reference"": ""PMID:32476786"", ""snippet"": ""While NOD2 mutations represent well established risk factors of CD, the role of other genes is incompletely understood."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study provides evidence of a specific NOD2 mutation associated with Crohn's disease."", ""reference"": ""PMID:11385577"", ""snippet"": ""Here we show, by using the transmission disequilibium test and case-control analysis, that a frameshift mutation caused by a cytosine insertion, 3020insC, which is expected to encode a truncated NOD2 protein, is associated with Crohn's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement supports the association of NOD2 with Crohn's disease (CD)."", ""reference"": ""PMID:17206682"", ""snippet"": ""The association of NOD2/CARD15 mutations with CD and BS, and possibly also early onset sarcoidosis, suggests a role for the gene in the development of granulomata and granulomatous diseases."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference emphasizes that the NOD2 association with Crohn's disease is well-established."", ""reference"": ""PMID:16987083"", ""snippet"": ""The mapping to CD of Nod2 variants that alter protein function represents one of the earliest, most well-established, associations in complex genetic disorders."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study confirms the role of genetic risk scores including multiple SNP variants for predicting Crohn's disease."", ""reference"": ""PMID:27076762"", ""snippet"": ""The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""NOD2""}"
1817	77	Crohn Disease	Crohn_Disease.yaml	genetic	1	ATG16L1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ATG16L1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""reference"": ""PMID:27698206"", ""snippet"": ""Conclusion In this meta-analysis, the ATG16L1 genotype was significantly associated with the risk of developing Crohn''s disease."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:25906181"", ""snippet"": ""single-nucleotide polymorphisms in ATG16L1 ... a key component in the autophagic response to invading pathogens, have been associated with an increased risk of developing Crohn disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference focuses on the association between CARD15 mutations and Crohns Disease, with no information regarding ATG16L1."", ""reference"": ""PMID:12840668"", ""snippet"": ""CARD15 mutations are present in 30-50% of CD patients compared to 7-20% of healthy controls. Interestingly, CD patients often carry mutations on their two chromosomes suggesting a mutation dose effect."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference highlights genetic risk factors in NOD2 and LRRK2 for Crohn's Disease, not ATG16L1."", ""reference"": ""PMID:29795570"", ""snippet"": ""ten rare genetic risk factors in NOD2 and LRRK2 are enriched in AJ (p < 0.005), including several novel contributing alleles, show evidence of association to CD."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The study involves identification of SNPs for risk prediction, however ATG16L1 is not mentioned explicitly. Thus, it only partially supports the statement."", ""reference"": ""PMID:27076762"", ""snippet"": ""We generated genetic risk scores (GRS) based on the number of risk alleles using weighted additive model. Discriminatory accuracy was measured by area under ROC curve (AUC)....The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively."", ""supports"": ""PARTIAL""}], ""name"": ""ATG16L1""}"
1818	77	Crohn Disease	Crohn_Disease.yaml	genetic	2	IL23R									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL23R""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This study identifies IL23R as a gene significantly associated with Crohn's disease, supporting the statement that IL23R is a genetic risk factor for the condition."", ""reference"": ""PMID:17068223"", ""snippet"": ""We found a highly significant association between Crohn's disease and the IL23R gene on chromosome 1p31, which encodes a subunit of the receptor for the proinflammatory cytokine interleukin-23."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study supports the association between IL23R and Crohn's disease, while also highlighting the interaction between IL23R variants and environmental factors like smoking."", ""reference"": ""PMID:24989722"", ""snippet"": ""We demonstrate a strong increased CD risk for smokers in both datasets (odds ratio 3.77, 95% confidence interval 2.88-4.94), and an additive interaction between IL23R SNPs and cigarette smoking."", ""supports"": ""SUPPORT""}], ""name"": ""IL23R""}"
1819	77	Crohn Disease	Crohn_Disease.yaml	genetic	3	LRRK2									Risk Factor																										Hyperactive LRRK2 variants (e.g., G2019S, N2081D) impair autophagy and drive Paneth-cell dysfunction, leading to intestinal inflammation.																						"{""association"": ""Risk Factor"", ""name"": ""LRRK2"", ""notes"": ""Hyperactive LRRK2 variants (e.g., G2019S, N2081D) impair autophagy and drive Paneth-cell dysfunction, leading to intestinal inflammation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""LRRK2"", ""notes"": ""Hyperactive LRRK2 variants (e.g., G2019S, N2081D) impair autophagy and drive Paneth-cell dysfunction, leading to intestinal inflammation.""}"
1820	77	Crohn Disease	Crohn_Disease.yaml	genetic	4	TNFSF15									Risk Factor																										Encodes TL1A, a TNF superfamily cytokine involved in T-cell costimulation and fibroblast activation in fistulizing disease.																						"{""association"": ""Risk Factor"", ""name"": ""TNFSF15"", ""notes"": ""Encodes TL1A, a TNF superfamily cytokine involved in T-cell costimulation and fibroblast activation in fistulizing disease.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TNFSF15"", ""notes"": ""Encodes TL1A, a TNF superfamily cytokine involved in T-cell costimulation and fibroblast activation in fistulizing disease.""}"
1821	77	Crohn Disease	Crohn_Disease.yaml	genetic	5	CARD9									Risk Factor																										Involved in antifungal immunity; variants associated with fungal dysbiosis and impaired pathogen clearance.																						"{""association"": ""Risk Factor"", ""name"": ""CARD9"", ""notes"": ""Involved in antifungal immunity; variants associated with fungal dysbiosis and impaired pathogen clearance.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CARD9"", ""notes"": ""Involved in antifungal immunity; variants associated with fungal dysbiosis and impaired pathogen clearance.""}"
1882	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	genetic	0	FGFR2 Mutations									Causative																										"Over 40 different FGFR2 mutations have been identified. Common mutations include C342Y, C342R, and C342S in the Ig-III domain. Unlike Apert syndrome, mutations are distributed across multiple exons (exons 7, 8, 9, 10). Some mutations are shared with other FGFR2-related syndromes.
"																						"{""association"": ""Causative"", ""name"": ""FGFR2 Mutations"", ""notes"": ""Over 40 different FGFR2 mutations have been identified. Common mutations include C342Y, C342R, and C342S in the Ig-III domain. Unlike Apert syndrome, mutations are distributed across multiple exons (exons 7, 8, 9, 10). Some mutations are shared with other FGFR2-related syndromes.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Demonstrates allelic heterogeneity with multiple different FGFR2 mutations causing Crouzon syndrome, including mutations in exon IIIa and IIIc."", ""reference"": ""PMID:8528214"", ""snippet"": ""Five different mutations were found including two novel (W290G, C342W) and two previously reported, recurrent mutations for Crouzon syndrome (A344A, S354C), and one new mutation for Jackson-Weiss syndrome (C342R)"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms that Crouzon syndrome FGFR2 mutations occur in the extracellular domain, similar to other craniosynostosis syndromes but distinguishing it from those with limb involvement."", ""reference"": ""PMID:7493034"", ""snippet"": ""All mutations described so far for other craniosynostotic syndromes with associated limb anomalies--Jackson-Weiss, Pfeiffer, and Apert--also occur in the extracellular domain of FGFR2"", ""supports"": ""SUPPORT""}], ""name"": ""FGFR2 Mutations"", ""notes"": ""Over 40 different FGFR2 mutations have been identified. Common mutations include C342Y, C342R, and C342S in the Ig-III domain. Unlike Apert syndrome, mutations are distributed across multiple exons (exons 7, 8, 9, 10). Some mutations are shared with other FGFR2-related syndromes.\n""}"
1893	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	genetic	0	FGFR3 A391E Mutation									Causative																										"A single recurrent mutation, c.1172C>A (p.Ala391Glu), in FGFR3 causes this syndrome. The mutation is in the transmembrane domain and causes ligand-independent receptor activation through constitutive dimerization.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 A391E Mutation"", ""notes"": ""A single recurrent mutation, c.1172C>A (p.Ala391Glu), in FGFR3 causes this syndrome. The mutation is in the transmembrane domain and causes ligand-independent receptor activation through constitutive dimerization.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This is the landmark paper identifying the A391E mutation in FGFR3 as the cause of Crouzon syndrome with acanthosis nigricans, demonstrating the genetic basis of this distinct disorder.\n"", ""reference"": ""PMID:7493034"", ""snippet"": ""We now report the unexpected observation of a FGFR3 transmembrane domain mutation, Ala391Glu, in three unrelated families with Crouzon syndrome and acanthosis nigricans, a specific skin disorder of hyperkeratosis and hyperpigmentation."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review confirms FGFR3 mutations cause CSAN and places it in the context of other FGFR3-related disorders.\n"", ""reference"": ""PMID:10696568"", ""snippet"": ""Mutations in the FGFR3 gene also result in hypochondroplasia, the lethal thanatophoric dysplasias, the recently described SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans) dysplasia, and two craniosynostosis disorders: Muenke coronal craniosynostosis and Crouzon syndrome with acanthosis nigricans."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR3 A391E Mutation"", ""notes"": ""A single recurrent mutation, c.1172C>A (p.Ala391Glu), in FGFR3 causes this syndrome. The mutation is in the transmembrane domain and causes ligand-independent receptor activation through constitutive dimerization.\n""}"
1930	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	genetic	0	CFTR									Causative																										Autosomal recessive, over 2000 mutations described, F508del most common																						"{""association"": ""Causative"", ""name"": ""CFTR"", ""notes"": ""Autosomal recessive, over 2000 mutations described, F508del most common""}"	{}	"{""association"": ""Causative"", ""name"": ""CFTR"", ""notes"": ""Autosomal recessive, over 2000 mutations described, F508del most common""}"
1951	84	Danon disease	Danon_disease.yaml	genetic	0	LAMP2 mutations									Causative																										"Danon disease is caused by loss-of-function mutations in the LAMP2 gene located on chromosome Xq24. The LAMP-2B isoform is particularly important for cardiac and skeletal muscle function. Various mutation types have been described, including point mutations and complete gene deletions.
"																						"{""association"": ""Causative"", ""name"": ""LAMP2 mutations"", ""notes"": ""Danon disease is caused by loss-of-function mutations in the LAMP2 gene located on chromosome Xq24. The LAMP-2B isoform is particularly important for cardiac and skeletal muscle function. Various mutation types have been described, including point mutations and complete gene deletions.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms LAMP-2 deficiency as the cause of Danon disease."", ""reference"": ""DOI:10.3390/biom14101272"", ""snippet"": ""Danon disease, an X-linked dominant vacuolar cardiomyopathy and skeletal myopathy, is caused by a primary deficiency of lysosome-associated membrane protein-2 (LAMP-2)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents complete LAMP2 gene deletion causing Danon disease."", ""reference"": ""DOI:10.3390/genes14081539"", ""snippet"": ""Genetic testing revealed an Xq24 microdeletion encompassing the entire LAMP2 gene."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""LAMP2"", ""term"": {""id"": ""hgnc:6501"", ""label"": ""LAMP2""}}, ""name"": ""LAMP2 mutations"", ""notes"": ""Danon disease is caused by loss-of-function mutations in the LAMP2 gene located on chromosome Xq24. The LAMP-2B isoform is particularly important for cardiac and skeletal muscle function. Various mutation types have been described, including point mutations and complete gene deletions.\n""}"
1952	84	Danon disease	Danon_disease.yaml	genetic	1	Sex-specific phenotypic differences									Modifying																										"Male patients present with the classic severe triad of cardiomyopathy, myopathy, and intellectual disability with early onset and rapid progression towards heart failure. Female carriers typically present with milder and variable symptoms, predominantly involving cardiac muscle, often with later onset due to mosaic LAMP-2 expression from X-chromosome inactivation.
"																						"{""association"": ""Modifying"", ""name"": ""Sex-specific phenotypic differences"", ""notes"": ""Male patients present with the classic severe triad of cardiomyopathy, myopathy, and intellectual disability with early onset and rapid progression towards heart failure. Female carriers typically present with milder and variable symptoms, predominantly involving cardiac muscle, often with later onset due to mosaic LAMP-2 expression from X-chromosome inactivation.\n""}"	{}	"{""association"": ""Modifying"", ""evidence"": [{""explanation"": ""Documents distinct phenotypic presentations between males and females."", ""reference"": ""DOI:10.1111/nan.12587"", ""snippet"": ""Danon disease is a severe multisystem disorder clinically characterized by hypertrophic cardiomyopathy, skeletal myopathy and mental retardation in male patients, and by a milder phenotype (predominantly involving cardiac muscle) in female patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms sex-specific differences in disease severity and progression."", ""reference"": ""DOI:10.3390/genes14081539"", ""snippet"": ""Danon disease is typically lethal by the mid-twenties in male patients due to cardiomyopathy and heart failure. Female patients usually present with milder and variable symptoms."", ""supports"": ""SUPPORT""}], ""name"": ""Sex-specific phenotypic differences"", ""notes"": ""Male patients present with the classic severe triad of cardiomyopathy, myopathy, and intellectual disability with early onset and rapid progression towards heart failure. Female carriers typically present with milder and variable symptoms, predominantly involving cardiac muscle, often with later onset due to mosaic LAMP-2 expression from X-chromosome inactivation.\n""}"
1966	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	genetic	0	APOE									APOE 4 allele is a major genetic risk factor for DLB																										The APOE 4 allele increases risk for DLB and is associated with more pronounced cortical Lewy pathology and higher prevalence of concomitant Alzheimer pathology. APOE represents a shared genetic risk factor between DLB and Alzheimer's disease.																						"{""association"": ""APOE 4 allele is a major genetic risk factor for DLB"", ""name"": ""APOE"", ""notes"": ""The APOE 4 allele increases risk for DLB and is associated with more pronounced cortical Lewy pathology and higher prevalence of concomitant Alzheimer pathology. APOE represents a shared genetic risk factor between DLB and Alzheimer's disease.""}"	{}	"{""association"": ""APOE 4 allele is a major genetic risk factor for DLB"", ""evidence"": [{""explanation"": ""This confirms that the APOE 4 allele is a shared genetic risk locus between DLB and Alzheimer's disease."", ""reference"": ""PMID:30097731"", ""snippet"": ""DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."", ""supports"": ""SUPPORT""}, {""explanation"": ""This demonstrates that APOE 4 is associated with more pronounced Lewy pathology in DLB."", ""reference"": ""PMID:29222591"", ""snippet"": ""Intravitam PET and post-mortem studies revealed more pronounced cortical atrophy, elevated cortical and limbic Lewy pathologies (with APOE 4)."", ""supports"": ""SUPPORT""}], ""name"": ""APOE"", ""notes"": ""The APOE 4 allele increases risk for DLB and is associated with more pronounced cortical Lewy pathology and higher prevalence of concomitant Alzheimer pathology. APOE represents a shared genetic risk factor between DLB and Alzheimer's disease.""}"
1967	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	genetic	1	GBA									GBA gene variants significantly increase risk for DLB																										Variants in the glucocerebrosidase (GBA) gene are important genetic risk factors for DLB. GBA mutation carriers have earlier age of onset, more severe cognitive impairment, and more rapid symptom progression. Specific variants including N370S, E326K, and L444P are strongly associated with DLB.																						"{""association"": ""GBA gene variants significantly increase risk for DLB"", ""name"": ""GBA"", ""notes"": ""Variants in the glucocerebrosidase (GBA) gene are important genetic risk factors for DLB. GBA mutation carriers have earlier age of onset, more severe cognitive impairment, and more rapid symptom progression. Specific variants including N370S, E326K, and L444P are strongly associated with DLB.""}"	{}	"{""association"": ""GBA gene variants significantly increase risk for DLB"", ""evidence"": [{""explanation"": ""This meta-analysis confirms that specific GBA variants are strongly associated with DLB and correlate with earlier onset and more severe clinical presentation."", ""reference"": ""PMID:35332438"", ""snippet"": ""GBA variants increased the risk of DLB, especially N370S, E326K, and L444P which are strongly associated with DLB, but T369M was not. Patients harbouring GBA variants have an earlier age of onset, more severe cognitive impairment, and rapid symptom progression."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review confirms that GBA variants are important genetic risk factors for dementia with Lewy bodies."", ""reference"": ""PMID:28734699"", ""snippet"": ""More recently, association and exome sequencing studies in larger groups have been conducted, and have shown that several variants in GBA and the APOE 4 allele are important genetic risk factors for DLB."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that GBA represents a shared genetic risk locus between DLB and Parkinson's disease."", ""reference"": ""PMID:30097731"", ""snippet"": ""DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."", ""supports"": ""SUPPORT""}], ""name"": ""GBA"", ""notes"": ""Variants in the glucocerebrosidase (GBA) gene are important genetic risk factors for DLB. GBA mutation carriers have earlier age of onset, more severe cognitive impairment, and more rapid symptom progression. Specific variants including N370S, E326K, and L444P are strongly associated with DLB.""}"
1968	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	genetic	2	SNCA									SNCA gene variants associated with DLB risk																										The SNCA gene encoding alpha-synuclein shows genetic association with DLB, representing a shared genetic risk factor with Parkinson's disease. Variation at SNCA influences risk for developing Lewy body pathology.																						"{""association"": ""SNCA gene variants associated with DLB risk"", ""name"": ""SNCA"", ""notes"": ""The SNCA gene encoding alpha-synuclein shows genetic association with DLB, representing a shared genetic risk factor with Parkinson's disease. Variation at SNCA influences risk for developing Lewy body pathology.""}"	{}	"{""association"": ""SNCA gene variants associated with DLB risk"", ""evidence"": [{""explanation"": ""This confirms that SNCA represents a shared genetic risk locus between DLB and Parkinson's disease."", ""reference"": ""PMID:30097731"", ""snippet"": ""DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."", ""supports"": ""SUPPORT""}], ""name"": ""SNCA"", ""notes"": ""The SNCA gene encoding alpha-synuclein shows genetic association with DLB, representing a shared genetic risk factor with Parkinson's disease. Variation at SNCA influences risk for developing Lewy body pathology.""}"
1985	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	genetic	0	COL1A1-PDGFB Fusion									Somatic Fusion Oncogene																										The t(17;22)(q22;q13) translocation or ring chromosomes create the COL1A1-PDGFB fusion in >90% of cases. This fusion is both diagnostic and represents the primary therapeutic target for imatinib.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""COL1A1-PDGFB Fusion"", ""notes"": ""The t(17;22)(q22;q13) translocation or ring chromosomes create the COL1A1-PDGFB fusion in >90% of cases. This fusion is both diagnostic and represents the primary therapeutic target for imatinib.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""evidence"": [{""explanation"": ""Abstract describes the COL1A1-PDGFB fusion underlying DFSP."", ""reference"": ""PMID:17950782"", ""snippet"": ""fusion of exon 2 of PDGFB to various exons of the COL1A1 gene."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1-PDGFB Fusion"", ""notes"": ""The t(17;22)(q22;q13) translocation or ring chromosomes create the COL1A1-PDGFB fusion in >90% of cases. This fusion is both diagnostic and represents the primary therapeutic target for imatinib.""}"
2003	88	Dermatomyositis	Dermatomyositis.yaml	genetic	0	HLA-DRB1*0301									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*0301""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*0301""}"
2019	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	genetic	0	EWSR1-WT1 Fusion									Somatic Fusion Oncogene																										The t(11;22)(p13;q12) translocation creates the EWSR1-WT1 fusion in virtually all DSRCT cases. This fusion is both diagnostic and represents the primary oncogenic driver.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWSR1-WT1 Fusion"", ""notes"": ""The t(11;22)(p13;q12) translocation creates the EWSR1-WT1 fusion in virtually all DSRCT cases. This fusion is both diagnostic and represents the primary oncogenic driver.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWSR1-WT1 Fusion"", ""notes"": ""The t(11;22)(p13;q12) translocation creates the EWSR1-WT1 fusion in virtually all DSRCT cases. This fusion is both diagnostic and represents the primary oncogenic driver.""}"
2054	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	genetic	0	BCL2 Translocation									GCB Subtype Marker																										The t(14;18)(q32;q21) translocation occurs in 30% of GCB-DLBCL, placing BCL2 under IGH enhancer control. When combined with MYC rearrangement, defines double-hit lymphoma with aggressive behavior.																						"{""association"": ""GCB Subtype Marker"", ""name"": ""BCL2 Translocation"", ""notes"": ""The t(14;18)(q32;q21) translocation occurs in 30% of GCB-DLBCL, placing BCL2 under IGH enhancer control. When combined with MYC rearrangement, defines double-hit lymphoma with aggressive behavior.""}"	{}	"{""association"": ""GCB Subtype Marker"", ""name"": ""BCL2 Translocation"", ""notes"": ""The t(14;18)(q32;q21) translocation occurs in 30% of GCB-DLBCL, placing BCL2 under IGH enhancer control. When combined with MYC rearrangement, defines double-hit lymphoma with aggressive behavior.""}"
2055	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	genetic	1	MYC Rearrangement									Adverse Prognostic Marker																										MYC translocations occur in 10-15% of DLBCL. MYC rearrangement with BCL2 and/or BCL6 defines high-grade B-cell lymphoma (double/triple hit) with poor prognosis requiring intensified therapy.																						"{""association"": ""Adverse Prognostic Marker"", ""name"": ""MYC Rearrangement"", ""notes"": ""MYC translocations occur in 10-15% of DLBCL. MYC rearrangement with BCL2 and/or BCL6 defines high-grade B-cell lymphoma (double/triple hit) with poor prognosis requiring intensified therapy.""}"	{}	"{""association"": ""Adverse Prognostic Marker"", ""name"": ""MYC Rearrangement"", ""notes"": ""MYC translocations occur in 10-15% of DLBCL. MYC rearrangement with BCL2 and/or BCL6 defines high-grade B-cell lymphoma (double/triple hit) with poor prognosis requiring intensified therapy.""}"
2056	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	genetic	2	MYD88 L265P Mutation									ABC Subtype Marker																										MYD88 L265P is present in 30% of ABC-DLBCL and drives NF-kB activation through TLR signaling. Associated with extranodal disease, particularly CNS and testicular involvement.																						"{""association"": ""ABC Subtype Marker"", ""name"": ""MYD88 L265P Mutation"", ""notes"": ""MYD88 L265P is present in 30% of ABC-DLBCL and drives NF-kB activation through TLR signaling. Associated with extranodal disease, particularly CNS and testicular involvement.""}"	{}	"{""association"": ""ABC Subtype Marker"", ""name"": ""MYD88 L265P Mutation"", ""notes"": ""MYD88 L265P is present in 30% of ABC-DLBCL and drives NF-kB activation through TLR signaling. Associated with extranodal disease, particularly CNS and testicular involvement.""}"
2057	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	genetic	3	BCL6 Rearrangement									Lymphoma Driver																										BCL6 translocations occur in 30% of DLBCL and may contribute to oncogenesis. BCL6 is a transcriptional repressor essential for germinal center function.																						"{""association"": ""Lymphoma Driver"", ""name"": ""BCL6 Rearrangement"", ""notes"": ""BCL6 translocations occur in 30% of DLBCL and may contribute to oncogenesis. BCL6 is a transcriptional repressor essential for germinal center function.""}"	{}	"{""association"": ""Lymphoma Driver"", ""name"": ""BCL6 Rearrangement"", ""notes"": ""BCL6 translocations occur in 30% of DLBCL and may contribute to oncogenesis. BCL6 is a transcriptional repressor essential for germinal center function.""}"
2084	93	Down_syndrome	Down_syndrome.yaml	genetic	0	Trisomy 21									Causal																										Presence of an extra copy of chromosome 21 is the genetic basis of Down syndrome.																						"{""association"": ""Causal"", ""name"": ""Trisomy 21"", ""notes"": ""Presence of an extra copy of chromosome 21 is the genetic basis of Down syndrome.""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""Confirms trisomy 21 as the genetic basis of Down syndrome."", ""reference"": ""PMID:32029743"", ""snippet"": ""DS is among the most genetically complex of the conditions that are compatible with human survival post-term, and the most frequent survivable autosomal aneuploidy."", ""supports"": ""SUPPORT""}], ""name"": ""Trisomy 21"", ""notes"": ""Presence of an extra copy of chromosome 21 is the genetic basis of Down syndrome.""}"
2085	93	Down_syndrome	Down_syndrome.yaml	genetic	1	APP									Risk Factor																										Amyloid precursor protein gene on chromosome 21; triplication drives early Alzheimer-like pathology in Down syndrome.																						"{""association"": ""Risk Factor"", ""name"": ""APP"", ""notes"": ""Amyloid precursor protein gene on chromosome 21; triplication drives early Alzheimer-like pathology in Down syndrome.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""APP"", ""notes"": ""Amyloid precursor protein gene on chromosome 21; triplication drives early Alzheimer-like pathology in Down syndrome.""}"
2086	93	Down_syndrome	Down_syndrome.yaml	genetic	2	DYRK1A									Risk Factor																										Dual-specificity tyrosine-phosphorylation-regulated kinase 1A on chromosome 21; triplication perturbs neurodevelopment and contributes to intellectual disability.																						"{""association"": ""Risk Factor"", ""name"": ""DYRK1A"", ""notes"": ""Dual-specificity tyrosine-phosphorylation-regulated kinase 1A on chromosome 21; triplication perturbs neurodevelopment and contributes to intellectual disability.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""DYRK1A"", ""notes"": ""Dual-specificity tyrosine-phosphorylation-regulated kinase 1A on chromosome 21; triplication perturbs neurodevelopment and contributes to intellectual disability.""}"
2087	93	Down_syndrome	Down_syndrome.yaml	genetic	3	IFNAR1									Risk Factor																										Interferon alpha/beta receptor 1 on chromosome 21; triplication contributes to interferon hyperactivation.																						"{""association"": ""Risk Factor"", ""name"": ""IFNAR1"", ""notes"": ""Interferon alpha/beta receptor 1 on chromosome 21; triplication contributes to interferon hyperactivation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IFNAR1"", ""notes"": ""Interferon alpha/beta receptor 1 on chromosome 21; triplication contributes to interferon hyperactivation.""}"
2088	93	Down_syndrome	Down_syndrome.yaml	genetic	4	IFNAR2									Risk Factor																										Interferon alpha/beta receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.																						"{""association"": ""Risk Factor"", ""name"": ""IFNAR2"", ""notes"": ""Interferon alpha/beta receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IFNAR2"", ""notes"": ""Interferon alpha/beta receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.""}"
2089	93	Down_syndrome	Down_syndrome.yaml	genetic	5	IFNGR2									Risk Factor																										Interferon gamma receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.																						"{""association"": ""Risk Factor"", ""name"": ""IFNGR2"", ""notes"": ""Interferon gamma receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IFNGR2"", ""notes"": ""Interferon gamma receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.""}"
2090	93	Down_syndrome	Down_syndrome.yaml	genetic	6	IL10RB									Risk Factor																										Interleukin 10 receptor subunit beta on chromosome 21; triplication contributes to interferon hyperactivation.																						"{""association"": ""Risk Factor"", ""name"": ""IL10RB"", ""notes"": ""Interleukin 10 receptor subunit beta on chromosome 21; triplication contributes to interferon hyperactivation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL10RB"", ""notes"": ""Interleukin 10 receptor subunit beta on chromosome 21; triplication contributes to interferon hyperactivation.""}"
2091	93	Down_syndrome	Down_syndrome.yaml	genetic	7	OLIG2									Risk Factor																										Oligodendrocyte transcription factor 2; overexpression shifts neurogenesis toward astrogliogenesis, reducing neuronal output.																						"{""association"": ""Risk Factor"", ""name"": ""OLIG2"", ""notes"": ""Oligodendrocyte transcription factor 2; overexpression shifts neurogenesis toward astrogliogenesis, reducing neuronal output.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""OLIG2"", ""notes"": ""Oligodendrocyte transcription factor 2; overexpression shifts neurogenesis toward astrogliogenesis, reducing neuronal output.""}"
2116	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	0	SCN1A								Positive	Pathogenic Mutations																										De novo loss-of-function mutations found in approximately 70-80% of Dravet syndrome patients. Primary causal gene encoding Nav1.1 voltage-gated sodium channel.																						"{""association"": ""Pathogenic Mutations"", ""name"": ""SCN1A"", ""notes"": ""De novo loss-of-function mutations found in approximately 70-80% of Dravet syndrome patients. Primary causal gene encoding Nav1.1 voltage-gated sodium channel."", ""presence"": ""Positive""}"	{}	"{""association"": ""Pathogenic Mutations"", ""evidence"": [{""reference"": ""PMID:21463282"", ""snippet"": ""Complete loss of function in the Na(v) 1.1 channel encoded by the SCN1A gene is associated with severe myoclonic epilepsy in infancy (SMEI)"", ""supports"": ""SUPPORT""}], ""name"": ""SCN1A"", ""notes"": ""De novo loss-of-function mutations found in approximately 70-80% of Dravet syndrome patients. Primary causal gene encoding Nav1.1 voltage-gated sodium channel."", ""presence"": ""Positive""}"
2117	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	1	SCN1B									Rare Pathogenic Mutations																										Encodes beta-1 subunit of voltage-gated sodium channels. Rare variants associated with Dravet syndrome phenotype.																						"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""SCN1B"", ""notes"": ""Encodes beta-1 subunit of voltage-gated sodium channels. Rare variants associated with Dravet syndrome phenotype.""}"	{}	"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""SCN1B"", ""notes"": ""Encodes beta-1 subunit of voltage-gated sodium channels. Rare variants associated with Dravet syndrome phenotype.""}"
2118	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	2	SCN9A									Rare Associated Variants																										Encodes Nav1.7 sodium channel. Rare variants reported in atypical cases.																						"{""association"": ""Rare Associated Variants"", ""name"": ""SCN9A"", ""notes"": ""Encodes Nav1.7 sodium channel. Rare variants reported in atypical cases.""}"	{}	"{""association"": ""Rare Associated Variants"", ""name"": ""SCN9A"", ""notes"": ""Encodes Nav1.7 sodium channel. Rare variants reported in atypical cases.""}"
2119	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	3	GABRA1									Rare Pathogenic Mutations																										Encodes GABA-A receptor alpha-1 subunit. Rare variants can cause Dravet-like epileptic encephalopathy.																						"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""GABRA1"", ""notes"": ""Encodes GABA-A receptor alpha-1 subunit. Rare variants can cause Dravet-like epileptic encephalopathy.""}"	{}	"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""GABRA1"", ""notes"": ""Encodes GABA-A receptor alpha-1 subunit. Rare variants can cause Dravet-like epileptic encephalopathy.""}"
2120	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	4	GABRG2									Rare Pathogenic Mutations																										Encodes GABA-A receptor gamma-2 subunit. Variants associated with epileptic encephalopathy phenotypes overlapping with Dravet syndrome.																						"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""GABRG2"", ""notes"": ""Encodes GABA-A receptor gamma-2 subunit. Variants associated with epileptic encephalopathy phenotypes overlapping with Dravet syndrome.""}"	{}	"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""GABRG2"", ""notes"": ""Encodes GABA-A receptor gamma-2 subunit. Variants associated with epileptic encephalopathy phenotypes overlapping with Dravet syndrome.""}"
2121	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	5	STXBP1									Rare Pathogenic Mutations																										Encodes syntaxin-binding protein 1. Mutations cause early infantile epileptic encephalopathy with phenotypic overlap.																						"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""STXBP1"", ""notes"": ""Encodes syntaxin-binding protein 1. Mutations cause early infantile epileptic encephalopathy with phenotypic overlap.""}"	{}	"{""association"": ""Rare Pathogenic Mutations"", ""name"": ""STXBP1"", ""notes"": ""Encodes syntaxin-binding protein 1. Mutations cause early infantile epileptic encephalopathy with phenotypic overlap.""}"
2122	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	6	HCN1									Rare Associated Variants																										Encodes hyperpolarization-activated cyclic nucleotide-gated channel 1. Variants reported in early infantile epileptic encephalopathy.																						"{""association"": ""Rare Associated Variants"", ""name"": ""HCN1"", ""notes"": ""Encodes hyperpolarization-activated cyclic nucleotide-gated channel 1. Variants reported in early infantile epileptic encephalopathy.""}"	{}	"{""association"": ""Rare Associated Variants"", ""name"": ""HCN1"", ""notes"": ""Encodes hyperpolarization-activated cyclic nucleotide-gated channel 1. Variants reported in early infantile epileptic encephalopathy.""}"
2123	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	7	CHD2									Modifier Gene																										Encodes chromodomain helicase DNA-binding protein 2. Variants may modify disease severity and phenotype in Dravet syndrome.																						"{""association"": ""Modifier Gene"", ""name"": ""CHD2"", ""notes"": ""Encodes chromodomain helicase DNA-binding protein 2. Variants may modify disease severity and phenotype in Dravet syndrome.""}"	{}	"{""association"": ""Modifier Gene"", ""name"": ""CHD2"", ""notes"": ""Encodes chromodomain helicase DNA-binding protein 2. Variants may modify disease severity and phenotype in Dravet syndrome.""}"
2124	95	Dravet_syndrome	Dravet_syndrome.yaml	genetic	8	DEPDC5									Modifier Gene																										Encodes DEP domain-containing protein 5. Polygenic modifier that may influence disease expressivity and severity.																						"{""association"": ""Modifier Gene"", ""name"": ""DEPDC5"", ""notes"": ""Encodes DEP domain-containing protein 5. Polygenic modifier that may influence disease expressivity and severity.""}"	{}	"{""association"": ""Modifier Gene"", ""name"": ""DEPDC5"", ""notes"": ""Encodes DEP domain-containing protein 5. Polygenic modifier that may influence disease expressivity and severity.""}"
2150	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	genetic	0	DMD									Causative																										X-linked recessive, deletions most common (60-70%), duplications 5-10%, point mutations 25-30%																						"{""association"": ""Causative"", ""name"": ""DMD"", ""notes"": ""X-linked recessive, deletions most common (60-70%), duplications 5-10%, point mutations 25-30%""}"	{}	"{""association"": ""Causative"", ""name"": ""DMD"", ""notes"": ""X-linked recessive, deletions most common (60-70%), duplications 5-10%, point mutations 25-30%""}"
2168	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	genetic	0	PIK3CA									Somatic Mutation																										PIK3CA mutations occur in approximately 80% of EBV-positive gastric cancers, the highest rate among gastric cancer subtypes. Hotspot mutations in the helical (E545K) and kinase (H1047R) domains activate PI3K signaling.																						"{""association"": ""Somatic Mutation"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 80% of EBV-positive gastric cancers, the highest rate among gastric cancer subtypes. Hotspot mutations in the helical (E545K) and kinase (H1047R) domains activate PI3K signaling.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 80% of EBV-positive gastric cancers, the highest rate among gastric cancer subtypes. Hotspot mutations in the helical (E545K) and kinase (H1047R) domains activate PI3K signaling.""}"
2169	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	genetic	1	ARID1A									Somatic Mutation																										ARID1A mutations occur in approximately 55% of EBV-positive gastric cancers, contributing to chromatin remodeling dysfunction.																						"{""association"": ""Somatic Mutation"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations occur in approximately 55% of EBV-positive gastric cancers, contributing to chromatin remodeling dysfunction.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations occur in approximately 55% of EBV-positive gastric cancers, contributing to chromatin remodeling dysfunction.""}"
2170	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	genetic	2	CDKN2A									Epigenetically Silenced																										CDKN2A (p16INK4A) is silenced by promoter hypermethylation rather than mutation in EBV-positive gastric cancer, removing G1/S checkpoint control.																						"{""association"": ""Epigenetically Silenced"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A (p16INK4A) is silenced by promoter hypermethylation rather than mutation in EBV-positive gastric cancer, removing G1/S checkpoint control.""}"	{}	"{""association"": ""Epigenetically Silenced"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A (p16INK4A) is silenced by promoter hypermethylation rather than mutation in EBV-positive gastric cancer, removing G1/S checkpoint control.""}"
2188	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	genetic	0	EGFR									Somatic Activating Mutations																										EGFR (7p11.2) encodes the epidermal growth factor receptor. Activating mutations occur somatically in the tyrosine kinase domain (exons 18-21). Exon 19 deletions and L858R are classical sensitizing mutations. T790M (exon 20) and C797S (exon 20) are acquired resistance mutations. Exon 20 insertions are primary resistance mutations.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""EGFR"", ""notes"": ""EGFR (7p11.2) encodes the epidermal growth factor receptor. Activating mutations occur somatically in the tyrosine kinase domain (exons 18-21). Exon 19 deletions and L858R are classical sensitizing mutations. T790M (exon 20) and C797S (exon 20) are acquired resistance mutations. Exon 20 insertions are primary resistance mutations.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Activating Mutations"", ""evidence"": [{""explanation"": ""Abstract identifies exon 19 deletion and L858R as the most common EGFR mutations."", ""reference"": ""PMID:26490356"", ""snippet"": ""Exon 19 deletion and exon 21 L858R mutation were the most common epidermal growth factor receptor (EGFR) mutations."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""EGFR"", ""notes"": ""EGFR (7p11.2) encodes the epidermal growth factor receptor. Activating mutations occur somatically in the tyrosine kinase domain (exons 18-21). Exon 19 deletions and L858R are classical sensitizing mutations. T790M (exon 20) and C797S (exon 20) are acquired resistance mutations. Exon 20 insertions are primary resistance mutations.""}"
2209	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	genetic	0	ESR1									Acquired Mutations (Resistance)																										ESR1 mutations are rare in primary tumors but emerge in ~30-40% of metastatic ER+ breast cancer after aromatase inhibitor therapy. Mutations in the ligand-binding domain (Y537S, D538G) cause constitutive receptor activation and endocrine resistance.																						"{""association"": ""Acquired Mutations (Resistance)"", ""name"": ""ESR1"", ""notes"": ""ESR1 mutations are rare in primary tumors but emerge in ~30-40% of metastatic ER+ breast cancer after aromatase inhibitor therapy. Mutations in the ligand-binding domain (Y537S, D538G) cause constitutive receptor activation and endocrine resistance.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Acquired Mutations (Resistance)"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""ESR1"", ""notes"": ""ESR1 mutations are rare in primary tumors but emerge in ~30-40% of metastatic ER+ breast cancer after aromatase inhibitor therapy. Mutations in the ligand-binding domain (Y537S, D538G) cause constitutive receptor activation and endocrine resistance.""}"
2210	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	genetic	1	PIK3CA									Somatic Mutations																										PIK3CA hotspot mutations (E545K, H1047R) occur in approximately 40% of ER+ breast cancers. Confer partial endocrine resistance and identify patients who benefit from PI3K inhibitor alpelisib.																						"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA hotspot mutations (E545K, H1047R) occur in approximately 40% of ER+ breast cancers. Confer partial endocrine resistance and identify patients who benefit from PI3K inhibitor alpelisib.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Mutations"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""PIK3CA"", ""notes"": ""PIK3CA hotspot mutations (E545K, H1047R) occur in approximately 40% of ER+ breast cancers. Confer partial endocrine resistance and identify patients who benefit from PI3K inhibitor alpelisib.""}"
2211	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	genetic	2	CCND1									Amplification																										CCND1 (cyclin D1) amplification occurs in ~15% of ER+ breast cancers and may confer sensitivity to CDK4/6 inhibitors.																						"{""association"": ""Amplification"", ""name"": ""CCND1"", ""notes"": ""CCND1 (cyclin D1) amplification occurs in ~15% of ER+ breast cancers and may confer sensitivity to CDK4/6 inhibitors.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Amplification"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""CCND1"", ""notes"": ""CCND1 (cyclin D1) amplification occurs in ~15% of ER+ breast cancers and may confer sensitivity to CDK4/6 inhibitors.""}"
2230	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	0	NPC1									Host factor																										Niemann-Pick C1 protein is a late endosomal/lysosomal cholesterol transporter that serves as the essential receptor for Ebola virus GP-mediated membrane fusion and cytosolic entry. Genetic depletion blocks EBOV entry.																						"{""association"": ""Host factor"", ""name"": ""NPC1"", ""notes"": ""Niemann-Pick C1 protein is a late endosomal/lysosomal cholesterol transporter that serves as the essential receptor for Ebola virus GP-mediated membrane fusion and cytosolic entry. Genetic depletion blocks EBOV entry.""}"	{}	"{""association"": ""Host factor"", ""name"": ""NPC1"", ""notes"": ""Niemann-Pick C1 protein is a late endosomal/lysosomal cholesterol transporter that serves as the essential receptor for Ebola virus GP-mediated membrane fusion and cytosolic entry. Genetic depletion blocks EBOV entry.""}"
2231	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	1	HAVCR1									Host factor																										Hepatitis A virus cellular receptor 1 (TIM-1) is a phosphatidylserine receptor that serves as an attachment factor for Ebola virus, facilitating viral entry into host cells.																						"{""association"": ""Host factor"", ""name"": ""HAVCR1"", ""notes"": ""Hepatitis A virus cellular receptor 1 (TIM-1) is a phosphatidylserine receptor that serves as an attachment factor for Ebola virus, facilitating viral entry into host cells.""}"	{}	"{""association"": ""Host factor"", ""name"": ""HAVCR1"", ""notes"": ""Hepatitis A virus cellular receptor 1 (TIM-1) is a phosphatidylserine receptor that serves as an attachment factor for Ebola virus, facilitating viral entry into host cells.""}"
2232	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	2	SLC39A9									Host factor																										Zinc transporter protein identified by CRISPR screen as a crucial entry factor for Ebola virus. Impacts glycosylation processes required for viral internalization.																						"{""association"": ""Host factor"", ""name"": ""SLC39A9"", ""notes"": ""Zinc transporter protein identified by CRISPR screen as a crucial entry factor for Ebola virus. Impacts glycosylation processes required for viral internalization.""}"	{}	"{""association"": ""Host factor"", ""name"": ""SLC39A9"", ""notes"": ""Zinc transporter protein identified by CRISPR screen as a crucial entry factor for Ebola virus. Impacts glycosylation processes required for viral internalization.""}"
2233	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	3	PIK3C3									Host factor																										Class III phosphatidylinositol 3-kinase (VPS34) identified by CRISPR screen as essential for EBOV entry. Its kinase activity is indispensable for the internalization of Ebola virions through macropinocytosis.																						"{""association"": ""Host factor"", ""name"": ""PIK3C3"", ""notes"": ""Class III phosphatidylinositol 3-kinase (VPS34) identified by CRISPR screen as essential for EBOV entry. Its kinase activity is indispensable for the internalization of Ebola virions through macropinocytosis.""}"	{}	"{""association"": ""Host factor"", ""name"": ""PIK3C3"", ""notes"": ""Class III phosphatidylinositol 3-kinase (VPS34) identified by CRISPR screen as essential for EBOV entry. Its kinase activity is indispensable for the internalization of Ebola virions through macropinocytosis.""}"
2234	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	4	CTSB									Host factor																										Cathepsin B is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.																						"{""association"": ""Host factor"", ""name"": ""CTSB"", ""notes"": ""Cathepsin B is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.""}"	{}	"{""association"": ""Host factor"", ""name"": ""CTSB"", ""notes"": ""Cathepsin B is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.""}"
2235	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	genetic	5	CTSL									Host factor																										Cathepsin L is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.																						"{""association"": ""Host factor"", ""name"": ""CTSL"", ""notes"": ""Cathepsin L is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.""}"	{}	"{""association"": ""Host factor"", ""name"": ""CTSL"", ""notes"": ""Cathepsin L is an endosomal protease that primes Ebola virus glycoprotein (GP) for receptor binding and membrane fusion in late endosomes.""}"
2277	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	0	COL1A1									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""COL1A1""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This statement supports that pathogenic variants in COL1A1 are associated with some subtypes of Ehlers-Danlos Syndrome (EDS)."", ""reference"": ""PMID:36896471"", ""snippet"": ""Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively)."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1""}"
2278	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	1	COL3A1						Vascular EDS			Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""COL3A1"", ""subtype"": ""Vascular EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The literature explicitly states that vascular Ehlers-Danlos syndrome (vEDS) is caused by pathogenic variants in the COL3A1 gene."", ""reference"": ""PMID:34560710"", ""snippet"": ""vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract confirms the association of vascular EDS with pathogenic variants in the COL3A1 gene."", ""reference"": ""PMID:30837697"", ""snippet"": ""Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the association between pathogenic COL3A1 variants and vascular Ehlers-Danlos syndrome."", ""reference"": ""PMID:35699227"", ""snippet"": ""Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively identified through registries and specialized clinics."", ""supports"": ""SUPPORT""}], ""name"": ""COL3A1"", ""subtype"": ""Vascular EDS""}"
2279	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	2	COL5A1						Classical EDS			Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""COL5A1"", ""subtype"": ""Classical EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The reference clearly states that mutations in the COL5A1 gene are associated with classical Ehlers-Danlos Syndrome, thus supporting the statement."", ""reference"": ""PMID:16278879"", ""snippet"": ""Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."", ""supports"": ""SUPPORT""}], ""name"": ""COL5A1"", ""subtype"": ""Classical EDS""}"
2280	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	3	COL5A2						Classical EDS			Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""COL5A2"", ""subtype"": ""Classical EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The reference confirms that mutations in the COL5A2 gene, encoding the alpha2-chain of type V collagen, are associated with classical EDS and account for approximately 50% of classic EDS cases along with COL5A1."", ""reference"": ""PMID:16278879"", ""snippet"": ""Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."", ""supports"": ""SUPPORT""}], ""name"": ""COL5A2"", ""subtype"": ""Classical EDS""}"
2281	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	4	ADAMTS2						Dermatosparaxis EDS			Pathogenic Variants																										Loss of procollagen N-proteinase activity leads to failure to remove N-propeptides, resulting in defective fibrillogenesis and fragile skin.																						"{""association"": ""Pathogenic Variants"", ""name"": ""ADAMTS2"", ""notes"": ""Loss of procollagen N-proteinase activity leads to failure to remove N-propeptides, resulting in defective fibrillogenesis and fragile skin."", ""subtype"": ""Dermatosparaxis EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This study demonstrates that ADAMTS2 mutations cause Ehlers-Danlos syndrome type VIIC (dermatosparaxis) by disrupting procollagen processing."", ""reference"": ""PMID:12646579"", ""snippet"": ""mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin."", ""supports"": ""SUPPORT""}], ""name"": ""ADAMTS2"", ""notes"": ""Loss of procollagen N-proteinase activity leads to failure to remove N-propeptides, resulting in defective fibrillogenesis and fragile skin."", ""subtype"": ""Dermatosparaxis EDS""}"
2282	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	5	TNXB						Classical-like EDS			Pathogenic Variants																										Tenascin-X deficiency causes defective ECM organization and altered cell-matrix interactions, leading to pain via TLR5-mediated A-fiber hypersensitivity.																						"{""association"": ""Pathogenic Variants"", ""name"": ""TNXB"", ""notes"": ""Tenascin-X deficiency causes defective ECM organization and altered cell-matrix interactions, leading to pain via TLR5-mediated A-fiber hypersensitivity."", ""subtype"": ""Classical-like EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This GeneReviews entry confirms that biallelic pathogenic variants in TNXB cause classical-like EDS."", ""reference"": ""PMID:36108117"", ""snippet"": ""The diagnosis of TNXB-related clEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in TNXB identified by molecular genetic testing."", ""supports"": ""SUPPORT""}], ""name"": ""TNXB"", ""notes"": ""Tenascin-X deficiency causes defective ECM organization and altered cell-matrix interactions, leading to pain via TLR5-mediated A-fiber hypersensitivity."", ""subtype"": ""Classical-like EDS""}"
2283	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	6	C1R						Periodontal EDS			Pathogenic Variants																										Mutations lead to intracellular activation of C1r/C1s proteases causing extracellular collagen degradation.																						"{""association"": ""Pathogenic Variants"", ""name"": ""C1R"", ""notes"": ""Mutations lead to intracellular activation of C1r/C1s proteases causing extracellular collagen degradation."", ""subtype"": ""Periodontal EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This study demonstrates that C1R mutations cause periodontal EDS by triggering intracellular activation of complement proteases."", ""reference"": ""PMID:36960056"", ""snippet"": ""pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."", ""supports"": ""SUPPORT""}], ""name"": ""C1R"", ""notes"": ""Mutations lead to intracellular activation of C1r/C1s proteases causing extracellular collagen degradation."", ""subtype"": ""Periodontal EDS""}"
2284	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	7	C1S						Periodontal EDS			Pathogenic Variants																										Mutations result in activated C1s protease that degrades collagen I, leading to periodontal tissue destruction and ECM instability.																						"{""association"": ""Pathogenic Variants"", ""name"": ""C1S"", ""notes"": ""Mutations result in activated C1s protease that degrades collagen I, leading to periodontal tissue destruction and ECM instability."", ""subtype"": ""Periodontal EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This study demonstrates that C1S mutations cause periodontal EDS, with activated C1s degrading collagen I."", ""reference"": ""PMID:36960056"", ""snippet"": ""pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."", ""supports"": ""SUPPORT""}], ""name"": ""C1S"", ""notes"": ""Mutations result in activated C1s protease that degrades collagen I, leading to periodontal tissue destruction and ECM instability."", ""subtype"": ""Periodontal EDS""}"
2285	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	genetic	8	PLOD1						Kyphoscoliotic EDS			Pathogenic Variants																																				Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic EDS as an example of a less common subtype.												"{""association"": ""Pathogenic Variants"", ""name"": ""PLOD1"", ""review_notes"": ""Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic EDS as an example of a less common subtype."", ""subtype"": ""Kyphoscoliotic EDS""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This source clearly states that pathogenic variants in the PLOD1 gene are responsible for kyphoscoliotic Ehlers-Danlos syndrome."", ""reference"": ""PMID:32174067"", ""snippet"": ""Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is an autosomal recessive connective tissue disorder... The disorder results from a deficiency of the enzyme collagen lysyl hydroxylase 1 due to mutations in the gene PLOD1."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the association between PLOD1 mutations and kyphoscoliotic Ehlers-Danlos syndrome."", ""reference"": ""PMID:15979919"", ""snippet"": ""The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) is an inheritable connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in PLOD1."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source reinforces the role of PLOD1 pathogenic variants in causing kyphoscoliotic Ehlers-Danlos syndrome."", ""reference"": ""PMID:29982180"", ""snippet"": ""Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study adds further confirmation of the genetic association between PLOD1 and kyphoscoliotic Ehlers-Danlos syndrome."", ""reference"": ""PMID:36054293"", ""snippet"": ""The autosomal recessive kyphoscoliotic EDS results from deficiency of either lysyl hydroxylase 1 (encoded by PLOD1), crucial for collagen cross-linking... "", ""supports"": ""SUPPORT""}], ""name"": ""PLOD1"", ""review_notes"": ""Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic EDS as an example of a less common subtype."", ""subtype"": ""Kyphoscoliotic EDS""}"
2318	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	genetic	0	COL5A1									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""COL5A1""}"	"{""inheritance"": [{""description"": ""A single pathogenic variant inherited from one parent is sufficient to cause disease; most cases are inherited, though de novo mutations occur."", ""name"": ""Autosomal Dominant""}], ""variants"": [{""description"": ""Single nucleotide changes resulting in altered amino acid sequence."", ""name"": ""Missense Mutations""}, {""description"": ""Changes affecting mRNA splicing and leading to exon skipping or intronic retention."", ""name"": ""Splice Site Mutations""}, {""description"": ""Insertions or deletions causing a shift in the reading frame and often resulting in a premature stop codon."", ""name"": ""Frameshift Mutations""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This reference confirms the existence of missense and splice site mutations in the COL5A1 gene among Ehlers-Danlos Syndrome patients."", ""reference"": ""PMID:30858776"", ""snippet"": ""Among all tested patients, nine mutations of COL5A1 gene were detected (8 missense mutations and 1 splice site)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the presence of missense mutations specifically related to COL5A1 in Ehlers-Danlos Syndrome."", ""reference"": ""PMID:33656776"", ""snippet"": ""Glycine substitution mutation of COL5A1 in classic Ehlers-Danlos syndrome: a case report and literature review."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the study primarily investigates the association of COL5A1 polymorphisms with musculoskeletal injuries, it partially supports the statement by recognizing relevant genetic variants."", ""reference"": ""PMID:35241120"", ""snippet"": ""This study supports that rs12722 is associated with an elevated susceptibility to ligament injury, especially in the Caucasian population."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference doesn't support the existence of frameshift mutations in COL5A1, making the specific part of the statement regarding frameshift mutations unsubstantiated."", ""reference"": ""PMID:2683783"", ""snippet"": ""Mutations in the majority of the 20 known collagen genes have not yet been identified."", ""supports"": ""WRONG_STATEMENT""}], ""inheritance"": [{""description"": ""A single pathogenic variant inherited from one parent is sufficient to cause disease; most cases are inherited, though de novo mutations occur."", ""name"": ""Autosomal Dominant""}], ""name"": ""COL5A1"", ""variants"": [{""description"": ""Single nucleotide changes resulting in altered amino acid sequence."", ""name"": ""Missense Mutations""}, {""description"": ""Changes affecting mRNA splicing and leading to exon skipping or intronic retention."", ""name"": ""Splice Site Mutations""}, {""description"": ""Insertions or deletions causing a shift in the reading frame and often resulting in a premature stop codon."", ""name"": ""Frameshift Mutations""}]}"
2341	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	genetic	0	Loss of Heterozygosity at 11p15									Characteristic Genetic Event																										LOH at 11p15.5 with loss of the maternal allele occurs in approximately 80% of ERMS cases. This leads to biallelic IGF2 expression.																						"{""association"": ""Characteristic Genetic Event"", ""name"": ""Loss of Heterozygosity at 11p15"", ""notes"": ""LOH at 11p15.5 with loss of the maternal allele occurs in approximately 80% of ERMS cases. This leads to biallelic IGF2 expression.""}"	{}	"{""association"": ""Characteristic Genetic Event"", ""name"": ""Loss of Heterozygosity at 11p15"", ""notes"": ""LOH at 11p15.5 with loss of the maternal allele occurs in approximately 80% of ERMS cases. This leads to biallelic IGF2 expression.""}"
2342	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	genetic	1	RAS Pathway Mutations									Oncogenic Driver Mutations																										NRAS, KRAS, HRAS, and FGFR4 mutations collectively occur in 35-45% of ERMS cases and are mutually exclusive. These represent therapeutic targets.																						"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""RAS Pathway Mutations"", ""notes"": ""NRAS, KRAS, HRAS, and FGFR4 mutations collectively occur in 35-45% of ERMS cases and are mutually exclusive. These represent therapeutic targets.""}"	{}	"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""RAS Pathway Mutations"", ""notes"": ""NRAS, KRAS, HRAS, and FGFR4 mutations collectively occur in 35-45% of ERMS cases and are mutually exclusive. These represent therapeutic targets.""}"
2343	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	genetic	2	TP53 Mutations									Tumor Suppressor Loss																										TP53 mutations occur in a subset of ERMS, particularly the anaplastic variant, and are associated with worse prognosis.																						"{""association"": ""Tumor Suppressor Loss"", ""name"": ""TP53 Mutations"", ""notes"": ""TP53 mutations occur in a subset of ERMS, particularly the anaplastic variant, and are associated with worse prognosis.""}"	{}	"{""association"": ""Tumor Suppressor Loss"", ""name"": ""TP53 Mutations"", ""notes"": ""TP53 mutations occur in a subset of ERMS, particularly the anaplastic variant, and are associated with worse prognosis.""}"
2364	104	Endometriosis	Endometriosis.yaml	genetic	0	WNT4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""WNT4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""WNT4""}"
2365	104	Endometriosis	Endometriosis.yaml	genetic	1	VEZT									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""VEZT""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""VEZT""}"
2366	104	Endometriosis	Endometriosis.yaml	genetic	2	GREB1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""GREB1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""GREB1""}"
2367	104	Endometriosis	Endometriosis.yaml	genetic	3	ID4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ID4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ID4""}"
2395	105	Epilepsy	Epilepsy.yaml	genetic	0	SCN1A									Causative																										Dravet syndrome, GEFS+																						"{""association"": ""Causative"", ""name"": ""SCN1A"", ""notes"": ""Dravet syndrome, GEFS+""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Establishes SCN1A haploinsufficiency as the genetic cause of Dravet syndrome epileptic encephalopathy."", ""reference"": ""PMID:37812819"", ""snippet"": ""It is caused by haploinsufficiency of SCN1A gene encoding for the -subunit of the voltage-gated sodium channel Nav1.1."", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates that SCN1A haploinsufficiency causes seizures through GABAergic interneuron dysfunction, and this mechanism is active throughout life, not just during development."", ""reference"": ""PMID:37812819"", ""snippet"": ""Induction of heterozygous Nav1.1 mutation at P30 and P60 elicited susceptibility to the development of both spontaneous and hyperthermia-induced seizures and SUDEP rates comparable to P2-induced mice, with symptom onset accompanied by the characteristic GABAergic interneuron dysfunction."", ""supports"": ""SUPPORT""}], ""name"": ""SCN1A"", ""notes"": ""Dravet syndrome, GEFS+""}"
2396	105	Epilepsy	Epilepsy.yaml	genetic	1	SCN2A									Causative																										Early infantile epileptic encephalopathy																						"{""association"": ""Causative"", ""name"": ""SCN2A"", ""notes"": ""Early infantile epileptic encephalopathy""}"	{}	"{""association"": ""Causative"", ""name"": ""SCN2A"", ""notes"": ""Early infantile epileptic encephalopathy""}"
2397	105	Epilepsy	Epilepsy.yaml	genetic	2	KCNQ2									Causative																										Benign familial neonatal seizures																						"{""association"": ""Causative"", ""name"": ""KCNQ2"", ""notes"": ""Benign familial neonatal seizures""}"	{}	"{""association"": ""Causative"", ""name"": ""KCNQ2"", ""notes"": ""Benign familial neonatal seizures""}"
2398	105	Epilepsy	Epilepsy.yaml	genetic	3	GABRA1									Causative																										Juvenile myoclonic epilepsy																						"{""association"": ""Causative"", ""name"": ""GABRA1"", ""notes"": ""Juvenile myoclonic epilepsy""}"	{}	"{""association"": ""Causative"", ""name"": ""GABRA1"", ""notes"": ""Juvenile myoclonic epilepsy""}"
2399	105	Epilepsy	Epilepsy.yaml	genetic	4	CDKL5									Causative																										Early-onset epileptic encephalopathy																						"{""association"": ""Causative"", ""name"": ""CDKL5"", ""notes"": ""Early-onset epileptic encephalopathy""}"	{}	"{""association"": ""Causative"", ""name"": ""CDKL5"", ""notes"": ""Early-onset epileptic encephalopathy""}"
2428	106	Essential Hypertension	Essential_Hypertension.yaml	genetic	0	ACE									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ACE""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This confirms genetic factors, including variants in RAAS genes like ACE, influence hypertension susceptibility."", ""reference"": ""PMID:39765782"", ""snippet"": ""Genetic and environmental factors influence the susceptibility to hypertensive renal damage, with African American populations having a higher tendency due to genetic variants."", ""supports"": ""SUPPORT""}], ""name"": ""ACE""}"
2429	106	Essential Hypertension	Essential_Hypertension.yaml	genetic	1	AGT									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""AGT""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This confirms genetic variants in AGT and other RAAS components contribute to hypertension risk."", ""reference"": ""PMID:39765782"", ""snippet"": ""Genetic and environmental factors influence the susceptibility to hypertensive renal damage, with African American populations having a higher tendency due to genetic variants."", ""supports"": ""SUPPORT""}], ""name"": ""AGT""}"
2430	106	Essential Hypertension	Essential_Hypertension.yaml	genetic	2	ADD1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ADD1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ADD1""}"
2448	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	genetic	0	JAK2									Somatic Activating Mutations																										JAK2 V617F occurs in approximately 55% of ET patients. Associated with older age, higher hemoglobin, and increased thrombosis risk compared to CALR-mutated ET.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 55% of ET patients. Associated with older age, higher hemoglobin, and increased thrombosis risk compared to CALR-mutated ET.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 55% of ET patients. Associated with older age, higher hemoglobin, and increased thrombosis risk compared to CALR-mutated ET.""}"
2449	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	genetic	1	CALR									Somatic Frameshift Mutations																										CALR exon 9 frameshift mutations occur in approximately 25% of ET. Type 1 mutations more common. Associated with younger age, higher platelet count, and lower thrombosis risk than JAK2 mutations.																						"{""association"": ""Somatic Frameshift Mutations"", ""name"": ""CALR"", ""notes"": ""CALR exon 9 frameshift mutations occur in approximately 25% of ET. Type 1 mutations more common. Associated with younger age, higher platelet count, and lower thrombosis risk than JAK2 mutations.""}"	{}	"{""association"": ""Somatic Frameshift Mutations"", ""name"": ""CALR"", ""notes"": ""CALR exon 9 frameshift mutations occur in approximately 25% of ET. Type 1 mutations more common. Associated with younger age, higher platelet count, and lower thrombosis risk than JAK2 mutations.""}"
2450	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	genetic	2	MPL									Somatic Activating Mutations																										MPL W515L/K mutations occur in approximately 3% of ET. Activates JAK-STAT signaling through the thrombopoietin receptor.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""MPL"", ""notes"": ""MPL W515L/K mutations occur in approximately 3% of ET. Activates JAK-STAT signaling through the thrombopoietin receptor.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""MPL"", ""notes"": ""MPL W515L/K mutations occur in approximately 3% of ET. Activates JAK-STAT signaling through the thrombopoietin receptor.""}"
2466	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	genetic	0	EWS-FLI1 Fusion									Somatic Fusion Oncogene																										The t(11;22)(q24;q12) translocation creates the EWS-FLI1 fusion in 85% of cases. EWS-ERG t(21;22) accounts for most remaining cases. All Ewing sarcomas harbor EWS-ETS family fusions, which are both diagnostic and represent the primary oncogenic driver.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWS-FLI1 Fusion"", ""notes"": ""The t(11;22)(q24;q12) translocation creates the EWS-FLI1 fusion in 85% of cases. EWS-ERG t(21;22) accounts for most remaining cases. All Ewing sarcomas harbor EWS-ETS family fusions, which are both diagnostic and represent the primary oncogenic driver.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""EWS-FLI1 Fusion"", ""notes"": ""The t(11;22)(q24;q12) translocation creates the EWS-FLI1 fusion in 85% of cases. EWS-ERG t(21;22) accounts for most remaining cases. All Ewing sarcomas harbor EWS-ETS family fusions, which are both diagnostic and represent the primary oncogenic driver.""}"
2485	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	genetic	0	FGFR2 Fusions									Somatic Gene Fusion																										FGFR2 fusions occur in 10-15% of intrahepatic cholangiocarcinomas. Common partners include BICC1, PPHLN1, AHCYL1, TACC3, MGEA5, and others. Over 100 different fusion partners have been identified. Detected by RNA-based NGS, FISH, or break-apart assays.																						"{""association"": ""Somatic Gene Fusion"", ""name"": ""FGFR2 Fusions"", ""notes"": ""FGFR2 fusions occur in 10-15% of intrahepatic cholangiocarcinomas. Common partners include BICC1, PPHLN1, AHCYL1, TACC3, MGEA5, and others. Over 100 different fusion partners have been identified. Detected by RNA-based NGS, FISH, or break-apart assays.""}"	{}	"{""association"": ""Somatic Gene Fusion"", ""evidence"": [{""explanation"": ""Abstract reports FGFR2 fusion prevalence in intrahepatic cholangiocarcinoma."", ""reference"": ""PMID:35871236"", ""snippet"": ""Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with a prevalence of 10-15%."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR2 Fusions"", ""notes"": ""FGFR2 fusions occur in 10-15% of intrahepatic cholangiocarcinomas. Common partners include BICC1, PPHLN1, AHCYL1, TACC3, MGEA5, and others. Over 100 different fusion partners have been identified. Detected by RNA-based NGS, FISH, or break-apart assays.""}"
2486	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	genetic	1	FGFR2 Mutations/Amplifications									Somatic Alterations																										Activating FGFR2 point mutations and amplifications are less common than fusions but may also respond to FGFR inhibitors. V564F/I gatekeeper mutations are associated with acquired resistance.																						"{""association"": ""Somatic Alterations"", ""name"": ""FGFR2 Mutations/Amplifications"", ""notes"": ""Activating FGFR2 point mutations and amplifications are less common than fusions but may also respond to FGFR inhibitors. V564F/I gatekeeper mutations are associated with acquired resistance.""}"	{}	"{""association"": ""Somatic Alterations"", ""name"": ""FGFR2 Mutations/Amplifications"", ""notes"": ""Activating FGFR2 point mutations and amplifications are less common than fusions but may also respond to FGFR inhibitors. V564F/I gatekeeper mutations are associated with acquired resistance.""}"
2487	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	genetic	2	FGFR Resistance Mutations									Secondary Resistance																										Acquired resistance to FGFR inhibitors often involves secondary FGFR2 kinase domain mutations (V564F, N549H/K, E565A, L617V, K659M). Polyclonal resistance is common. Monitoring for resistance mutations helps guide subsequent therapy.																						"{""association"": ""Secondary Resistance"", ""name"": ""FGFR Resistance Mutations"", ""notes"": ""Acquired resistance to FGFR inhibitors often involves secondary FGFR2 kinase domain mutations (V564F, N549H/K, E565A, L617V, K659M). Polyclonal resistance is common. Monitoring for resistance mutations helps guide subsequent therapy.""}"	{}	"{""association"": ""Secondary Resistance"", ""name"": ""FGFR Resistance Mutations"", ""notes"": ""Acquired resistance to FGFR inhibitors often involves secondary FGFR2 kinase domain mutations (V564F, N549H/K, E565A, L617V, K659M). Polyclonal resistance is common. Monitoring for resistance mutations helps guide subsequent therapy.""}"
2507	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	genetic	0	FGFR3									Somatic Activating Mutations and Fusions																										FGFR3 alterations occur in 15-20% of metastatic urothelial carcinomas. Common mutations include S249C, Y373C, R248C, and G370C. FGFR3-TACC3 fusions and other rearrangements also activate the pathway. FGFR2 alterations are less common.																						"{""association"": ""Somatic Activating Mutations and Fusions"", ""name"": ""FGFR3"", ""notes"": ""FGFR3 alterations occur in 15-20% of metastatic urothelial carcinomas. Common mutations include S249C, Y373C, R248C, and G370C. FGFR3-TACC3 fusions and other rearrangements also activate the pathway. FGFR2 alterations are less common.""}"	{}	"{""association"": ""Somatic Activating Mutations and Fusions"", ""evidence"": [{""explanation"": ""Supports clinically relevant FGFR3 mutations in urothelial carcinoma."", ""reference"": ""PMID:31264434"", ""snippet"": ""Specific mutations have been identified that predict response to therapy including ERCC2 mutations and cisplatin, DNA damage and repair mutations and checkpoint inhibitors, and FGFR3 mutations and FGFR tyrosine kinase inhibitors such as erdafitinib."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR3"", ""notes"": ""FGFR3 alterations occur in 15-20% of metastatic urothelial carcinomas. Common mutations include S249C, Y373C, R248C, and G370C. FGFR3-TACC3 fusions and other rearrangements also activate the pathway. FGFR2 alterations are less common.""}"
2549	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	genetic	0	FLT3-ITD									Somatic Oncogenic Mutation																										Internal tandem duplications in the juxtamembrane domain (exons 14-15) cause constitutive receptor dimerization and activation. ITD length and allelic ratio impact prognosis. Co-occurrence with NPM1 mutations partially mitigates the adverse prognostic impact.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""FLT3-ITD"", ""notes"": ""Internal tandem duplications in the juxtamembrane domain (exons 14-15) cause constitutive receptor dimerization and activation. ITD length and allelic ratio impact prognosis. Co-occurrence with NPM1 mutations partially mitigates the adverse prognostic impact.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""FLT3-ITD"", ""notes"": ""Internal tandem duplications in the juxtamembrane domain (exons 14-15) cause constitutive receptor dimerization and activation. ITD length and allelic ratio impact prognosis. Co-occurrence with NPM1 mutations partially mitigates the adverse prognostic impact.""}"
2550	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	genetic	1	FLT3-TKD									Somatic Oncogenic Mutation																										Point mutations in the tyrosine kinase domain, most commonly D835Y, cause constitutive kinase activation. Less adverse prognostic impact than ITD mutations but still targetable with FLT3 inhibitors.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""FLT3-TKD"", ""notes"": ""Point mutations in the tyrosine kinase domain, most commonly D835Y, cause constitutive kinase activation. Less adverse prognostic impact than ITD mutations but still targetable with FLT3 inhibitors.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""FLT3-TKD"", ""notes"": ""Point mutations in the tyrosine kinase domain, most commonly D835Y, cause constitutive kinase activation. Less adverse prognostic impact than ITD mutations but still targetable with FLT3 inhibitors.""}"
2575	113	Fabry disease	Fabry_Disease.yaml	genetic	0	GLA gene mutations								Pathogenic	X-linked recessive																										"Loss-of-function mutations in GLA cause deficiency of -galactosidase A. Disease shows X-linked inheritance with hemizygous males severely affected and heterozygous females showing variable phenotypes due to X-inactivation. Genetic testing is the gold standard for diagnosis and can identify a wide spectrum of variants including point mutations, insertions, deletions, and deep intronic variants. Long-read sequencing approaches enable comprehensive variant detection.
"																						"{""association"": ""X-linked recessive"", ""name"": ""GLA gene mutations"", ""notes"": ""Loss-of-function mutations in GLA cause deficiency of -galactosidase A. Disease shows X-linked inheritance with hemizygous males severely affected and heterozygous females showing variable phenotypes due to X-inactivation. Genetic testing is the gold standard for diagnosis and can identify a wide spectrum of variants including point mutations, insertions, deletions, and deep intronic variants. Long-read sequencing approaches enable comprehensive variant detection.\n"", ""presence"": ""Pathogenic""}"	"{""inheritance"": [{""description"": ""Males are hemizygous and severely affected; females are heterozygous carriers with variable presentation. In males, diagnosis is based on enzyme activity testing showing very low or absent -galactosidase A activity in classical forms (near zero) or reduced activity (under 30%) in late-onset forms."", ""evidence"": [{""explanation"": ""Confirms X-linked recessive inheritance pattern of Fabry disease"", ""reference"": ""PMID:31939530"", ""snippet"": ""Fabry disease (FD) is a recessive monogenic inheritance disease linked to chromosome X, secondary to mutations in the GLA gene"", ""supports"": ""SUPPORT""}, {""explanation"": ""Describes enzyme activity testing thresholds for diagnosis in males based on disease form severity"", ""reference"": ""PMID:32723516"", ""snippet"": ""In male, diagnosis is made with alpha-galactosidase A enzyme activity dosage in leukocyte, that is very low or null in classical forms and under 30 percent in late-onset forms"", ""supports"": ""SUPPORT""}], ""name"": ""X-linked recessive""}]}"	"{""association"": ""X-linked recessive"", ""evidence"": [{""explanation"": ""Confirms that Fabry disease is X-linked and caused by deficiency of alpha-galactosidase A enzyme"", ""reference"": ""PMID:39100494"", ""snippet"": ""Fabry disease (FD) is an X-linked lysosomal disease caused by an enzyme deficiency of alpha-galactosidase A (-gal A)"", ""supports"": ""SUPPORT""}, {""explanation"": ""Establishes genetic testing as diagnostic gold standard and highlights need for comprehensive sequencing approaches to detect all variant types"", ""reference"": ""PMID:39609713"", ""snippet"": ""Genetic testing is the gold standard for precise diagnosis of FD, however conventional genetic testing could miss deep intronic variants and large deletions or duplications"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""description"": ""Males are hemizygous and severely affected; females are heterozygous carriers with variable presentation. In males, diagnosis is based on enzyme activity testing showing very low or absent -galactosidase A activity in classical forms (near zero) or reduced activity (under 30%) in late-onset forms."", ""evidence"": [{""explanation"": ""Confirms X-linked recessive inheritance pattern of Fabry disease"", ""reference"": ""PMID:31939530"", ""snippet"": ""Fabry disease (FD) is a recessive monogenic inheritance disease linked to chromosome X, secondary to mutations in the GLA gene"", ""supports"": ""SUPPORT""}, {""explanation"": ""Describes enzyme activity testing thresholds for diagnosis in males based on disease form severity"", ""reference"": ""PMID:32723516"", ""snippet"": ""In male, diagnosis is made with alpha-galactosidase A enzyme activity dosage in leukocyte, that is very low or null in classical forms and under 30 percent in late-onset forms"", ""supports"": ""SUPPORT""}], ""name"": ""X-linked recessive""}], ""name"": ""GLA gene mutations"", ""notes"": ""Loss-of-function mutations in GLA cause deficiency of -galactosidase A. Disease shows X-linked inheritance with hemizygous males severely affected and heterozygous females showing variable phenotypes due to X-inactivation. Genetic testing is the gold standard for diagnosis and can identify a wide spectrum of variants including point mutations, insertions, deletions, and deep intronic variants. Long-read sequencing approaches enable comprehensive variant detection.\n"", ""presence"": ""Pathogenic""}"
2595	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	genetic	0	APC									Germline Loss-of-Function Mutations																										APC (5q22.2) encodes adenomatous polyposis coli, a key component of the -catenin destruction complex. Most germline mutations are truncating (nonsense, frameshift) resulting in loss of function. De novo mutations account for 20-30% of cases. Mutation location correlates with phenotype: MCR mutations (codons 1250-1464) cause classic severe FAP; 5' mutations (before codon 157) and 3' mutations (after codon 1595) cause attenuated FAP.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""APC"", ""notes"": ""APC (5q22.2) encodes adenomatous polyposis coli, a key component of the -catenin destruction complex. Most germline mutations are truncating (nonsense, frameshift) resulting in loss of function. De novo mutations account for 20-30% of cases. Mutation location correlates with phenotype: MCR mutations (codons 1250-1464) cause classic severe FAP; 5' mutations (before codon 157) and 3' mutations (after codon 1595) cause attenuated FAP.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""evidence"": [{""explanation"": ""Review confirms germline APC mutations affect -catenin binding domains and somatic second hits occur in downstream regions."", ""reference"": ""PMID:28668823"", ""snippet"": ""Several lines of evidence show that germline mutations affect the functional domains of the APC gene that are responsible for interactions of the transcript with -catenin, whereas somatic second mutations involve the downstream region of the gene."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""APC"", ""notes"": ""APC (5q22.2) encodes adenomatous polyposis coli, a key component of the -catenin destruction complex. Most germline mutations are truncating (nonsense, frameshift) resulting in loss of function. De novo mutations account for 20-30% of cases. Mutation location correlates with phenotype: MCR mutations (codons 1250-1464) cause classic severe FAP; 5' mutations (before codon 157) and 3' mutations (after codon 1595) cause attenuated FAP.""}"
2618	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	genetic	0	MEFV									Primary causal gene																										Encodes pyrin protein; gain-of-function mutations lower activation threshold for inflammasome assembly																						"{""association"": ""Primary causal gene"", ""name"": ""MEFV"", ""notes"": ""Encodes pyrin protein; gain-of-function mutations lower activation threshold for inflammasome assembly""}"	{}	"{""association"": ""Primary causal gene"", ""evidence"": [{""explanation"": ""Mutations in the MEFV gene result in increased activation of pyrin, causing excessive inflammation."", ""reference"": ""PMID:28154935"", ""snippet"": ""Familial Mediterranean fever (FMF) is caused by mutations within the Mediterranean fever (MEFV) gene. These gain of function mutations lead to an increased activation of the inflammasome pyrin with a subsequent disproportional proinflammatory reaction."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article discusses the role of pyrin in inducing inflammatory responses, supporting the effect of MEFV gene mutations in causing excessive inflammation."", ""reference"": ""PMID:25307949"", ""snippet"": ""Mutations in the MEFV gene are associated with the human autoinflammatory disease familial Mediterranean fever (FMF). Pyrin can interact with the inflammasome adaptor ASC and induce inflammatory caspase-1 activation in monocytic cells."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mutation spectrum in the MEFV gene is related to the pathogenesis involving pyrin and inflammation, supporting the given statement."", ""reference"": ""PMID:36889987"", ""snippet"": ""MEFV gene mutation spectrum in patients with familial mediterranean fever"", ""supports"": ""SUPPORT""}], ""name"": ""MEFV"", ""notes"": ""Encodes pyrin protein; gain-of-function mutations lower activation threshold for inflammasome assembly""}"
2619	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	genetic	1	PKN1									Modifier gene																										Serine/threonine kinase that phosphorylates pyrin to maintain autoinhibition; acts downstream of RhoA																						"{""association"": ""Modifier gene"", ""name"": ""PKN1"", ""notes"": ""Serine/threonine kinase that phosphorylates pyrin to maintain autoinhibition; acts downstream of RhoA""}"	{}	"{""association"": ""Modifier gene"", ""name"": ""PKN1"", ""notes"": ""Serine/threonine kinase that phosphorylates pyrin to maintain autoinhibition; acts downstream of RhoA""}"
2620	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	genetic	2	PKN2									Modifier gene																										Partner kinase to PKN1; phosphorylates pyrin and enables 14-3-3 binding for inflammasome suppression																						"{""association"": ""Modifier gene"", ""name"": ""PKN2"", ""notes"": ""Partner kinase to PKN1; phosphorylates pyrin and enables 14-3-3 binding for inflammasome suppression""}"	{}	"{""association"": ""Modifier gene"", ""name"": ""PKN2"", ""notes"": ""Partner kinase to PKN1; phosphorylates pyrin and enables 14-3-3 binding for inflammasome suppression""}"
2621	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	genetic	3	RHOA									Upstream regulator																										Small GTPase whose inactivation relieves pyrin inhibition by reducing PKN activity																						"{""association"": ""Upstream regulator"", ""name"": ""RHOA"", ""notes"": ""Small GTPase whose inactivation relieves pyrin inhibition by reducing PKN activity""}"	{}	"{""association"": ""Upstream regulator"", ""name"": ""RHOA"", ""notes"": ""Small GTPase whose inactivation relieves pyrin inhibition by reducing PKN activity""}"
2652	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	0	FANCA									Pathogenic Variants																										Most common FA gene, accounting for approximately 60-70% of cases.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCA"", ""notes"": ""Most common FA gene, accounting for approximately 60-70% of cases.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCA is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCA"", ""notes"": ""Most common FA gene, accounting for approximately 60-70% of cases.""}"
2653	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	1	FANCB									Pathogenic Variants																										Component of FA core complex; X-linked inheritance pattern.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCB"", ""notes"": ""Component of FA core complex; X-linked inheritance pattern.""}"	"{""inheritance"": [{""name"": ""X-linked""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCB causes X-linked Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""a hemizygous pathogenic variant in FANCB known to cause X-linked FA"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""X-linked""}], ""name"": ""FANCB"", ""notes"": ""Component of FA core complex; X-linked inheritance pattern.""}"
2654	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	2	FANCC									Pathogenic Variants																										Second most common FA gene in certain populations.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCC"", ""notes"": ""Second most common FA gene in certain populations.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCC is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCC"", ""notes"": ""Second most common FA gene in certain populations.""}"
2655	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	3	FANCE									Pathogenic Variants																										Component of FA core complex.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCE"", ""notes"": ""Component of FA core complex.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCE is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCE"", ""notes"": ""Component of FA core complex.""}"
2656	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	4	FANCF									Pathogenic Variants																										Component of FA core complex.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCF"", ""notes"": ""Component of FA core complex.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCF is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCF"", ""notes"": ""Component of FA core complex.""}"
2657	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	5	FANCG									Pathogenic Variants																										Associated with more severe phenotype requiring earlier intervention.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCG"", ""notes"": ""Associated with more severe phenotype requiring earlier intervention.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCG is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCG"", ""notes"": ""Associated with more severe phenotype requiring earlier intervention.""}"
2658	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	6	FANCL									Pathogenic Variants																										E3 ubiquitin ligase component of FA core complex that monoubiquitinates FANCD2-FANCI complex.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCL"", ""notes"": ""E3 ubiquitin ligase component of FA core complex that monoubiquitinates FANCD2-FANCI complex.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCL is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCL"", ""notes"": ""E3 ubiquitin ligase component of FA core complex that monoubiquitinates FANCD2-FANCI complex.""}"
2659	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	7	FANCM									Pathogenic Variants																										DNA translocase that recognizes stalled replication forks and recruits the FA core complex. FANCM has historically been proposed as FA-M in some sources, but classification differs across curation resources.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCM"", ""notes"": ""DNA translocase that recognizes stalled replication forks and recruits the FA core complex. FANCM has historically been proposed as FA-M in some sources, but classification differs across curation resources.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews lists FANCM among FA-associated genes; some ontology resources classify FANCM-related disease separately from canonical FA complementation groups."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCM"", ""notes"": ""DNA translocase that recognizes stalled replication forks and recruits the FA core complex. FANCM has historically been proposed as FA-M in some sources, but classification differs across curation resources.""}"
2660	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	8	UBE2T									Pathogenic Variants																										Also known as FANCT; E2 ubiquitin-conjugating enzyme that works with FANCL to monoubiquitinate FANCD2-FANCI.																						"{""association"": ""Pathogenic Variants"", ""name"": ""UBE2T"", ""notes"": ""Also known as FANCT; E2 ubiquitin-conjugating enzyme that works with FANCL to monoubiquitinate FANCD2-FANCI.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms UBE2T (FANCT) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""UBE2T"", ""notes"": ""Also known as FANCT; E2 ubiquitin-conjugating enzyme that works with FANCL to monoubiquitinate FANCD2-FANCI.""}"
2661	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	9	FANCD2									Pathogenic Variants																										Forms complex with FANCI; monoubiquitination is central to FA pathway activation and DNA repair.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCD2"", ""notes"": ""Forms complex with FANCI; monoubiquitination is central to FA pathway activation and DNA repair.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCD2 is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCD2"", ""notes"": ""Forms complex with FANCI; monoubiquitination is central to FA pathway activation and DNA repair.""}"
2662	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	10	FANCI									Pathogenic Variants																										Forms complex with FANCD2; phosphorylation and monoubiquitination regulate ICL repair.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FANCI"", ""notes"": ""Forms complex with FANCD2; phosphorylation and monoubiquitination regulate ICL repair.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCI is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""FANCI"", ""notes"": ""Forms complex with FANCD2; phosphorylation and monoubiquitination regulate ICL repair.""}"
2663	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	11	SLX4									Pathogenic Variants																										Also known as FANCP; nuclease scaffold protein that coordinates multiple nucleases for DNA unhooking.																						"{""association"": ""Pathogenic Variants"", ""name"": ""SLX4"", ""notes"": ""Also known as FANCP; nuclease scaffold protein that coordinates multiple nucleases for DNA unhooking.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms SLX4 (FANCP) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""SLX4"", ""notes"": ""Also known as FANCP; nuclease scaffold protein that coordinates multiple nucleases for DNA unhooking.""}"
2664	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	12	BRCA2									Pathogenic Variants																										Also known as FANCD1; essential for homologous recombination repair downstream of ICL unhooking.																						"{""association"": ""Pathogenic Variants"", ""name"": ""BRCA2"", ""notes"": ""Also known as FANCD1; essential for homologous recombination repair downstream of ICL unhooking.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms BRCA2 (FANCD1) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""BRCA2"", ""notes"": ""Also known as FANCD1; essential for homologous recombination repair downstream of ICL unhooking.""}"
2665	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	13	PALB2									Pathogenic Variants																										Also known as FANCN; partner and localizer of BRCA2, required for HR repair.																						"{""association"": ""Pathogenic Variants"", ""name"": ""PALB2"", ""notes"": ""Also known as FANCN; partner and localizer of BRCA2, required for HR repair.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms PALB2 (FANCN) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""PALB2"", ""notes"": ""Also known as FANCN; partner and localizer of BRCA2, required for HR repair.""}"
2666	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	14	BRCA1									Pathogenic Variants																										Also known as FANCS; involved in homologous recombination and DNA damage response.																						"{""association"": ""Pathogenic Variants"", ""name"": ""BRCA1"", ""notes"": ""Also known as FANCS; involved in homologous recombination and DNA damage response.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms BRCA1 (FANCS) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""BRCA1"", ""notes"": ""Also known as FANCS; involved in homologous recombination and DNA damage response.""}"
2667	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	15	BRIP1									Pathogenic Variants																										Also known as FANCJ/BACH1; BRCA1-interacting helicase involved in homologous recombination.																						"{""association"": ""Pathogenic Variants"", ""name"": ""BRIP1"", ""notes"": ""Also known as FANCJ/BACH1; BRCA1-interacting helicase involved in homologous recombination.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms BRIP1 (FANCJ) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""BRIP1"", ""notes"": ""Also known as FANCJ/BACH1; BRCA1-interacting helicase involved in homologous recombination.""}"
2668	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	16	ERCC4									Pathogenic Variants																										Also known as FANCQ/XPF; structure-specific nuclease with roles in interstrand crosslink and nucleotide excision repair.																						"{""association"": ""Pathogenic Variants"", ""name"": ""ERCC4"", ""notes"": ""Also known as FANCQ/XPF; structure-specific nuclease with roles in interstrand crosslink and nucleotide excision repair.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms ERCC4 (FANCQ) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""ERCC4"", ""notes"": ""Also known as FANCQ/XPF; structure-specific nuclease with roles in interstrand crosslink and nucleotide excision repair.""}"
2669	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	17	RAD51C									Pathogenic Variants																										Also known as FANCO; RAD51 paralog essential for homologous recombination.																						"{""association"": ""Pathogenic Variants"", ""name"": ""RAD51C"", ""notes"": ""Also known as FANCO; RAD51 paralog essential for homologous recombination.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51C (FANCO) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""RAD51C"", ""notes"": ""Also known as FANCO; RAD51 paralog essential for homologous recombination.""}"
2670	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	18	RAD51									Pathogenic Variants																										Also known as FANCR; dominant-negative heterozygous variants cause the autosomal dominant FA-R subtype.																						"{""association"": ""Pathogenic Variants"", ""name"": ""RAD51"", ""notes"": ""Also known as FANCR; dominant-negative heterozygous variants cause the autosomal dominant FA-R subtype.""}"	"{""inheritance"": [{""name"": ""Autosomal dominant""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51 (FANCR) as the autosomal dominant FA subtype gene."", ""reference"": ""PMID:20301575"", ""snippet"": ""a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal dominant""}], ""name"": ""RAD51"", ""notes"": ""Also known as FANCR; dominant-negative heterozygous variants cause the autosomal dominant FA-R subtype.""}"
2671	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	19	XRCC2									Pathogenic Variants																										Also known as FANCU; involved in homologous recombination repair.																						"{""association"": ""Pathogenic Variants"", ""name"": ""XRCC2"", ""notes"": ""Also known as FANCU; involved in homologous recombination repair.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms XRCC2 (FANCU) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""XRCC2"", ""notes"": ""Also known as FANCU; involved in homologous recombination repair.""}"
2672	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	20	MAD2L2									Pathogenic Variants																										Also known as REV7 and FANCV; component of DNA polymerase zeta for translesion synthesis.																						"{""association"": ""Pathogenic Variants"", ""name"": ""MAD2L2"", ""notes"": ""Also known as REV7 and FANCV; component of DNA polymerase zeta for translesion synthesis.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms MAD2L2/REV7 (FANCV) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""MAD2L2"", ""notes"": ""Also known as REV7 and FANCV; component of DNA polymerase zeta for translesion synthesis.""}"
2673	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	21	RFWD3									Pathogenic Variants																										Also known as FANCW; E3 ubiquitin ligase active at stalled replication forks that supports homologous recombination.																						"{""association"": ""Pathogenic Variants"", ""name"": ""RFWD3"", ""notes"": ""Also known as FANCW; E3 ubiquitin ligase active at stalled replication forks that supports homologous recombination.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RFWD3 (FANCW) is one of the 21 genes causing autosomal recessive Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""name"": ""RFWD3"", ""notes"": ""Also known as FANCW; E3 ubiquitin ligase active at stalled replication forks that supports homologous recombination.""}"
2674	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	22	ALDH2									Risk Modifier																										Aldehyde dehydrogenase 2; detoxifies acetaldehyde. ALDH2*2 variant accelerates bone marrow failure progression in FA patients.																						"{""association"": ""Risk Modifier"", ""name"": ""ALDH2"", ""notes"": ""Aldehyde dehydrogenase 2; detoxifies acetaldehyde. ALDH2*2 variant accelerates bone marrow failure progression in FA patients.""}"	{}	"{""association"": ""Risk Modifier"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study of 64 Japanese FA patients showed ALDH2 deficiency accelerates bone marrow failure progression."", ""reference"": ""PMID:24037726"", ""snippet"": ""the ALDH2 variant is associated with accelerated progression of BMF"", ""supports"": ""SUPPORT""}], ""name"": ""ALDH2"", ""notes"": ""Aldehyde dehydrogenase 2; detoxifies acetaldehyde. ALDH2*2 variant accelerates bone marrow failure progression in FA patients.""}"
2675	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	23	ADH5									Risk Modifier																										Alcohol dehydrogenase 5; detoxifies formaldehyde, providing tier-1 protection against aldehyde-induced DNA damage.																						"{""association"": ""Risk Modifier"", ""name"": ""ADH5"", ""notes"": ""Alcohol dehydrogenase 5; detoxifies formaldehyde, providing tier-1 protection against aldehyde-induced DNA damage.""}"	{}	"{""association"": ""Risk Modifier"", ""evidence"": [{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Demonstrates that ADH5 formaldehyde catabolism is essential in FA-deficient cells."", ""reference"": ""PMID:22081012"", ""snippet"": ""a synthetic lethal interaction in avian cells between ADH5, encoding the main formaldehyde-detoxifying enzyme, and the Fanconi anemia (FA) DNA-repair pathway"", ""supports"": ""SUPPORT""}], ""name"": ""ADH5"", ""notes"": ""Alcohol dehydrogenase 5; detoxifies formaldehyde, providing tier-1 protection against aldehyde-induced DNA damage.""}"
2676	116	Fanconi_Anemia	Fanconi_Anemia.yaml	genetic	24	KMT2D									Disease Modifier																										Histone methyltransferase; loss in squamous cell carcinomas can epigenetically suppress FA/BRCA gene expression under metabolic stress.																						"{""association"": ""Disease Modifier"", ""name"": ""KMT2D"", ""notes"": ""Histone methyltransferase; loss in squamous cell carcinomas can epigenetically suppress FA/BRCA gene expression under metabolic stress.""}"	{}	"{""association"": ""Disease Modifier"", ""name"": ""KMT2D"", ""notes"": ""Histone methyltransferase; loss in squamous cell carcinomas can epigenetically suppress FA/BRCA gene expression under metabolic stress.""}"
2823	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	genetic	0	ACVR1									Causative																										The c.617G>A (p.R206H) mutation is found in approximately 97% of classically affected individuals. One of the most highly conserved disease-causing mutations in the human genome.																						"{""association"": ""Causative"", ""name"": ""ACVR1"", ""notes"": ""The c.617G>A (p.R206H) mutation is found in approximately 97% of classically affected individuals. One of the most highly conserved disease-causing mutations in the human genome.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""The R206H mutation is identified as the causative mutation in all classic FOP cases and is highly conserved."", ""reference"": ""PMID:17572636"", ""snippet"": ""Substitution of adenine for guanine at nucleotide 617 replaces an evolutionarily conserved arginine with histidine at residue 206 of ACVR1 in all classically affected individuals, making this one of the most highly conserved disease-causing mutations in the human genome."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms R206H as the predominant mutation while noting variant cases."", ""reference"": ""PMID:29097342"", ""snippet"": ""Most patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder of heterotopic ossification, have the same causative mutation in ACVR1, R206H."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""ACVR1"", ""notes"": ""The c.617G>A (p.R206H) mutation is found in approximately 97% of classically affected individuals. One of the most highly conserved disease-causing mutations in the human genome.""}"
2847	118	Fibromyalgia	Fibromyalgia.yaml	genetic	0	COMT									Risk Factor																										Catecholamine metabolism																						"{""association"": ""Risk Factor"", ""name"": ""COMT"", ""notes"": ""Catecholamine metabolism""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""COMT"", ""notes"": ""Catecholamine metabolism""}"
2848	118	Fibromyalgia	Fibromyalgia.yaml	genetic	1	SLC6A4									Risk Factor																										Serotonin transporter																						"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter""}"
2849	118	Fibromyalgia	Fibromyalgia.yaml	genetic	2	HTR2A									Risk Factor																										Serotonin receptor																						"{""association"": ""Risk Factor"", ""name"": ""HTR2A"", ""notes"": ""Serotonin receptor""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HTR2A"", ""notes"": ""Serotonin receptor""}"
2850	118	Fibromyalgia	Fibromyalgia.yaml	genetic	3	TAAR1									Risk Factor																										Dopamine availability, pain sensitivity																						"{""association"": ""Risk Factor"", ""name"": ""TAAR1"", ""notes"": ""Dopamine availability, pain sensitivity""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TAAR1"", ""notes"": ""Dopamine availability, pain sensitivity""}"
2851	118	Fibromyalgia	Fibromyalgia.yaml	genetic	4	RGS4									Risk Factor																										Descending pain inhibition																						"{""association"": ""Risk Factor"", ""name"": ""RGS4"", ""notes"": ""Descending pain inhibition""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""RGS4"", ""notes"": ""Descending pain inhibition""}"
2852	118	Fibromyalgia	Fibromyalgia.yaml	genetic	5	CNR1									Risk Factor																										Cannabinoid receptor CB-1																						"{""association"": ""Risk Factor"", ""name"": ""CNR1"", ""notes"": ""Cannabinoid receptor CB-1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CNR1"", ""notes"": ""Cannabinoid receptor CB-1""}"
2853	118	Fibromyalgia	Fibromyalgia.yaml	genetic	6	GRIA4									Risk Factor																										Excitatory nociceptive transmission																						"{""association"": ""Risk Factor"", ""name"": ""GRIA4"", ""notes"": ""Excitatory nociceptive transmission""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""GRIA4"", ""notes"": ""Excitatory nociceptive transmission""}"
2854	118	Fibromyalgia	Fibromyalgia.yaml	genetic	7	TRPV2									Protective Factor																										TRP channel, protective haplotypes																						"{""association"": ""Protective Factor"", ""name"": ""TRPV2"", ""notes"": ""TRP channel, protective haplotypes""}"	{}	"{""association"": ""Protective Factor"", ""name"": ""TRPV2"", ""notes"": ""TRP channel, protective haplotypes""}"
2855	118	Fibromyalgia	Fibromyalgia.yaml	genetic	8	TRPV3									Risk Factor																										TRP channel, contributes to symptoms																						"{""association"": ""Risk Factor"", ""name"": ""TRPV3"", ""notes"": ""TRP channel, contributes to symptoms""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TRPV3"", ""notes"": ""TRP channel, contributes to symptoms""}"
2891	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	genetic	0	FMR1									Causative																										X-linked, CGG repeat expansion (>200 repeats), most common inherited cause of intellectual disability																						"{""association"": ""Causative"", ""name"": ""FMR1"", ""notes"": ""X-linked, CGG repeat expansion (>200 repeats), most common inherited cause of intellectual disability""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Review confirms FMR1 gene mutations cause Fragile X syndrome."", ""reference"": ""PMID:24346713"", ""snippet"": ""Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene."", ""supports"": ""SUPPORT""}], ""name"": ""FMR1"", ""notes"": ""X-linked, CGG repeat expansion (>200 repeats), most common inherited cause of intellectual disability""}"
2909	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	genetic	0	MAPT									Mutations cause autosomal dominant FTD with tau pathology																										Microtubule-associated protein tau gene on chromosome 17q21. Mutations lead to FTLD-tau pathology. Patients show earlier onset, prominent behavioral disinhibition, stereotyped behaviors, and temporal lobe predominance of atrophy.																						"{""association"": ""Mutations cause autosomal dominant FTD with tau pathology"", ""name"": ""MAPT"", ""notes"": ""Microtubule-associated protein tau gene on chromosome 17q21. Mutations lead to FTLD-tau pathology. Patients show earlier onset, prominent behavioral disinhibition, stereotyped behaviors, and temporal lobe predominance of atrophy.""}"	{}	"{""association"": ""Mutations cause autosomal dominant FTD with tau pathology"", ""evidence"": [{""explanation"": ""This confirms the distinct clinical and anatomical phenotype associated with MAPT mutations in frontotemporal dementia."", ""reference"": ""PMID:26473392"", ""snippet"": ""MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy."", ""supports"": ""SUPPORT""}], ""name"": ""MAPT"", ""notes"": ""Microtubule-associated protein tau gene on chromosome 17q21. Mutations lead to FTLD-tau pathology. Patients show earlier onset, prominent behavioral disinhibition, stereotyped behaviors, and temporal lobe predominance of atrophy.""}"
2910	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	genetic	1	GRN									Mutations cause autosomal dominant FTD with TDP-43 pathology																										Progranulin gene on chromosome 17q21. Haploinsufficiency leads to FTLD-TDP pathology. Patients more likely to present with non-fluent aphasia and are older at symptom onset. GRN and C9orf72 are the most frequent genetic causes.																						"{""association"": ""Mutations cause autosomal dominant FTD with TDP-43 pathology"", ""name"": ""GRN"", ""notes"": ""Progranulin gene on chromosome 17q21. Haploinsufficiency leads to FTLD-TDP pathology. Patients more likely to present with non-fluent aphasia and are older at symptom onset. GRN and C9orf72 are the most frequent genetic causes.""}"	{}	"{""association"": ""Mutations cause autosomal dominant FTD with TDP-43 pathology"", ""evidence"": [{""explanation"": ""This demonstrates the characteristic clinical presentation of GRN-related FTD with language deficits."", ""reference"": ""PMID:26473392"", ""snippet"": ""GRN patients were older at death and more likely to present with non-fluent aphasia."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms GRN as one of the two most common genetic causes of FTD."", ""reference"": ""PMID:30711676"", ""snippet"": ""Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs."", ""supports"": ""SUPPORT""}], ""name"": ""GRN"", ""notes"": ""Progranulin gene on chromosome 17q21. Haploinsufficiency leads to FTLD-TDP pathology. Patients more likely to present with non-fluent aphasia and are older at symptom onset. GRN and C9orf72 are the most frequent genetic causes.""}"
2911	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	genetic	2	C9orf72									Hexanucleotide repeat expansion causes autosomal dominant FTD, often with ALS																										Hexanucleotide (GGGGCC) repeat expansion on chromosome 9p21. Most common genetic cause of FTD. Causes FTLD-TDP pathology. Unique features include co-occurrence with ALS, psychotic symptoms, and paradoxically preserved social warmth.																						"{""association"": ""Hexanucleotide repeat expansion causes autosomal dominant FTD, often with ALS"", ""name"": ""C9orf72"", ""notes"": ""Hexanucleotide (GGGGCC) repeat expansion on chromosome 9p21. Most common genetic cause of FTD. Causes FTLD-TDP pathology. Unique features include co-occurrence with ALS, psychotic symptoms, and paradoxically preserved social warmth.""}"	{}	"{""association"": ""Hexanucleotide repeat expansion causes autosomal dominant FTD, often with ALS"", ""evidence"": [{""explanation"": ""This highlights the distinctive clinical features of C9orf72-related FTD including the frequent association with ALS and unique behavioral profile."", ""reference"": ""PMID:26473392"", ""snippet"": ""C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms C9orf72 as one of the most common genetic causes of FTD."", ""reference"": ""PMID:30711676"", ""snippet"": ""Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs."", ""supports"": ""SUPPORT""}], ""name"": ""C9orf72"", ""notes"": ""Hexanucleotide (GGGGCC) repeat expansion on chromosome 9p21. Most common genetic cause of FTD. Causes FTLD-TDP pathology. Unique features include co-occurrence with ALS, psychotic symptoms, and paradoxically preserved social warmth.""}"
2922	122	Galactosemia	Galactosemia.yaml	genetic	0	GALT variants (Classic galactosemia)																							"Classic galactosemia is caused by biallelic pathogenic variants in GALT (9p13.3). The most common variants include Q188R (most common in European populations), K285N, S135L, and L195P. The Duarte variant (N314D) causes partial enzyme deficiency.
"																																		"{""features"": ""Classic galactosemia is caused by biallelic pathogenic variants in GALT (9p13.3). The most common variants include Q188R (most common in European populations), K285N, S135L, and L195P. The Duarte variant (N314D) causes partial enzyme deficiency.\n"", ""name"": ""GALT variants (Classic galactosemia)""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""features"": ""Classic galactosemia is caused by biallelic pathogenic variants in GALT (9p13.3). The most common variants include Q188R (most common in European populations), K285N, S135L, and L195P. The Duarte variant (N314D) causes partial enzyme deficiency.\n"", ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""GALT variants (Classic galactosemia)""}"
2923	122	Galactosemia	Galactosemia.yaml	genetic	1	GALK1 variants (Galactokinase deficiency)																							"Caused by biallelic pathogenic variants in GALK1 (17q25.1).
"																																		"{""features"": ""Caused by biallelic pathogenic variants in GALK1 (17q25.1).\n"", ""name"": ""GALK1 variants (Galactokinase deficiency)""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""features"": ""Caused by biallelic pathogenic variants in GALK1 (17q25.1).\n"", ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""GALK1 variants (Galactokinase deficiency)""}"
2924	122	Galactosemia	Galactosemia.yaml	genetic	2	GALE variants (Epimerase deficiency)																							"Caused by biallelic pathogenic variants in GALE (1p36.11).
"																																		"{""features"": ""Caused by biallelic pathogenic variants in GALE (1p36.11).\n"", ""name"": ""GALE variants (Epimerase deficiency)""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""features"": ""Caused by biallelic pathogenic variants in GALE (1p36.11).\n"", ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""GALE variants (Epimerase deficiency)""}"
2946	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	genetic	0	CDH1									Somatic and Germline Mutations																										Somatic CDH1 alterations (mutation, deletion, methylation) occur in approximately 50% of diffuse-type gastric cancers. Germline CDH1 mutations cause hereditary diffuse gastric cancer (HDGC) syndrome with lifetime risk greater than 70%.																						"{""association"": ""Somatic and Germline Mutations"", ""name"": ""CDH1"", ""notes"": ""Somatic CDH1 alterations (mutation, deletion, methylation) occur in approximately 50% of diffuse-type gastric cancers. Germline CDH1 mutations cause hereditary diffuse gastric cancer (HDGC) syndrome with lifetime risk greater than 70%.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Somatic and Germline Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""CDH1"", ""notes"": ""Somatic CDH1 alterations (mutation, deletion, methylation) occur in approximately 50% of diffuse-type gastric cancers. Germline CDH1 mutations cause hereditary diffuse gastric cancer (HDGC) syndrome with lifetime risk greater than 70%.""}"
2947	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	genetic	1	TP53									Somatic Mutations																										TP53 mutations occur in approximately 30-50% of gastric cancers, particularly intestinal type. More common in advanced-stage disease.																						"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30-50% of gastric cancers, particularly intestinal type. More common in advanced-stage disease.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30-50% of gastric cancers, particularly intestinal type. More common in advanced-stage disease.""}"
2948	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	genetic	2	RHOA									Somatic Mutations																										RHOA mutations occur in approximately 15-25% of diffuse-type gastric cancer, affecting cell migration and invasion pathways.																						"{""association"": ""Somatic Mutations"", ""name"": ""RHOA"", ""notes"": ""RHOA mutations occur in approximately 15-25% of diffuse-type gastric cancer, affecting cell migration and invasion pathways.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""RHOA"", ""notes"": ""RHOA mutations occur in approximately 15-25% of diffuse-type gastric cancer, affecting cell migration and invasion pathways.""}"
2949	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	genetic	3	ARID1A									Somatic Mutations																										ARID1A, encoding a SWI/SNF chromatin remodeling complex subunit, is mutated in approximately 20% of gastric cancers, particularly those associated with EBV or microsatellite instability.																						"{""association"": ""Somatic Mutations"", ""name"": ""ARID1A"", ""notes"": ""ARID1A, encoding a SWI/SNF chromatin remodeling complex subunit, is mutated in approximately 20% of gastric cancers, particularly those associated with EBV or microsatellite instability.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""ARID1A"", ""notes"": ""ARID1A, encoding a SWI/SNF chromatin remodeling complex subunit, is mutated in approximately 20% of gastric cancers, particularly those associated with EBV or microsatellite instability.""}"
2979	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	genetic	0	FOXF1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""FOXF1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FOXF1""}"
2980	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	genetic	1	MHC region									Risk Factor																										Associated with Barrett's esophagus																						"{""association"": ""Risk Factor"", ""name"": ""MHC region"", ""notes"": ""Associated with Barrett's esophagus""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""MHC region"", ""notes"": ""Associated with Barrett's esophagus""}"
3000	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	genetic	0	KIT									Somatic Activating Mutations																										KIT mutations occur in approximately 85% of GISTs. Exon 11 mutations (juxtamembrane domain) are most common and predict good imatinib response. Exon 9 mutations require higher imatinib doses. Exon 13/17 mutations are less common.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""KIT"", ""notes"": ""KIT mutations occur in approximately 85% of GISTs. Exon 11 mutations (juxtamembrane domain) are most common and predict good imatinib response. Exon 9 mutations require higher imatinib doses. Exon 13/17 mutations are less common.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""KIT"", ""notes"": ""KIT mutations occur in approximately 85% of GISTs. Exon 11 mutations (juxtamembrane domain) are most common and predict good imatinib response. Exon 9 mutations require higher imatinib doses. Exon 13/17 mutations are less common.""}"
3001	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	genetic	1	PDGFRA									Somatic Activating Mutations																										PDGFRA mutations occur in approximately 10% of GISTs. The D842V mutation in exon 18 is most common and confers primary resistance to imatinib but responds to avapritinib.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""PDGFRA"", ""notes"": ""PDGFRA mutations occur in approximately 10% of GISTs. The D842V mutation in exon 18 is most common and confers primary resistance to imatinib but responds to avapritinib.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""PDGFRA"", ""notes"": ""PDGFRA mutations occur in approximately 10% of GISTs. The D842V mutation in exon 18 is most common and confers primary resistance to imatinib but responds to avapritinib.""}"
3022	127	Gaucher Disease	Gaucher_Disease.yaml	genetic	0	GBA									Causative																										Autosomal recessive, N370S most common in Ashkenazi Jewish, L444P associated with neuronopathic forms																						"{""association"": ""Causative"", ""name"": ""GBA"", ""notes"": ""Autosomal recessive, N370S most common in Ashkenazi Jewish, L444P associated with neuronopathic forms""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Review confirms glucocerebrosidase (encoded by GBA) deficiency causes the disease."", ""reference"": ""PMID:28218669"", ""snippet"": ""It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages."", ""supports"": ""SUPPORT""}], ""name"": ""GBA"", ""notes"": ""Autosomal recessive, N370S most common in Ashkenazi Jewish, L444P associated with neuronopathic forms""}"
3045	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	genetic	0	SLC6A4									Risk Factor																										Serotonin transporter																						"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter""}"
3046	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	genetic	1	COMT									Risk Factor																										Catecholamine metabolism																						"{""association"": ""Risk Factor"", ""name"": ""COMT"", ""notes"": ""Catecholamine metabolism""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""COMT"", ""notes"": ""Catecholamine metabolism""}"
3047	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	genetic	2	CRHR1									Risk Factor																										CRH receptor																						"{""association"": ""Risk Factor"", ""name"": ""CRHR1"", ""notes"": ""CRH receptor""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CRHR1"", ""notes"": ""CRH receptor""}"
3048	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	genetic	3	NPY									Risk Factor																										Neuropeptide Y																						"{""association"": ""Risk Factor"", ""name"": ""NPY"", ""notes"": ""Neuropeptide Y""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""NPY"", ""notes"": ""Neuropeptide Y""}"
3074	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	genetic	0	HLA-DRB1*04									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*04""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*04""}"
3093	130	Glaucoma	Glaucoma.yaml	genetic	0	MYOC									Causative																										Primary open-angle glaucoma																						"{""association"": ""Causative"", ""name"": ""MYOC"", ""notes"": ""Primary open-angle glaucoma""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Establishes MYOC as a causative gene for POAG, accounting for a significant proportion of cases."", ""reference"": ""PMID:37217093"", ""snippet"": ""Mutations in the gene MYOC account for approximately 5% of cases of primary open angle glaucoma (POAG)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates tissue-specific pathogenicity of MYOC mutations in the trabecular meshwork of the eye."", ""reference"": ""PMID:37217093"", ""snippet"": ""While myocilin is expressed in numerous tissues, mutant myocilin is only associated with disease in the anterior segment of the eye, in the trabecular meshwork."", ""supports"": ""SUPPORT""}], ""name"": ""MYOC"", ""notes"": ""Primary open-angle glaucoma""}"
3094	130	Glaucoma	Glaucoma.yaml	genetic	1	OPTN									Risk Factor																										Normal-tension glaucoma																						"{""association"": ""Risk Factor"", ""name"": ""OPTN"", ""notes"": ""Normal-tension glaucoma""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Confirms OPTN mutations as a genetic risk factor for primary open angle glaucoma."", ""reference"": ""PMID:26302410"", ""snippet"": ""Certain mutations in optineurin (gene OPTN) are associated with primary open angle glaucoma."", ""supports"": ""SUPPORT""}, {""explanation"": ""Explains how OPTN variants contribute to glaucoma through dysregulated autophagy in retinal cells."", ""reference"": ""PMID:26302410"", ""snippet"": ""Thus, an optimum level of optineurin-mediated autophagy is crucial for survival of retinal cells, and impaired autophagy is likely to contribute to glaucoma pathogenesis."", ""supports"": ""SUPPORT""}], ""name"": ""OPTN"", ""notes"": ""Normal-tension glaucoma""}"
3095	130	Glaucoma	Glaucoma.yaml	genetic	2	WDR36									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""WDR36""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""WDR36""}"
3096	130	Glaucoma	Glaucoma.yaml	genetic	3	CAV1/CAV2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CAV1/CAV2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CAV1/CAV2""}"
3120	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	0	TERT									Promoter Mutation																										TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. Creates ETS binding sites leading to telomerase reactivation. One of three defining molecular features for diagnosis.																						"{""association"": ""Promoter Mutation"", ""name"": ""TERT"", ""notes"": ""TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. Creates ETS binding sites leading to telomerase reactivation. One of three defining molecular features for diagnosis.""}"	{}	"{""association"": ""Promoter Mutation"", ""evidence"": [{""explanation"": ""Abstract reports TERT promoter mutations in the majority of IDH-wildtype glioblastomas."", ""reference"": ""PMID:30333046"", ""snippet"": ""TERT promoter (TERTp) mutations are found in the majority of World Health Organization (WHO) grade IV adult IDH wild-type glioblastoma (IDH-wt GBM)."", ""supports"": ""SUPPORT""}], ""name"": ""TERT"", ""notes"": ""TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. Creates ETS binding sites leading to telomerase reactivation. One of three defining molecular features for diagnosis.""}"
3121	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	1	EGFR									Amplification																										EGFR amplification occurs in 40-50% of cases. EGFRvIII variant (deletion of exons 2-7) present in approximately 50% of EGFR-amplified tumors. EGFR amplification is one of three defining molecular features.																						"{""association"": ""Amplification"", ""name"": ""EGFR"", ""notes"": ""EGFR amplification occurs in 40-50% of cases. EGFRvIII variant (deletion of exons 2-7) present in approximately 50% of EGFR-amplified tumors. EGFR amplification is one of three defining molecular features.""}"	{}	"{""association"": ""Amplification"", ""name"": ""EGFR"", ""notes"": ""EGFR amplification occurs in 40-50% of cases. EGFRvIII variant (deletion of exons 2-7) present in approximately 50% of EGFR-amplified tumors. EGFR amplification is one of three defining molecular features.""}"
3122	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	2	PTEN									Loss/Mutation																										PTEN is lost or mutated in 40-50% of glioblastomas through chromosome 10 loss, mutation, or promoter methylation. Loss activates PI3K/AKT signaling.																						"{""association"": ""Loss/Mutation"", ""name"": ""PTEN"", ""notes"": ""PTEN is lost or mutated in 40-50% of glioblastomas through chromosome 10 loss, mutation, or promoter methylation. Loss activates PI3K/AKT signaling.""}"	{}	"{""association"": ""Loss/Mutation"", ""name"": ""PTEN"", ""notes"": ""PTEN is lost or mutated in 40-50% of glioblastomas through chromosome 10 loss, mutation, or promoter methylation. Loss activates PI3K/AKT signaling.""}"
3123	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	3	CDKN2A/CDKN2B									Homozygous Deletion																										Homozygous deletion of CDKN2A/CDKN2B at 9p21 occurs in approximately 60% of glioblastomas. Eliminates p16INK4a and p14ARF tumor suppressors, disrupting both RB and p53 pathways.																						"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A/CDKN2B"", ""notes"": ""Homozygous deletion of CDKN2A/CDKN2B at 9p21 occurs in approximately 60% of glioblastomas. Eliminates p16INK4a and p14ARF tumor suppressors, disrupting both RB and p53 pathways.""}"	{}	"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A/CDKN2B"", ""notes"": ""Homozygous deletion of CDKN2A/CDKN2B at 9p21 occurs in approximately 60% of glioblastomas. Eliminates p16INK4a and p14ARF tumor suppressors, disrupting both RB and p53 pathways.""}"
3124	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	4	TP53									Somatic Mutation																										TP53 mutations occur in approximately 30% of IDH-wildtype glioblastomas, less common than in IDH-mutant tumors.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of IDH-wildtype glioblastomas, less common than in IDH-mutant tumors.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of IDH-wildtype glioblastomas, less common than in IDH-mutant tumors.""}"
3125	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	genetic	5	NF1									Somatic Mutation																										NF1 mutations occur in approximately 10-15% of glioblastomas, activating RAS/MAPK signaling. More common in mesenchymal subtype.																						"{""association"": ""Somatic Mutation"", ""name"": ""NF1"", ""notes"": ""NF1 mutations occur in approximately 10-15% of glioblastomas, activating RAS/MAPK signaling. More common in mesenchymal subtype.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""NF1"", ""notes"": ""NF1 mutations occur in approximately 10-15% of glioblastomas, activating RAS/MAPK signaling. More common in mesenchymal subtype.""}"
3153	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	genetic	0	G6PD								Pathogenic Variants																																																	"{""name"": ""G6PD"", ""presence"": ""Pathogenic Variants""}"	"{""inheritance"": [{""name"": ""X-linked recessive""}]}"	"{""evidence"": [{""explanation"": ""The snippet indicates that G6PD deficiency is caused by mutations in the X-linked gene G6PD, which aligns with the statement about the genetic inheritance being X-linked recessive."", ""reference"": ""PMID:32702756"", ""snippet"": ""Glucose 6-phosphate dehydrogenase (G6PD) deficiency is 1 of the commonest human enzymopathies, caused by inherited mutations of the X-linked gene G6PD."", ""supports"": ""SUPPORT""}, {""explanation"": ""The snippet explicitly mentions that G6PD deficiency is an X-linked recessive disorder."", ""reference"": ""PMID:33560519"", ""snippet"": ""Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited X-linked recessive disorder."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference specifies the location of the G6PD gene on the X-chromosome and indicates that the disorder is inherited in a recessive manner."", ""reference"": ""PMID:24460025"", ""snippet"": ""Glucose-6-Phosphate Dehydrogenase (G6PD) gene is located at the X-chromosome at Xq28 and the disease is recessively inherited predominantly in males."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""X-linked recessive""}], ""name"": ""G6PD"", ""presence"": ""Pathogenic Variants""}"
3178	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	genetic	0	PTCH1			VERY_FREQUENT						Causative (Primary)																										PTCH1 mutations account for approximately 85-95% of Gorlin syndrome cases. The gene is located on chromosome 9q22.3. Over 300 different pathogenic variants have been reported, including frameshift, nonsense, splice site, and missense mutations. Large deletions may occur. Penetrance is high but expressivity is variable.																						"{""association"": ""Causative (Primary)"", ""frequency"": ""VERY_FREQUENT"", ""name"": ""PTCH1"", ""notes"": ""PTCH1 mutations account for approximately 85-95% of Gorlin syndrome cases. The gene is located on chromosome 9q22.3. Over 300 different pathogenic variants have been reported, including frameshift, nonsense, splice site, and missense mutations. Large deletions may occur. Penetrance is high but expressivity is variable.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative (Primary)"", ""evidence"": [{""explanation"": ""Large cohort study confirming PTCH1 as the predominant causative gene in Gorlin syndrome."", ""reference"": ""PMID:28596197"", ""snippet"": ""A total of 126 patients had a heterozygous pathogenic variant, 9 had SUFU pathogenic variants and 46 had no identified mutation."", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates genotype-phenotype correlation with milder disease in missense variant carriers."", ""reference"": ""PMID:28596197"", ""snippet"": ""Patients with a missense variant in PTCH1 were diagnosed later (p=0.03) and were less likely to develop at least 10 BCCs and jaw cysts than those with other pathogenic PTCH1 variants."", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""PTCH1"", ""notes"": ""PTCH1 mutations account for approximately 85-95% of Gorlin syndrome cases. The gene is located on chromosome 9q22.3. Over 300 different pathogenic variants have been reported, including frameshift, nonsense, splice site, and missense mutations. Large deletions may occur. Penetrance is high but expressivity is variable.""}"
3179	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	genetic	1	SUFU			OCCASIONAL						Causative (Alternative)																										SUFU mutations account for approximately 5% of Gorlin syndrome cases. SUFU mutations are associated with a markedly higher risk of medulloblastoma (up to 20-fold) and meningioma compared to PTCH1 mutations, but lower rates of jaw cysts.																						"{""association"": ""Causative (Alternative)"", ""frequency"": ""OCCASIONAL"", ""name"": ""SUFU"", ""notes"": ""SUFU mutations account for approximately 5% of Gorlin syndrome cases. SUFU mutations are associated with a markedly higher risk of medulloblastoma (up to 20-fold) and meningioma compared to PTCH1 mutations, but lower rates of jaw cysts.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Causative (Alternative)"", ""evidence"": [{""explanation"": ""Establishes SUFU as a causative gene for Gorlin syndrome."", ""reference"": ""PMID:25403219"", ""snippet"": ""We demonstrate convincing evidence that SUFU mutations can cause classical Gorlin syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents distinct phenotypic spectrum in SUFU versus PTCH1 mutation carriers."", ""reference"": ""PMID:28596197"", ""snippet"": ""Patients with SUFU pathogenic variants were significantly more likely than those with PTCH1 pathogenic variants to develop a medulloblastoma (p=0.009), a meningioma (p=0.02) or an ovarian fibroma (p=0.015), but were less likely to develop a jaw cyst (p=0.0004)."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""SUFU"", ""notes"": ""SUFU mutations account for approximately 5% of Gorlin syndrome cases. SUFU mutations are associated with a markedly higher risk of medulloblastoma (up to 20-fold) and meningioma compared to PTCH1 mutations, but lower rates of jaw cysts.""}"
3211	134	Gout	Gout.yaml	genetic	0	SLC2A9									Risk Factor																										Major urate transporter																						"{""association"": ""Risk Factor"", ""name"": ""SLC2A9"", ""notes"": ""Major urate transporter""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC2A9"", ""notes"": ""Major urate transporter""}"
3212	134	Gout	Gout.yaml	genetic	1	ABCG2									Risk Factor																										Urate efflux transporter																						"{""association"": ""Risk Factor"", ""name"": ""ABCG2"", ""notes"": ""Urate efflux transporter""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ABCG2"", ""notes"": ""Urate efflux transporter""}"
3213	134	Gout	Gout.yaml	genetic	2	SLC22A12									Risk Factor																										URAT1 urate reabsorption																						"{""association"": ""Risk Factor"", ""name"": ""SLC22A12"", ""notes"": ""URAT1 urate reabsorption""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC22A12"", ""notes"": ""URAT1 urate reabsorption""}"
3231	135	Grange syndrome	Grange_syndrome.yaml	genetic	0	YY1AP1									Causal																										Autosomal recessive biallelic loss-of-function mutations in YY1AP1 (YY1-associated protein 1) cause Grange syndrome. YY1AP1 encodes a ~90 kDa nuclear protein that associates with the transcription factor YY1 and is a core component of the INO80 ATP-dependent chromatin-remodeling complex. Loss-of-function mutations impair VSMC differentiation and vascular homeostasis, leading to systemic vascular stenosis and occlusions.																						"{""association"": ""Causal"", ""name"": ""YY1AP1"", ""notes"": ""Autosomal recessive biallelic loss-of-function mutations in YY1AP1 (YY1-associated protein 1) cause Grange syndrome. YY1AP1 encodes a ~90 kDa nuclear protein that associates with the transcription factor YY1 and is a core component of the INO80 ATP-dependent chromatin-remodeling complex. Loss-of-function mutations impair VSMC differentiation and vascular homeostasis, leading to systemic vascular stenosis and occlusions.""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""Guo et al. 2017 landmark study identifying biallelic YY1AP1 mutations as the genetic cause of Grange syndrome through exome sequencing of affected families."", ""reference"": ""PMID:27939641"", ""snippet"": ""Exome-sequencing analysis of DNA from three affected siblings with Grange syndrome identified compound heterozygous nonsense variants in YY1AP1, and homozygous nonsense or frameshift YY1AP1 variants were subsequently identified in additional unrelated probands with Grange syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""Raggio et al. 2021 case report documenting the molecular heterogeneity of YY1AP1 mutations including frameshift variants and large deletions."", ""reference"": ""PMID:33971976"", ""snippet"": ""We found a frameshift variant in one copy and a large deletion involving two exons in the other copy of a gene called YY1AP1."", ""supports"": ""SUPPORT""}, {""explanation"": ""Karakaya et al. 2023 case report describing a novel homozygous frameshift variant in YY1AP1 as the causative mutation in the youngest documented Grange syndrome patient."", ""reference"": ""PMID:37323195"", ""snippet"": ""subsequently confirmed to carry a novel homozygous frameshift variant (c.2291del; p.Pro764Leufs*12) in the YY1AP1 gene through whole-exome sequencing."", ""supports"": ""SUPPORT""}, {""explanation"": ""Viora-Dupont et al. 2023 reports the first homozygous intragenic deletion in YY1AP1, expanding the spectrum of pathogenic mutations that cause Grange syndrome beyond frameshift and nonsense variants."", ""reference"": ""PMID:37698238"", ""snippet"": ""Copy number variant analysis from exome data identified a homozygous intragenic out-of-frame deletion of 1.84 kb encompassing exons seven and eight of YY1AP1, confirming a molecular diagnosis of GRNG."", ""supports"": ""SUPPORT""}, {""explanation"": ""Rath et al. 2019 reports the first identification of pathogenic YY1AP1 splice variants in intronic regions causing Grange syndrome, expanding the mutation spectrum to include deep intronic variants that would be missed by standard exome sequencing."", ""reference"": ""PMID:30556293"", ""snippet"": ""Whole exome sequencing including near-splice regions led to the identification of two intronic YY1AP1 variants which were predicted to interfere with normal splicing... RT-PCR analyses confirmed skipping of exon 6 on one allele and exonization of 22 bp in intron 6 on the other."", ""supports"": ""SUPPORT""}, {""explanation"": ""Ciuffetelli et al. 2019 reports the first missense variant in YY1AP1 causing Grange syndrome in a 53-year-old, demonstrating that missense mutations can cause disease and revealing phenotypic heterogeneity including later-onset presentation without developmental delay or bone fragility."", ""reference"": ""PMID:31633303"", ""snippet"": ""Grange syndrome is caused by homozygous or compound heterozygous loss-of-function variants in the YYA1P1 gene... This is the first report of a missense variant associated with Grange syndrome characterized by later onset of vascular disease and a lack of developmental delay and bone fragility."", ""supports"": ""SUPPORT""}, {""explanation"": ""Saida et al. 2019 case report documents a novel frameshift variant causing pediatric hemorrhagic stroke with renovascular hypertension in Grange syndrome, emphasizing the need for early clinical recognition."", ""reference"": ""PMID:31270375"", ""snippet"": ""We report the case of a 7-year-old girl with Grange syndrome who showed RVH and multiple seizure episodes... a novel homozygous pathogenic variant in the YY1AP1 gene (NM_001198903.1: c.1169del: p.Lys390Argfs*12)."", ""supports"": ""SUPPORT""}], ""name"": ""YY1AP1"", ""notes"": ""Autosomal recessive biallelic loss-of-function mutations in YY1AP1 (YY1-associated protein 1) cause Grange syndrome. YY1AP1 encodes a ~90 kDa nuclear protein that associates with the transcription factor YY1 and is a core component of the INO80 ATP-dependent chromatin-remodeling complex. Loss-of-function mutations impair VSMC differentiation and vascular homeostasis, leading to systemic vascular stenosis and occlusions.""}"
3250	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	genetic	0	HLA-DP									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DP""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DP""}"
3251	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	genetic	1	SERPINA1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""SERPINA1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SERPINA1""}"
3271	137	Graves' Disease	Graves_Disease.yaml	genetic	0	HLA-DRB1									Risk Factor																										Major HLA class II susceptibility locus; mediates antigen presentation of TSHR peptides to autoreactive T cells.																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1"", ""notes"": ""Major HLA class II susceptibility locus; mediates antigen presentation of TSHR peptides to autoreactive T cells.""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This study suggests that variants within the HLA region, including DRB1 (which encompasses HLA-DR3), are associated with Graves' disease, supporting the statement that HLA-DR3 is a risk factor."", ""reference"": ""PMID:30484670"", ""snippet"": ""Within HLA, some variants of the DRB1, DQA1 and DQB1 genes appear to be possible predictors of the development and recurrence of Graves' disease."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1"", ""notes"": ""Major HLA class II susceptibility locus; mediates antigen presentation of TSHR peptides to autoreactive T cells.""}"
3272	137	Graves' Disease	Graves_Disease.yaml	genetic	1	CTLA4									Risk Factor																										Immune checkpoint gene that modulates T cell tolerance; genetic variants increase susceptibility to Graves' disease.																						"{""association"": ""Risk Factor"", ""name"": ""CTLA4"", ""notes"": ""Immune checkpoint gene that modulates T cell tolerance; genetic variants increase susceptibility to Graves' disease.""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This case-control and family study demonstrates that CTLA4 polymorphisms confer genetic susceptibility to Graves' disease."", ""reference"": ""PMID:10404810"", ""snippet"": ""An increase in frequency of the G (alanine) allele was seen in Graves' patients compared with control subjects (42% vs. 31.5%, respectively; corrected P<0.0002; odds ratio = 1.58)"", ""supports"": ""SUPPORT""}], ""name"": ""CTLA4"", ""notes"": ""Immune checkpoint gene that modulates T cell tolerance; genetic variants increase susceptibility to Graves' disease.""}"
3273	137	Graves' Disease	Graves_Disease.yaml	genetic	2	PTPN22									Risk Factor																										Immune regulatory phosphatase affecting T cell signaling; susceptibility locus for autoimmune disorders including Graves' disease.																						"{""association"": ""Risk Factor"", ""name"": ""PTPN22"", ""notes"": ""Immune regulatory phosphatase affecting T cell signaling; susceptibility locus for autoimmune disorders including Graves' disease.""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This meta-analysis of 18 studies demonstrates that PTPN22 R620W polymorphism is associated with Graves' disease susceptibility."", ""reference"": ""PMID:33103521"", ""snippet"": ""the T allele significantly increased AITD susceptibility in all genetic models involving Caucasians"", ""supports"": ""SUPPORT""}], ""name"": ""PTPN22"", ""notes"": ""Immune regulatory phosphatase affecting T cell signaling; susceptibility locus for autoimmune disorders including Graves' disease.""}"
3274	137	Graves' Disease	Graves_Disease.yaml	genetic	3	CD40									Risk Factor																										B-T costimulatory receptor required for germinal center reactions and TRAb generation.																						"{""association"": ""Risk Factor"", ""name"": ""CD40"", ""notes"": ""B-T costimulatory receptor required for germinal center reactions and TRAb generation.""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This study mapped CD40 as a susceptibility gene for Graves' disease through linkage and association analyses."", ""reference"": ""PMID:12593727"", ""snippet"": ""our results suggested that the CD40 gene was a new susceptibility gene for GD within certain families because it was both linked and associated with GD"", ""supports"": ""SUPPORT""}], ""name"": ""CD40"", ""notes"": ""B-T costimulatory receptor required for germinal center reactions and TRAb generation.""}"
3275	137	Graves' Disease	Graves_Disease.yaml	genetic	4	FCRL3									Risk Factor																										B cell receptor with genetic association to Graves' disease susceptibility.																						"{""association"": ""Risk Factor"", ""name"": ""FCRL3"", ""notes"": ""B cell receptor with genetic association to Graves' disease susceptibility.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FCRL3"", ""notes"": ""B cell receptor with genetic association to Graves' disease susceptibility.""}"
3276	137	Graves' Disease	Graves_Disease.yaml	genetic	5	TSHR									Risk Factor																										Principal autoantigen; thyrotropin receptor gene variants contribute to disease susceptibility in addition to being the primary target of autoantibodies.																						"{""association"": ""Risk Factor"", ""name"": ""TSHR"", ""notes"": ""Principal autoantigen; thyrotropin receptor gene variants contribute to disease susceptibility in addition to being the primary target of autoantibodies.""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This meta-analysis demonstrates that TSHR gene polymorphisms are significantly associated with Graves' disease susceptibility across Asian, European, and South American populations."", ""reference"": ""PMID:27231040"", ""snippet"": ""both TSHR rs179247A/G and rs12101255T/C polymorphism had significant association with GD"", ""supports"": ""SUPPORT""}], ""name"": ""TSHR"", ""notes"": ""Principal autoantigen; thyrotropin receptor gene variants contribute to disease susceptibility in addition to being the primary target of autoantibodies.""}"
3320	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	0	H3F3A									Somatic Mutation (K27M)																										H3F3A encodes the replication-independent histone variant H3.3. K27M mutation is most common in DIPG (approximately 80%) and thalamic tumors. H3.3 K27M is associated with slightly older age at diagnosis (median 6-7 years).																						"{""association"": ""Somatic Mutation (K27M)"", ""name"": ""H3F3A"", ""notes"": ""H3F3A encodes the replication-independent histone variant H3.3. K27M mutation is most common in DIPG (approximately 80%) and thalamic tumors. H3.3 K27M is associated with slightly older age at diagnosis (median 6-7 years).""}"	{}	"{""association"": ""Somatic Mutation (K27M)"", ""name"": ""H3F3A"", ""notes"": ""H3F3A encodes the replication-independent histone variant H3.3. K27M mutation is most common in DIPG (approximately 80%) and thalamic tumors. H3.3 K27M is associated with slightly older age at diagnosis (median 6-7 years).""}"
3321	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	1	HIST1H3B/HIST1H3C									Somatic Mutation (K27M)																										HIST1H3B and HIST1H3C encode replication-dependent histone H3.1 variants. H3.1 K27M mutations occur in approximately 15% of DIPG, associated with younger age, ACVR1 mutations, and slightly better prognosis.																						"{""association"": ""Somatic Mutation (K27M)"", ""name"": ""HIST1H3B/HIST1H3C"", ""notes"": ""HIST1H3B and HIST1H3C encode replication-dependent histone H3.1 variants. H3.1 K27M mutations occur in approximately 15% of DIPG, associated with younger age, ACVR1 mutations, and slightly better prognosis.""}"	{}	"{""association"": ""Somatic Mutation (K27M)"", ""name"": ""HIST1H3B/HIST1H3C"", ""notes"": ""HIST1H3B and HIST1H3C encode replication-dependent histone H3.1 variants. H3.1 K27M mutations occur in approximately 15% of DIPG, associated with younger age, ACVR1 mutations, and slightly better prognosis.""}"
3322	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	2	ACVR1									Somatic Mutation																										ACVR1 (activin A receptor type I, also known as ALK2) mutations occur in approximately 20-30% of DIPG, almost exclusively co-occurring with H3.1 K27M. These activating mutations drive BMP signaling and are also found in fibrodysplasia ossificans progressiva.																						"{""association"": ""Somatic Mutation"", ""name"": ""ACVR1"", ""notes"": ""ACVR1 (activin A receptor type I, also known as ALK2) mutations occur in approximately 20-30% of DIPG, almost exclusively co-occurring with H3.1 K27M. These activating mutations drive BMP signaling and are also found in fibrodysplasia ossificans progressiva.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""ACVR1"", ""notes"": ""ACVR1 (activin A receptor type I, also known as ALK2) mutations occur in approximately 20-30% of DIPG, almost exclusively co-occurring with H3.1 K27M. These activating mutations drive BMP signaling and are also found in fibrodysplasia ossificans progressiva.""}"
3323	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	3	TP53									Somatic Mutation																										TP53 mutations occur in approximately 40-50% of DIPG, often co-occurring with H3.3 K27M. Associated with worse prognosis.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 40-50% of DIPG, often co-occurring with H3.3 K27M. Associated with worse prognosis.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 40-50% of DIPG, often co-occurring with H3.3 K27M. Associated with worse prognosis.""}"
3324	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	4	PPM1D									Somatic Mutation																										PPM1D (protein phosphatase Mg2+/Mn2+ dependent 1D) truncating mutations occur in approximately 10-15% of DIPG, functionally similar to TP53 loss.																						"{""association"": ""Somatic Mutation"", ""name"": ""PPM1D"", ""notes"": ""PPM1D (protein phosphatase Mg2+/Mn2+ dependent 1D) truncating mutations occur in approximately 10-15% of DIPG, functionally similar to TP53 loss.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""PPM1D"", ""notes"": ""PPM1D (protein phosphatase Mg2+/Mn2+ dependent 1D) truncating mutations occur in approximately 10-15% of DIPG, functionally similar to TP53 loss.""}"
3325	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	5	PDGFRA									Amplification/Mutation																										PDGFRA amplification or activating mutations occur in approximately 30% of DIPG. Drives proliferation through RTK signaling.																						"{""association"": ""Amplification/Mutation"", ""name"": ""PDGFRA"", ""notes"": ""PDGFRA amplification or activating mutations occur in approximately 30% of DIPG. Drives proliferation through RTK signaling.""}"	{}	"{""association"": ""Amplification/Mutation"", ""name"": ""PDGFRA"", ""notes"": ""PDGFRA amplification or activating mutations occur in approximately 30% of DIPG. Drives proliferation through RTK signaling.""}"
3326	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	genetic	6	EZHIP									Overexpression																										EZHIP (EZH inhibitory protein) overexpression can cause H3K27me3 loss in the absence of H3 K27M mutation. Defines a subset of H3 K27-altered tumors that lack histone mutations but have similar epigenetic phenotype.																						"{""association"": ""Overexpression"", ""name"": ""EZHIP"", ""notes"": ""EZHIP (EZH inhibitory protein) overexpression can cause H3K27me3 loss in the absence of H3 K27M mutation. Defines a subset of H3 K27-altered tumors that lack histone mutations but have similar epigenetic phenotype.""}"	{}	"{""association"": ""Overexpression"", ""name"": ""EZHIP"", ""notes"": ""EZHIP (EZH inhibitory protein) overexpression can cause H3K27me3 loss in the absence of H3 K27M mutation. Defines a subset of H3 K27-altered tumors that lack histone mutations but have similar epigenetic phenotype.""}"
3344	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	genetic	0	ERBB2									Somatic Amplification																										ERBB2 (17q12) encodes the HER2 receptor tyrosine kinase. Amplification occurs somatically and is not inherited. The amplicon often includes neighboring genes including GRB7 and TOP2A. Amplification level correlates with HER2 protein expression and response to HER2-targeted therapy.																						"{""association"": ""Somatic Amplification"", ""name"": ""ERBB2"", ""notes"": ""ERBB2 (17q12) encodes the HER2 receptor tyrosine kinase. Amplification occurs somatically and is not inherited. The amplicon often includes neighboring genes including GRB7 and TOP2A. Amplification level correlates with HER2 protein expression and response to HER2-targeted therapy.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Amplification"", ""evidence"": [{""explanation"": ""Abstract reports HER2 amplification frequency in breast cancer."", ""reference"": ""PMID:23628726"", ""snippet"": ""HER2 gene amplification is observed in about 15% of breast cancers."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""ERBB2"", ""notes"": ""ERBB2 (17q12) encodes the HER2 receptor tyrosine kinase. Amplification occurs somatically and is not inherited. The amplicon often includes neighboring genes including GRB7 and TOP2A. Amplification level correlates with HER2 protein expression and response to HER2-targeted therapy.""}"
3345	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	genetic	1	PIK3CA									Co-occurring Mutations																										PIK3CA mutations occur in approximately 30% of HER2+ breast cancers and may confer resistance to HER2-targeted therapy. Testing is recommended for treatment selection (alpelisib in ER+/HER2+ cases).																						"{""association"": ""Co-occurring Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 30% of HER2+ breast cancers and may confer resistance to HER2-targeted therapy. Testing is recommended for treatment selection (alpelisib in ER+/HER2+ cases).""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Co-occurring Mutations"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 30% of HER2+ breast cancers and may confer resistance to HER2-targeted therapy. Testing is recommended for treatment selection (alpelisib in ER+/HER2+ cases).""}"
3362	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	genetic	0	ERBB2 (HER2)									Somatic Amplification																										ERBB2 amplification occurs in 3-5% of metastatic CRC, enriched in RAS/BRAF wild-type tumors where it may represent 5-14%. Amplification is the primary mechanism, though activating mutations also occur rarely. Copy number correlates with response to HER2-targeted therapy.																						"{""association"": ""Somatic Amplification"", ""name"": ""ERBB2 (HER2)"", ""notes"": ""ERBB2 amplification occurs in 3-5% of metastatic CRC, enriched in RAS/BRAF wild-type tumors where it may represent 5-14%. Amplification is the primary mechanism, though activating mutations also occur rarely. Copy number correlates with response to HER2-targeted therapy.""}"	{}	"{""association"": ""Somatic Amplification"", ""name"": ""ERBB2 (HER2)"", ""notes"": ""ERBB2 amplification occurs in 3-5% of metastatic CRC, enriched in RAS/BRAF wild-type tumors where it may represent 5-14%. Amplification is the primary mechanism, though activating mutations also occur rarely. Copy number correlates with response to HER2-targeted therapy.""}"
3363	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	genetic	1	ERBB2 Activating Mutations									Somatic Activating Mutation																										Activating mutations in ERBB2 (e.g., S310F, L755S, V777L) occur in approximately 2% of CRC and may respond to HER2-targeted therapies. These are distinct from amplification and can co-occur with RAS mutations.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""ERBB2 Activating Mutations"", ""notes"": ""Activating mutations in ERBB2 (e.g., S310F, L755S, V777L) occur in approximately 2% of CRC and may respond to HER2-targeted therapies. These are distinct from amplification and can co-occur with RAS mutations.""}"	{}	"{""association"": ""Somatic Activating Mutation"", ""name"": ""ERBB2 Activating Mutations"", ""notes"": ""Activating mutations in ERBB2 (e.g., S310F, L755S, V777L) occur in approximately 2% of CRC and may respond to HER2-targeted therapies. These are distinct from amplification and can co-occur with RAS mutations.""}"
3364	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	genetic	2	RAS/BRAF Wild-Type									Enrichment Context																										HER2 amplification is strongly associated with RAS wild-type status and is typically mutually exclusive with BRAF V600E. This makes HER2-positive CRC a distinct molecular subgroup within RAS/BRAF wild-type tumors.																						"{""association"": ""Enrichment Context"", ""name"": ""RAS/BRAF Wild-Type"", ""notes"": ""HER2 amplification is strongly associated with RAS wild-type status and is typically mutually exclusive with BRAF V600E. This makes HER2-positive CRC a distinct molecular subgroup within RAS/BRAF wild-type tumors.""}"	{}	"{""association"": ""Enrichment Context"", ""name"": ""RAS/BRAF Wild-Type"", ""notes"": ""HER2 amplification is strongly associated with RAS wild-type status and is typically mutually exclusive with BRAF V600E. This makes HER2-positive CRC a distinct molecular subgroup within RAS/BRAF wild-type tumors.""}"
3382	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	genetic	0	ERBB2 (HER2)									Somatic Amplification																										ERBB2 amplification occurs in 15-20% of gastric adenocarcinomas, with higher rates at the gastroesophageal junction (up to 30%) and in intestinal-type tumors. Copy number gain correlates with protein expression and clinical benefit from HER2-targeted therapy.																						"{""association"": ""Somatic Amplification"", ""name"": ""ERBB2 (HER2)"", ""notes"": ""ERBB2 amplification occurs in 15-20% of gastric adenocarcinomas, with higher rates at the gastroesophageal junction (up to 30%) and in intestinal-type tumors. Copy number gain correlates with protein expression and clinical benefit from HER2-targeted therapy.""}"	{}	"{""association"": ""Somatic Amplification"", ""name"": ""ERBB2 (HER2)"", ""notes"": ""ERBB2 amplification occurs in 15-20% of gastric adenocarcinomas, with higher rates at the gastroesophageal junction (up to 30%) and in intestinal-type tumors. Copy number gain correlates with protein expression and clinical benefit from HER2-targeted therapy.""}"
3383	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	genetic	1	TP53									Co-occurring Mutations																										TP53 mutations frequently co-occur with HER2 amplification. The chromosomally unstable (CIN) molecular subtype defined by TCGA is enriched for both HER2 amplification and TP53 mutations.																						"{""association"": ""Co-occurring Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations frequently co-occur with HER2 amplification. The chromosomally unstable (CIN) molecular subtype defined by TCGA is enriched for both HER2 amplification and TP53 mutations.""}"	{}	"{""association"": ""Co-occurring Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations frequently co-occur with HER2 amplification. The chromosomally unstable (CIN) molecular subtype defined by TCGA is enriched for both HER2 amplification and TP53 mutations.""}"
3384	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	genetic	2	PIK3CA									Potential Resistance Mechanism																										PIK3CA mutations may co-occur with HER2 amplification and potentially contribute to resistance to HER2-targeted therapies through parallel PI3K pathway activation.																						"{""association"": ""Potential Resistance Mechanism"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations may co-occur with HER2 amplification and potentially contribute to resistance to HER2-targeted therapies through parallel PI3K pathway activation.""}"	{}	"{""association"": ""Potential Resistance Mechanism"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations may co-occur with HER2 amplification and potentially contribute to resistance to HER2-targeted therapies through parallel PI3K pathway activation.""}"
3402	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	genetic	0	P4HTM									Causative																										Biallelic loss-of-function mutations including missense, nonsense, and frameshift variants. The gene encodes prolyl 4-hydroxylase transmembrane (P4H-TM), an ER membrane enzyme with roles in hypoxia signaling and calcium regulation.																						"{""association"": ""Causative"", ""name"": ""P4HTM"", ""notes"": ""Biallelic loss-of-function mutations including missense, nonsense, and frameshift variants. The gene encodes prolyl 4-hydroxylase transmembrane (P4H-TM), an ER membrane enzyme with roles in hypoxia signaling and calcium regulation.""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""The study demonstrated that P4HTM variants cause loss of function through protein misfolding."", ""reference"": ""PMID:30940925"", ""snippet"": ""Variant characterization demonstrates that the variants affect protein folding by yielding an insoluble protein product."", ""supports"": ""SUPPORT""}, {""explanation"": ""Initial identification of P4HTM as a candidate gene for HIDEA syndrome in a Finnish kindred."", ""reference"": ""PMID:25078763"", ""snippet"": ""Whole-genome sequencing of one affected individual pinpointed three genes with potentially protein damaging homozygous sequence changes within the predisposition locus transketolase (TKT), prolyl 4-hydroxylase transmembrane (P4HTM), and ubiquitin specific peptidase 4 (USP4)."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""P4HTM"", ""notes"": ""Biallelic loss-of-function mutations including missense, nonsense, and frameshift variants. The gene encodes prolyl 4-hydroxylase transmembrane (P4H-TM), an ER membrane enzyme with roles in hypoxia signaling and calcium regulation.""}"
3430	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	genetic	0	TP53									Somatic Mutations																										TP53 mutations occur in greater than 80% of HPV-negative HNSCC. Mutation spectrum shows tobacco carcinogen signature with G-to-T transversions. TP53 mutation is associated with worse prognosis and treatment resistance.																						"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in greater than 80% of HPV-negative HNSCC. Mutation spectrum shows tobacco carcinogen signature with G-to-T transversions. TP53 mutation is associated with worse prognosis and treatment resistance.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in greater than 80% of HPV-negative HNSCC. Mutation spectrum shows tobacco carcinogen signature with G-to-T transversions. TP53 mutation is associated with worse prognosis and treatment resistance.""}"
3431	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	genetic	1	CDKN2A									Deletion/Methylation																										CDKN2A is inactivated in 60-70% of HPV-negative HNSCC through homozygous deletion, promoter hypermethylation, or point mutation.																						"{""association"": ""Deletion/Methylation"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A is inactivated in 60-70% of HPV-negative HNSCC through homozygous deletion, promoter hypermethylation, or point mutation.""}"	{}	"{""association"": ""Deletion/Methylation"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A is inactivated in 60-70% of HPV-negative HNSCC through homozygous deletion, promoter hypermethylation, or point mutation.""}"
3432	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	genetic	2	PIK3CA									Somatic Mutations																										PIK3CA activating mutations occur in approximately 10-15% of HPV-negative HNSCC, activating PI3K/AKT/mTOR signaling.																						"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA activating mutations occur in approximately 10-15% of HPV-negative HNSCC, activating PI3K/AKT/mTOR signaling.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA activating mutations occur in approximately 10-15% of HPV-negative HNSCC, activating PI3K/AKT/mTOR signaling.""}"
3433	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	genetic	3	NOTCH1									Loss-of-Function Mutations																										NOTCH1 inactivating mutations occur in 15-20% of cases, impairing squamous differentiation.																						"{""association"": ""Loss-of-Function Mutations"", ""name"": ""NOTCH1"", ""notes"": ""NOTCH1 inactivating mutations occur in 15-20% of cases, impairing squamous differentiation.""}"	{}	"{""association"": ""Loss-of-Function Mutations"", ""name"": ""NOTCH1"", ""notes"": ""NOTCH1 inactivating mutations occur in 15-20% of cases, impairing squamous differentiation.""}"
3434	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	genetic	4	EGFR									Amplification/Overexpression																										EGFR is overexpressed in 80-90% of HNSCC and amplified in approximately 15%. Provides rationale for EGFR-targeted therapy.																						"{""association"": ""Amplification/Overexpression"", ""name"": ""EGFR"", ""notes"": ""EGFR is overexpressed in 80-90% of HNSCC and amplified in approximately 15%. Provides rationale for EGFR-targeted therapy.""}"	{}	"{""association"": ""Amplification/Overexpression"", ""name"": ""EGFR"", ""notes"": ""EGFR is overexpressed in 80-90% of HNSCC and amplified in approximately 15%. Provides rationale for EGFR-targeted therapy.""}"
3456	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	genetic	0	TP53									Wild-type (rarely mutated)																										Unlike HPV-negative HNSCC where TP53 mutations occur in greater than 80% of cases, HPV-positive tumors typically have wild-type TP53 because p53 function is eliminated through E6-mediated degradation.																						"{""association"": ""Wild-type (rarely mutated)"", ""name"": ""TP53"", ""notes"": ""Unlike HPV-negative HNSCC where TP53 mutations occur in greater than 80% of cases, HPV-positive tumors typically have wild-type TP53 because p53 function is eliminated through E6-mediated degradation.""}"	{}	"{""association"": ""Wild-type (rarely mutated)"", ""name"": ""TP53"", ""notes"": ""Unlike HPV-negative HNSCC where TP53 mutations occur in greater than 80% of cases, HPV-positive tumors typically have wild-type TP53 because p53 function is eliminated through E6-mediated degradation.""}"
3457	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	genetic	1	PIK3CA									Somatic Mutations																										PIK3CA mutations occur in approximately 20-30% of HPV-positive HNSCC, activating PI3K/AKT/mTOR signaling. This is the most commonly mutated oncogene in HPV-positive tumors.																						"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 20-30% of HPV-positive HNSCC, activating PI3K/AKT/mTOR signaling. This is the most commonly mutated oncogene in HPV-positive tumors.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 20-30% of HPV-positive HNSCC, activating PI3K/AKT/mTOR signaling. This is the most commonly mutated oncogene in HPV-positive tumors.""}"
3458	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	genetic	2	CDKN2A									Rarely Inactivated																										CDKN2A (p16) is typically wild-type and overexpressed in HPV-positive HNSCC due to E7-mediated pRB inactivation, in contrast to HPV-negative HNSCC where CDKN2A is frequently deleted or silenced.																						"{""association"": ""Rarely Inactivated"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A (p16) is typically wild-type and overexpressed in HPV-positive HNSCC due to E7-mediated pRB inactivation, in contrast to HPV-negative HNSCC where CDKN2A is frequently deleted or silenced.""}"	{}	"{""association"": ""Rarely Inactivated"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A (p16) is typically wild-type and overexpressed in HPV-positive HNSCC due to E7-mediated pRB inactivation, in contrast to HPV-negative HNSCC where CDKN2A is frequently deleted or silenced.""}"
3484	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	genetic	0	HLA-DR3									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3""}"
3485	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	genetic	1	HLA-DR4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"
3486	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	genetic	2	CTLA4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CTLA4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CTLA4""}"
3487	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	genetic	3	PTPN22									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""PTPN22""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PTPN22""}"
3506	147	Heart Failure	Heart_Failure.yaml	genetic	0	TTN									Causative																										Titin mutations cause dilated cardiomyopathy																						"{""association"": ""Causative"", ""name"": ""TTN"", ""notes"": ""Titin mutations cause dilated cardiomyopathy""}"	{}	"{""association"": ""Causative"", ""name"": ""TTN"", ""notes"": ""Titin mutations cause dilated cardiomyopathy""}"
3507	147	Heart Failure	Heart_Failure.yaml	genetic	1	MYH7									Causative																										Causes hypertrophic and dilated cardiomyopathy																						"{""association"": ""Causative"", ""name"": ""MYH7"", ""notes"": ""Causes hypertrophic and dilated cardiomyopathy""}"	{}	"{""association"": ""Causative"", ""name"": ""MYH7"", ""notes"": ""Causes hypertrophic and dilated cardiomyopathy""}"
3508	147	Heart Failure	Heart_Failure.yaml	genetic	2	LMNA									Causative																										Lamin A/C mutations cause cardiomyopathy																						"{""association"": ""Causative"", ""name"": ""LMNA"", ""notes"": ""Lamin A/C mutations cause cardiomyopathy""}"	{}	"{""association"": ""Causative"", ""name"": ""LMNA"", ""notes"": ""Lamin A/C mutations cause cardiomyopathy""}"
3532	148	Hemochromatosis	Hemochromatosis.yaml	genetic	0	HFE Mutations									Causative																										Most common mutation is C282Y (p.Cys282Tyr) homozygosity, accounting for 80-90% of hereditary hemochromatosis cases. H63D (p.His63Asp) compound heterozygosity also contributes.																						"{""association"": ""Causative"", ""name"": ""HFE Mutations"", ""notes"": ""Most common mutation is C282Y (p.Cys282Tyr) homozygosity, accounting for 80-90% of hereditary hemochromatosis cases. H63D (p.His63Asp) compound heterozygosity also contributes.""}"	"{""inheritance"": [{""name"": ""Autosomal Recessive""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Review confirms C282Y homozygosity as the most common cause of hereditary hemochromatosis."", ""reference"": ""PMID:23985001"", ""snippet"": ""most commonly in C282Y homozygous individuals"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Recessive""}], ""name"": ""HFE Mutations"", ""notes"": ""Most common mutation is C282Y (p.Cys282Tyr) homozygosity, accounting for 80-90% of hereditary hemochromatosis cases. H63D (p.His63Asp) compound heterozygosity also contributes.""}"
3552	149	Hemophilia A	Hemophilia_A.yaml	genetic	0	F8									Causative																										X-linked recessive, intron 22 inversion most common severe mutation																						"{""association"": ""Causative"", ""name"": ""F8"", ""notes"": ""X-linked recessive, intron 22 inversion most common severe mutation""}"	{}	"{""association"": ""Causative"", ""name"": ""F8"", ""notes"": ""X-linked recessive, intron 22 inversion most common severe mutation""}"
3586	151	Hepatitis B	Hepatitis_B.yaml	genetic	0	HBV Genotype								Multiple Genotypes (A-H)																											Influences disease progression and treatment response																						"{""name"": ""HBV Genotype"", ""notes"": ""Influences disease progression and treatment response"", ""presence"": ""Multiple Genotypes (A-H)""}"	{}	"{""evidence"": [{""explanation"": ""The reference supports the presence of multiple HBV genotypes (A-H) and indicates that these genotypes influence disease progression and treatment response."", ""reference"": ""PMID:19072424"", ""snippet"": ""There are eight different genotypes named A-H. Genotypes have distinct geographic distribution in different regions of the world. There exists a difference in the disease profile between different genotypes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the influence of various factors, including viral genotypes, on the clinical course of HBV infection."", ""reference"": ""PMID:26255971"", ""snippet"": ""The clinical course of hepatitis B virus (HBV) infection greatly differs in individuals. Various viral, host, and environmental factors influence the natural history of HBV infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement that different HBV genotypes influence disease progression and treatment response."", ""reference"": ""PMID:34593148"", ""snippet"": ""Various HBV genotypes and their impact on the clinical course are discussed. The relationship of HBV serologies and HBV DNA to disease progression is outlined."", ""supports"": ""SUPPORT""}], ""name"": ""HBV Genotype"", ""notes"": ""Influences disease progression and treatment response"", ""presence"": ""Multiple Genotypes (A-H)""}"
3625	152	Hepatitis C	Hepatitis_C.yaml	genetic	0	IL28B Polymorphisms									Susceptibility																										IL28B (IFNL3) variants influence spontaneous clearance and response to interferon-based therapy																						"{""association"": ""Susceptibility"", ""name"": ""IL28B Polymorphisms"", ""notes"": ""IL28B (IFNL3) variants influence spontaneous clearance and response to interferon-based therapy""}"	{}	"{""association"": ""Susceptibility"", ""name"": ""IL28B Polymorphisms"", ""notes"": ""IL28B (IFNL3) variants influence spontaneous clearance and response to interferon-based therapy""}"
3645	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	genetic	0	TERT Promoter									Somatic Activating Mutation																										TERT promoter mutations (C228T, C250T) are the most common genetic alterations in HCC, present in approximately 60% of cases. These mutations create binding sites for ETS transcription factors, reactivating telomerase expression and enabling unlimited cell division.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""TERT Promoter"", ""notes"": ""TERT promoter mutations (C228T, C250T) are the most common genetic alterations in HCC, present in approximately 60% of cases. These mutations create binding sites for ETS transcription factors, reactivating telomerase expression and enabling unlimited cell division.""}"	{}	"{""association"": ""Somatic Activating Mutation"", ""name"": ""TERT Promoter"", ""notes"": ""TERT promoter mutations (C228T, C250T) are the most common genetic alterations in HCC, present in approximately 60% of cases. These mutations create binding sites for ETS transcription factors, reactivating telomerase expression and enabling unlimited cell division.""}"
3646	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	genetic	1	TP53									Somatic Loss of Function																										TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated with aflatoxin B1 exposure.																						"{""association"": ""Somatic Loss of Function"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated with aflatoxin B1 exposure.""}"	{}	"{""association"": ""Somatic Loss of Function"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated with aflatoxin B1 exposure.""}"
3647	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	genetic	2	CTNNB1									Somatic Activating Mutation																										CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive WNT pathway activation. Associated with distinct clinical features including cholestasis and immune exclusion, potentially affecting immunotherapy response.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive WNT pathway activation. Associated with distinct clinical features including cholestasis and immune exclusion, potentially affecting immunotherapy response.""}"	{}	"{""association"": ""Somatic Activating Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive WNT pathway activation. Associated with distinct clinical features including cholestasis and immune exclusion, potentially affecting immunotherapy response.""}"
3648	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	genetic	3	AXIN1									Somatic Loss of Function																										AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.																						"{""association"": ""Somatic Loss of Function"", ""name"": ""AXIN1"", ""notes"": ""AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.""}"	{}	"{""association"": ""Somatic Loss of Function"", ""name"": ""AXIN1"", ""notes"": ""AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.""}"
3649	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	genetic	4	ARID1A									Somatic Loss of Function																										ARID1A mutations affect chromatin remodeling and occur in approximately 10% of HCC. Part of the SWI/SNF complex alterations seen across multiple cancer types.																						"{""association"": ""Somatic Loss of Function"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations affect chromatin remodeling and occur in approximately 10% of HCC. Part of the SWI/SNF complex alterations seen across multiple cancer types.""}"	{}	"{""association"": ""Somatic Loss of Function"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations affect chromatin remodeling and occur in approximately 10% of HCC. Part of the SWI/SNF complex alterations seen across multiple cancer types.""}"
3679	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	genetic	0	BRCA1									Germline Loss-of-Function Mutations																										BRCA1 (17q21.31) encodes a protein essential for DNA double-strand break repair by homologous recombination. It functions in the RAD51-mediated strand invasion step and also has roles in cell cycle checkpoint activation. Mutations include truncating variants, large deletions, and pathogenic missense mutations. Founder mutations are common in Ashkenazi Jewish (185delAG, 5382insC), Icelandic, and other populations.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""BRCA1"", ""notes"": ""BRCA1 (17q21.31) encodes a protein essential for DNA double-strand break repair by homologous recombination. It functions in the RAD51-mediated strand invasion step and also has roles in cell cycle checkpoint activation. Mutations include truncating variants, large deletions, and pathogenic missense mutations. Founder mutations are common in Ashkenazi Jewish (185delAG, 5382insC), Icelandic, and other populations.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""evidence"": [{""explanation"": ""Review confirms BRCA1 and BRCA2 work together to protect the genome from DNA double-strand damage."", ""reference"": ""PMID:22193408"", ""snippet"": ""the proteins work in concert to protect the genome from double-strand DNA damage during DNA replication."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""BRCA1"", ""notes"": ""BRCA1 (17q21.31) encodes a protein essential for DNA double-strand break repair by homologous recombination. It functions in the RAD51-mediated strand invasion step and also has roles in cell cycle checkpoint activation. Mutations include truncating variants, large deletions, and pathogenic missense mutations. Founder mutations are common in Ashkenazi Jewish (185delAG, 5382insC), Icelandic, and other populations.""}"
3680	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	genetic	1	BRCA2									Germline Loss-of-Function Mutations																										BRCA2 (13q13.1) encodes a protein that facilitates RAD51 loading onto single- stranded DNA at sites of DNA double-strand breaks, enabling homologous recombination repair. Also known as FANCD1 as biallelic mutations cause Fanconi anemia. Founder mutations include 6174delT in Ashkenazi Jewish and 999del5 in Icelandic populations.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""BRCA2"", ""notes"": ""BRCA2 (13q13.1) encodes a protein that facilitates RAD51 loading onto single- stranded DNA at sites of DNA double-strand breaks, enabling homologous recombination repair. Also known as FANCD1 as biallelic mutations cause Fanconi anemia. Founder mutations include 6174delT in Ashkenazi Jewish and 999del5 in Icelandic populations.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""BRCA2"", ""notes"": ""BRCA2 (13q13.1) encodes a protein that facilitates RAD51 loading onto single- stranded DNA at sites of DNA double-strand breaks, enabling homologous recombination repair. Also known as FANCD1 as biallelic mutations cause Fanconi anemia. Founder mutations include 6174delT in Ashkenazi Jewish and 999del5 in Icelandic populations.""}"
3711	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	0	RET						Autosomal Dominant			Germline Mutations																																																"{""association"": ""Germline Mutations"", ""name"": ""RET"", ""subtype"": ""Autosomal Dominant""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""While the study identifies an autosomal dominant RET mutation in a family with Hirschsprung Disease, it also indicates that the genetic mechanisms are complex and not fully understood, suggesting that autosomal dominant RET mutations may be one of several contributing genetic factors."", ""reference"": ""PMID:32942321"", ""snippet"": ""This case report provides an overview of a family with a history of HD with a novel, unreported autosomal dominant RET mutation... The family examined in this study clearly demonstrates that (1) the genotype to phenotype correlation of patients with RET mutation-associated HD is not directly related, and (2) genetic mechanisms underlying the different HD phenotypes, as well as the model of inheritance of HD, are complex and not yet fully understood."", ""supports"": ""PARTIAL""}, {""explanation"": ""This supports the association between RET mutations and Hirschsprung Disease but also suggests a rare and complex interaction with certain mutations displaying dual functions."", ""reference"": ""PMID:24972642"", ""snippet"": ""The co-occurrence of Hirschsprung's disease (HSCR) and multiple endocrine neoplasia type 2 (MEN2) is a relatively rare event... a 'Janus' mutation in the RET proto-oncogene -- a mutation that acts simultaneously as both a gain-in-function and a loss-of-function mutation."", ""supports"": ""PARTIAL""}, {""explanation"": ""RET mutations are implicated in Hirschsprung Disease, but the inheritance pattern may be more complex than simply autosomal dominant."", ""reference"": ""PMID:11955539"", ""snippet"": ""Several genes, including the major susceptibility gene RET, have roles in development of Hirschsprung's disease... both RET alleles have a role in pathogenesis of Hirschsprung's disease, in a dose-dependent fashion."", ""supports"": ""PARTIAL""}], ""name"": ""RET"", ""subtype"": ""Autosomal Dominant""}"
3712	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	1	EDNRB						Autosomal Recessive			Germline Mutations																																																"{""association"": ""Germline Mutations"", ""name"": ""EDNRB"", ""subtype"": ""Autosomal Recessive""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""The paper discusses the association of EDNRB germline mutations with Hirschsprung disease, supporting the genetic association."", ""reference"": ""PMID:38253735"", ""snippet"": ""HSCR, a multifactorial disorder of enteric nervous system (ENS) development, is associated with at least 24 genes and seven chromosomal loci, with RET and EDNRB as its major genes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text supports the genetic association of Hirschsprung Disease with EDNRB mutations, noting that such mutations can follow autosomal recessive inheritance."", ""reference"": ""PMID:9359036"", ""snippet"": ""Genes involved include RET, GDNF, EDNRB and EDN3. Mutations of these genes may give dominant, recessive, or polygenic patterns of inheritance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The paper mentions that mutations in the recessive EDNRB gene are implicated in Hirschsprung Disease."", ""reference"": ""PMID:9718653"", ""snippet"": ""HD mutations have been mapped to a number of genes, i.e., RET proto-oncogene, at 10q11.2; the recessive EDNRB gene, located at 13q22; its ligand endothelin 3 (EDN3); and the glial cell line-derived neurotrophic factor (GDNF) in humans."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference directly supports the association of EDNRB mutations with Hirschsprung disease, subtype autosomal recessive."", ""reference"": ""PMID:11434563"", ""snippet"": ""Mutations in the genes encoding the endothelin type-B receptor (EDNRB) and its physiological ligand endothelin 3 (EDN3) are now known to account for the majority of HSCR II patients."", ""supports"": ""SUPPORT""}], ""name"": ""EDNRB"", ""subtype"": ""Autosomal Recessive""}"
3713	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	2	GDNF						Autosomal Dominant			Germline Mutations																										GDNF is a neurotrophic ligand that provides chemoattraction and trophic support for enteric neural crest cells. GDNF availability determines enteric neuron number by controlling precursor proliferation.																						"{""association"": ""Germline Mutations"", ""name"": ""GDNF"", ""notes"": ""GDNF is a neurotrophic ligand that provides chemoattraction and trophic support for enteric neural crest cells. GDNF availability determines enteric neuron number by controlling precursor proliferation."", ""subtype"": ""Autosomal Dominant""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""The reference suggests that mutations in GDNF can contribute to Hirschsprung disease and may exhibit dominant, recessive, or polygenic inheritance patterns. It does not confirm exclusively autosomal dominant inheritance."", ""reference"": ""PMID:9359036"", ""snippet"": ""Genes involved include RET, GDNF, EDNRB and EDN3. Mutations of these genes may give dominant, recessive, or polygenic patterns of inheritance."", ""supports"": ""PARTIAL""}, {""explanation"": ""This indicates GDNF mutations can be involved in Hirschsprung disease, typically in conjunction with other factors such as RET mutations, and does not specify autosomal dominant inheritance exclusively."", ""reference"": ""PMID:9473110"", ""snippet"": ""GDNF mutations were found in association with RET protooncogene mutations in Hirschsprung patients. Mutations in GDNF per se are thought neither necessary nor sufficient to cause Hirschsprung's disease (HD)."", ""supports"": ""PARTIAL""}, {""explanation"": ""While GDNF is implicated in the disease, the text does not isolate it to an autosomal dominant inheritance pattern but suggests interaction with other loci."", ""reference"": ""PMID:9718653"", ""snippet"": ""GDNF may modulate the disease phenotype by interacting with other susceptibility loci (e.g., RET)."", ""supports"": ""PARTIAL""}, {""explanation"": ""The excerpt pertains to EDNRB mutations and does not provide evidence regarding GDNF mutations being autosomal dominant."", ""reference"": ""PMID:8852660"", ""snippet"": ""These data might suggest that EDNRB mutations could be dosage sensitive: heterozygosity would predispose to isolated HSCR with incomplete penetrance, while homozygosity would result in more complex neurocristopathies."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference is about mutations in KIF26A, not GDNF, and discusses autosomal recessive patterns."", ""reference"": ""PMID:36564622"", ""snippet"": ""Our report, therefore, reveals a recognizable autosomal-recessive human KIF26A deficiency phenotype characterized by severe ENS dysfunction and a range of brain malformations."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""GDNF"", ""notes"": ""GDNF is a neurotrophic ligand that provides chemoattraction and trophic support for enteric neural crest cells. GDNF availability determines enteric neuron number by controlling precursor proliferation."", ""subtype"": ""Autosomal Dominant""}"
3714	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	3	SOX10						Autosomal Dominant			Germline Mutations																										SOX10 is a core ENS regulatory gene involved in neural crest cell development and enteric nervous system formation. Mutations contribute to HSCR through shared transcriptional control with RET and EDNRB.																						"{""association"": ""Germline Mutations"", ""name"": ""SOX10"", ""notes"": ""SOX10 is a core ENS regulatory gene involved in neural crest cell development and enteric nervous system formation. Mutations contribute to HSCR through shared transcriptional control with RET and EDNRB."", ""subtype"": ""Autosomal Dominant""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""This foundational study identified SOX10 mutations as responsible for neural crest defects in Hirschsprung disease mouse models and proposed it as a human HSCR candidate gene."", ""reference"": ""PMID:9425902"", ""snippet"": ""We propose SOX10 as a candidate disease gene for individuals with HSCR whose disease does not have an identified genetic origin."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study reports the first SOX10 mutation in an isolated HSCR patient without syndromic features."", ""reference"": ""PMID:20130826"", ""snippet"": ""Mutations in SOX10 are associated with several neurocristopathies such as Waardenburg syndrome type IV (WS4), a congenital disorder characterized by the association of hearing loss, pigmentary abnormalities, and absence of ganglion cells in the myenteric and submucosal plexus of the gastrointestinal tract, also known as aganglionic megacolon or Hirschsprung disease (HSCR)."", ""supports"": ""SUPPORT""}], ""name"": ""SOX10"", ""notes"": ""SOX10 is a core ENS regulatory gene involved in neural crest cell development and enteric nervous system formation. Mutations contribute to HSCR through shared transcriptional control with RET and EDNRB."", ""subtype"": ""Autosomal Dominant""}"
3715	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	4	PHOX2B									Germline Mutations																										PHOX2B is a core ENS regulatory gene that controls neural crest cell differentiation and enteric ganglia development. It participates in gene regulatory networks with RET.																						"{""association"": ""Germline Mutations"", ""name"": ""PHOX2B"", ""notes"": ""PHOX2B is a core ENS regulatory gene that controls neural crest cell differentiation and enteric ganglia development. It participates in gene regulatory networks with RET.""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""This report demonstrates the association between PHOX2B variants and Hirschsprung disease, particularly in syndromic cases with CCHS."", ""reference"": ""PMID:41253684"", ""snippet"": ""Hirschsprung disease (HD) can be associated with congenital central hypoventilation syndrome (CCHS). CCHS is mostly due to PHOX2B pathogenic variants."", ""supports"": ""SUPPORT""}], ""name"": ""PHOX2B"", ""notes"": ""PHOX2B is a core ENS regulatory gene that controls neural crest cell differentiation and enteric ganglia development. It participates in gene regulatory networks with RET.""}"
3716	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	5	NRG1									Germline Mutations																										NRG1 (Neuregulin 1) is involved in neural crest cell migration and ENS development. It participates in gene regulatory networks controlling enteric nervous system formation.																						"{""association"": ""Germline Mutations"", ""name"": ""NRG1"", ""notes"": ""NRG1 (Neuregulin 1) is involved in neural crest cell migration and ENS development. It participates in gene regulatory networks controlling enteric nervous system formation.""}"	{}	"{""association"": ""Germline Mutations"", ""evidence"": [{""explanation"": ""This report lists NRG1 among the key genes associated with Hirschsprung disease variants."", ""reference"": ""PMID:38169757"", ""snippet"": ""RET, NRG1, and L1CAM genes are reported as pathological gene variants associated with the incidence of different variants of Hirschsprung's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review identifies neuregulin (NRG1) as a newly discovered HSCR gene."", ""reference"": ""PMID:34422713"", ""snippet"": ""The discovery of new HSCR genes such as neuregulin and BACE2 as well as the deeper understanding of the roles and mechanisms of known HSCR genes provided solid evidence that many HSCR cases are in the form of complex polygenic/oligogenic disorder where rare variants act in the sensitized background of HSCR-associated common variants."", ""supports"": ""SUPPORT""}], ""name"": ""NRG1"", ""notes"": ""NRG1 (Neuregulin 1) is involved in neural crest cell migration and ENS development. It participates in gene regulatory networks controlling enteric nervous system formation.""}"
3717	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	6	ZEB2									Germline Mutations																										ZEB2 is a transcription factor involved in neural crest cell development and enteric nervous system formation. Part of the gene regulatory network explaining RET-EDNRB epistasis.																						"{""association"": ""Germline Mutations"", ""name"": ""ZEB2"", ""notes"": ""ZEB2 is a transcription factor involved in neural crest cell development and enteric nervous system formation. Part of the gene regulatory network explaining RET-EDNRB epistasis.""}"	{}	"{""association"": ""Germline Mutations"", ""name"": ""ZEB2"", ""notes"": ""ZEB2 is a transcription factor involved in neural crest cell development and enteric nervous system formation. Part of the gene regulatory network explaining RET-EDNRB epistasis.""}"
3718	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	7	NRTN									Germline Mutations																										NRTN (Neurturin) is a neurotrophic ligand in the GDNF family that guides chemotaxis and supports proliferation and survival of enteric neural crest cells.																						"{""association"": ""Germline Mutations"", ""name"": ""NRTN"", ""notes"": ""NRTN (Neurturin) is a neurotrophic ligand in the GDNF family that guides chemotaxis and supports proliferation and survival of enteric neural crest cells.""}"	{}	"{""association"": ""Germline Mutations"", ""name"": ""NRTN"", ""notes"": ""NRTN (Neurturin) is a neurotrophic ligand in the GDNF family that guides chemotaxis and supports proliferation and survival of enteric neural crest cells.""}"
3719	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	genetic	8	NCAM1									Germline Mutations																										NCAM1 is an adhesion receptor whose signaling is required for GDNF-based therapeutic responses. It determines the success of GDNF-based treatments for Hirschsprung disease.																						"{""association"": ""Germline Mutations"", ""name"": ""NCAM1"", ""notes"": ""NCAM1 is an adhesion receptor whose signaling is required for GDNF-based therapeutic responses. It determines the success of GDNF-based treatments for Hirschsprung disease.""}"	{}	"{""association"": ""Germline Mutations"", ""name"": ""NCAM1"", ""notes"": ""NCAM1 is an adhesion receptor whose signaling is required for GDNF-based therapeutic responses. It determines the success of GDNF-based treatments for Hirschsprung disease.""}"
3739	157	Holt-Oram syndrome	Holt_Oram.yaml	genetic	0	TBX5								Positive	Causative																										"Loss-of-function mutations in TBX5 cause Holt-Oram syndrome with autosomal dominant inheritance. Heterozygous loss-of-function variants account for approximately 90% of familial cases. The T-box transcription factor TBX5 is essential for cardiac and upper limb development. Gene dosage sensitivity is critical, as even partial loss of TBX5 function due to haploinsufficiency disrupts regulatory networks.
"																						"{""association"": ""Causative"", ""name"": ""TBX5"", ""notes"": ""Loss-of-function mutations in TBX5 cause Holt-Oram syndrome with autosomal dominant inheritance. Heterozygous loss-of-function variants account for approximately 90% of familial cases. The T-box transcription factor TBX5 is essential for cardiac and upper limb development. Gene dosage sensitivity is critical, as even partial loss of TBX5 function due to haploinsufficiency disrupts regulatory networks.\n"", ""presence"": ""Positive""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Directly establishes the causal relationship between TBX5 sequence variants and HOS development"", ""reference"": ""PMID:36936432"", ""snippet"": ""Sequence alteration of T-box transcription factor 5 (TBX5) is correlated with the incidence of HOS"", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates that TBX5 haploinsufficiency is sufficient to cause cardiac phenotypes similar to HOS"", ""reference"": ""PMID:38189150"", ""snippet"": ""Atrial rhythm abnormalities in mice caused by Tbx5 haploinsufficiency were rescued by Zfpm2 haploinsufficiency"", ""supports"": ""SUPPORT""}], ""name"": ""TBX5"", ""notes"": ""Loss-of-function mutations in TBX5 cause Holt-Oram syndrome with autosomal dominant inheritance. Heterozygous loss-of-function variants account for approximately 90% of familial cases. The T-box transcription factor TBX5 is essential for cardiac and upper limb development. Gene dosage sensitivity is critical, as even partial loss of TBX5 function due to haploinsufficiency disrupts regulatory networks.\n"", ""presence"": ""Positive""}"
3766	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	0	HTT									Pathogenic CAG Repeat Expansion																										Primary causal gene encoding huntingtin protein; CAG repeat expansion leads to polyglutamine tract elongation.																						"{""association"": ""Pathogenic CAG Repeat Expansion"", ""name"": ""HTT"", ""notes"": ""Primary causal gene encoding huntingtin protein; CAG repeat expansion leads to polyglutamine tract elongation.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Pathogenic CAG Repeat Expansion"", ""evidence"": [{""explanation"": ""The literature explicitly states that Huntington's disease is caused by an expanded CAG trinucleotide repeat in the HTT gene and is inherited in an autosomal dominant manner."", ""reference"": ""PMID:27188817"", ""snippet"": ""Huntington disease is devastating to patients and their families - with autosomal dominant inheritance... The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that Huntington's disease is caused by the expansion of the HTT CAG repeat and follows an autosomal dominant inheritance pattern."", ""reference"": ""PMID:33579864"", ""snippet"": ""Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of the HTT CAG repeat."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source supports the statement by indicating that Huntington's disease is an autosomal dominant disorder caused by a CAG expansion in the HTT gene."", ""reference"": ""PMID:31820322"", ""snippet"": ""Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by confirming that Huntington's disease is among the CAG repeat diseases and is autosomal dominantly inherited."", ""reference"": ""PMID:37863037"", ""snippet"": ""Among the CAG/polyQ repeat diseases are Huntington's disease (HD) and spinocerebellar ataxia type 1 (SCA1), in which the expansions are within widely expressed proteins. Although both HD and SCA1 are autosomal dominantly inherited..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source supports the statement by confirming that Huntington's disease is caused by an expanded CAG repeat in the HTT gene and follows an autosomal dominant inheritance pattern."", ""reference"": ""PMID:33579866"", ""snippet"": ""Huntington's disease (HD) (OMIM 143100) is caused by an expanded CAG repeat tract in the HTT gene. The inherited CAG length is known to expand further in somatic and germline cells in HD subjects."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by confirming that Huntington's disease is an autosomal dominant disorder caused by CAG repeat expansion."", ""reference"": ""PMID:36352624"", ""snippet"": ""Huntington's Disease (HD) is an autosomal dominant, progressive neuropsychiatric illness caused by CAG repeat expansion."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source supports the statement by confirming that Huntington's disease is caused by a CAG trinucleotide expansion in the HTT gene and follows an autosomal dominant inheritance pattern."", ""reference"": ""PMID:31263285"", ""snippet"": ""Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin gene (HTT)..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by confirming that the HTT CAG repeat expansion causes neurodegeneration in Huntington's disease."", ""reference"": ""PMID:31491822"", ""snippet"": ""The expression of the HTT CAG repeat expansion mutation causes neurodegeneration in Huntington's disease (HD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source supports the statement by confirming that Huntington's disease is caused by the expansion of a CAG trinucleotide repeat in the HTT gene."", ""reference"": ""PMID:26439718"", ""snippet"": ""Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by confirming that Huntington's disease is caused by the expansion of a CAG trinucleotide repeat in the HTT gene and is autosomal dominant."", ""reference"": ""PMID:28832564"", ""snippet"": ""Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion of a CAG trinucleotide repeat in HTT..."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""HTT"", ""notes"": ""Primary causal gene encoding huntingtin protein; CAG repeat expansion leads to polyglutamine tract elongation.""}"
3767	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	1	MSH3									Genetic Modifier																										DNA mismatch repair gene; modulates somatic CAG instability and influences age at onset via somatic expansion.																						"{""association"": ""Genetic Modifier"", ""name"": ""MSH3"", ""notes"": ""DNA mismatch repair gene; modulates somatic CAG instability and influences age at onset via somatic expansion.""}"	{}	"{""association"": ""Genetic Modifier"", ""name"": ""MSH3"", ""notes"": ""DNA mismatch repair gene; modulates somatic CAG instability and influences age at onset via somatic expansion.""}"
3768	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	2	MLH1									Genetic Modifier																										DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.																						"{""association"": ""Genetic Modifier"", ""name"": ""MLH1"", ""notes"": ""DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.""}"	{}	"{""association"": ""Genetic Modifier"", ""name"": ""MLH1"", ""notes"": ""DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.""}"
3769	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	3	PMS1									Genetic Modifier																										DNA mismatch repair gene; influences somatic CAG repeat expansion.																						"{""association"": ""Genetic Modifier"", ""name"": ""PMS1"", ""notes"": ""DNA mismatch repair gene; influences somatic CAG repeat expansion.""}"	{}	"{""association"": ""Genetic Modifier"", ""name"": ""PMS1"", ""notes"": ""DNA mismatch repair gene; influences somatic CAG repeat expansion.""}"
3770	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	4	PMS2									Genetic Modifier																										DNA mismatch repair gene; influences somatic CAG repeat expansion.																						"{""association"": ""Genetic Modifier"", ""name"": ""PMS2"", ""notes"": ""DNA mismatch repair gene; influences somatic CAG repeat expansion.""}"	{}	"{""association"": ""Genetic Modifier"", ""name"": ""PMS2"", ""notes"": ""DNA mismatch repair gene; influences somatic CAG repeat expansion.""}"
3771	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	5	LIG1									Genetic Modifier																										DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.																						"{""association"": ""Genetic Modifier"", ""name"": ""LIG1"", ""notes"": ""DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.""}"	{}	"{""association"": ""Genetic Modifier"", ""name"": ""LIG1"", ""notes"": ""DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.""}"
3772	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	6	PPARGC1A									Pathophysiological Role																										PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.																						"{""association"": ""Pathophysiological Role"", ""name"": ""PPARGC1A"", ""notes"": ""PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""PPARGC1A"", ""notes"": ""PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.""}"
3773	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	7	SLC1A2									Pathophysiological Role																										EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.																						"{""association"": ""Pathophysiological Role"", ""name"": ""SLC1A2"", ""notes"": ""EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""SLC1A2"", ""notes"": ""EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.""}"
3774	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	8	BDNF									Pathophysiological Role																										Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.																						"{""association"": ""Pathophysiological Role"", ""name"": ""BDNF"", ""notes"": ""Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""BDNF"", ""notes"": ""Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.""}"
3775	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	9	NTRK2									Pathophysiological Role																										TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.																						"{""association"": ""Pathophysiological Role"", ""name"": ""NTRK2"", ""notes"": ""TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""NTRK2"", ""notes"": ""TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.""}"
3776	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	10	DRD1									Pathophysiological Role																										Dopamine D1 receptor; marker of direct pathway medium spiny neurons.																						"{""association"": ""Pathophysiological Role"", ""name"": ""DRD1"", ""notes"": ""Dopamine D1 receptor; marker of direct pathway medium spiny neurons.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""DRD1"", ""notes"": ""Dopamine D1 receptor; marker of direct pathway medium spiny neurons.""}"
3777	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	11	DRD2									Pathophysiological Role																										Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.																						"{""association"": ""Pathophysiological Role"", ""name"": ""DRD2"", ""notes"": ""Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""DRD2"", ""notes"": ""Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.""}"
3778	159	Huntington's Disease	Huntingtons_Disease.yaml	genetic	12	SQSTM1									Pathophysiological Role																										p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.																						"{""association"": ""Pathophysiological Role"", ""name"": ""SQSTM1"", ""notes"": ""p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.""}"	{}	"{""association"": ""Pathophysiological Role"", ""name"": ""SQSTM1"", ""notes"": ""p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.""}"
3849	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	0	MYH7									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""MYH7""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The title of the referenced article explicitly indicates the association of a pathogenic variant in MYH7 with hypertrophic cardiomyopathy."", ""reference"": ""PMID:38423942"", ""snippet"": ""Hypertrophic cardiomyopathy: New pathogenic variant in MYH7."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the specific mutations in MYH7 are not detailed in this snippet, the article supports the general assertion that genetic mutations, particularly in sarcomeric genes like MYH7, are common in hypertrophic cardiomyopathy."", ""reference"": ""PMID:23905887"", ""snippet"": ""Genetic mutations can be identified in approximately 60% of patients; these are commonest in genes that encode proteins of the cardiac sarcomere."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article details a specific pathogenic variant (p.V878L) in the MYH7 gene associated with hypertrophic cardiomyopathy."", ""reference"": ""PMID:31735781"", ""snippet"": ""By NGS, we determined that these subjects with HCM symptoms carried a missense heterozygous genetic mutation c.2632C>A (p.V878L) in the myosin heavy chain 7 (MYH7) gene with an autosomal dominant pattern of inheritance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article identifies the commonly studied pathogenic variant (p.R403Q) in MYH7 which leads to hypertrophic cardiomyopathy."", ""reference"": ""PMID:36797478"", ""snippet"": ""The dominant-negative c.1208G>A (p.R403Q) pathogenic variant (PV) in beta-myosin (MYH7) is a common and well-studied PV that leads to increased cardiac contractility and HCM onset."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article categorizes MYH7 as one of the 'definitive' genes associated with hypertrophic cardiomyopathy."", ""reference"": ""PMID:30681346"", ""snippet"": ""Of 33 HCM genes, only 8 (24%) were categorized as definitive (MYBPC3, MYH7, TNNT2, TNNI3, TPM1, ACTC1, MYL2, and MYL3)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article explicitly states that MYH7 variants cause hypertrophic cardiomyopathy, reinforcing the genetic association."", ""reference"": ""PMID:37565978"", ""snippet"": ""MYH7 variants cause hypertrophic cardiomyopathy (HCM), noncompaction cardiomyopathy (NCCM), and dilated cardiomyopathy (DCM)."", ""supports"": ""SUPPORT""}], ""name"": ""MYH7""}"
3850	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	1	MYBPC3									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""MYBPC3""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The study identifies a novel pathogenic variant in MYBPC3 associated with hypertrophic cardiomyopathy."", ""reference"": ""PMID:34180388"", ""snippet"": ""The proband carries a novel heterozygous nonsense variant of MYBPC3:c.2731G > T (p.E911X) ... suggesting the functional damages to the protein of MYBPC3."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review discusses that mutations in MYBPC3 (which encodes cMyBP-C) cause HCM."", ""reference"": ""PMID:24240729"", ""snippet"": ""The second wave started in 1995 by the discovery that mutations in the gene encoding cMyBP-C cause hypertrophic cardiomyopathy (HCM)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Study identifies MYBPC3 as a common gene associated with hypertrophic cardiomyopathy."", ""reference"": ""PMID:37409452"", ""snippet"": ""The 2 sarcomere genes most commonly associated with hypertrophic cardiomyopathy (HCM), MYBPC3 (myosin-binding protein C3)..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study includes MYBPC3 as one of the genes with pathogenic variants associated with inherited cardiomyopathy."", ""reference"": ""PMID:35544052"", ""snippet"": ""Pathogenic variants associated with inherited cardiomyopathy ... MYBPC3 ... were classified ..."", ""supports"": ""SUPPORT""}], ""name"": ""MYBPC3""}"
3851	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	2	TNNT2									Pathogenic Variants																										Can present with relatively modest LVH but disproportionate arrhythmic risk																						"{""association"": ""Pathogenic Variants"", ""name"": ""TNNT2"", ""notes"": ""Can present with relatively modest LVH but disproportionate arrhythmic risk""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The study identifies pathogenic variants in TNNT2 among patients with hypertrophic cardiomyopathy, supporting the genetic association."", ""reference"": ""PMID:33588347"", ""snippet"": ""Variants were identified and annotated using in silico tools, and further classified as pathogenic or benign according to the American College of Medical Genetics and Genomics guidelines. Variants with functional effects were identified...and TNNT2..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study reveals that the troponin T gene (TNNT2) is one of the implicated genes in hypertrophic cardiomyopathy."", ""reference"": ""PMID:7665141"", ""snippet"": ""Genes on five loci on separate chromosomes are responsible for a familial disease in which all or part of the ventricular muscle undergoes thickening with a histological picture of irregular hypertrophy and disorganized arrangement of myocytes (disarray). The three genes identified so far encode for beta heavy chain myosin (chromosome 14), troponin T (chromosome 1) and alpha tropomyosin (chromosome 15)."", ""supports"": ""SUPPORT""}], ""name"": ""TNNT2"", ""notes"": ""Can present with relatively modest LVH but disproportionate arrhythmic risk""}"
3852	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	3	ALPK3									Pathogenic Variants																										Emerging gene; biallelic variants linked to pediatric-onset cardiomyopathy, heterozygous variants show variable adult-onset HCM. Involved in sarcomere and nuclear signaling.																						"{""association"": ""Pathogenic Variants"", ""name"": ""ALPK3"", ""notes"": ""Emerging gene; biallelic variants linked to pediatric-onset cardiomyopathy, heterozygous variants show variable adult-onset HCM. Involved in sarcomere and nuclear signaling.""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""ALPK3"", ""notes"": ""Emerging gene; biallelic variants linked to pediatric-onset cardiomyopathy, heterozygous variants show variable adult-onset HCM. Involved in sarcomere and nuclear signaling.""}"
3853	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	4	FHOD3									Pathogenic Variants																										Emerging gene; formin homology domain protein regulating actin cytoskeleton. Variants perturb myofibrillogenesis and cytoskeletal integrity, contributing to sarcomere remodeling.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FHOD3"", ""notes"": ""Emerging gene; formin homology domain protein regulating actin cytoskeleton. Variants perturb myofibrillogenesis and cytoskeletal integrity, contributing to sarcomere remodeling.""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""FHOD3"", ""notes"": ""Emerging gene; formin homology domain protein regulating actin cytoskeleton. Variants perturb myofibrillogenesis and cytoskeletal integrity, contributing to sarcomere remodeling.""}"
3854	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	5	TRIM63									Pathogenic Variants																										Emerging gene; muscle-specific RING-finger protein (MuRF1) involved in proteostasis. Loss- or gain-of-function variants may alter sarcomeric protein turnover. Homozygous cases reported with severe remodeling.																						"{""association"": ""Pathogenic Variants"", ""name"": ""TRIM63"", ""notes"": ""Emerging gene; muscle-specific RING-finger protein (MuRF1) involved in proteostasis. Loss- or gain-of-function variants may alter sarcomeric protein turnover. Homozygous cases reported with severe remodeling.""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""TRIM63"", ""notes"": ""Emerging gene; muscle-specific RING-finger protein (MuRF1) involved in proteostasis. Loss- or gain-of-function variants may alter sarcomeric protein turnover. Homozygous cases reported with severe remodeling.""}"
3855	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	genetic	6	SVIL									Pathogenic Variants																										Emerging gene; supervillin is a cytoskeletal-membrane linker. Rare variants recently reported in HCM cohorts, hypothesized to affect sarcomere-cytoskeleton coupling. Associated with apical/septal phenotypes in some populations.																						"{""association"": ""Pathogenic Variants"", ""name"": ""SVIL"", ""notes"": ""Emerging gene; supervillin is a cytoskeletal-membrane linker. Rare variants recently reported in HCM cohorts, hypothesized to affect sarcomere-cytoskeleton coupling. Associated with apical/septal phenotypes in some populations.""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""SVIL"", ""notes"": ""Emerging gene; supervillin is a cytoskeletal-membrane linker. Rare variants recently reported in HCM cohorts, hypothesized to affect sarcomere-cytoskeleton coupling. Associated with apical/septal phenotypes in some populations.""}"
3883	162	Hypochondrogenesis	Hypochondrogenesis.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous mutations in COL2A1, typically glycine substitutions in the triple helical domain. The position and nature of the substitution influences phenotypic severity along the type 2 collagenopathy spectrum.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1, typically glycine substitutions in the triple helical domain. The position and nature of the substitution influences phenotypic severity along the type 2 collagenopathy spectrum.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Identifies a specific glycine-to-serine substitution in COL2A1 as causative of achondrogenesis II-hypochondrogenesis."", ""reference"": ""PMID:2572591"", ""snippet"": ""Here we demonstrate that the mutation in the type II procollagen gene is a single base change that converts the codon for glycine (GGC) at amino acid 943 of the alpha 1 (II) chain to a codon for serine (AGC)."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Identifies another specific COL2A1 glycine substitution mutation in a hypochondrogenesis patient."", ""reference"": ""PMID:8175802"", ""snippet"": ""Sequencing of exon 35 demonstrated a single base mutation that converted the codon for glycine at position 604 to a codon for alanine."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms that de novo dominant COL2A1 mutations cause hypochondrogenesis."", ""reference"": ""PMID:2572591"", ""snippet"": ""These findings confirm the proposal that new dominant mutations in the type II procollagen gene may account for some cases of Type II achondrogenesis-hypochondrogenesis."", ""supports"": ""SUPPORT""}], ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1, typically glycine substitutions in the triple helical domain. The position and nature of the substitution influences phenotypic severity along the type 2 collagenopathy spectrum.\n""}"
3894	163	Hypochondroplasia	Hypochondroplasia.yaml	genetic	0	FGFR3 N540K mutation									Causative																										"The c.1620C>A or c.1620C>G (p.Asn540Lys) mutation is found in 50-70% of clinically diagnosed hypochondroplasia cases. Other FGFR3 mutations account for additional cases, but 30-50% of clinically diagnosed patients have no identifiable FGFR3 mutation, suggesting genetic heterogeneity or phenotypic overlap with other conditions.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 N540K mutation"", ""notes"": ""The c.1620C>A or c.1620C>G (p.Asn540Lys) mutation is found in 50-70% of clinically diagnosed hypochondroplasia cases. Other FGFR3 mutations account for additional cases, but 30-50% of clinically diagnosed patients have no identifiable FGFR3 mutation, suggesting genetic heterogeneity or phenotypic overlap with other conditions.\n""}"	"{""variants"": [{""description"": ""The most common causative mutation."", ""name"": ""c.1620C>A (p.Asn540Lys)""}, {""description"": ""Alternative nucleotide change resulting in the same amino acid substitution."", ""name"": ""c.1620C>G (p.Asn540Lys)""}]}"	"{""association"": ""Causative"", ""name"": ""FGFR3 N540K mutation"", ""notes"": ""The c.1620C>A or c.1620C>G (p.Asn540Lys) mutation is found in 50-70% of clinically diagnosed hypochondroplasia cases. Other FGFR3 mutations account for additional cases, but 30-50% of clinically diagnosed patients have no identifiable FGFR3 mutation, suggesting genetic heterogeneity or phenotypic overlap with other conditions.\n"", ""variants"": [{""description"": ""The most common causative mutation."", ""name"": ""c.1620C>A (p.Asn540Lys)""}, {""description"": ""Alternative nucleotide change resulting in the same amino acid substitution."", ""name"": ""c.1620C>G (p.Asn540Lys)""}]}"
3906	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	genetic	0	IDH1									Somatic Oncogenic Mutation																										Mutations at R132 in IDH1 (most commonly R132H) occur in 6-10% of AML. IDH1 encodes the cytoplasmic isocitrate dehydrogenase. Mutations create neomorphic enzyme activity producing 2-HG. Targetable with ivosidenib.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""IDH1"", ""notes"": ""Mutations at R132 in IDH1 (most commonly R132H) occur in 6-10% of AML. IDH1 encodes the cytoplasmic isocitrate dehydrogenase. Mutations create neomorphic enzyme activity producing 2-HG. Targetable with ivosidenib.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""IDH1"", ""notes"": ""Mutations at R132 in IDH1 (most commonly R132H) occur in 6-10% of AML. IDH1 encodes the cytoplasmic isocitrate dehydrogenase. Mutations create neomorphic enzyme activity producing 2-HG. Targetable with ivosidenib.""}"
3907	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	genetic	1	IDH2									Somatic Oncogenic Mutation																										Mutations at R140 (most common) or R172 in IDH2 occur in 8-12% of AML. IDH2 encodes the mitochondrial isocitrate dehydrogenase. Mutations create neomorphic enzyme activity. Targetable with enasidenib.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""IDH2"", ""notes"": ""Mutations at R140 (most common) or R172 in IDH2 occur in 8-12% of AML. IDH2 encodes the mitochondrial isocitrate dehydrogenase. Mutations create neomorphic enzyme activity. Targetable with enasidenib.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""IDH2"", ""notes"": ""Mutations at R140 (most common) or R172 in IDH2 occur in 8-12% of AML. IDH2 encodes the mitochondrial isocitrate dehydrogenase. Mutations create neomorphic enzyme activity. Targetable with enasidenib.""}"
3927	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	genetic	0	IDH1									Somatic Mutation																										IDH1 R132H mutation accounts for >90% of IDH-mutant astrocytomas. Can be detected by R132H-specific immunohistochemistry. Other R132 variants (R132C, R132S, R132G) occur less frequently.																						"{""association"": ""Somatic Mutation"", ""name"": ""IDH1"", ""notes"": ""IDH1 R132H mutation accounts for >90% of IDH-mutant astrocytomas. Can be detected by R132H-specific immunohistochemistry. Other R132 variants (R132C, R132S, R132G) occur less frequently.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""IDH1"", ""notes"": ""IDH1 R132H mutation accounts for >90% of IDH-mutant astrocytomas. Can be detected by R132H-specific immunohistochemistry. Other R132 variants (R132C, R132S, R132G) occur less frequently.""}"
3928	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	genetic	1	IDH2									Somatic Mutation																										IDH2 R172 mutations occur in approximately 3% of IDH-mutant gliomas, more common in oligodendrogliomas. Requires sequencing for detection.																						"{""association"": ""Somatic Mutation"", ""name"": ""IDH2"", ""notes"": ""IDH2 R172 mutations occur in approximately 3% of IDH-mutant gliomas, more common in oligodendrogliomas. Requires sequencing for detection.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""IDH2"", ""notes"": ""IDH2 R172 mutations occur in approximately 3% of IDH-mutant gliomas, more common in oligodendrogliomas. Requires sequencing for detection.""}"
3929	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	genetic	2	TP53									Somatic Mutation																										TP53 mutations are present in approximately 70% of IDH-mutant astrocytomas and are typically mutually exclusive with 1p/19q codeletion, helping distinguish astrocytomas from oligodendrogliomas.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are present in approximately 70% of IDH-mutant astrocytomas and are typically mutually exclusive with 1p/19q codeletion, helping distinguish astrocytomas from oligodendrogliomas.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are present in approximately 70% of IDH-mutant astrocytomas and are typically mutually exclusive with 1p/19q codeletion, helping distinguish astrocytomas from oligodendrogliomas.""}"
3930	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	genetic	3	ATRX									Somatic Mutation																										ATRX loss occurs in approximately 70% of IDH-mutant astrocytomas. Associated with alternative lengthening of telomeres (ALT). ATRX loss is mutually exclusive with 1p/19q codeletion.																						"{""association"": ""Somatic Mutation"", ""name"": ""ATRX"", ""notes"": ""ATRX loss occurs in approximately 70% of IDH-mutant astrocytomas. Associated with alternative lengthening of telomeres (ALT). ATRX loss is mutually exclusive with 1p/19q codeletion.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""ATRX"", ""notes"": ""ATRX loss occurs in approximately 70% of IDH-mutant astrocytomas. Associated with alternative lengthening of telomeres (ALT). ATRX loss is mutually exclusive with 1p/19q codeletion.""}"
3931	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	genetic	4	CDKN2A									Homozygous Deletion																										Homozygous deletion of CDKN2A/CDKN2B (9p21) confers grade 4 status regardless of histological features and is associated with worse prognosis.																						"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A"", ""notes"": ""Homozygous deletion of CDKN2A/CDKN2B (9p21) confers grade 4 status regardless of histological features and is associated with worse prognosis.""}"	{}	"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A"", ""notes"": ""Homozygous deletion of CDKN2A/CDKN2B (9p21) confers grade 4 status regardless of histological features and is associated with worse prognosis.""}"
3950	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	genetic	0	IDH1									Somatic Neomorphic Mutation																										IDH1 R132 mutations (R132C, R132H, R132G, R132S, R132L) occur in approximately 15% of intrahepatic cholangiocarcinomas. The R132C substitution is most common in cholangiocarcinoma (unlike R132H in glioma). Ivosidenib specifically targets IDH1 mutant protein.																						"{""association"": ""Somatic Neomorphic Mutation"", ""name"": ""IDH1"", ""notes"": ""IDH1 R132 mutations (R132C, R132H, R132G, R132S, R132L) occur in approximately 15% of intrahepatic cholangiocarcinomas. The R132C substitution is most common in cholangiocarcinoma (unlike R132H in glioma). Ivosidenib specifically targets IDH1 mutant protein.""}"	{}	"{""association"": ""Somatic Neomorphic Mutation"", ""evidence"": [{""explanation"": ""Abstract reports IDH1/2 hotspot mutations in intrahepatic cholangiocarcinoma."", ""reference"": ""PMID:24569570"", ""snippet"": ""Hotspot mutations in IDH isoforms 1 or 2 occur in approximately 15% of intrahepatic cholangiocarcinomas."", ""supports"": ""SUPPORT""}], ""name"": ""IDH1"", ""notes"": ""IDH1 R132 mutations (R132C, R132H, R132G, R132S, R132L) occur in approximately 15% of intrahepatic cholangiocarcinomas. The R132C substitution is most common in cholangiocarcinoma (unlike R132H in glioma). Ivosidenib specifically targets IDH1 mutant protein.""}"
3951	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	genetic	1	IDH2									Somatic Neomorphic Mutation																										IDH2 R172 and R140 mutations occur in approximately 3-5% of intrahepatic cholangiocarcinomas. Enasidenib targets IDH2 mutations but is not FDA-approved for cholangiocarcinoma.																						"{""association"": ""Somatic Neomorphic Mutation"", ""name"": ""IDH2"", ""notes"": ""IDH2 R172 and R140 mutations occur in approximately 3-5% of intrahepatic cholangiocarcinomas. Enasidenib targets IDH2 mutations but is not FDA-approved for cholangiocarcinoma.""}"	{}	"{""association"": ""Somatic Neomorphic Mutation"", ""evidence"": [{""explanation"": ""Abstract reports IDH1/2 hotspot mutations in intrahepatic cholangiocarcinoma."", ""reference"": ""PMID:24569570"", ""snippet"": ""Hotspot mutations in IDH isoforms 1 or 2 occur in approximately 15% of intrahepatic cholangiocarcinomas."", ""supports"": ""SUPPORT""}], ""name"": ""IDH2"", ""notes"": ""IDH2 R172 and R140 mutations occur in approximately 3-5% of intrahepatic cholangiocarcinomas. Enasidenib targets IDH2 mutations but is not FDA-approved for cholangiocarcinoma.""}"
3952	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	genetic	2	ARID1A									Co-occurring Mutations																										ARID1A mutations co-occur with IDH mutations in cholangiocarcinoma more frequently than expected by chance, suggesting cooperative oncogenic effects.																						"{""association"": ""Co-occurring Mutations"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations co-occur with IDH mutations in cholangiocarcinoma more frequently than expected by chance, suggesting cooperative oncogenic effects.""}"	{}	"{""association"": ""Co-occurring Mutations"", ""name"": ""ARID1A"", ""notes"": ""ARID1A mutations co-occur with IDH mutations in cholangiocarcinoma more frequently than expected by chance, suggesting cooperative oncogenic effects.""}"
3953	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	genetic	3	BAP1									Co-occurring Mutations																										BAP1 mutations may co-occur with IDH mutations in cholangiocarcinoma. Germline BAP1 mutations are associated with tumor predisposition syndrome including cholangiocarcinoma.																						"{""association"": ""Co-occurring Mutations"", ""name"": ""BAP1"", ""notes"": ""BAP1 mutations may co-occur with IDH mutations in cholangiocarcinoma. Germline BAP1 mutations are associated with tumor predisposition syndrome including cholangiocarcinoma.""}"	{}	"{""association"": ""Co-occurring Mutations"", ""name"": ""BAP1"", ""notes"": ""BAP1 mutations may co-occur with IDH mutations in cholangiocarcinoma. Germline BAP1 mutations are associated with tumor predisposition syndrome including cholangiocarcinoma.""}"
3971	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	0	IDH1									Somatic Mutation																										IDH1 R132H is the most common mutation but IDH1 R132C and other variants occur more frequently in oligodendrogliomas than astrocytomas.																						"{""association"": ""Somatic Mutation"", ""name"": ""IDH1"", ""notes"": ""IDH1 R132H is the most common mutation but IDH1 R132C and other variants occur more frequently in oligodendrogliomas than astrocytomas.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""IDH1"", ""notes"": ""IDH1 R132H is the most common mutation but IDH1 R132C and other variants occur more frequently in oligodendrogliomas than astrocytomas.""}"
3972	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	1	IDH2									Somatic Mutation																										IDH2 R172 mutations are more common in oligodendrogliomas (up to 5%) than astrocytomas.																						"{""association"": ""Somatic Mutation"", ""name"": ""IDH2"", ""notes"": ""IDH2 R172 mutations are more common in oligodendrogliomas (up to 5%) than astrocytomas.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""IDH2"", ""notes"": ""IDH2 R172 mutations are more common in oligodendrogliomas (up to 5%) than astrocytomas.""}"
3973	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	2	CIC									Somatic Mutation																										CIC (Capicua transcriptional repressor) on 19q13.2 is mutated in approximately 70% of oligodendrogliomas. Functions as a transcriptional repressor downstream of receptor tyrosine kinase signaling.																						"{""association"": ""Somatic Mutation"", ""name"": ""CIC"", ""notes"": ""CIC (Capicua transcriptional repressor) on 19q13.2 is mutated in approximately 70% of oligodendrogliomas. Functions as a transcriptional repressor downstream of receptor tyrosine kinase signaling.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""CIC"", ""notes"": ""CIC (Capicua transcriptional repressor) on 19q13.2 is mutated in approximately 70% of oligodendrogliomas. Functions as a transcriptional repressor downstream of receptor tyrosine kinase signaling.""}"
3974	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	3	FUBP1									Somatic Mutation																										FUBP1 (far upstream element binding protein 1) on 1p31.1 is mutated in approximately 30% of oligodendrogliomas. Regulates MYC expression.																						"{""association"": ""Somatic Mutation"", ""name"": ""FUBP1"", ""notes"": ""FUBP1 (far upstream element binding protein 1) on 1p31.1 is mutated in approximately 30% of oligodendrogliomas. Regulates MYC expression.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""FUBP1"", ""notes"": ""FUBP1 (far upstream element binding protein 1) on 1p31.1 is mutated in approximately 30% of oligodendrogliomas. Regulates MYC expression.""}"
3975	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	4	TERT									Promoter Mutation																										TERT promoter mutations (C228T or C250T) occur in approximately 70-80% of oligodendrogliomas. Creates ETS binding sites leading to TERT upregulation and telomerase activation.																						"{""association"": ""Promoter Mutation"", ""name"": ""TERT"", ""notes"": ""TERT promoter mutations (C228T or C250T) occur in approximately 70-80% of oligodendrogliomas. Creates ETS binding sites leading to TERT upregulation and telomerase activation.""}"	{}	"{""association"": ""Promoter Mutation"", ""name"": ""TERT"", ""notes"": ""TERT promoter mutations (C228T or C250T) occur in approximately 70-80% of oligodendrogliomas. Creates ETS binding sites leading to TERT upregulation and telomerase activation.""}"
3976	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	genetic	5	NOTCH1									Somatic Mutation																										NOTCH1 mutations occur in approximately 10-15% of oligodendrogliomas and may be associated with worse prognosis.																						"{""association"": ""Somatic Mutation"", ""name"": ""NOTCH1"", ""notes"": ""NOTCH1 mutations occur in approximately 10-15% of oligodendrogliomas and may be associated with worse prognosis.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""NOTCH1"", ""notes"": ""NOTCH1 mutations occur in approximately 10-15% of oligodendrogliomas and may be associated with worse prognosis.""}"
3996	168	IgA Nephropathy	IgA_Nephropathy.yaml	genetic	0	CFHR1/CFHR3 Deletion									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CFHR1/CFHR3 Deletion""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CFHR1/CFHR3 Deletion""}"
3997	168	IgA Nephropathy	IgA_Nephropathy.yaml	genetic	1	HLA-DQB1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DQB1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DQB1""}"
3998	168	IgA Nephropathy	IgA_Nephropathy.yaml	genetic	2	DEFA									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""DEFA""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""DEFA""}"
4041	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	genetic	0	HTR3E									Risk Factor																										Serotonin receptor																						"{""association"": ""Risk Factor"", ""name"": ""HTR3E"", ""notes"": ""Serotonin receptor""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HTR3E"", ""notes"": ""Serotonin receptor""}"
4042	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	genetic	1	SCN5A									Risk Factor																										Sodium channel																						"{""association"": ""Risk Factor"", ""name"": ""SCN5A"", ""notes"": ""Sodium channel""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SCN5A"", ""notes"": ""Sodium channel""}"
4064	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	genetic	0	FGFR2 Mutations									Causative																										"Various FGFR2 mutations have been identified, including some shared with Crouzon and Pfeiffer syndromes (e.g., C342R, A344G). The phenotypic outcome depends on genetic background and potentially other modifying factors.
"																						"{""association"": ""Causative"", ""name"": ""FGFR2 Mutations"", ""notes"": ""Various FGFR2 mutations have been identified, including some shared with Crouzon and Pfeiffer syndromes (e.g., C342R, A344G). The phenotypic outcome depends on genetic background and potentially other modifying factors.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""First identification of FGFR2 mutation in JWS, establishing FGFR2 as the causative gene."", ""reference"": ""PMID:7874170"", ""snippet"": ""We now report an FGFR2 mutation in the conserved region of the immunoglobulin IIIc domain in the Jackson-Weiss syndrome family in which the syndrome was originally described."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms FGFR2 mutations cause JWS along with related craniosynostosis syndromes."", ""reference"": ""PMID:8644708"", ""snippet"": ""Fibroblast growth factor receptor 2 (FGFR2) mutations have been associated with the craniosynostotic conditions Crouzon, Jackson-Weiss, and Pfeiffer syndromes."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Identifies novel FGFR2 mutations specific to JWS that overlap with Crouzon syndrome mutations."", ""reference"": ""PMID:9385368"", ""snippet"": ""Mutations in the fibroblast growth factor receptor 2 (FGFR2) gene have been recently identified as causes of this syndrome and of at least four other craniosynostotic disorders, namely the Apert, Beare-Stevenson cutis gyrata, Crouzon and Pfeiffer syndromes."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR2 Mutations"", ""notes"": ""Various FGFR2 mutations have been identified, including some shared with Crouzon and Pfeiffer syndromes (e.g., C342R, A344G). The phenotypic outcome depends on genetic background and potentially other modifying factors.\n""}"
4078	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	0	SYNGAP1									Associated																										Synaptic Ras GTPase-activating protein in NMDA receptor complex; loss-of-function variants reported in EMA cases; implicates excitatory synaptic dysfunction and altered dendritic spine/plasticity.																						"{""association"": ""Associated"", ""name"": ""SYNGAP1"", ""notes"": ""Synaptic Ras GTPase-activating protein in NMDA receptor complex; loss-of-function variants reported in EMA cases; implicates excitatory synaptic dysfunction and altered dendritic spine/plasticity.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This large cohort study of 57 SYNGAP1 patients found 65% had eyelid myoclonia with absences, demonstrating strong overlap with Jeavons syndrome phenotype."", ""reference"": ""PMID:30541864"", ""snippet"": ""Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review identifies SYNGAP1 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome)."", ""reference"": ""PMID:34070602"", ""snippet"": ""Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."", ""supports"": ""SUPPORT""}], ""name"": ""SYNGAP1"", ""notes"": ""Synaptic Ras GTPase-activating protein in NMDA receptor complex; loss-of-function variants reported in EMA cases; implicates excitatory synaptic dysfunction and altered dendritic spine/plasticity.""}"
4079	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	1	NEXMIF									Associated																										Also known as KIAA2022; X-linked gene producing EMA-like phenotypes, often pharmacoresistant; female-predominant effects via X-inactivation/mosaicism; synaptic/neurodevelopmental dysfunction from haploinsufficiency.																						"{""association"": ""Associated"", ""name"": ""NEXMIF"", ""notes"": ""Also known as KIAA2022; X-linked gene producing EMA-like phenotypes, often pharmacoresistant; female-predominant effects via X-inactivation/mosaicism; synaptic/neurodevelopmental dysfunction from haploinsufficiency.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review identifies NEXMIF (KIAA2022) as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome)."", ""reference"": ""PMID:34070602"", ""snippet"": ""Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."", ""supports"": ""SUPPORT""}], ""name"": ""NEXMIF"", ""notes"": ""Also known as KIAA2022; X-linked gene producing EMA-like phenotypes, often pharmacoresistant; female-predominant effects via X-inactivation/mosaicism; synaptic/neurodevelopmental dysfunction from haploinsufficiency.""}"
4080	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	2	RORB									Associated																										Nuclear receptor involved in neuronal differentiation; alterations reported in some EMA cases; may affect cortical network development/excitability.																						"{""association"": ""Associated"", ""name"": ""RORB"", ""notes"": ""Nuclear receptor involved in neuronal differentiation; alterations reported in some EMA cases; may affect cortical network development/excitability.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review identifies RORB as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome)."", ""reference"": ""PMID:34070602"", ""snippet"": ""Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."", ""supports"": ""SUPPORT""}], ""name"": ""RORB"", ""notes"": ""Nuclear receptor involved in neuronal differentiation; alterations reported in some EMA cases; may affect cortical network development/excitability.""}"
4081	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	3	CHD2									Associated																										Chromatin remodeling dysfunction may perturb neuronal gene expression and cortical excitability; variants observed in EMA cases with GTCS comorbidity.																						"{""association"": ""Associated"", ""name"": ""CHD2"", ""notes"": ""Chromatin remodeling dysfunction may perturb neuronal gene expression and cortical excitability; variants observed in EMA cases with GTCS comorbidity.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The literature indicates that CHD2 mutations may overlap with phenotypes seen in Jeavons Syndrome, but it does not specifically state a direct genetic association exclusive to Jeavons Syndrome."", ""reference"": ""PMID:26262932"", ""snippet"": ""Conversely, CHD2 could be responsible for a proper phenotype characterized by infantile-onset generalized epilepsy, intellectual disability, and photosensitivity, which might overlap with MAE, Lennox-Gastaut, Dravet, and Jeavons syndromes."", ""supports"": ""PARTIAL""}, {""explanation"": ""This review identifies CHD2 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome)."", ""reference"": ""PMID:34070602"", ""snippet"": ""Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."", ""supports"": ""SUPPORT""}], ""name"": ""CHD2"", ""notes"": ""Chromatin remodeling dysfunction may perturb neuronal gene expression and cortical excitability; variants observed in EMA cases with GTCS comorbidity.""}"
4082	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	4	CSNK2B									Associated																										Casein kinase 2 beta; de novo missense variant reported in child with eyelid myoclonia; influences neuronal development and Wnt/-catenin signaling; proposed novel candidate gene.																						"{""association"": ""Associated"", ""name"": ""CSNK2B"", ""notes"": ""Casein kinase 2 beta; de novo missense variant reported in child with eyelid myoclonia; influences neuronal development and Wnt/-catenin signaling; proposed novel candidate gene.""}"	{}	"{""association"": ""Associated"", ""name"": ""CSNK2B"", ""notes"": ""Casein kinase 2 beta; de novo missense variant reported in child with eyelid myoclonia; influences neuronal development and Wnt/-catenin signaling; proposed novel candidate gene.""}"
4083	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	5	SLC2A1									Associated																										GLUT1 glucose transporter; rare EMA reports suggest metabolic contributions in some patients; impaired glucose transport can alter neuronal metabolism and seizure threshold.																						"{""association"": ""Associated"", ""name"": ""SLC2A1"", ""notes"": ""GLUT1 glucose transporter; rare EMA reports suggest metabolic contributions in some patients; impaired glucose transport can alter neuronal metabolism and seizure threshold.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study indicates that no pathogenic mutations in SLC2A1 were found in the cohort, suggesting a low frequency of association with certain types of epilepsy, including Jeavons syndrome."", ""reference"": ""PMID:28419980"", ""snippet"": ""We did not detect any pathogenic mutations in SLC2A1 in this cohort. Our data suggests that the frequency of GLUT1 mutations in NAFE is low."", ""supports"": ""REFUTE""}], ""name"": ""SLC2A1"", ""notes"": ""GLUT1 glucose transporter; rare EMA reports suggest metabolic contributions in some patients; impaired glucose transport can alter neuronal metabolism and seizure threshold.""}"
4084	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	6	KCNB1									Associated																										Voltage-gated potassium channel Kv2.1; rare variants reported in EMA-like presentations; perturbation can change neuronal repolarization and network excitability.																						"{""association"": ""Associated"", ""name"": ""KCNB1"", ""notes"": ""Voltage-gated potassium channel Kv2.1; rare variants reported in EMA-like presentations; perturbation can change neuronal repolarization and network excitability.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review notes KCNB1 alterations in some EMA patients, though evidence is limited."", ""reference"": ""PMID:34070602"", ""snippet"": ""Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1)."", ""supports"": ""PARTIAL""}], ""name"": ""KCNB1"", ""notes"": ""Voltage-gated potassium channel Kv2.1; rare variants reported in EMA-like presentations; perturbation can change neuronal repolarization and network excitability.""}"
4085	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	7	NAA10									Associated																										N-terminal acetyltransferase; rare EMA reports; N-terminal acetylation defects could impact multiple neuronal proteins and circuit development.																						"{""association"": ""Associated"", ""name"": ""NAA10"", ""notes"": ""N-terminal acetyltransferase; rare EMA reports; N-terminal acetylation defects could impact multiple neuronal proteins and circuit development.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""This review notes NAA10 alterations in some EMA patients, though evidence is limited."", ""reference"": ""PMID:34070602"", ""snippet"": ""Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1)."", ""supports"": ""PARTIAL""}], ""name"": ""NAA10"", ""notes"": ""N-terminal acetyltransferase; rare EMA reports; N-terminal acetylation defects could impact multiple neuronal proteins and circuit development.""}"
4086	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	genetic	8	GABRA1									Associated																																																"{""association"": ""Associated"", ""name"": ""GABRA1""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The abstract does not mention Jeavons syndrome and focuses on juvenile myoclonic epilepsy related to GABRA1 mutations in a different population."", ""reference"": ""PMID:14631097"", ""snippet"": ""An Ala322Asp mutation in the GABRA1 gene was recently reported to be responsible for causing the autosomal dominant (AD) form of juvenile myoclonic epilepsy (JME) in a French-Canadian family."", ""supports"": ""REFUTE""}, {""explanation"": ""The study focuses on clinical features and treatment response in Jeavons syndrome without mentioning GABRA1 or a genetic association."", ""reference"": ""PMID:30082241"", ""snippet"": ""We identified 30 patients who met the diagnostic criteria of Jeavons syndrome at a single institution..."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The database mentions epilepsy genetic association studies but does not specifically address Jeavons syndrome or GABRA1."", ""reference"": ""PMID:20074235"", ""snippet"": ""We have created the Epilepsy Genetic Association Database (epiGAD)..."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""GABRA1""}"
4107	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	genetic	0	KIT Exon 11 Mutations									Somatic Oncogenic Mutation																										Mutations in the juxtamembrane domain encoded by exon 11 disrupt autoinhibitory function, leading to constitutive receptor activation. These mutations typically show good response to imatinib therapy.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 11 Mutations"", ""notes"": ""Mutations in the juxtamembrane domain encoded by exon 11 disrupt autoinhibitory function, leading to constitutive receptor activation. These mutations typically show good response to imatinib therapy.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 11 Mutations"", ""notes"": ""Mutations in the juxtamembrane domain encoded by exon 11 disrupt autoinhibitory function, leading to constitutive receptor activation. These mutations typically show good response to imatinib therapy.""}"
4108	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	genetic	1	KIT Exon 13 Mutations (K642E)									Somatic Oncogenic Mutation																										Point mutations in the kinase domain affecting the ATP-binding pocket. K642E is the most common exon 13 mutation and is sensitive to imatinib.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 13 Mutations (K642E)"", ""notes"": ""Point mutations in the kinase domain affecting the ATP-binding pocket. K642E is the most common exon 13 mutation and is sensitive to imatinib.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 13 Mutations (K642E)"", ""notes"": ""Point mutations in the kinase domain affecting the ATP-binding pocket. K642E is the most common exon 13 mutation and is sensitive to imatinib.""}"
4109	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	genetic	2	KIT Exon 17 Mutations (D820Y)									Somatic Oncogenic Mutation																										Mutations in the activation loop of the kinase domain. Some exon 17 mutations, particularly D816V, confer resistance to imatinib but may respond to other KIT inhibitors.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 17 Mutations (D820Y)"", ""notes"": ""Mutations in the activation loop of the kinase domain. Some exon 17 mutations, particularly D816V, confer resistance to imatinib but may respond to other KIT inhibitors.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""KIT Exon 17 Mutations (D820Y)"", ""notes"": ""Mutations in the activation loop of the kinase domain. Some exon 17 mutations, particularly D816V, confer resistance to imatinib but may respond to other KIT inhibitors.""}"
4110	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	genetic	3	KIT Amplification									Somatic Alteration																										Gene amplification without mutation occurs in some acral and mucosal melanomas. Response to KIT inhibitors is generally poorer for amplification compared to activating point mutations.																						"{""association"": ""Somatic Alteration"", ""name"": ""KIT Amplification"", ""notes"": ""Gene amplification without mutation occurs in some acral and mucosal melanomas. Response to KIT inhibitors is generally poorer for amplification compared to activating point mutations.""}"	{}	"{""association"": ""Somatic Alteration"", ""name"": ""KIT Amplification"", ""notes"": ""Gene amplification without mutation occurs in some acral and mucosal melanomas. Response to KIT inhibitors is generally poorer for amplification compared to activating point mutations.""}"
4126	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	genetic	0	KRAS									Somatic Activating Mutation																										KRAS (12p12.1) encodes a small GTPase in the RAS family. G12C is the most common KRAS mutation in NSCLC, resulting from a G>T transversion associated with smoking. Other common KRAS mutations include G12D and G12V. KRAS mutations are generally mutually exclusive with EGFR, ALK, and ROS1 alterations.																						"{""association"": ""Somatic Activating Mutation"", ""name"": ""KRAS"", ""notes"": ""KRAS (12p12.1) encodes a small GTPase in the RAS family. G12C is the most common KRAS mutation in NSCLC, resulting from a G>T transversion associated with smoking. Other common KRAS mutations include G12D and G12V. KRAS mutations are generally mutually exclusive with EGFR, ALK, and ROS1 alterations.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Activating Mutation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""KRAS"", ""notes"": ""KRAS (12p12.1) encodes a small GTPase in the RAS family. G12C is the most common KRAS mutation in NSCLC, resulting from a G>T transversion associated with smoking. Other common KRAS mutations include G12D and G12V. KRAS mutations are generally mutually exclusive with EGFR, ALK, and ROS1 alterations.""}"
4127	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	genetic	1	STK11									Co-occurring Inactivation																										STK11/LKB1 (19p13.3) encodes a serine/threonine kinase tumor suppressor. Co-mutation with KRAS G12C occurs in ~20-30% of cases and is associated with reduced immunotherapy benefit. May still respond to KRAS G12C inhibitors.																						"{""association"": ""Co-occurring Inactivation"", ""name"": ""STK11"", ""notes"": ""STK11/LKB1 (19p13.3) encodes a serine/threonine kinase tumor suppressor. Co-mutation with KRAS G12C occurs in ~20-30% of cases and is associated with reduced immunotherapy benefit. May still respond to KRAS G12C inhibitors.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Co-occurring Inactivation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""STK11"", ""notes"": ""STK11/LKB1 (19p13.3) encodes a serine/threonine kinase tumor suppressor. Co-mutation with KRAS G12C occurs in ~20-30% of cases and is associated with reduced immunotherapy benefit. May still respond to KRAS G12C inhibitors.""}"
4128	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	genetic	2	KEAP1									Co-occurring Inactivation																										KEAP1 (19p13.2) encodes a negative regulator of NRF2 antioxidant response. Co-mutation with KRAS G12C (~15-20%) associated with worse outcomes and potential resistance to targeted therapy.																						"{""association"": ""Co-occurring Inactivation"", ""name"": ""KEAP1"", ""notes"": ""KEAP1 (19p13.2) encodes a negative regulator of NRF2 antioxidant response. Co-mutation with KRAS G12C (~15-20%) associated with worse outcomes and potential resistance to targeted therapy.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Co-occurring Inactivation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""KEAP1"", ""notes"": ""KEAP1 (19p13.2) encodes a negative regulator of NRF2 antioxidant response. Co-mutation with KRAS G12C (~15-20%) associated with worse outcomes and potential resistance to targeted therapy.""}"
4147	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	genetic	0	HHV-8 Viral Oncogenes									Viral Oncogene Expression																										HHV-8 encodes multiple oncogenes: vGPCR (constitutively active GPCR), vFLIP (NF-kappaB activator), vCyclin (cell cycle driver), LANA (tumor suppressor inhibitor), vIL-6, vBCL-2, and K1. These cooperate to drive transformation through multiple mechanisms.																						"{""association"": ""Viral Oncogene Expression"", ""name"": ""HHV-8 Viral Oncogenes"", ""notes"": ""HHV-8 encodes multiple oncogenes: vGPCR (constitutively active GPCR), vFLIP (NF-kappaB activator), vCyclin (cell cycle driver), LANA (tumor suppressor inhibitor), vIL-6, vBCL-2, and K1. These cooperate to drive transformation through multiple mechanisms.""}"	{}	"{""association"": ""Viral Oncogene Expression"", ""name"": ""HHV-8 Viral Oncogenes"", ""notes"": ""HHV-8 encodes multiple oncogenes: vGPCR (constitutively active GPCR), vFLIP (NF-kappaB activator), vCyclin (cell cycle driver), LANA (tumor suppressor inhibitor), vIL-6, vBCL-2, and K1. These cooperate to drive transformation through multiple mechanisms.""}"
4175	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	0	ITPKC									Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation																										Associated with coronary lesions and hyperinflammation; rationale for calcineurin inhibitors																						"{""association"": ""Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation"", ""name"": ""ITPKC"", ""notes"": ""Associated with coronary lesions and hyperinflammation; rationale for calcineurin inhibitors""}"	{}	"{""association"": ""Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation"", ""name"": ""ITPKC"", ""notes"": ""Associated with coronary lesions and hyperinflammation; rationale for calcineurin inhibitors""}"
4176	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	1	FCGR2A									Mediates immune-complex driven neutrophil/monocyte activation																										Mechanistic basis for IVIG competing at FcRs; genetic association with susceptibility																						"{""association"": ""Mediates immune-complex driven neutrophil/monocyte activation"", ""name"": ""FCGR2A"", ""notes"": ""Mechanistic basis for IVIG competing at FcRs; genetic association with susceptibility""}"	{}	"{""association"": ""Mediates immune-complex driven neutrophil/monocyte activation"", ""name"": ""FCGR2A"", ""notes"": ""Mechanistic basis for IVIG competing at FcRs; genetic association with susceptibility""}"
4177	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	2	FCGR3A									Mediates immune-complex driven neutrophil/monocyte activation																										Involved in FcR signaling and immune complex handling																						"{""association"": ""Mediates immune-complex driven neutrophil/monocyte activation"", ""name"": ""FCGR3A"", ""notes"": ""Involved in FcR signaling and immune complex handling""}"	{}	"{""association"": ""Mediates immune-complex driven neutrophil/monocyte activation"", ""name"": ""FCGR3A"", ""notes"": ""Involved in FcR signaling and immune complex handling""}"
4178	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	3	BLK									B lymphoid tyrosine kinase involved in B-cell receptor signaling																										Genetic locus implicated in altered B-cell/plasmablast responses																						"{""association"": ""B lymphoid tyrosine kinase involved in B-cell receptor signaling"", ""name"": ""BLK"", ""notes"": ""Genetic locus implicated in altered B-cell/plasmablast responses""}"	{}	"{""association"": ""B lymphoid tyrosine kinase involved in B-cell receptor signaling"", ""name"": ""BLK"", ""notes"": ""Genetic locus implicated in altered B-cell/plasmablast responses""}"
4179	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	4	CD40									Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation																										CD40L on T cells linked to endothelial cell activation and inflammation																						"{""association"": ""Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation"", ""name"": ""CD40"", ""notes"": ""CD40L on T cells linked to endothelial cell activation and inflammation""}"	{}	"{""association"": ""Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation"", ""name"": ""CD40"", ""notes"": ""CD40L on T cells linked to endothelial cell activation and inflammation""}"
4180	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	5	HLA-B									HLA associations support antigen-driven or superantigen-like T-cell responses																										Shapes disease susceptibility; useful for dissecting trigger(s) and host response subtypes																						"{""association"": ""HLA associations support antigen-driven or superantigen-like T-cell responses"", ""name"": ""HLA-B"", ""notes"": ""Shapes disease susceptibility; useful for dissecting trigger(s) and host response subtypes""}"	{}	"{""association"": ""HLA associations support antigen-driven or superantigen-like T-cell responses"", ""name"": ""HLA-B"", ""notes"": ""Shapes disease susceptibility; useful for dissecting trigger(s) and host response subtypes""}"
4181	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	6	CASP3									Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis																										Apoptosis modulation is investigational																						"{""association"": ""Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis"", ""name"": ""CASP3"", ""notes"": ""Apoptosis modulation is investigational""}"	{}	"{""association"": ""Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis"", ""name"": ""CASP3"", ""notes"": ""Apoptosis modulation is investigational""}"
4182	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	7	ORAI1									Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling																										Heightened T-cell responses contribute to hyperinflammation																						"{""association"": ""Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling"", ""name"": ""ORAI1"", ""notes"": ""Heightened T-cell responses contribute to hyperinflammation""}"	{}	"{""association"": ""Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling"", ""name"": ""ORAI1"", ""notes"": ""Heightened T-cell responses contribute to hyperinflammation""}"
4183	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	8	STIM1									Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling																										Points to SOCE or calcineurin/NFAT modulation as therapeutic option																						"{""association"": ""Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling"", ""name"": ""STIM1"", ""notes"": ""Points to SOCE or calcineurin/NFAT modulation as therapeutic option""}"	{}	"{""association"": ""Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling"", ""name"": ""STIM1"", ""notes"": ""Points to SOCE or calcineurin/NFAT modulation as therapeutic option""}"
4184	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	9	TGFBR2									TGF- receptor involved in endothelial-to-mesenchymal transition																										Drives EndMT and luminal myofibroblast proliferation leading to stenosis/aneurysm formation																						"{""association"": ""TGF- receptor involved in endothelial-to-mesenchymal transition"", ""name"": ""TGFBR2"", ""notes"": ""Drives EndMT and luminal myofibroblast proliferation leading to stenosis/aneurysm formation""}"	{}	"{""association"": ""TGF- receptor involved in endothelial-to-mesenchymal transition"", ""name"": ""TGFBR2"", ""notes"": ""Drives EndMT and luminal myofibroblast proliferation leading to stenosis/aneurysm formation""}"
4185	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	10	SMAD3									TGF- signaling mediator involved in vascular remodeling																										Anti-fibrotic or TGF- pathway modulation is theoretical target																						"{""association"": ""TGF- signaling mediator involved in vascular remodeling"", ""name"": ""SMAD3"", ""notes"": ""Anti-fibrotic or TGF- pathway modulation is theoretical target""}"	{}	"{""association"": ""TGF- signaling mediator involved in vascular remodeling"", ""name"": ""SMAD3"", ""notes"": ""Anti-fibrotic or TGF- pathway modulation is theoretical target""}"
4186	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	11	TGFB2									TGF- signaling involved in chronic vascular remodeling																										Informs long-term vascular remodeling targets																						"{""association"": ""TGF- signaling involved in chronic vascular remodeling"", ""name"": ""TGFB2"", ""notes"": ""Informs long-term vascular remodeling targets""}"	{}	"{""association"": ""TGF- signaling involved in chronic vascular remodeling"", ""name"": ""TGFB2"", ""notes"": ""Informs long-term vascular remodeling targets""}"
4187	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	12	IL1B									IL-1 promotes endothelial injury, inflammation and remodeling																										Direct IL-1 blockade (anakinra) has mechanistic and clinical rationale for IVIG-resistant KD																						"{""association"": ""IL-1 promotes endothelial injury, inflammation and remodeling"", ""name"": ""IL1B"", ""notes"": ""Direct IL-1 blockade (anakinra) has mechanistic and clinical rationale for IVIG-resistant KD""}"	{}	"{""association"": ""IL-1 promotes endothelial injury, inflammation and remodeling"", ""name"": ""IL1B"", ""notes"": ""Direct IL-1 blockade (anakinra) has mechanistic and clinical rationale for IVIG-resistant KD""}"
4188	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	13	IL1R1									IL-1 receptor; downstream of inflammasome activation																										IL-1 pathway is therapeutic target																						"{""association"": ""IL-1 receptor; downstream of inflammasome activation"", ""name"": ""IL1R1"", ""notes"": ""IL-1 pathway is therapeutic target""}"	{}	"{""association"": ""IL-1 receptor; downstream of inflammasome activation"", ""name"": ""IL1R1"", ""notes"": ""IL-1 pathway is therapeutic target""}"
4189	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	14	TNF									Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade																										Anti-TNF therapy (infliximab) used for IVIG-resistant cases																						"{""association"": ""Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade"", ""name"": ""TNF"", ""notes"": ""Anti-TNF therapy (infliximab) used for IVIG-resistant cases""}"	{}	"{""association"": ""Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade"", ""name"": ""TNF"", ""notes"": ""Anti-TNF therapy (infliximab) used for IVIG-resistant cases""}"
4190	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	15	IL17A									Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance																										Promotes neutrophil recruitment; IL-17/IL-23 pathway inhibitors are investigational																						"{""association"": ""Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance"", ""name"": ""IL17A"", ""notes"": ""Promotes neutrophil recruitment; IL-17/IL-23 pathway inhibitors are investigational""}"	{}	"{""association"": ""Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance"", ""name"": ""IL17A"", ""notes"": ""Promotes neutrophil recruitment; IL-17/IL-23 pathway inhibitors are investigational""}"
4191	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	16	IL23A									IL-23 involved in Th17 axis and IL-17 signaling																										Potential investigational approach in select patients																						"{""association"": ""IL-23 involved in Th17 axis and IL-17 signaling"", ""name"": ""IL23A"", ""notes"": ""Potential investigational approach in select patients""}"	{}	"{""association"": ""IL-23 involved in Th17 axis and IL-17 signaling"", ""name"": ""IL23A"", ""notes"": ""Potential investigational approach in select patients""}"
4192	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	17	NLRP3									NLRP3 inflammasome activation leads to IL-1 release and pyroptosis																										NLRP3 or IL-1 pathway inhibition offers mechanistic target																						"{""association"": ""NLRP3 inflammasome activation leads to IL-1 release and pyroptosis"", ""name"": ""NLRP3"", ""notes"": ""NLRP3 or IL-1 pathway inhibition offers mechanistic target""}"	{}	"{""association"": ""NLRP3 inflammasome activation leads to IL-1 release and pyroptosis"", ""name"": ""NLRP3"", ""notes"": ""NLRP3 or IL-1 pathway inhibition offers mechanistic target""}"
4193	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	18	NOS3									Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis																										Supports vascular-protective strategies and monitoring of endothelial function																						"{""association"": ""Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis"", ""name"": ""NOS3"", ""notes"": ""Supports vascular-protective strategies and monitoring of endothelial function""}"	{}	"{""association"": ""Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis"", ""name"": ""NOS3"", ""notes"": ""Supports vascular-protective strategies and monitoring of endothelial function""}"
4194	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	19	ICAM1									Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction																										Adhesion-inflammation axis is biomarker and potential target																						"{""association"": ""Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction"", ""name"": ""ICAM1"", ""notes"": ""Adhesion-inflammation axis is biomarker and potential target""}"	{}	"{""association"": ""Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction"", ""name"": ""ICAM1"", ""notes"": ""Adhesion-inflammation axis is biomarker and potential target""}"
4195	177	Kawasaki Disease	Kawasaki_Disease.yaml	genetic	20	VCAM1									Upregulated by TNF/IL-1 leading to vascular injury																										Part of adhesion-inflammation axis																						"{""association"": ""Upregulated by TNF/IL-1 leading to vascular injury"", ""name"": ""VCAM1"", ""notes"": ""Part of adhesion-inflammation axis""}"	{}	"{""association"": ""Upregulated by TNF/IL-1 leading to vascular injury"", ""name"": ""VCAM1"", ""notes"": ""Part of adhesion-inflammation axis""}"
4219	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	genetic	0	GJB2									Causative																										"Autosomal dominant. The D66H mutation (c.196G>C) in exon 1 is the most common pathogenic variant causing classic Vohwinkel syndrome. The mutation occurs at a highly conserved residue in the first extracellular domain of connexin 26.
"																						"{""association"": ""Causative"", ""name"": ""GJB2"", ""notes"": ""Autosomal dominant. The D66H mutation (c.196G>C) in exon 1 is the most common pathogenic variant causing classic Vohwinkel syndrome. The mutation occurs at a highly conserved residue in the first extracellular domain of connexin 26.\n""}"	"{""variants"": [{""description"": ""Missense mutation (c.196G>C) causing substitution of aspartate to histidine at position 66 in the first extracellular domain. Most common mutation in classic Vohwinkel syndrome.\n"", ""name"": ""D66H""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Identifies D66H as a common mutation in classic Vohwinkel syndrome across multiple families."", ""reference"": ""PMID:10369869"", ""snippet"": ""All 10 affected members were heterozygous for a non-conservative mutation, D66H, in Cx26. The same mutation was found subsequently in affected individuals from two unrelated Spanish and Italian pedigrees segregating VS, suggesting that D66H in Cx26 is a common mutation in classical VS.\n"", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms the specific nucleotide change causing the D66H mutation."", ""reference"": ""PMID:20031451"", ""snippet"": ""Genetic study showed a nucleotide change (c.196G>C) in exon 1 of GJB2 gene, producing a missense mutation, D66H.\n"", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""GJB2"", ""term"": {""id"": ""hgnc:4284"", ""label"": ""GJB2""}}, ""name"": ""GJB2"", ""notes"": ""Autosomal dominant. The D66H mutation (c.196G>C) in exon 1 is the most common pathogenic variant causing classic Vohwinkel syndrome. The mutation occurs at a highly conserved residue in the first extracellular domain of connexin 26.\n"", ""variants"": [{""description"": ""Missense mutation (c.196G>C) causing substitution of aspartate to histidine at position 66 in the first extracellular domain. Most common mutation in classic Vohwinkel syndrome.\n"", ""name"": ""D66H""}]}"
4220	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	genetic	1	LOR									Causative																										"Autosomal dominant. Frameshift mutations (commonly 730insG) cause the ichthyotic variant (Camisa syndrome). The mutation produces an abnormal C-terminal peptide with nuclear localization signals.
"																						"{""association"": ""Causative"", ""name"": ""LOR"", ""notes"": ""Autosomal dominant. Frameshift mutations (commonly 730insG) cause the ichthyotic variant (Camisa syndrome). The mutation produces an abnormal C-terminal peptide with nuclear localization signals.\n""}"	"{""variants"": [{""description"": ""Recurrent insertion mutation causing frameshift after codon 231, producing an abnormal C-terminal peptide that mislocalizes to the nucleus.\n"", ""name"": ""730insG""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Identifies the specific loricrin mutation causing the ichthyotic variant."", ""reference"": ""PMID:9326398"", ""snippet"": ""a G insertion producing a frameshift after codon 231 and an abnormal C-terminal peptide lacking residues necessary for cross-linking.\n"", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms the recurrent nature of loricrin insertion mutations."", ""reference"": ""PMID:12072018"", ""snippet"": ""identified a recurrent insertion mutation in the loricrin gene resulting in a mutant polypeptide with an unusual C terminus.\n"", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""LOR"", ""term"": {""id"": ""hgnc:6663"", ""label"": ""LOR""}}, ""name"": ""LOR"", ""notes"": ""Autosomal dominant. Frameshift mutations (commonly 730insG) cause the ichthyotic variant (Camisa syndrome). The mutation produces an abnormal C-terminal peptide with nuclear localization signals.\n"", ""variants"": [{""description"": ""Recurrent insertion mutation causing frameshift after codon 231, producing an abnormal C-terminal peptide that mislocalizes to the nucleus.\n"", ""name"": ""730insG""}]}"
4245	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	0	47,XXY Karyotype								Diagnostic																																																	"{""name"": ""47,XXY Karyotype"", ""presence"": ""Diagnostic""}"	{}	"{""evidence"": [{""explanation"": ""The study discusses that Klinefelter syndrome typically exhibits a 47,XXY karyotype."", ""reference"": ""PMID:34375016"", ""snippet"": ""Patients with Klinefelter syndrome (KS) show a typically 47,XXY karyotype; however, some variations have been observed, including 47,XX,der(Y), 46,XY/47,XXY, 48,XXXY, 48,XXYY, and mosaicism or structural sex chromosome abnormalities in some patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that Klinefelter syndrome is associated with an extra sex chromosome, typically 47,XXY."", ""reference"": ""PMID:9160389"", ""snippet"": ""Cytogenetic surveys of neonates have found that approximately one boy in 500 is born with an extra sex chromosome. ... This study estimates what proportion of those not detected prenatally will be diagnosed postnatally and what the indications for karyotyping are likely to be."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identifies Klinefelter syndrome as a congenital disorder related to the 47,XXY karyotype."", ""reference"": ""PMID:31630146"", ""snippet"": ""Klinefelter syndrome (KS) is one of the most common congenital disorders of male infertility. Given its high heterogeneity in clinical and genetic presentation, the relationship between transcriptome, clinical phenotype, and associated co-morbidities seen in KS has not been fully clarified."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that Klinefelter syndrome is an aneuploidy condition predominantly associated with the 47,XXY karyotype."", ""reference"": ""PMID:37054629"", ""snippet"": ""Klinefelter syndrome is the most frequently found aneuploidy among male patients. Its clinical presentation is very heterogeneous, and thus poses a challenge for a timely diagnosis."", ""supports"": ""SUPPORT""}], ""name"": ""47,XXY Karyotype"", ""presence"": ""Diagnostic""}"
4246	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	1	KDM6A									X-dosage escape gene																										Escape from X-inactivation alters demethylase activity and chromatin regulation, contributing to dose-dependent transcriptional changes in tissues.																						"{""association"": ""X-dosage escape gene"", ""name"": ""KDM6A"", ""notes"": ""Escape from X-inactivation alters demethylase activity and chromatin regulation, contributing to dose-dependent transcriptional changes in tissues.""}"	{}	"{""association"": ""X-dosage escape gene"", ""name"": ""KDM6A"", ""notes"": ""Escape from X-inactivation alters demethylase activity and chromatin regulation, contributing to dose-dependent transcriptional changes in tissues.""}"
4247	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	2	SHOX									Pseudoautosomal region gene																										PAR1 gene with copy-number effects linked to tall stature phenotype due to gene dosage changes.																						"{""association"": ""Pseudoautosomal region gene"", ""name"": ""SHOX"", ""notes"": ""PAR1 gene with copy-number effects linked to tall stature phenotype due to gene dosage changes.""}"	{}	"{""association"": ""Pseudoautosomal region gene"", ""name"": ""SHOX"", ""notes"": ""PAR1 gene with copy-number effects linked to tall stature phenotype due to gene dosage changes.""}"
4248	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	3	TLR7									X-dosage escape gene																										Escape from X-inactivation produces increased innate immune signaling, contributing to heightened immune responses.																						"{""association"": ""X-dosage escape gene"", ""name"": ""TLR7"", ""notes"": ""Escape from X-inactivation produces increased innate immune signaling, contributing to heightened immune responses.""}"	{}	"{""association"": ""X-dosage escape gene"", ""name"": ""TLR7"", ""notes"": ""Escape from X-inactivation produces increased innate immune signaling, contributing to heightened immune responses.""}"
4249	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	4	AR									Androgen signaling pathway																										Androgen receptor dysfunction contributes to hypogonadism phenotype.																						"{""association"": ""Androgen signaling pathway"", ""name"": ""AR"", ""notes"": ""Androgen receptor dysfunction contributes to hypogonadism phenotype.""}"	{}	"{""association"": ""Androgen signaling pathway"", ""name"": ""AR"", ""notes"": ""Androgen receptor dysfunction contributes to hypogonadism phenotype.""}"
4250	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	5	INSL3									Leydig cell function marker																										INSL3 dynamics reflect Leydig cell health with age-dependent alterations in KS.																						"{""association"": ""Leydig cell function marker"", ""name"": ""INSL3"", ""notes"": ""INSL3 dynamics reflect Leydig cell health with age-dependent alterations in KS.""}"	{}	"{""association"": ""Leydig cell function marker"", ""name"": ""INSL3"", ""notes"": ""INSL3 dynamics reflect Leydig cell health with age-dependent alterations in KS.""}"
4251	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	genetic	6	Mosaicism (46,XY/47,XXY)								Occasional																																																	"{""name"": ""Mosaicism (46,XY/47,XXY)"", ""presence"": ""Occasional""}"	{}	"{""evidence"": [{""explanation"": ""The reference discusses the occurrence of mosaicism in Klinefelter syndrome with a frequency of 11%, supporting that mosaicism is occasionally present in Klinefelter Syndrome."", ""reference"": ""PMID:1176138"", ""snippet"": ""The percentage with mosaicism was 36 in both triple-X and Turner's syndrome, it was 7 and 11% in XYY and Klinefelter's syndrome, respectively..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report shows that 46,XY/47,XXY mosaicism is not uncommon in Klinefelter's syndrome, supporting the statement."", ""reference"": ""PMID:3490207"", ""snippet"": ""46,XY/47,XXY mosaicism is not uncommon. However, mosaicism of multiple sex chromosome aneuploidy is rarely observed."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions cases of mosaicism in Klinefelter's syndrome, providing support to the statement."", ""reference"": ""PMID:5720649"", ""snippet"": ""Chromosomal mosaicism in two emotionally disturbed adolescents with Klinefelter's syndrome (46,XY-47,XXY and 46,XY-47,XYY-48,XXYY)."", ""supports"": ""SUPPORT""}], ""name"": ""Mosaicism (46,XY/47,XXY)"", ""presence"": ""Occasional""}"
4276	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous mutations in COL2A1, characteristically exon-skipping mutations and small in-frame deletions in the triple helical domain. These produce shortened collagen alpha chains that are incorporated into fibrils but cause structural abnormalities.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1, characteristically exon-skipping mutations and small in-frame deletions in the triple helical domain. These produce shortened collagen alpha chains that are incorporated into fibrils but cause structural abnormalities.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study identifies a 28bp deletion at the exon 12 splice boundary in COL2A1 causing Kniest dysplasia, demonstrating that exon-boundary mutations (which lead to exon skipping) cause the disorder."", ""reference"": ""PMID:7981752"", ""snippet"": ""We studied a 2-year-old girl presenting with manifestations of Kniest dysplasia and her mother showing a Stickler phenotype. Analysing COL2A1 in both patients, we detected the same 28 basepair deletion spanning the 3'-exon/intron boundary of exon 12 in mother and daughter."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study confirms that Kniest dysplasia is associated with heterozygous COL2A1 mutations that are frequently de novo."", ""reference"": ""PMID:25592122"", ""snippet"": ""Six dominant disease-causing COL2A1 variants were detected. In three cases, testing of parental samples revealed that the disease-causing variant was not present in either parent."", ""supports"": ""SUPPORT""}], ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1, characteristically exon-skipping mutations and small in-frame deletions in the triple helical domain. These produce shortened collagen alpha chains that are incorporated into fibrils but cause structural abnormalities.\n""}"
4327	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	0	SOX2									Associated																																																"{""association"": ""Associated"", ""name"": ""SOX2""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""COMPUTATIONAL"", ""explanation"": ""Single-cell analysis links SOX2 to esophageal malformation gene expression patterns."", ""reference"": ""DOI:10.1038/s41598-024-53098-w"", ""snippet"": ""FOXF1, FOXC1, and FOXD1, as well as the SRY-box transcription factor, SOX2, demonstrate the most significant preferential expression in both mouse and human embryos."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""SOX2"", ""term"": {""id"": ""hgnc:11195"", ""label"": ""SOX2""}}, ""name"": ""SOX2""}"
4328	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	1	FOXF1									Associated																																																"{""association"": ""Associated"", ""name"": ""FOXF1""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""COMPUTATIONAL"", ""explanation"": ""Single-cell analysis highlights FOXF1 among genes enriched in esophageal malformation contexts."", ""reference"": ""DOI:10.1038/s41598-024-53098-w"", ""snippet"": ""FOXF1, FOXC1, and FOXD1, as well as the SRY-box transcription factor, SOX2, demonstrate the most significant preferential expression in both mouse and human embryos."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""FOXF1"", ""term"": {""id"": ""hgnc:3809"", ""label"": ""FOXF1""}}, ""name"": ""FOXF1""}"
4329	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	2	FOXC1									Associated																																																"{""association"": ""Associated"", ""name"": ""FOXC1""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""COMPUTATIONAL"", ""explanation"": ""Single-cell analysis highlights FOXC1 among genes enriched in esophageal malformation contexts."", ""reference"": ""DOI:10.1038/s41598-024-53098-w"", ""snippet"": ""FOXF1, FOXC1, and FOXD1, as well as the SRY-box transcription factor, SOX2, demonstrate the most significant preferential expression in both mouse and human embryos."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""FOXC1"", ""term"": {""id"": ""hgnc:3800"", ""label"": ""FOXC1""}}, ""name"": ""FOXC1""}"
4330	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	genetic	3	RERE									Associated																																																"{""association"": ""Associated"", ""name"": ""RERE""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report identifies a 1p36 deletion including RERE in a neonate with type IV LTEC."", ""reference"": ""PMID:30245899"", ""snippet"": ""a 1p36 deletion including the RERE gene was detected."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""RERE"", ""term"": {""id"": ""hgnc:9965"", ""label"": ""RERE""}}, ""name"": ""RERE""}"
4378	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	genetic	0	TP53									Germline Loss-of-Function Mutations																										TP53 (17p13.1) encodes the p53 tumor suppressor protein. Germline pathogenic variants cause LFS with high but incomplete penetrance. Most mutations are missense variants in the DNA-binding domain (exons 5-8). Some mutations (R175H, R248Q, R248W, R273H, R273C) have dominant-negative effects beyond simple loss of function. The Brazilian founder mutation R337H has attenuated penetrance but high association with adrenocortical carcinoma.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 (17p13.1) encodes the p53 tumor suppressor protein. Germline pathogenic variants cause LFS with high but incomplete penetrance. Most mutations are missense variants in the DNA-binding domain (exons 5-8). Some mutations (R175H, R248Q, R248W, R273H, R273C) have dominant-negative effects beyond simple loss of function. The Brazilian founder mutation R337H has attenuated penetrance but high association with adrenocortical carcinoma.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""evidence"": [{""explanation"": ""Clinical gradient of germline TP53 mutations demonstrates that dominant-negative missense mutations cause earlier tumor onset (21.3 years) compared to loss-of-function mutations (28.5 years), supporting mutation-specific phenotype stratification."", ""reference"": ""PMID:26014290"", ""snippet"": ""The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""TP53"", ""notes"": ""TP53 (17p13.1) encodes the p53 tumor suppressor protein. Germline pathogenic variants cause LFS with high but incomplete penetrance. Most mutations are missense variants in the DNA-binding domain (exons 5-8). Some mutations (R175H, R248Q, R248W, R273H, R273C) have dominant-negative effects beyond simple loss of function. The Brazilian founder mutation R337H has attenuated penetrance but high association with adrenocortical carcinoma.""}"
4409	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	genetic	0	HFE									Causative																										Hereditary hemochromatosis																						"{""association"": ""Causative"", ""name"": ""HFE"", ""notes"": ""Hereditary hemochromatosis""}"	{}	"{""association"": ""Causative"", ""name"": ""HFE"", ""notes"": ""Hereditary hemochromatosis""}"
4410	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	genetic	1	ATP7B									Causative																										Wilson disease																						"{""association"": ""Causative"", ""name"": ""ATP7B"", ""notes"": ""Wilson disease""}"	{}	"{""association"": ""Causative"", ""name"": ""ATP7B"", ""notes"": ""Wilson disease""}"
4411	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	genetic	2	SERPINA1									Causative																										Alpha-1 antitrypsin deficiency																						"{""association"": ""Causative"", ""name"": ""SERPINA1"", ""notes"": ""Alpha-1 antitrypsin deficiency""}"	{}	"{""association"": ""Causative"", ""name"": ""SERPINA1"", ""notes"": ""Alpha-1 antitrypsin deficiency""}"
4538	191	Lyme Disease	Lyme_Disease.yaml	genetic	0	HLA-DR4									Susceptibility																										HLA-DRB1*04 alleles associated with antibiotic-refractory Lyme arthritis and autoimmune mechanisms																						"{""association"": ""Susceptibility"", ""name"": ""HLA-DR4"", ""notes"": ""HLA-DRB1*04 alleles associated with antibiotic-refractory Lyme arthritis and autoimmune mechanisms""}"	{}	"{""association"": ""Susceptibility"", ""name"": ""HLA-DR4"", ""notes"": ""HLA-DRB1*04 alleles associated with antibiotic-refractory Lyme arthritis and autoimmune mechanisms""}"
4587	194	Lynch Syndrome	Lynch_Syndrome.yaml	genetic	0	MLH1									Germline Mutation																																																"{""association"": ""Germline Mutation"", ""name"": ""MLH1""}"	"{""inheritance"": [{""evidence"": [{""explanation"": ""This supports autosomal dominant inheritance for Lynch syndrome caused by pathogenic mismatch repair variants including MLH1."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes."", ""supports"": ""SUPPORT""}], ""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""The reference directly indicates that Lynch syndrome is caused by germline mutations in the MLH1 gene among others."", ""reference"": ""PMID:28038733"", ""snippet"": ""Lynch syndrome is due to germline mutations in mismatch repair genes: MLH1, MSH2, MSH6 and PMS2."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the term 'epimutation' is used, it is within the context of the DNA mismatch repair gene MLH1 being a cause of Lynch syndrome."", ""reference"": ""PMID:26886015"", ""snippet"": ""Constitutional epimutation of the DNA mismatch repair gene, MLH1, represents a minor cause of Lynch syndrome."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""evidence"": [{""explanation"": ""This supports autosomal dominant inheritance for Lynch syndrome caused by pathogenic mismatch repair variants including MLH1."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes."", ""supports"": ""SUPPORT""}], ""name"": ""Autosomal Dominant""}], ""name"": ""MLH1""}"
4588	194	Lynch Syndrome	Lynch_Syndrome.yaml	genetic	1	MSH2									Germline Mutation																																																"{""association"": ""Germline Mutation"", ""name"": ""MSH2""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""While the MSH2 gene is mentioned, the research did not find a statistically significant association between MSH2 and breast cancer risk."", ""reference"": ""PMID:29345684"", ""snippet"": ""Our data demonstrate that two LS genes, MSH6 and PMS2, are associated with an increased risk for breast cancer..."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study reports a significant proportion of Lynch syndrome families with mutations in MSH2."", ""reference"": ""PMID:25430799"", ""snippet"": ""Sixty-seven (59%) families had mutations in MSH2..."", ""supports"": ""SUPPORT""}], ""name"": ""MSH2""}"
4589	194	Lynch Syndrome	Lynch_Syndrome.yaml	genetic	2	MSH6									Germline Mutation																																																"{""association"": ""Germline Mutation"", ""name"": ""MSH6""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""The study explicitly states that germline mutations in MSH6 are associated with Lynch Syndrome cancers."", ""reference"": ""PMID:20028993"", ""snippet"": ""Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies germline mutations in MSH6 as a cause of Lynch Syndrome."", ""reference"": ""PMID:28038733"", ""snippet"": ""Lynch syndrome is due to germline mutations in mismatch repair genes: MLH1, MSH2, MSH6 and PMS2."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights that a specific variant of MSH6 is associated with families affected by Lynch Syndrome."", ""reference"": ""PMID:33516942"", ""snippet"": ""A MSH6 3'UTR variant (c.*23_26dup) was found in 13 unrelated families consulted for Lynch/Muir-Torre Syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies families with Lynch Syndrome who have mutations in the MSH6 gene."", ""reference"": ""PMID:25430799"", ""snippet"": ""Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2."", ""supports"": ""SUPPORT""}, {""explanation"": ""This informs about Lynch Syndrome diagnosis in individuals with MSH6 mutations."", ""reference"": ""PMID:33094597"", ""snippet"": ""Genetic analysis turned out positive for biallelic MSH6 mutations in the two girls, leading to CMMRD syndrome diagnosis. Both parents and two out of three alive siblings were diagnosed with Lynch syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""MSH6""}"
4590	194	Lynch Syndrome	Lynch_Syndrome.yaml	genetic	3	PMS2									Germline Mutation																																																"{""association"": ""Germline Mutation"", ""name"": ""PMS2""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""This study confirms that germline mutations in PMS2 are associated with Lynch syndrome."", ""reference"": ""PMID:18602922"", ""snippet"": ""PMS2 mutations contribute significantly to Lynch syndrome, but the penetrance for monoallelic mutation carriers appears to be lower than that for the other mismatch repair genes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses analyzing VUS in the MMR gene PMS2 for functional activity, indicating the association of PMS2 germline mutations with Lynch syndrome."", ""reference"": ""PMID:24027009"", ""snippet"": ""Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes. Frequently a variant of uncertain significance (VUS), rather than an obviously pathogenic mutation, is identified in one of these genes. The inability to define pathogenicity of such variants precludes targeted healthcare."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identifies a mutation of the PMS2 gene associated with Lynch syndrome, supporting the genetic association."", ""reference"": ""PMID:37072247"", ""snippet"": ""As a result of our analysis, we managed to identify a mutation in the PMS2 gene in one patient's breast tumor tissue. The presence of this mutation indicates that the resulting cancer may be a consequence of LS."", ""supports"": ""SUPPORT""}, {""explanation"": ""PMS2 is one of the genes where germline mutations have been identified as causing Lynch syndrome."", ""reference"": ""PMID:25430799"", ""snippet"": ""We identified 54 different mutations; 13 of them are novel... Seven founder mutations were detected in 61/113 (54%) families... Gene distribution in the Israeli population is unique...7 (6%) in PMS2."", ""supports"": ""SUPPORT""}], ""name"": ""PMS2""}"
4591	194	Lynch Syndrome	Lynch_Syndrome.yaml	genetic	4	EPCAM									Germline Mutation																																																"{""association"": ""Germline Mutation"", ""name"": ""EPCAM""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""reference"": ""PMID:23411950"", ""snippet"": ""Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:30461124"", ""snippet"": ""Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair."", ""supports"": ""SUPPORT""}, {""explanation"": ""EPCAM deletion is mentioned as one of the variants related to Lynch Syndrome."", ""reference"": ""PMID:37088804"", ""snippet"": ""Four EO cases stood out: two with POLE/POLD1 variants in the key exonuclease domain, one with a BMPR1A duplication and one with an EPCAM deletion."", ""supports"": ""SUPPORT""}], ""name"": ""EPCAM""}"
4613	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	genetic	0	ACADM variants																							"Caused by biallelic pathogenic variants in ACADM (1p31.1). The most common variant in European populations is c.985A>G (p.Lys329Glu), accounting for ~80% of alleles in affected individuals of European ancestry. Over 100 pathogenic variants have been identified.
"																																		"{""features"": ""Caused by biallelic pathogenic variants in ACADM (1p31.1). The most common variant in European populations is c.985A>G (p.Lys329Glu), accounting for ~80% of alleles in affected individuals of European ancestry. Over 100 pathogenic variants have been identified.\n"", ""name"": ""ACADM variants""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""features"": ""Caused by biallelic pathogenic variants in ACADM (1p31.1). The most common variant in European populations is c.985A>G (p.Lys329Glu), accounting for ~80% of alleles in affected individuals of European ancestry. Over 100 pathogenic variants have been identified.\n"", ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""ACADM variants""}"
4628	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	genetic	0	MET									Somatic Splice Site Mutation																										MET (7q31.2) encodes the hepatocyte growth factor receptor. Exon 14 skipping results from mutations at splice donor (3') or acceptor (5') sites, or within the exon itself. Over 100 different METex14 mutations have been identified. MET amplification can co-occur and may affect inhibitor sensitivity. MET is also a resistance mechanism in EGFR-mutant NSCLC.																						"{""association"": ""Somatic Splice Site Mutation"", ""name"": ""MET"", ""notes"": ""MET (7q31.2) encodes the hepatocyte growth factor receptor. Exon 14 skipping results from mutations at splice donor (3') or acceptor (5') sites, or within the exon itself. Over 100 different METex14 mutations have been identified. MET amplification can co-occur and may affect inhibitor sensitivity. MET is also a resistance mechanism in EGFR-mutant NSCLC.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Splice Site Mutation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""MET"", ""notes"": ""MET (7q31.2) encodes the hepatocyte growth factor receptor. Exon 14 skipping results from mutations at splice donor (3') or acceptor (5') sites, or within the exon itself. Over 100 different METex14 mutations have been identified. MET amplification can co-occur and may affect inhibitor sensitivity. MET is also a resistance mechanism in EGFR-mutant NSCLC.""}"
4649	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	genetic	0	MLH1									Loss of Function (Somatic or Germline)																										MLH1 loss occurs via germline mutation (Lynch syndrome) or somatic promoter hypermethylation (sporadic). MLH1 hypermethylation accounts for 80% of sporadic MSI-H CRC and is often associated with BRAF V600E mutation.																						"{""association"": ""Loss of Function (Somatic or Germline)"", ""name"": ""MLH1"", ""notes"": ""MLH1 loss occurs via germline mutation (Lynch syndrome) or somatic promoter hypermethylation (sporadic). MLH1 hypermethylation accounts for 80% of sporadic MSI-H CRC and is often associated with BRAF V600E mutation.""}"	{}	"{""association"": ""Loss of Function (Somatic or Germline)"", ""name"": ""MLH1"", ""notes"": ""MLH1 loss occurs via germline mutation (Lynch syndrome) or somatic promoter hypermethylation (sporadic). MLH1 hypermethylation accounts for 80% of sporadic MSI-H CRC and is often associated with BRAF V600E mutation.""}"
4650	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	genetic	1	MSH2									Germline Loss of Function																										MSH2 germline mutations are the second most common cause of Lynch syndrome. EPCAM deletions can also cause MSH2 silencing through promoter methylation.																						"{""association"": ""Germline Loss of Function"", ""name"": ""MSH2"", ""notes"": ""MSH2 germline mutations are the second most common cause of Lynch syndrome. EPCAM deletions can also cause MSH2 silencing through promoter methylation.""}"	{}	"{""association"": ""Germline Loss of Function"", ""name"": ""MSH2"", ""notes"": ""MSH2 germline mutations are the second most common cause of Lynch syndrome. EPCAM deletions can also cause MSH2 silencing through promoter methylation.""}"
4651	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	genetic	2	MSH6									Germline Loss of Function																										MSH6 germline mutations cause Lynch syndrome with attenuated phenotype and later age of onset.																						"{""association"": ""Germline Loss of Function"", ""name"": ""MSH6"", ""notes"": ""MSH6 germline mutations cause Lynch syndrome with attenuated phenotype and later age of onset.""}"	{}	"{""association"": ""Germline Loss of Function"", ""name"": ""MSH6"", ""notes"": ""MSH6 germline mutations cause Lynch syndrome with attenuated phenotype and later age of onset.""}"
4652	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	genetic	3	PMS2									Germline Loss of Function																										PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1/MSH2 mutations.																						"{""association"": ""Germline Loss of Function"", ""name"": ""PMS2"", ""notes"": ""PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1/MSH2 mutations.""}"	{}	"{""association"": ""Germline Loss of Function"", ""name"": ""PMS2"", ""notes"": ""PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1/MSH2 mutations.""}"
4653	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	genetic	4	BRAF V600E									Somatic Activating Mutation (Sporadic MSI-H)																										BRAF V600E is present in approximately 40-50% of sporadic MSI-H CRC, virtually always with MLH1 hypermethylation. Its presence excludes Lynch syndrome. Unlike MSS BRAF-mutant CRC, MSI-H BRAF-mutant tumors respond well to checkpoint inhibitors.																						"{""association"": ""Somatic Activating Mutation (Sporadic MSI-H)"", ""name"": ""BRAF V600E"", ""notes"": ""BRAF V600E is present in approximately 40-50% of sporadic MSI-H CRC, virtually always with MLH1 hypermethylation. Its presence excludes Lynch syndrome. Unlike MSS BRAF-mutant CRC, MSI-H BRAF-mutant tumors respond well to checkpoint inhibitors.""}"	{}	"{""association"": ""Somatic Activating Mutation (Sporadic MSI-H)"", ""name"": ""BRAF V600E"", ""notes"": ""BRAF V600E is present in approximately 40-50% of sporadic MSI-H CRC, virtually always with MLH1 hypermethylation. Its presence excludes Lynch syndrome. Unlike MSS BRAF-mutant CRC, MSI-H BRAF-mutant tumors respond well to checkpoint inhibitors.""}"
4674	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	genetic	0	MLH1									Germline or Promoter Hypermethylation																										MLH1 loss is most common in endometrial cancer, usually due to somatic promoter hypermethylation. Germline MLH1 mutations cause Lynch syndrome.																						"{""association"": ""Germline or Promoter Hypermethylation"", ""name"": ""MLH1"", ""notes"": ""MLH1 loss is most common in endometrial cancer, usually due to somatic promoter hypermethylation. Germline MLH1 mutations cause Lynch syndrome.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline or Promoter Hypermethylation"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""MLH1"", ""notes"": ""MLH1 loss is most common in endometrial cancer, usually due to somatic promoter hypermethylation. Germline MLH1 mutations cause Lynch syndrome.""}"
4675	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	genetic	1	MSH2									Germline Loss-of-Function Mutations																										MSH2 germline mutations cause Lynch syndrome with high endometrial cancer risk. Loss of MSH2 causes concurrent loss of MSH6.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""MSH2"", ""notes"": ""MSH2 germline mutations cause Lynch syndrome with high endometrial cancer risk. Loss of MSH2 causes concurrent loss of MSH6.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""MSH2"", ""notes"": ""MSH2 germline mutations cause Lynch syndrome with high endometrial cancer risk. Loss of MSH2 causes concurrent loss of MSH6.""}"
4676	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	genetic	2	MSH6									Germline Loss-of-Function Mutations																										MSH6 mutations are particularly associated with endometrial cancer risk in Lynch syndrome.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""MSH6"", ""notes"": ""MSH6 mutations are particularly associated with endometrial cancer risk in Lynch syndrome.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""MSH6"", ""notes"": ""MSH6 mutations are particularly associated with endometrial cancer risk in Lynch syndrome.""}"
4677	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	genetic	3	PMS2									Germline Loss-of-Function Mutations																										PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1 or MSH2 mutations.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""PMS2"", ""notes"": ""PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1 or MSH2 mutations.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""PMS2"", ""notes"": ""PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1 or MSH2 mutations.""}"
4698	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	genetic	0	SLC6A4									Risk Factor																										Serotonin transporter gene																						"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter gene""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC6A4"", ""notes"": ""Serotonin transporter gene""}"
4699	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	genetic	1	BDNF									Risk Factor																										Val66Met polymorphism																						"{""association"": ""Risk Factor"", ""name"": ""BDNF"", ""notes"": ""Val66Met polymorphism""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""BDNF"", ""notes"": ""Val66Met polymorphism""}"
4700	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	genetic	2	FKBP5									Risk Factor																										HPA axis regulation																						"{""association"": ""Risk Factor"", ""name"": ""FKBP5"", ""notes"": ""HPA axis regulation""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FKBP5"", ""notes"": ""HPA axis regulation""}"
4701	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	genetic	3	HTR2A									Risk Factor																										Serotonin receptor gene																						"{""association"": ""Risk Factor"", ""name"": ""HTR2A"", ""notes"": ""Serotonin receptor gene""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HTR2A"", ""notes"": ""Serotonin receptor gene""}"
4729	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	genetic	0	BAP1									Germline and Somatic Mutations																										Germline BAP1 mutations define the BAP1 tumor predisposition syndrome with increased risk of mesothelioma (pleural and peritoneal), uveal melanoma, cutaneous melanoma, and renal cell carcinoma. Somatic BAP1 loss occurs in 60-70% of sporadic mesotheliomas.																						"{""association"": ""Germline and Somatic Mutations"", ""name"": ""BAP1"", ""notes"": ""Germline BAP1 mutations define the BAP1 tumor predisposition syndrome with increased risk of mesothelioma (pleural and peritoneal), uveal melanoma, cutaneous melanoma, and renal cell carcinoma. Somatic BAP1 loss occurs in 60-70% of sporadic mesotheliomas.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""BAP1"", ""notes"": ""Germline BAP1 mutations define the BAP1 tumor predisposition syndrome with increased risk of mesothelioma (pleural and peritoneal), uveal melanoma, cutaneous melanoma, and renal cell carcinoma. Somatic BAP1 loss occurs in 60-70% of sporadic mesotheliomas.""}"
4730	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	genetic	1	NF2									Somatic Mutations																										NF2 inactivation through mutation, deletion, or methylation occurs in approximately 50% of mesotheliomas. Encodes merlin, a tumor suppressor regulating the Hippo pathway.																						"{""association"": ""Somatic Mutations"", ""name"": ""NF2"", ""notes"": ""NF2 inactivation through mutation, deletion, or methylation occurs in approximately 50% of mesotheliomas. Encodes merlin, a tumor suppressor regulating the Hippo pathway.""}"	{}	"{""association"": ""Somatic Mutations"", ""name"": ""NF2"", ""notes"": ""NF2 inactivation through mutation, deletion, or methylation occurs in approximately 50% of mesotheliomas. Encodes merlin, a tumor suppressor regulating the Hippo pathway.""}"
4731	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	genetic	2	CDKN2A									Homozygous Deletion																										CDKN2A homozygous deletion is the most common genetic alteration in mesothelioma (approximately 70%). FISH detection of CDKN2A deletion helps distinguish malignant from reactive mesothelial proliferation.																						"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A homozygous deletion is the most common genetic alteration in mesothelioma (approximately 70%). FISH detection of CDKN2A deletion helps distinguish malignant from reactive mesothelial proliferation.""}"	{}	"{""association"": ""Homozygous Deletion"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A homozygous deletion is the most common genetic alteration in mesothelioma (approximately 70%). FISH detection of CDKN2A deletion helps distinguish malignant from reactive mesothelial proliferation.""}"
4753	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	genetic	0	CCND1/IGH Translocation									Defining Genetic Lesion																										The t(11;14)(q13;q32) translocation is the hallmark of MCL, present in virtually all cases. It places CCND1 under IGH enhancer control, causing cyclin D1 overexpression. Detected by FISH, karyotype, or cyclin D1 IHC.																						"{""association"": ""Defining Genetic Lesion"", ""name"": ""CCND1/IGH Translocation"", ""notes"": ""The t(11;14)(q13;q32) translocation is the hallmark of MCL, present in virtually all cases. It places CCND1 under IGH enhancer control, causing cyclin D1 overexpression. Detected by FISH, karyotype, or cyclin D1 IHC.""}"	{}	"{""association"": ""Defining Genetic Lesion"", ""name"": ""CCND1/IGH Translocation"", ""notes"": ""The t(11;14)(q13;q32) translocation is the hallmark of MCL, present in virtually all cases. It places CCND1 under IGH enhancer control, causing cyclin D1 overexpression. Detected by FISH, karyotype, or cyclin D1 IHC.""}"
4754	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	genetic	1	TP53 Mutation									Adverse Prognostic Marker																										TP53 mutations occur in 20-30% of MCL and are associated with aggressive biology, blastoid morphology, and poor response to chemotherapy. May retain sensitivity to BTK inhibitors and novel agents.																						"{""association"": ""Adverse Prognostic Marker"", ""name"": ""TP53 Mutation"", ""notes"": ""TP53 mutations occur in 20-30% of MCL and are associated with aggressive biology, blastoid morphology, and poor response to chemotherapy. May retain sensitivity to BTK inhibitors and novel agents.""}"	{}	"{""association"": ""Adverse Prognostic Marker"", ""name"": ""TP53 Mutation"", ""notes"": ""TP53 mutations occur in 20-30% of MCL and are associated with aggressive biology, blastoid morphology, and poor response to chemotherapy. May retain sensitivity to BTK inhibitors and novel agents.""}"
4755	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	genetic	2	ATM Mutation/Deletion									Intermediate-Risk Marker																										ATM abnormalities occur in 40-50% of MCL and impair DNA damage responses. Associated with genomic instability and disease progression.																						"{""association"": ""Intermediate-Risk Marker"", ""name"": ""ATM Mutation/Deletion"", ""notes"": ""ATM abnormalities occur in 40-50% of MCL and impair DNA damage responses. Associated with genomic instability and disease progression.""}"	{}	"{""association"": ""Intermediate-Risk Marker"", ""name"": ""ATM Mutation/Deletion"", ""notes"": ""ATM abnormalities occur in 40-50% of MCL and impair DNA damage responses. Associated with genomic instability and disease progression.""}"
4788	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	genetic	0	BCKDHA						Type IA			Causative																										E1-alpha subunit of BCKD complex, accounts for approximately 45% of cases, autosomal recessive																						"{""association"": ""Causative"", ""name"": ""BCKDHA"", ""notes"": ""E1-alpha subunit of BCKD complex, accounts for approximately 45% of cases, autosomal recessive"", ""subtype"": ""Type IA""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms BCKDHA mutations cause MSUD."", ""reference"": ""PMID:35672312"", ""snippet"": ""We establish and characterize the Bckdha (branched chain keto acid dehydrogenase a)-/- mouse that exhibits a lethal neonatal phenotype mimicking human MSUD."", ""supports"": ""SUPPORT""}], ""name"": ""BCKDHA"", ""notes"": ""E1-alpha subunit of BCKD complex, accounts for approximately 45% of cases, autosomal recessive"", ""subtype"": ""Type IA""}"
4789	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	genetic	1	BCKDHB						Type IB			Causative																										E1-beta subunit of BCKD complex, accounts for approximately 35% of cases, autosomal recessive																						"{""association"": ""Causative"", ""name"": ""BCKDHB"", ""notes"": ""E1-beta subunit of BCKD complex, accounts for approximately 35% of cases, autosomal recessive"", ""subtype"": ""Type IB""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms BCKDHB (E1-beta) mutations cause Type I MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""BCKDHB"", ""notes"": ""E1-beta subunit of BCKD complex, accounts for approximately 35% of cases, autosomal recessive"", ""subtype"": ""Type IB""}"
4790	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	genetic	2	DBT						Type II			Causative																										E2 subunit (dihydrolipoamide branched chain transacylase), accounts for approximately 20% of cases, autosomal recessive																						"{""association"": ""Causative"", ""name"": ""DBT"", ""notes"": ""E2 subunit (dihydrolipoamide branched chain transacylase), accounts for approximately 20% of cases, autosomal recessive"", ""subtype"": ""Type II""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms DBT (E2) mutations cause Type II MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""DBT"", ""notes"": ""E2 subunit (dihydrolipoamide branched chain transacylase), accounts for approximately 20% of cases, autosomal recessive"", ""subtype"": ""Type II""}"
4791	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	genetic	3	DLD						Type III			Causative																										E3 subunit (dihydrolipoamide dehydrogenase), shared with pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes																						"{""association"": ""Causative"", ""name"": ""DLD"", ""notes"": ""E3 subunit (dihydrolipoamide dehydrogenase), shared with pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes"", ""subtype"": ""Type III""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms DLD (E3) mutations cause Type III MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""DLD"", ""notes"": ""E3 subunit (dihydrolipoamide dehydrogenase), shared with pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes"", ""subtype"": ""Type III""}"
4825	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	0	FBN1									Pathogenic Variants																										Primary causative gene encoding fibrillin-1, a structural ECM glycoprotein.																						"{""association"": ""Pathogenic Variants"", ""name"": ""FBN1"", ""notes"": ""Primary causative gene encoding fibrillin-1, a structural ECM glycoprotein.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract directly states that FBN1 gene mutations are associated with Marfan syndrome and related disorders."", ""reference"": ""PMID:31163209"", ""snippet"": ""FBN1 gene mutations lead to MFS and related connective tissue disorders."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study focuses on patients with Marfan syndrome who have pathogenic FBN1 variants, supporting the association."", ""reference"": ""PMID:34916231"", ""snippet"": ""We retrospectively evaluated 278 patients with pathogenic or likely pathogenic FBN1 variants."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study describes aortic risks in patients with Marfan syndrome with pathogenic FBN1 variants, supporting the association."", ""reference"": ""PMID:32130918"", ""snippet"": ""Aortic risk has not been evaluated in patients with Marfan syndrome and documented pathogenic variants in the FBN1 gene."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract states that pathogenic variants in FBN1 cause Marfan syndrome, supporting the association."", ""reference"": ""PMID:35419902"", ""snippet"": ""Different pathogenic variants in the fibrillin-1 gene (FBN1) cause Marfan syndrome and acromelic dysplasias."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The article reviews studies concerning the potential ocular manifestations of Marfan syndrome caused by FBN1 mutations."", ""reference"": ""PMID:36004597"", ""snippet"": ""Marfan syndrome is an orphan disease that is caused by a mutation in the FBN1 gene located on chromosome 15 (15q21.1)."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract states that pathogenic variants in FBN1 cause autosomal dominant Marfan syndrome, supporting the association."", ""reference"": ""PMID:30485715"", ""snippet"": ""Pathogenic variants in FBN1 cause autosomal dominant Marfan syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study reports cases of Marfan syndrome associated with compound-heterozygous FBN1 mutations, supporting the association."", ""reference"": ""PMID:19059503"", ""snippet"": ""We report two families in which the probands have compound-heterozygous Marfan syndrome (MFS)."", ""supports"": ""SUPPORT""}], ""name"": ""FBN1"", ""notes"": ""Primary causative gene encoding fibrillin-1, a structural ECM glycoprotein.""}"
4826	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	1	TGFBR1									Implicated																										Type I TGF-beta receptor; variants can cause overlapping Loeys-Dietz syndrome phenotype.																						"{""association"": ""Implicated"", ""name"": ""TGFBR1"", ""notes"": ""Type I TGF-beta receptor; variants can cause overlapping Loeys-Dietz syndrome phenotype.""}"	{}	"{""association"": ""Implicated"", ""name"": ""TGFBR1"", ""notes"": ""Type I TGF-beta receptor; variants can cause overlapping Loeys-Dietz syndrome phenotype.""}"
4827	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	2	TGFBR2									Implicated																										Type II TGF-beta receptor; mutations alter TGF-beta signaling in aortic disease.																						"{""association"": ""Implicated"", ""name"": ""TGFBR2"", ""notes"": ""Type II TGF-beta receptor; mutations alter TGF-beta signaling in aortic disease.""}"	{}	"{""association"": ""Implicated"", ""name"": ""TGFBR2"", ""notes"": ""Type II TGF-beta receptor; mutations alter TGF-beta signaling in aortic disease.""}"
4828	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	3	SMAD2									Implicated																										Canonical TGF-beta signaling mediator; nuclear translocation drives ECM remodeling.																						"{""association"": ""Implicated"", ""name"": ""SMAD2"", ""notes"": ""Canonical TGF-beta signaling mediator; nuclear translocation drives ECM remodeling.""}"	{}	"{""association"": ""Implicated"", ""name"": ""SMAD2"", ""notes"": ""Canonical TGF-beta signaling mediator; nuclear translocation drives ECM remodeling.""}"
4829	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	4	SMAD3									Implicated																										TGF-beta effector involved in medial remodeling and inflammatory responses.																						"{""association"": ""Implicated"", ""name"": ""SMAD3"", ""notes"": ""TGF-beta effector involved in medial remodeling and inflammatory responses.""}"	{}	"{""association"": ""Implicated"", ""name"": ""SMAD3"", ""notes"": ""TGF-beta effector involved in medial remodeling and inflammatory responses.""}"
4830	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	5	ACTA2									Implicated																										Alpha-smooth muscle actin; pathogenic variants cause familial thoracic aortic aneurysm and dissection.																						"{""association"": ""Implicated"", ""name"": ""ACTA2"", ""notes"": ""Alpha-smooth muscle actin; pathogenic variants cause familial thoracic aortic aneurysm and dissection.""}"	{}	"{""association"": ""Implicated"", ""name"": ""ACTA2"", ""notes"": ""Alpha-smooth muscle actin; pathogenic variants cause familial thoracic aortic aneurysm and dissection.""}"
4831	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	6	AGTR1									Implicated																										Angiotensin II type 1 receptor; modulates hemodynamic stress and pro-fibrotic signaling.																						"{""association"": ""Implicated"", ""name"": ""AGTR1"", ""notes"": ""Angiotensin II type 1 receptor; modulates hemodynamic stress and pro-fibrotic signaling.""}"	{}	"{""association"": ""Implicated"", ""name"": ""AGTR1"", ""notes"": ""Angiotensin II type 1 receptor; modulates hemodynamic stress and pro-fibrotic signaling.""}"
4832	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	7	ITGAV									Implicated																										Integrin alpha-V subunit; mediates cell-ECM adhesion and mechanotransduction.																						"{""association"": ""Implicated"", ""name"": ""ITGAV"", ""notes"": ""Integrin alpha-V subunit; mediates cell-ECM adhesion and mechanotransduction.""}"	{}	"{""association"": ""Implicated"", ""name"": ""ITGAV"", ""notes"": ""Integrin alpha-V subunit; mediates cell-ECM adhesion and mechanotransduction.""}"
4833	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	8	NOS2									Implicated																										Inducible nitric oxide synthase; upregulated in inflamed aortic tissue.																						"{""association"": ""Implicated"", ""name"": ""NOS2"", ""notes"": ""Inducible nitric oxide synthase; upregulated in inflamed aortic tissue.""}"	{}	"{""association"": ""Implicated"", ""name"": ""NOS2"", ""notes"": ""Inducible nitric oxide synthase; upregulated in inflamed aortic tissue.""}"
4834	204	Marfan Syndrome	Marfan_Syndrome.yaml	genetic	9	VCAN									Implicated																										Versican proteoglycan; accumulation drives AKT/NOS2 pathways in aortic disease.																						"{""association"": ""Implicated"", ""name"": ""VCAN"", ""notes"": ""Versican proteoglycan; accumulation drives AKT/NOS2 pathways in aortic disease.""}"	{}	"{""association"": ""Implicated"", ""name"": ""VCAN"", ""notes"": ""Versican proteoglycan; accumulation drives AKT/NOS2 pathways in aortic disease.""}"
4874	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	0	MKS1									Causative																																																"{""association"": ""Causative"", ""name"": ""MKS1""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""This mouse model study identifies the MKS1 gene underlying MKS type 1."", ""reference"": ""PMID:19776033"", ""snippet"": ""The gene mutated in type 1 MKS encodes a protein associated with the base of the cilium in vertebrates and nematodes."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""MKS1"", ""term"": {""id"": ""hgnc:7121"", ""label"": ""MKS1""}}, ""name"": ""MKS1""}"
4875	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	1	TMEM67									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM67""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study identifies TMEM67 as the causal gene for MKS3."", ""reference"": ""PMID:19211713"", ""snippet"": ""In humans, the underlying mutated gene, TMEM67, encodes transmembrane protein 67, also called meckelin (OMIM 609884), which is an integral protein of the renal epithelial cell and membrane of the primary cilium."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM67"", ""term"": {""id"": ""hgnc:28396"", ""label"": ""TMEM67""}}, ""name"": ""TMEM67""}"
4876	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	2	CC2D2A									Causative																																																"{""association"": ""Causative"", ""name"": ""CC2D2A""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study identifies CC2D2A as a causative MKS gene (MKS6)."", ""reference"": ""PMID:18513680"", ""snippet"": ""we identified the sixth locus and the fifth gene, CC2D2A (MKS6), behind MKS."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report identifies pathogenic CC2D2A variants in MKS, including a frameshift allele."", ""reference"": ""PMID:28374938"", ""snippet"": ""A medical exome analysis detected a heterozygous frameshift mutation, c.4582_4583delCG p.(Arg1528Serfs*17) in CC2D2A in the maternally derived allele."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series reports a novel CC2D2A variant in MKS fetuses."", ""reference"": ""PMID:34981460"", ""snippet"": ""Whole exome sequencing identified a compound heterozygous of two novel variants of CEP290 and a heterozygous of a novel variant of CC2D2A."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}, ""name"": ""CC2D2A""}"
4877	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	3	TMEM216									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM216""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study reports TMEM216 mutations causing Meckel syndrome."", ""reference"": ""PMID:20512146"", ""snippet"": ""Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM216"", ""term"": {""id"": ""hgnc:25018"", ""label"": ""TMEM216""}}, ""name"": ""TMEM216""}"
4878	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	4	TMEM231									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM231""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report identifies TMEM231 as a Meckel-Gruber syndrome locus."", ""reference"": ""PMID:23349226"", ""snippet"": ""Mutations in TMEM231 cause Meckel-Gruber syndrome."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM231"", ""term"": {""id"": ""hgnc:37234"", ""label"": ""TMEM231""}}, ""name"": ""TMEM231""}"
4879	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	5	B9D2									Causative																																																"{""association"": ""Causative"", ""name"": ""B9D2""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study reports a pathogenic B9D2 mutation segregating with MKS."", ""reference"": ""PMID:21763481"", ""snippet"": ""We identified a homozygous c.301A>C (p.Ser101Arg) B9D2 mutation that segregates with MKS"", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""B9D2"", ""term"": {""id"": ""hgnc:28636"", ""label"": ""B9D2""}}, ""name"": ""B9D2""}"
4880	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	6	B9D1									Causative																																																"{""association"": ""Causative"", ""name"": ""B9D1""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""Loss of B9d1 causes MKS-like phenotypes with ciliary dysfunction in model organisms."", ""reference"": ""PMID:21763481"", ""snippet"": ""Mice lacking B9d1 displayed polydactyly, kidney cysts, ductal plate malformations, and abnormal patterning of the neural tube, concomitant with compromised ciliogenesis, ciliary protein localization, and Hedgehog (Hh) signal transduction."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report identifies pathogenic B9D1 variants in a recurrent MKS pedigree."", ""reference"": ""PMID:40933483"", ""snippet"": ""Compound heterozygous missense and intronic variants in B9D1 contribute to a recurrent Meckel syndrome pedigree."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""B9D1"", ""term"": {""id"": ""hgnc:24123"", ""label"": ""B9D1""}}, ""name"": ""B9D1""}"
4881	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	7	CEP290									Causative																																																"{""association"": ""Causative"", ""name"": ""CEP290""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study identifies CEP290 loss-of-function mutations as a cause of Meckel-Gruber syndrome."", ""reference"": ""PMID:17705300"", ""snippet"": ""Mutations of the CEP290 gene encoding a centrosomal protein cause Meckel-Gruber syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Prenatal case report identifies compound heterozygous CEP290 variants in suspected MKS."", ""reference"": ""PMID:35352487"", ""snippet"": ""compound heterozygous mutations of CEP290 c.3175dup and CEP290 c.1201dup were detected through WES."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series reports novel CEP290 variants in MKS fetuses."", ""reference"": ""PMID:34981460"", ""snippet"": ""Whole exome sequencing identified a compound heterozygous of two novel variants of CEP290 and a heterozygous of a novel variant of CC2D2A."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""CEP290"", ""term"": {""id"": ""hgnc:29021"", ""label"": ""CEP290""}}, ""name"": ""CEP290""}"
4882	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	8	RPGRIP1L									Causative																																																"{""association"": ""Causative"", ""name"": ""RPGRIP1L""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study reports RPGRIP1L mutations in Meckel syndrome."", ""reference"": ""PMID:17558409"", ""snippet"": ""we identified missense and truncating mutations in RPGRIP1L (KIAA1005) in both CORS and MKS"", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""RPGRIP1L"", ""term"": {""id"": ""hgnc:29168"", ""label"": ""RPGRIP1L""}}, ""name"": ""RPGRIP1L""}"
4883	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	9	NPHP3									Causative																																																"{""association"": ""Causative"", ""name"": ""NPHP3""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study links NPHP3 loss of function to a Meckel-Gruber-like syndrome in humans."", ""reference"": ""PMID:18371931"", ""snippet"": ""Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""NPHP3"", ""term"": {""id"": ""hgnc:7907"", ""label"": ""NPHP3""}}, ""name"": ""NPHP3""}"
4884	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	10	TCTN2									Causative																																																"{""association"": ""Causative"", ""name"": ""TCTN2""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report identifies TCTN2 (MKS8) as a Meckel syndrome locus."", ""reference"": ""PMID:21462283"", ""snippet"": ""A TCTN2 mutation defines a novel Meckel Gruber syndrome locus."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TCTN2"", ""term"": {""id"": ""hgnc:25774"", ""label"": ""TCTN2""}}, ""name"": ""TCTN2""}"
4885	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	11	TMEM237									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM237""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""CNV analysis in a MKS/JBTS referral cohort identified a TMEM237 deletion consistent with MKS involvement."", ""reference"": ""PMID:26729329"", ""snippet"": ""These analyses identified a putative intragenic AHI1 deletion that included three exons spanning at least 3.4 kb and an intergenic MPP4 to TMEM237 deletion that included exons spanning at least 21.5 kb."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM237"", ""term"": {""id"": ""hgnc:14432"", ""label"": ""TMEM237""}}, ""name"": ""TMEM237""}"
4886	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	12	TMEM107									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM107""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study defines TMEM107 mutations as a Meckel syndrome locus (MKS13)."", ""reference"": ""PMID:26123494"", ""snippet"": ""This study shows that known MKS loci account for the overwhelming majority of MKS cases but additional loci exist including MKS13 caused by TMEM107 mutation."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM107"", ""term"": {""id"": ""hgnc:28128"", ""label"": ""TMEM107""}}, ""name"": ""TMEM107""}"
4887	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	13	TXNDC15									Causative																																																"{""association"": ""Causative"", ""name"": ""TXNDC15""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study validates MKS causation by biallelic TXNDC15 variants."", ""reference"": ""PMID:31411728"", ""snippet"": ""We describe the second family with MKS due to a homozygous variant in B9D2 and fifth family with bi-allelic variant in TXNDC15."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report identifies a homozygous TXNDC15 mutation causing MKS14."", ""reference"": ""PMID:38156946"", ""snippet"": ""We report the case of a homozygous mutation in the TXNDC15 gene, causing MKS14 in the Chinese population."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report summarizes prior MKS cases with biallelic TXNDC15 variants, supporting causation."", ""reference"": ""PMID:39304719"", ""snippet"": ""Biallelic TXNDC15 variants have been reported in six individuals of Meckel syndrome (MKS) with perinatal lethal phenotypes"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""Mouse model confirms TXNDC15 loss produces an MKS phenotype."", ""reference"": ""PMID:41518077"", ""snippet"": ""Homozygous Txndc15mt/mt embryos displayed the complete MKS phenotype-fetal lethality, exencephaly, omphalocele, post-axial polydactyly, and polycystic kidneys-together with markedly reduced TXNDC15 protein in brain, liver, and kidney."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TXNDC15"", ""term"": {""id"": ""hgnc:20652"", ""label"": ""TXNDC15""}}, ""name"": ""TXNDC15""}"
4888	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	14	TMEM17									Causative																																																"{""association"": ""Causative"", ""name"": ""TMEM17""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report expands TMEM17-associated phenotypes to include MKS."", ""reference"": ""PMID:40841990"", ""snippet"": ""we report two unrelated fetuses with occipital encephalocele, polydactyly, and kidney cysts, in whom exome sequencing identified a founder homozygous missense variant (Arg94Trp) in TMEM17"", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""TMEM17"", ""term"": {""id"": ""hgnc:26623"", ""label"": ""TMEM17""}}, ""name"": ""TMEM17""}"
4889	206	Meckel Syndrome	Meckel_Syndrome.yaml	genetic	15	KIF7									Modifier																																																"{""association"": ""Modifier"", ""name"": ""KIF7""}"	{}	"{""association"": ""Modifier"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study suggests KIF7 variants can contribute to ciliopathy phenotypes, supporting a modifier role within the MKS/JBTS spectrum."", ""reference"": ""PMID:21552264"", ""snippet"": ""KIF7 is also a likely contributor of alleles across the ciliopathy spectrum, as sequencing of a diverse cohort identified several missense mutations detrimental to protein function."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""KIF7"", ""term"": {""id"": ""hgnc:30497"", ""label"": ""KIF7""}}, ""name"": ""KIF7""}"
4926	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	genetic	0	RET									Germline and Somatic Activating Mutations																										RET mutations are present in virtually all hereditary MTC. Common germline mutations include C634R (MEN2A), M918T (MEN2B), and others. Somatic RET mutations occur in 40-50% of sporadic cases. Genotype-phenotype correlations guide timing of prophylactic thyroidectomy.																						"{""association"": ""Germline and Somatic Activating Mutations"", ""name"": ""RET"", ""notes"": ""RET mutations are present in virtually all hereditary MTC. Common germline mutations include C634R (MEN2A), M918T (MEN2B), and others. Somatic RET mutations occur in 40-50% of sporadic cases. Genotype-phenotype correlations guide timing of prophylactic thyroidectomy.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Activating Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""RET"", ""notes"": ""RET mutations are present in virtually all hereditary MTC. Common germline mutations include C634R (MEN2A), M918T (MEN2B), and others. Somatic RET mutations occur in 40-50% of sporadic cases. Genotype-phenotype correlations guide timing of prophylactic thyroidectomy.""}"
4941	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	0	PTCH1									Somatic/Germline Mutation																										PTCH1 loss-of-function mutations occur in approximately 40-50% of SHH-activated medulloblastomas. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with predisposition to medulloblastoma, basal cell carcinomas, and skeletal abnormalities.																						"{""association"": ""Somatic/Germline Mutation"", ""name"": ""PTCH1"", ""notes"": ""PTCH1 loss-of-function mutations occur in approximately 40-50% of SHH-activated medulloblastomas. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with predisposition to medulloblastoma, basal cell carcinomas, and skeletal abnormalities.""}"	{}	"{""association"": ""Somatic/Germline Mutation"", ""name"": ""PTCH1"", ""notes"": ""PTCH1 loss-of-function mutations occur in approximately 40-50% of SHH-activated medulloblastomas. Germline PTCH1 mutations cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) with predisposition to medulloblastoma, basal cell carcinomas, and skeletal abnormalities.""}"
4942	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	1	SMO									Somatic Mutation																										SMO activating mutations occur in approximately 10-15% of SHH-activated tumors, more common in adults. These mutations can confer resistance to SMO inhibitors and are targetable by different therapeutic approaches.																						"{""association"": ""Somatic Mutation"", ""name"": ""SMO"", ""notes"": ""SMO activating mutations occur in approximately 10-15% of SHH-activated tumors, more common in adults. These mutations can confer resistance to SMO inhibitors and are targetable by different therapeutic approaches.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""SMO"", ""notes"": ""SMO activating mutations occur in approximately 10-15% of SHH-activated tumors, more common in adults. These mutations can confer resistance to SMO inhibitors and are targetable by different therapeutic approaches.""}"
4943	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	2	SUFU									Somatic/Germline Mutation																										SUFU loss-of-function mutations occur in approximately 10% of SHH-activated medulloblastomas, particularly in infants. Germline SUFU mutations predispose to medulloblastoma. SUFU mutations cause pathway activation downstream of SMO, conferring resistance to SMO inhibitors.																						"{""association"": ""Somatic/Germline Mutation"", ""name"": ""SUFU"", ""notes"": ""SUFU loss-of-function mutations occur in approximately 10% of SHH-activated medulloblastomas, particularly in infants. Germline SUFU mutations predispose to medulloblastoma. SUFU mutations cause pathway activation downstream of SMO, conferring resistance to SMO inhibitors.""}"	{}	"{""association"": ""Somatic/Germline Mutation"", ""name"": ""SUFU"", ""notes"": ""SUFU loss-of-function mutations occur in approximately 10% of SHH-activated medulloblastomas, particularly in infants. Germline SUFU mutations predispose to medulloblastoma. SUFU mutations cause pathway activation downstream of SMO, conferring resistance to SMO inhibitors.""}"
4944	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	3	GLI2									Amplification																										GLI2 amplification occurs in approximately 5-10% of SHH-activated tumors and is associated with worse prognosis. Causes pathway activation downstream of SMO, conferring resistance to SMO inhibitors.																						"{""association"": ""Amplification"", ""name"": ""GLI2"", ""notes"": ""GLI2 amplification occurs in approximately 5-10% of SHH-activated tumors and is associated with worse prognosis. Causes pathway activation downstream of SMO, conferring resistance to SMO inhibitors.""}"	{}	"{""association"": ""Amplification"", ""name"": ""GLI2"", ""notes"": ""GLI2 amplification occurs in approximately 5-10% of SHH-activated tumors and is associated with worse prognosis. Causes pathway activation downstream of SMO, conferring resistance to SMO inhibitors.""}"
4945	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	4	MYCN									Amplification																										MYCN amplification occurs in approximately 5-10% of SHH-activated tumors, often with TP53 mutation. Associated with worse prognosis and large cell/anaplastic features.																						"{""association"": ""Amplification"", ""name"": ""MYCN"", ""notes"": ""MYCN amplification occurs in approximately 5-10% of SHH-activated tumors, often with TP53 mutation. Associated with worse prognosis and large cell/anaplastic features.""}"	{}	"{""association"": ""Amplification"", ""name"": ""MYCN"", ""notes"": ""MYCN amplification occurs in approximately 5-10% of SHH-activated tumors, often with TP53 mutation. Associated with worse prognosis and large cell/anaplastic features.""}"
4946	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	5	TP53									Somatic/Germline Mutation																										TP53 mutations occur in approximately 10-15% of SHH-activated medulloblastomas. May be germline (Li-Fraumeni syndrome) or somatic. Defines a high-risk subgroup with worse prognosis under WHO 2021 classification.																						"{""association"": ""Somatic/Germline Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 10-15% of SHH-activated medulloblastomas. May be germline (Li-Fraumeni syndrome) or somatic. Defines a high-risk subgroup with worse prognosis under WHO 2021 classification.""}"	{}	"{""association"": ""Somatic/Germline Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 10-15% of SHH-activated medulloblastomas. May be germline (Li-Fraumeni syndrome) or somatic. Defines a high-risk subgroup with worse prognosis under WHO 2021 classification.""}"
4947	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	genetic	6	TERT									Promoter Mutation																										TERT promoter mutations occur in approximately 20-30% of adult SHH-activated medulloblastomas and are associated with worse prognosis in adults.																						"{""association"": ""Promoter Mutation"", ""name"": ""TERT"", ""notes"": ""TERT promoter mutations occur in approximately 20-30% of adult SHH-activated medulloblastomas and are associated with worse prognosis in adults.""}"	{}	"{""association"": ""Promoter Mutation"", ""name"": ""TERT"", ""notes"": ""TERT promoter mutations occur in approximately 20-30% of adult SHH-activated medulloblastomas and are associated with worse prognosis in adults.""}"
4962	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	0	CTNNB1									Somatic Mutation																										CTNNB1 exon 3 mutations are present in approximately 85-90% of WNT-activated medulloblastomas. Mutations occur at serine/threonine phosphorylation sites (codons 33, 37, 41, 45), preventing APC/Axin-mediated degradation.																						"{""association"": ""Somatic Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 exon 3 mutations are present in approximately 85-90% of WNT-activated medulloblastomas. Mutations occur at serine/threonine phosphorylation sites (codons 33, 37, 41, 45), preventing APC/Axin-mediated degradation.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""CTNNB1"", ""notes"": ""CTNNB1 exon 3 mutations are present in approximately 85-90% of WNT-activated medulloblastomas. Mutations occur at serine/threonine phosphorylation sites (codons 33, 37, 41, 45), preventing APC/Axin-mediated degradation.""}"
4963	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	1	APC									Germline/Somatic Mutation																										APC mutations occur in approximately 10-15% of WNT-activated medulloblastomas. Germline APC mutations cause Turcot syndrome (familial adenomatous polyposis with CNS tumors). Somatic APC mutations also occur.																						"{""association"": ""Germline/Somatic Mutation"", ""name"": ""APC"", ""notes"": ""APC mutations occur in approximately 10-15% of WNT-activated medulloblastomas. Germline APC mutations cause Turcot syndrome (familial adenomatous polyposis with CNS tumors). Somatic APC mutations also occur.""}"	{}	"{""association"": ""Germline/Somatic Mutation"", ""name"": ""APC"", ""notes"": ""APC mutations occur in approximately 10-15% of WNT-activated medulloblastomas. Germline APC mutations cause Turcot syndrome (familial adenomatous polyposis with CNS tumors). Somatic APC mutations also occur.""}"
4964	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	2	DDX3X									Somatic Mutation																										DDX3X mutations occur in approximately 50% of WNT-activated medulloblastomas. DDX3X encodes an RNA helicase that may cooperate with WNT signaling in tumorigenesis.																						"{""association"": ""Somatic Mutation"", ""name"": ""DDX3X"", ""notes"": ""DDX3X mutations occur in approximately 50% of WNT-activated medulloblastomas. DDX3X encodes an RNA helicase that may cooperate with WNT signaling in tumorigenesis.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""DDX3X"", ""notes"": ""DDX3X mutations occur in approximately 50% of WNT-activated medulloblastomas. DDX3X encodes an RNA helicase that may cooperate with WNT signaling in tumorigenesis.""}"
4965	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	3	SMARCA4									Somatic Mutation																										SMARCA4 mutations occur in approximately 25% of WNT-activated medulloblastomas. Encodes a SWI/SNF chromatin remodeling complex component.																						"{""association"": ""Somatic Mutation"", ""name"": ""SMARCA4"", ""notes"": ""SMARCA4 mutations occur in approximately 25% of WNT-activated medulloblastomas. Encodes a SWI/SNF chromatin remodeling complex component.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""SMARCA4"", ""notes"": ""SMARCA4 mutations occur in approximately 25% of WNT-activated medulloblastomas. Encodes a SWI/SNF chromatin remodeling complex component.""}"
4966	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	4	TP53									Somatic Mutation																										TP53 mutations are rare in WNT-activated medulloblastoma (approximately 5%), in contrast to SHH-activated tumors where they confer worse prognosis.																						"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are rare in WNT-activated medulloblastoma (approximately 5%), in contrast to SHH-activated tumors where they confer worse prognosis.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are rare in WNT-activated medulloblastoma (approximately 5%), in contrast to SHH-activated tumors where they confer worse prognosis.""}"
4967	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	genetic	5	Monosomy 6									Chromosomal Alteration																										Monosomy 6 is present in approximately 85% of WNT-activated medulloblastomas and is a useful cytogenetic marker for this subgroup. The mechanism by which it contributes to tumorigenesis is unclear.																						"{""association"": ""Chromosomal Alteration"", ""name"": ""Monosomy 6"", ""notes"": ""Monosomy 6 is present in approximately 85% of WNT-activated medulloblastomas and is a useful cytogenetic marker for this subgroup. The mechanism by which it contributes to tumorigenesis is unclear.""}"	{}	"{""association"": ""Chromosomal Alteration"", ""name"": ""Monosomy 6"", ""notes"": ""Monosomy 6 is present in approximately 85% of WNT-activated medulloblastomas and is a useful cytogenetic marker for this subgroup. The mechanism by which it contributes to tumorigenesis is unclear.""}"
4986	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	0	BRAF									Mutations																																																"{""association"": ""Mutations"", ""name"": ""BRAF""}"	{}	"{""association"": ""Mutations"", ""evidence"": [{""explanation"": ""The excerpt indicates that BRAF mutations are found in both malignant melanoma and melanocytic nevi, supporting the statement."", ""reference"": ""PMID:16750612"", ""snippet"": ""The most exciting finding is the discovery of oncogenic BRAF mutations in both malignant melanoma and melanocytic nevi."", ""supports"": ""SUPPORT""}, {""explanation"": ""The excerpt clearly states the presence of BRAF mutations in congenital melanocytic nevi."", ""reference"": ""PMID:37156689"", ""snippet"": ""A lot of congenital melanocytic nevi (CMN) carry the somatic mutation in the oncogene BRAF V600E."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although BRAF is a less common mutation in CMN, its presence still supports the statement."", ""reference"": ""PMID:31111470"", ""snippet"": ""BRAF is confirmed as a much rarer cause of multiple CMN."", ""supports"": ""SUPPORT""}, {""explanation"": ""The excerpt suggests the presence of BRAF mutations in GCMN, though less frequent in the Chinese population."", ""reference"": ""PMID:36085074"", ""snippet"": ""Mutations in NRAS have been previously detected in GCMN, but mutations in BRAF are generally lacking in the Chinese population."", ""supports"": ""SUPPORT""}], ""name"": ""BRAF""}"
4987	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	1	NRAS									Mutations																										Post-zygotic mosaic mutations at codon 61 (Q61K/R) are the dominant driver in 68-94% of large/giant CMN and associated melanomas																						"{""association"": ""Mutations"", ""name"": ""NRAS"", ""notes"": ""Post-zygotic mosaic mutations at codon 61 (Q61K/R) are the dominant driver in 68-94% of large/giant CMN and associated melanomas""}"	{}	"{""association"": ""Mutations"", ""evidence"": [{""explanation"": ""This reference directly describes a case of NRAS mutant melanoma arising in the context of giant congenital melanocytic nevus."", ""reference"": ""PMID:33851646"", ""snippet"": ""NRAS mutant melanoma arising in a giant congenital melanocytic nevus in an infant."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference provides statistical data supporting the association between NRAS mutations and congenital melanocytic nevi."", ""reference"": ""PMID:31111470"", ""snippet"": ""Multiple congenital melanocytic naevi (CMN) have been shown to be caused by NRAS mosaic mutations in 70-80% of cases."", ""supports"": ""SUPPORT""}], ""name"": ""NRAS"", ""notes"": ""Post-zygotic mosaic mutations at codon 61 (Q61K/R) are the dominant driver in 68-94% of large/giant CMN and associated melanomas""}"
4988	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	2	TERT									Promoter mutations																										TERT promoter activation or amplification associated with malignant transformation, enabling telomere maintenance and replicative immortality																						"{""association"": ""Promoter mutations"", ""name"": ""TERT"", ""notes"": ""TERT promoter activation or amplification associated with malignant transformation, enabling telomere maintenance and replicative immortality""}"	{}	"{""association"": ""Promoter mutations"", ""name"": ""TERT"", ""notes"": ""TERT promoter activation or amplification associated with malignant transformation, enabling telomere maintenance and replicative immortality""}"
4989	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	3	CDKN2A									Loss of function																										Deletion or loss enables escape from oncogene-induced senescence and promotes progression to invasive melanoma																						"{""association"": ""Loss of function"", ""name"": ""CDKN2A"", ""notes"": ""Deletion or loss enables escape from oncogene-induced senescence and promotes progression to invasive melanoma""}"	{}	"{""association"": ""Loss of function"", ""name"": ""CDKN2A"", ""notes"": ""Deletion or loss enables escape from oncogene-induced senescence and promotes progression to invasive melanoma""}"
4990	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	4	TP53									Mutations																										Somatic mutations in progressed lesions contribute to genomic instability and malignant transformation																						"{""association"": ""Mutations"", ""name"": ""TP53"", ""notes"": ""Somatic mutations in progressed lesions contribute to genomic instability and malignant transformation""}"	{}	"{""association"": ""Mutations"", ""name"": ""TP53"", ""notes"": ""Somatic mutations in progressed lesions contribute to genomic instability and malignant transformation""}"
4991	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	5	PTEN									Loss of function																										Loss or inactivation leads to PI3K-AKT-mTOR pathway activation, cooperating with MAPK signaling to promote survival and invasion																						"{""association"": ""Loss of function"", ""name"": ""PTEN"", ""notes"": ""Loss or inactivation leads to PI3K-AKT-mTOR pathway activation, cooperating with MAPK signaling to promote survival and invasion""}"	{}	"{""association"": ""Loss of function"", ""name"": ""PTEN"", ""notes"": ""Loss or inactivation leads to PI3K-AKT-mTOR pathway activation, cooperating with MAPK signaling to promote survival and invasion""}"
4992	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	6	MET									Pathway activation																										HGF/MET signaling enhances RAS-MAPK and PI3K-AKT pathways, implicated in both cutaneous and leptomeningeal melanocytic proliferation																						"{""association"": ""Pathway activation"", ""name"": ""MET"", ""notes"": ""HGF/MET signaling enhances RAS-MAPK and PI3K-AKT pathways, implicated in both cutaneous and leptomeningeal melanocytic proliferation""}"	{}	"{""association"": ""Pathway activation"", ""name"": ""MET"", ""notes"": ""HGF/MET signaling enhances RAS-MAPK and PI3K-AKT pathways, implicated in both cutaneous and leptomeningeal melanocytic proliferation""}"
4993	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	genetic	7	RAF1									Gene fusions																										Rare mosaic RAF1 fusions reported as oncogenic drivers in atypical CMN cases																						"{""association"": ""Gene fusions"", ""name"": ""RAF1"", ""notes"": ""Rare mosaic RAF1 fusions reported as oncogenic drivers in atypical CMN cases""}"	{}	"{""association"": ""Gene fusions"", ""name"": ""RAF1"", ""notes"": ""Rare mosaic RAF1 fusions reported as oncogenic drivers in atypical CMN cases""}"
5025	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	genetic	0	TNF- pathway involvement																																			"TNF- signaling is implicated in MRS pathophysiology based on therapeutic efficacy of TNF antagonists (infliximab). TNF- is a key mediator promoting macrophage activation and granuloma formation in orofacial tissues.
"																						"{""name"": ""TNF- pathway involvement"", ""notes"": ""TNF- signaling is implicated in MRS pathophysiology based on therapeutic efficacy of TNF antagonists (infliximab). TNF- is a key mediator promoting macrophage activation and granuloma formation in orofacial tissues.\n""}"	{}	"{""evidence"": [{""explanation"": ""Demonstrates TNF- involvement in MRS through effective therapeutic targeting with anti-TNF agents"", ""reference"": ""PMID:32782477"", ""snippet"": ""Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."", ""supports"": ""SUPPORT""}], ""name"": ""TNF- pathway involvement"", ""notes"": ""TNF- signaling is implicated in MRS pathophysiology based on therapeutic efficacy of TNF antagonists (infliximab). TNF- is a key mediator promoting macrophage activation and granuloma formation in orofacial tissues.\n""}"
5026	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	genetic	1	IFN- pathway involvement in autoimmune/allergic context																																			"Interferon-gamma (IFNG) is implicated as a key mediator in MRS pathophysiology, particularly in patients with concomitant autoimmune conditions (coeliac disease) or allergic diseases. IFN- drives Th1/Th17-mediated granulomatous inflammation and classical macrophage activation.
"																						"{""name"": ""IFN- pathway involvement in autoimmune/allergic context"", ""notes"": ""Interferon-gamma (IFNG) is implicated as a key mediator in MRS pathophysiology, particularly in patients with concomitant autoimmune conditions (coeliac disease) or allergic diseases. IFN- drives Th1/Th17-mediated granulomatous inflammation and classical macrophage activation.\n""}"	{}	"{""evidence"": [{""explanation"": ""Implicates IFN- as a central mediator linking MRS to autoimmune and allergic pathways"", ""reference"": ""PMID:31466978"", ""snippet"": ""interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease."", ""supports"": ""PARTIAL""}], ""name"": ""IFN- pathway involvement in autoimmune/allergic context"", ""notes"": ""Interferon-gamma (IFNG) is implicated as a key mediator in MRS pathophysiology, particularly in patients with concomitant autoimmune conditions (coeliac disease) or allergic diseases. IFN- drives Th1/Th17-mediated granulomatous inflammation and classical macrophage activation.\n""}"
5027	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	genetic	2	IL-12/IL-23 signaling pathway																																			"IL-12 and IL-23 cytokines drive Th1/Th17 T cell differentiation and promote IFN- production and macrophage activation in orofacial granulomas. Therapeutic responsiveness to IL-12/23 blockade (ustekinumab) validates this pathway's role in MRS pathogenesis.
"																						"{""name"": ""IL-12/IL-23 signaling pathway"", ""notes"": ""IL-12 and IL-23 cytokines drive Th1/Th17 T cell differentiation and promote IFN- production and macrophage activation in orofacial granulomas. Therapeutic responsiveness to IL-12/23 blockade (ustekinumab) validates this pathway's role in MRS pathogenesis.\n""}"	{}	"{""evidence"": [{""explanation"": ""Establishes IL-12/23 signaling as a central pathway driving IFN- production and orofacial granulomatous inflammation"", ""reference"": ""PMID:32782477"", ""snippet"": ""IL-12 and IL-23 are linked to the production of IFN-, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."", ""supports"": ""SUPPORT""}], ""name"": ""IL-12/IL-23 signaling pathway"", ""notes"": ""IL-12 and IL-23 cytokines drive Th1/Th17 T cell differentiation and promote IFN- production and macrophage activation in orofacial granulomas. Therapeutic responsiveness to IL-12/23 blockade (ustekinumab) validates this pathway's role in MRS pathogenesis.\n""}"
5028	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	genetic	3	SCN1A variants in rare phenotypes																																			"SCN1A variants have been identified in rare cases of Melkersson-Rosenthal syndrome, particularly in patients presenting with concomitant migraine or neurological symptoms (familial hemiplegic migraine-like presentation). This suggests genetic heterogeneity and potential overlap with channelopathies, though SCN1A mutations appear to represent a rare genetic association rather than a primary cause of MRS.
"																						"{""name"": ""SCN1A variants in rare phenotypes"", ""notes"": ""SCN1A variants have been identified in rare cases of Melkersson-Rosenthal syndrome, particularly in patients presenting with concomitant migraine or neurological symptoms (familial hemiplegic migraine-like presentation). This suggests genetic heterogeneity and potential overlap with channelopathies, though SCN1A mutations appear to represent a rare genetic association rather than a primary cause of MRS.\n""}"	{}	"{""evidence"": [{""explanation"": ""Documents rare SCN1A variant association in an MRS patient with facial palsy and migraine, suggesting genetic heterogeneity in MRS pathogenesis"", ""reference"": ""PMID:37510386"", ""snippet"": ""MRS is a disorder with variable expressivity and clinical as well as genetic heterogeneity; however, the causative gene remains to be identified... We identified a c.3521C>G missense heterozygous variant in SCN1A carried only by the affected sister."", ""supports"": ""PARTIAL""}], ""name"": ""SCN1A variants in rare phenotypes"", ""notes"": ""SCN1A variants have been identified in rare cases of Melkersson-Rosenthal syndrome, particularly in patients presenting with concomitant migraine or neurological symptoms (familial hemiplegic migraine-like presentation). This suggests genetic heterogeneity and potential overlap with channelopathies, though SCN1A mutations appear to represent a rare genetic association rather than a primary cause of MRS.\n""}"
5058	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	genetic	0	MCPyV T Antigens									Viral Oncogenes																										In MCPyV-positive MCC, viral small T and truncated large T antigens are the primary oncogenic drivers. Large T antigen binds RB1, while small T antigen promotes proliferation through multiple mechanisms. Tumors are addicted to viral oncoprotein expression.																						"{""association"": ""Viral Oncogenes"", ""name"": ""MCPyV T Antigens"", ""notes"": ""In MCPyV-positive MCC, viral small T and truncated large T antigens are the primary oncogenic drivers. Large T antigen binds RB1, while small T antigen promotes proliferation through multiple mechanisms. Tumors are addicted to viral oncoprotein expression.""}"	{}	"{""association"": ""Viral Oncogenes"", ""name"": ""MCPyV T Antigens"", ""notes"": ""In MCPyV-positive MCC, viral small T and truncated large T antigens are the primary oncogenic drivers. Large T antigen binds RB1, while small T antigen promotes proliferation through multiple mechanisms. Tumors are addicted to viral oncoprotein expression.""}"
5059	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	genetic	1	RB1									Somatic Mutations (in MCPyV-negative MCC)																										RB1 mutations occur in the majority of MCPyV-negative MCC but are virtually absent in virus-positive tumors, where viral LT antigen functionally inactivates RB1 protein.																						"{""association"": ""Somatic Mutations (in MCPyV-negative MCC)"", ""name"": ""RB1"", ""notes"": ""RB1 mutations occur in the majority of MCPyV-negative MCC but are virtually absent in virus-positive tumors, where viral LT antigen functionally inactivates RB1 protein.""}"	{}	"{""association"": ""Somatic Mutations (in MCPyV-negative MCC)"", ""name"": ""RB1"", ""notes"": ""RB1 mutations occur in the majority of MCPyV-negative MCC but are virtually absent in virus-positive tumors, where viral LT antigen functionally inactivates RB1 protein.""}"
5060	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	genetic	2	TP53									Somatic Mutations (in MCPyV-negative MCC)																										TP53 mutations with UV signature are common in virus-negative MCC. Virus-positive tumors retain wild-type TP53, suggesting different selective pressures.																						"{""association"": ""Somatic Mutations (in MCPyV-negative MCC)"", ""name"": ""TP53"", ""notes"": ""TP53 mutations with UV signature are common in virus-negative MCC. Virus-positive tumors retain wild-type TP53, suggesting different selective pressures.""}"	{}	"{""association"": ""Somatic Mutations (in MCPyV-negative MCC)"", ""name"": ""TP53"", ""notes"": ""TP53 mutations with UV signature are common in virus-negative MCC. Virus-positive tumors retain wild-type TP53, suggesting different selective pressures.""}"
5087	214	Migraine	Migraine.yaml	genetic	0	CACNA1A									Causative																										Familial hemiplegic migraine																						"{""association"": ""Causative"", ""name"": ""CACNA1A"", ""notes"": ""Familial hemiplegic migraine""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""CACNA1A encodes a voltage-gated calcium channel involved in ion transport and neurotransmitter release, and is one of the established causative genes for familial hemiplegic migraine."", ""reference"": ""PMID:38508838"", ""snippet"": ""Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"", ""supports"": ""SUPPORT""}], ""name"": ""CACNA1A"", ""notes"": ""Familial hemiplegic migraine""}"
5088	214	Migraine	Migraine.yaml	genetic	1	ATP1A2									Causative																										Familial hemiplegic migraine																						"{""association"": ""Causative"", ""name"": ""ATP1A2"", ""notes"": ""Familial hemiplegic migraine""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""ATP1A2 encodes a Na+/K+-ATPase involved in ion transport, and is one of the established causative genes for familial hemiplegic migraine type 2."", ""reference"": ""PMID:38508838"", ""snippet"": ""Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"", ""supports"": ""SUPPORT""}], ""name"": ""ATP1A2"", ""notes"": ""Familial hemiplegic migraine""}"
5089	214	Migraine	Migraine.yaml	genetic	2	SCN1A									Causative																										Familial hemiplegic migraine																						"{""association"": ""Causative"", ""name"": ""SCN1A"", ""notes"": ""Familial hemiplegic migraine""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""SCN1A encodes a voltage-gated sodium channel involved in ion transport, and is one of the established causative genes for familial hemiplegic migraine type 3."", ""reference"": ""PMID:38508838"", ""snippet"": ""Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"", ""supports"": ""SUPPORT""}], ""name"": ""SCN1A"", ""notes"": ""Familial hemiplegic migraine""}"
5090	214	Migraine	Migraine.yaml	genetic	3	TRPM8									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""TRPM8""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""TRPM8 is expressed in pain-related neural circuitry and genetic variants near TRPM8 are associated with altered migraine risk."", ""reference"": ""PMID:31873179"", ""snippet"": ""TRPM8 is highly expressed in migraine and pain neuronal circuitry, such as trigeminal and dorsal root ganglia"", ""supports"": ""SUPPORT""}], ""name"": ""TRPM8""}"
5091	214	Migraine	Migraine.yaml	genetic	4	LRP1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""LRP1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""GWAS of 5,122 migraineurs identified LRP1 SNP rs11172113 as genome-wide significant for migraine susceptibility."", ""reference"": ""PMID:21666692"", ""snippet"": ""rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5  10(-6)) with migraine."", ""supports"": ""SUPPORT""}, {""explanation"": ""LRP1's role in neuronal glutamate signaling provides mechanistic link to migraine."", ""reference"": ""PMID:21666692"", ""snippet"": ""LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology."", ""supports"": ""SUPPORT""}], ""name"": ""LRP1""}"
5117	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	genetic	0	HLA-DR4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR4""}"
5135	216	Monkeypox	Monkeypox.yaml	genetic	0	Monkeypox Virus Genome																							DNA virus from the Orthopoxvirus genus																																		"{""features"": ""DNA virus from the Orthopoxvirus genus"", ""name"": ""Monkeypox Virus Genome""}"	{}	"{""evidence"": [{""explanation"": ""The reference confirms that the monkeypox virus belongs to the Orthopoxvirus genus and details the structural features of its DNA genome."", ""reference"": ""PMID:12083817"", ""snippet"": ""Monkeypox virus (MPV) belongs to the orthopoxvirus genus of the family Poxviridae... The 196,858-bp MPV genome was analyzed with regard to structural features."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference reaffirms that the monkeypox virus belongs to the Orthopoxvirus genus and has a DNA-based genome."", ""reference"": ""PMID:38801573"", ""snippet"": ""The monkeypox virus is a part of the Poxviridae family, Orthopoxvirus genus, and is accountable for smallpox."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the genetic features and classification of the monkeypox virus as specified in the statement."", ""reference"": ""PMID:37611023"", ""snippet"": ""Monkeypox is a double-stranded DNA virus with an envelope and is a member of the Poxviridae family's Orthopoxvirus genus."", ""supports"": ""SUPPORT""}], ""features"": ""DNA virus from the Orthopoxvirus genus"", ""name"": ""Monkeypox Virus Genome""}"
5136	216	Monkeypox	Monkeypox.yaml	genetic	1	EGFR									Host receptor hijacked for viral spread																										Epidermal growth factor receptor; co-opted by poxviruses to enhance viral spread and cell-to-cell dissemination																						"{""association"": ""Host receptor hijacked for viral spread"", ""name"": ""EGFR"", ""notes"": ""Epidermal growth factor receptor; co-opted by poxviruses to enhance viral spread and cell-to-cell dissemination""}"	{}	"{""association"": ""Host receptor hijacked for viral spread"", ""name"": ""EGFR"", ""notes"": ""Epidermal growth factor receptor; co-opted by poxviruses to enhance viral spread and cell-to-cell dissemination""}"
5137	216	Monkeypox	Monkeypox.yaml	genetic	2	STAT1									Downregulated during infection																										Signal transducer and activator of transcription 1; central transcription factor for interferon signaling, suppressed during MPXV infection																						"{""association"": ""Downregulated during infection"", ""name"": ""STAT1"", ""notes"": ""Signal transducer and activator of transcription 1; central transcription factor for interferon signaling, suppressed during MPXV infection""}"	{}	"{""association"": ""Downregulated during infection"", ""name"": ""STAT1"", ""notes"": ""Signal transducer and activator of transcription 1; central transcription factor for interferon signaling, suppressed during MPXV infection""}"
5138	216	Monkeypox	Monkeypox.yaml	genetic	3	JAK2									Downregulated during infection																										Janus kinase 2; tyrosine kinase in JAK-STAT pathway, downregulated in infected PBMCs																						"{""association"": ""Downregulated during infection"", ""name"": ""JAK2"", ""notes"": ""Janus kinase 2; tyrosine kinase in JAK-STAT pathway, downregulated in infected PBMCs""}"	{}	"{""association"": ""Downregulated during infection"", ""name"": ""JAK2"", ""notes"": ""Janus kinase 2; tyrosine kinase in JAK-STAT pathway, downregulated in infected PBMCs""}"
5139	216	Monkeypox	Monkeypox.yaml	genetic	4	IRF3									Antagonized by viral proteins																										Interferon regulatory factor 3; targeted by viral inhibitors to blunt type I interferon responses																						"{""association"": ""Antagonized by viral proteins"", ""name"": ""IRF3"", ""notes"": ""Interferon regulatory factor 3; targeted by viral inhibitors to blunt type I interferon responses""}"	{}	"{""association"": ""Antagonized by viral proteins"", ""name"": ""IRF3"", ""notes"": ""Interferon regulatory factor 3; targeted by viral inhibitors to blunt type I interferon responses""}"
5140	216	Monkeypox	Monkeypox.yaml	genetic	5	NFKB1									Antagonized by viral proteins																										Nuclear factor kappa B subunit 1; master regulator of inflammatory gene expression, activity suppressed by viral immune evasion proteins																						"{""association"": ""Antagonized by viral proteins"", ""name"": ""NFKB1"", ""notes"": ""Nuclear factor kappa B subunit 1; master regulator of inflammatory gene expression, activity suppressed by viral immune evasion proteins""}"	{}	"{""association"": ""Antagonized by viral proteins"", ""name"": ""NFKB1"", ""notes"": ""Nuclear factor kappa B subunit 1; master regulator of inflammatory gene expression, activity suppressed by viral immune evasion proteins""}"
5141	216	Monkeypox	Monkeypox.yaml	genetic	6	IL6									Upregulated during infection																										Interleukin 6; proinflammatory cytokine elevated in early infection phase																						"{""association"": ""Upregulated during infection"", ""name"": ""IL6"", ""notes"": ""Interleukin 6; proinflammatory cytokine elevated in early infection phase""}"	{}	"{""association"": ""Upregulated during infection"", ""name"": ""IL6"", ""notes"": ""Interleukin 6; proinflammatory cytokine elevated in early infection phase""}"
5142	216	Monkeypox	Monkeypox.yaml	genetic	7	CXCL8									Upregulated during infection																										C-X-C motif chemokine ligand 8 (IL-8); early chemokine induced after infection																						"{""association"": ""Upregulated during infection"", ""name"": ""CXCL8"", ""notes"": ""C-X-C motif chemokine ligand 8 (IL-8); early chemokine induced after infection""}"	{}	"{""association"": ""Upregulated during infection"", ""name"": ""CXCL8"", ""notes"": ""C-X-C motif chemokine ligand 8 (IL-8); early chemokine induced after infection""}"
5143	216	Monkeypox	Monkeypox.yaml	genetic	8	IFNG									Dysregulated during infection																										Interferon gamma; type II interferon with altered kinetics during MPXV infection																						"{""association"": ""Dysregulated during infection"", ""name"": ""IFNG"", ""notes"": ""Interferon gamma; type II interferon with altered kinetics during MPXV infection""}"	{}	"{""association"": ""Dysregulated during infection"", ""name"": ""IFNG"", ""notes"": ""Interferon gamma; type II interferon with altered kinetics during MPXV infection""}"
5181	217	Muenke Syndrome	Muenke_Syndrome.yaml	genetic	0	FGFR3 P250R Mutation									Causative																										"A single recurrent mutation, c.749C>G (p.Pro250Arg), in FGFR3 causes all cases. This mutation is analogous to the P253R mutation in FGFR2 that causes Apert syndrome, affecting the homologous position in the Ig-II/III linker region. The mutation alters FGF ligand binding specificity.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 P250R Mutation"", ""notes"": ""A single recurrent mutation, c.749C>G (p.Pro250Arg), in FGFR3 causes all cases. This mutation is analogous to the P253R mutation in FGFR2 that causes Apert syndrome, affecting the homologous position in the Ig-II/III linker region. The mutation alters FGF ligand binding specificity.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This is the original paper defining Muenke syndrome, demonstrating that the P250R mutation in FGFR3 is the causative mutation in all cases of this craniosynostosis syndrome."", ""reference"": ""PMID:9042914"", ""snippet"": ""Here we present 61 individuals from 20 unrelated families where coronal synostosis is due to an amino acid substitution (Pro250Arg) that results from a single point mutation in the fibroblast growth factor receptor 3 gene on chromosome 4p."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR3 P250R Mutation"", ""notes"": ""A single recurrent mutation, c.749C>G (p.Pro250Arg), in FGFR3 causes all cases. This mutation is analogous to the P253R mutation in FGFR2 that causes Apert syndrome, affecting the homologous position in the Ig-II/III linker region. The mutation alters FGF ligand binding specificity.\n""}"
5195	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	genetic	0	RET									Germline Activating Mutations																										RET (10q11.21) encodes a receptor tyrosine kinase essential for neural crest development. Germline activating mutations cause ligand-independent dimerization and kinase activation. MEN2A is most commonly caused by cysteine mutations in extracellular domain (codons 609, 611, 618, 620, 634). MEN2B is caused by M918T in 95% of cases. De novo mutations account for 50% of MEN2B and 5% of MEN2A. Penetrance for MTC approaches 100% but age of onset varies with mutation.																						"{""association"": ""Germline Activating Mutations"", ""name"": ""RET"", ""notes"": ""RET (10q11.21) encodes a receptor tyrosine kinase essential for neural crest development. Germline activating mutations cause ligand-independent dimerization and kinase activation. MEN2A is most commonly caused by cysteine mutations in extracellular domain (codons 609, 611, 618, 620, 634). MEN2B is caused by M918T in 95% of cases. De novo mutations account for 50% of MEN2B and 5% of MEN2A. Penetrance for MTC approaches 100% but age of onset varies with mutation.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Activating Mutations"", ""evidence"": [{""explanation"": ""Review confirms RET proto-oncogene as the gene responsible for all MEN2 variants with specific mutations identified for each clinical variant."", ""reference"": ""PMID:11786689"", ""snippet"": ""The gene causing all three MEN2 variants is located on chromosome 10cen-10q11.2, and is the c-ret proto-oncogene which encodes a tyrosine kinase receptor with cadherin-like and cysteine-rich extracellular domains, and a tyrosine kinase intracellular domain. Specific mutations of c-ret have been identified for each of the three MEN2 variants."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""RET"", ""notes"": ""RET (10q11.21) encodes a receptor tyrosine kinase essential for neural crest development. Germline activating mutations cause ligand-independent dimerization and kinase activation. MEN2A is most commonly caused by cysteine mutations in extracellular domain (codons 609, 611, 618, 620, 634). MEN2B is caused by M918T in 95% of cases. De novo mutations account for 50% of MEN2B and 5% of MEN2A. Penetrance for MTC approaches 100% but age of onset varies with mutation.""}"
5219	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	0	HLA-DRB1									Risk Factor																										Notably DRB1*15:01 allele; strongest genetic risk factor for MS																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1"", ""notes"": ""Notably DRB1*15:01 allele; strongest genetic risk factor for MS""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The study confirms the association of the HLA-DRB1*15:01 allele with multiple sclerosis in a multigenerational family."", ""reference"": ""PMID:28676141"", ""snippet"": ""HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study uses HLA-DRB1*1501 as a genetic risk factor in developing a risk score for MS, supporting the association of HLA-DRB1 with MS."", ""reference"": ""PMID:27802296"", ""snippet"": ""Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible... Odds ratios for MS associated with each risk factor were derived from existing literature, and the log values of the odds ratios from each of the risk factors were combined in an additive model to provide an overall score."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article mentions the major histocompatibility region as a significant risk factor for MS, which includes the HLA-DRB1 allele."", ""reference"": ""PMID:21310812"", ""snippet"": ""A haplotype within the major histocompatibility region is the major risk factor for MS..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The chapter reviews the strong association between HLA-DRB1*15:01 and MS, supporting the statement."", ""reference"": ""PMID:25502788"", ""snippet"": ""One of the most consistent findings in multiple sclerosis (MS) is that development of MS is linked with carriage of the class II human leucocyte antigen (HLA) molecule HLA-DRB1*15:01; around 60 % of Caucasian MS patients carry this allele compared to 25-30 % of ethnically matched healthy individuals."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1"", ""notes"": ""Notably DRB1*15:01 allele; strongest genetic risk factor for MS""}"
5220	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	1	IL7R									Risk Factor																										Interleukin 7 receptor; involved in T cell homeostasis and immune regulation																						"{""association"": ""Risk Factor"", ""name"": ""IL7R"", ""notes"": ""Interleukin 7 receptor; involved in T cell homeostasis and immune regulation""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The first large-scale GWAS of multiple sclerosis identified IL7RA as a genome-wide significant susceptibility locus (P=2.94x10-7), establishing it as a heritable genetic risk factor for MS."", ""reference"": ""PMID:17660530"", ""snippet"": ""Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis"", ""supports"": ""SUPPORT""}], ""name"": ""IL7R"", ""notes"": ""Interleukin 7 receptor; involved in T cell homeostasis and immune regulation""}"
5221	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	2	IL2RA									Risk Factor																										Interleukin 2 receptor alpha chain; role in immune cell regulation																						"{""association"": ""Risk Factor"", ""name"": ""IL2RA"", ""notes"": ""Interleukin 2 receptor alpha chain; role in immune cell regulation""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The first large-scale GWAS of multiple sclerosis identified IL2RA as a genome-wide significant susceptibility locus (P=2.96x10-8), establishing it as a heritable genetic risk factor for MS."", ""reference"": ""PMID:17660530"", ""snippet"": ""Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis"", ""supports"": ""SUPPORT""}], ""name"": ""IL2RA"", ""notes"": ""Interleukin 2 receptor alpha chain; role in immune cell regulation""}"
5222	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	3	TYK2									Risk Factor																										Tyrosine kinase 2; involved in cytokine signaling pathways																						"{""association"": ""Risk Factor"", ""name"": ""TYK2"", ""notes"": ""Tyrosine kinase 2; involved in cytokine signaling pathways""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TYK2"", ""notes"": ""Tyrosine kinase 2; involved in cytokine signaling pathways""}"
5223	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	4	CD40									Risk Factor																										Costimulatory molecule on antigen presenting cells; involved in T and B cell interactions																						"{""association"": ""Risk Factor"", ""name"": ""CD40"", ""notes"": ""Costimulatory molecule on antigen presenting cells; involved in T and B cell interactions""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CD40"", ""notes"": ""Costimulatory molecule on antigen presenting cells; involved in T and B cell interactions""}"
5224	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	genetic	5	TNFRSF1A									Risk Factor																										TNF receptor superfamily member 1A; mediates inflammatory responses																						"{""association"": ""Risk Factor"", ""name"": ""TNFRSF1A"", ""notes"": ""TNF receptor superfamily member 1A; mediates inflammatory responses""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TNFRSF1A"", ""notes"": ""TNF receptor superfamily member 1A; mediates inflammatory responses""}"
5253	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	0	IL6									Implicated in cytokine storm pathophysiology																										Prominent proinflammatory cytokine elevated in MIS-C contributing to hyperinflammatory response																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL6"", ""notes"": ""Prominent proinflammatory cytokine elevated in MIS-C contributing to hyperinflammatory response""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL6"", ""notes"": ""Prominent proinflammatory cytokine elevated in MIS-C contributing to hyperinflammatory response""}"
5254	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	1	IL10									Implicated in cytokine storm pathophysiology																										Elevated regulatory cytokine within MIS-C multi-cytokine signature																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL10"", ""notes"": ""Elevated regulatory cytokine within MIS-C multi-cytokine signature""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL10"", ""notes"": ""Elevated regulatory cytokine within MIS-C multi-cytokine signature""}"
5255	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	2	TNF									Implicated in cytokine storm pathophysiology																										Central proinflammatory mediator elevated in MIS-C cohorts																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""TNF"", ""notes"": ""Central proinflammatory mediator elevated in MIS-C cohorts""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""TNF"", ""notes"": ""Central proinflammatory mediator elevated in MIS-C cohorts""}"
5256	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	3	IL18									Implicated in innate immune activation																										Elevated IL-18 and IL-18R expression drives innate activation and T-cell responses																						"{""association"": ""Implicated in innate immune activation"", ""name"": ""IL18"", ""notes"": ""Elevated IL-18 and IL-18R expression drives innate activation and T-cell responses""}"	{}	"{""association"": ""Implicated in innate immune activation"", ""name"": ""IL18"", ""notes"": ""Elevated IL-18 and IL-18R expression drives innate activation and T-cell responses""}"
5257	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	4	FAS									Implicated in immune dysregulation																										Upregulated CD95/FAS signaling in NK cells/monocytes as part of IL-18-FAS activation axis																						"{""association"": ""Implicated in immune dysregulation"", ""name"": ""FAS"", ""notes"": ""Upregulated CD95/FAS signaling in NK cells/monocytes as part of IL-18-FAS activation axis""}"	{}	"{""association"": ""Implicated in immune dysregulation"", ""name"": ""FAS"", ""notes"": ""Upregulated CD95/FAS signaling in NK cells/monocytes as part of IL-18-FAS activation axis""}"
5258	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	5	TRBV11-2									Implicated in T-cell dysregulation																										Marked TCR V21.3 (TRBV11-2) expansion with superantigen-like signature in many acute MIS-C cases																						"{""association"": ""Implicated in T-cell dysregulation"", ""name"": ""TRBV11-2"", ""notes"": ""Marked TCR V21.3 (TRBV11-2) expansion with superantigen-like signature in many acute MIS-C cases""}"	{}	"{""association"": ""Implicated in T-cell dysregulation"", ""name"": ""TRBV11-2"", ""notes"": ""Marked TCR V21.3 (TRBV11-2) expansion with superantigen-like signature in many acute MIS-C cases""}"
5259	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	6	SNX8									Autoantigen target in molecular mimicry																										Cross-reactive epitope with SARS-CoV-2 nucleocapsid; autoantibodies and T cells target SNX8																						"{""association"": ""Autoantigen target in molecular mimicry"", ""name"": ""SNX8"", ""notes"": ""Cross-reactive epitope with SARS-CoV-2 nucleocapsid; autoantibodies and T cells target SNX8""}"	{}	"{""association"": ""Autoantigen target in molecular mimicry"", ""name"": ""SNX8"", ""notes"": ""Cross-reactive epitope with SARS-CoV-2 nucleocapsid; autoantibodies and T cells target SNX8""}"
5260	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	7	MAVS									Implicated in antiviral signaling dysregulation																										Mitochondrial antiviral signaling pathway dysregulation linked to MIS-C autoantibody signature																						"{""association"": ""Implicated in antiviral signaling dysregulation"", ""name"": ""MAVS"", ""notes"": ""Mitochondrial antiviral signaling pathway dysregulation linked to MIS-C autoantibody signature""}"	{}	"{""association"": ""Implicated in antiviral signaling dysregulation"", ""name"": ""MAVS"", ""notes"": ""Mitochondrial antiviral signaling pathway dysregulation linked to MIS-C autoantibody signature""}"
5261	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	8	CFH									Autoantigen target in complement dysregulation																										Factor H autoantibodies reported; contributes to complement dysregulation																						"{""association"": ""Autoantigen target in complement dysregulation"", ""name"": ""CFH"", ""notes"": ""Factor H autoantibodies reported; contributes to complement dysregulation""}"	{}	"{""association"": ""Autoantigen target in complement dysregulation"", ""name"": ""CFH"", ""notes"": ""Factor H autoantibodies reported; contributes to complement dysregulation""}"
5262	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	9	IL1RN									Autoantigen target																										Anti-IL-1RA autoantibodies reported in subsets; relevant to cytokine regulation																						"{""association"": ""Autoantigen target"", ""name"": ""IL1RN"", ""notes"": ""Anti-IL-1RA autoantibodies reported in subsets; relevant to cytokine regulation""}"	{}	"{""association"": ""Autoantigen target"", ""name"": ""IL1RN"", ""notes"": ""Anti-IL-1RA autoantibodies reported in subsets; relevant to cytokine regulation""}"
5263	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	10	IFNG									Implicated in cytokine storm pathophysiology																										Elevated IFN- in cytokine signature linked to T-cell activation and cardiac disease																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IFNG"", ""notes"": ""Elevated IFN- in cytokine signature linked to T-cell activation and cardiac disease""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IFNG"", ""notes"": ""Elevated IFN- in cytokine signature linked to T-cell activation and cardiac disease""}"
5264	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	11	IL17A									Implicated in cytokine storm pathophysiology																										Increased in many MIS-C proteomic/transcriptomic profiles																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL17A"", ""notes"": ""Increased in many MIS-C proteomic/transcriptomic profiles""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL17A"", ""notes"": ""Increased in many MIS-C proteomic/transcriptomic profiles""}"
5265	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	12	IL1B									Implicated in cytokine storm pathophysiology																										Component of inflammatory cytokine milieu in MIS-C																						"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL1B"", ""notes"": ""Component of inflammatory cytokine milieu in MIS-C""}"	{}	"{""association"": ""Implicated in cytokine storm pathophysiology"", ""name"": ""IL1B"", ""notes"": ""Component of inflammatory cytokine milieu in MIS-C""}"
5266	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	13	CXCL9									Implicated in immune cell recruitment																										IFN-inducible chemokine elevated in MIS-C cytokine panels																						"{""association"": ""Implicated in immune cell recruitment"", ""name"": ""CXCL9"", ""notes"": ""IFN-inducible chemokine elevated in MIS-C cytokine panels""}"	{}	"{""association"": ""Implicated in immune cell recruitment"", ""name"": ""CXCL9"", ""notes"": ""IFN-inducible chemokine elevated in MIS-C cytokine panels""}"
5267	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	14	CXCL10									Implicated in immune cell recruitment																										Elevated chemokine linked to monocyte/T cell recruitment in MIS-C																						"{""association"": ""Implicated in immune cell recruitment"", ""name"": ""CXCL10"", ""notes"": ""Elevated chemokine linked to monocyte/T cell recruitment in MIS-C""}"	{}	"{""association"": ""Implicated in immune cell recruitment"", ""name"": ""CXCL10"", ""notes"": ""Elevated chemokine linked to monocyte/T cell recruitment in MIS-C""}"
5268	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	genetic	15	PLA2G2A									Biomarker candidate																										Proteomic biomarker linked to thrombotic-microangiopathy phenotype and complement activation																						"{""association"": ""Biomarker candidate"", ""name"": ""PLA2G2A"", ""notes"": ""Proteomic biomarker linked to thrombotic-microangiopathy phenotype and complement activation""}"	{}	"{""association"": ""Biomarker candidate"", ""name"": ""PLA2G2A"", ""notes"": ""Proteomic biomarker linked to thrombotic-microangiopathy phenotype and complement activation""}"
5300	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	genetic	0	HLA-DRB1									Susceptibility																										Some HLA alleles associated with increased risk																						"{""association"": ""Susceptibility"", ""name"": ""HLA-DRB1"", ""notes"": ""Some HLA alleles associated with increased risk""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""Critical review documents evidence for heritable component in ME/CFS."", ""reference"": ""PMID:32744306"", ""snippet"": ""evidence that it has a heritable component, ME/CFS has not yet benefited from the advances in technology and analytical tools that have improved our understanding of many other complex diseases"", ""supports"": ""PARTIAL""}], ""name"": ""HLA-DRB1"", ""notes"": ""Some HLA alleles associated with increased risk""}"
5328	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	genetic	0	HLA-B8									Risk Factor																										Associated with early-onset MG																						"{""association"": ""Risk Factor"", ""name"": ""HLA-B8"", ""notes"": ""Associated with early-onset MG""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-B8"", ""notes"": ""Associated with early-onset MG""}"
5329	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	genetic	1	HLA-DR3									Risk Factor																										Associated with early-onset MG and thymic hyperplasia																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3"", ""notes"": ""Associated with early-onset MG and thymic hyperplasia""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3"", ""notes"": ""Associated with early-onset MG and thymic hyperplasia""}"
5330	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	genetic	2	CHRNA1									Risk Factor																										Acetylcholine receptor alpha subunit, rare variants																						"{""association"": ""Risk Factor"", ""name"": ""CHRNA1"", ""notes"": ""Acetylcholine receptor alpha subunit, rare variants""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CHRNA1"", ""notes"": ""Acetylcholine receptor alpha subunit, rare variants""}"
5359	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	genetic	0	NPM1									Somatic Driver Mutation																										NPM1 mutations are 4-base pair insertions in exon 12, most commonly type A (TCTG duplication). Mutations disrupt the C-terminal nucleolar localization signal and create a nuclear export signal. NPM1 mutation is mutually exclusive with recurrent balanced translocations. When isolated (without FLT3-ITD high ratio), confers favorable prognosis.																						"{""association"": ""Somatic Driver Mutation"", ""name"": ""NPM1"", ""notes"": ""NPM1 mutations are 4-base pair insertions in exon 12, most commonly type A (TCTG duplication). Mutations disrupt the C-terminal nucleolar localization signal and create a nuclear export signal. NPM1 mutation is mutually exclusive with recurrent balanced translocations. When isolated (without FLT3-ITD high ratio), confers favorable prognosis.""}"	{}	"{""association"": ""Somatic Driver Mutation"", ""name"": ""NPM1"", ""notes"": ""NPM1 mutations are 4-base pair insertions in exon 12, most commonly type A (TCTG duplication). Mutations disrupt the C-terminal nucleolar localization signal and create a nuclear export signal. NPM1 mutation is mutually exclusive with recurrent balanced translocations. When isolated (without FLT3-ITD high ratio), confers favorable prognosis.""}"
5375	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	genetic	0	NRAS Q61R									Somatic Oncogenic Mutation																										Most common NRAS mutation in melanoma, substituting glutamine with arginine at codon 61. Impairs GTPase activity and GAP sensitivity, resulting in constitutively active NRAS.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61R"", ""notes"": ""Most common NRAS mutation in melanoma, substituting glutamine with arginine at codon 61. Impairs GTPase activity and GAP sensitivity, resulting in constitutively active NRAS.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61R"", ""notes"": ""Most common NRAS mutation in melanoma, substituting glutamine with arginine at codon 61. Impairs GTPase activity and GAP sensitivity, resulting in constitutively active NRAS.""}"
5376	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	genetic	1	NRAS Q61K									Somatic Oncogenic Mutation																										Common NRAS mutation substituting glutamine with lysine at codon 61. Functionally equivalent to Q61R with similar downstream pathway activation.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61K"", ""notes"": ""Common NRAS mutation substituting glutamine with lysine at codon 61. Functionally equivalent to Q61R with similar downstream pathway activation.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61K"", ""notes"": ""Common NRAS mutation substituting glutamine with lysine at codon 61. Functionally equivalent to Q61R with similar downstream pathway activation.""}"
5377	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	genetic	2	NRAS Q61L									Somatic Oncogenic Mutation																										NRAS mutation substituting glutamine with leucine at codon 61. Results in constitutive pathway activation similar to other Q61 mutations.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61L"", ""notes"": ""NRAS mutation substituting glutamine with leucine at codon 61. Results in constitutive pathway activation similar to other Q61 mutations.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""NRAS Q61L"", ""notes"": ""NRAS mutation substituting glutamine with leucine at codon 61. Results in constitutive pathway activation similar to other Q61 mutations.""}"
5389	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	genetic	0	NTRK1									Somatic Gene Fusions																										NTRK1 encodes TRKA receptor. Common fusion partners include TPM3, TPR, LMNA, and SQSTM1. Fusions are found in papillary thyroid cancer, NSCLC, colorectal cancer, and other tumor types.																						"{""association"": ""Somatic Gene Fusions"", ""name"": ""NTRK1"", ""notes"": ""NTRK1 encodes TRKA receptor. Common fusion partners include TPM3, TPR, LMNA, and SQSTM1. Fusions are found in papillary thyroid cancer, NSCLC, colorectal cancer, and other tumor types.""}"	{}	"{""association"": ""Somatic Gene Fusions"", ""evidence"": [{""explanation"": ""Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK1 fusion involvement."", ""reference"": ""PMID:33258061"", ""snippet"": ""NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."", ""supports"": ""SUPPORT""}], ""name"": ""NTRK1"", ""notes"": ""NTRK1 encodes TRKA receptor. Common fusion partners include TPM3, TPR, LMNA, and SQSTM1. Fusions are found in papillary thyroid cancer, NSCLC, colorectal cancer, and other tumor types.""}"
5390	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	genetic	1	NTRK2									Somatic Gene Fusions																										NTRK2 encodes TRKB receptor. Less commonly involved in oncogenic fusions than NTRK1 or NTRK3. Found in various tumor types including gliomas.																						"{""association"": ""Somatic Gene Fusions"", ""name"": ""NTRK2"", ""notes"": ""NTRK2 encodes TRKB receptor. Less commonly involved in oncogenic fusions than NTRK1 or NTRK3. Found in various tumor types including gliomas.""}"	{}	"{""association"": ""Somatic Gene Fusions"", ""evidence"": [{""explanation"": ""Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK2 fusion involvement."", ""reference"": ""PMID:33258061"", ""snippet"": ""NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."", ""supports"": ""SUPPORT""}], ""name"": ""NTRK2"", ""notes"": ""NTRK2 encodes TRKB receptor. Less commonly involved in oncogenic fusions than NTRK1 or NTRK3. Found in various tumor types including gliomas.""}"
5391	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	genetic	2	NTRK3									Somatic Gene Fusions																										NTRK3 encodes TRKC receptor. ETV6-NTRK3 fusion is characteristic of secretory breast carcinoma (>90%) and infantile fibrosarcoma (>90%). Also found in other pediatric and adult tumors.																						"{""association"": ""Somatic Gene Fusions"", ""name"": ""NTRK3"", ""notes"": ""NTRK3 encodes TRKC receptor. ETV6-NTRK3 fusion is characteristic of secretory breast carcinoma (>90%) and infantile fibrosarcoma (>90%). Also found in other pediatric and adult tumors.""}"	{}	"{""association"": ""Somatic Gene Fusions"", ""evidence"": [{""explanation"": ""Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK3 fusion involvement."", ""reference"": ""PMID:33258061"", ""snippet"": ""NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."", ""supports"": ""SUPPORT""}], ""name"": ""NTRK3"", ""notes"": ""NTRK3 encodes TRKC receptor. ETV6-NTRK3 fusion is characteristic of secretory breast carcinoma (>90%) and infantile fibrosarcoma (>90%). Also found in other pediatric and adult tumors.""}"
5408	227	Narcolepsy	Narcolepsy.yaml	genetic	0	HLA-DQB1*06:02									Risk Factor																										Present in >98% of Type 1 narcolepsy, but also 25% of general population																						"{""association"": ""Risk Factor"", ""name"": ""HLA-DQB1*06:02"", ""notes"": ""Present in >98% of Type 1 narcolepsy, but also 25% of general population""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Detection of autoreactive T cells in narcolepsy patients supports the HLA-mediated autoimmune mechanism."", ""reference"": ""PMID:32227223"", ""snippet"": ""Autoreactive T cells and autoantibodies have been detected in blood samples from patients"", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DQB1*06:02"", ""notes"": ""Present in >98% of Type 1 narcolepsy, but also 25% of general population""}"
5409	227	Narcolepsy	Narcolepsy.yaml	genetic	1	HCRT									Causative																										Rare mutations in hypocretin gene cause familial narcolepsy																						"{""association"": ""Causative"", ""name"": ""HCRT"", ""notes"": ""Rare mutations in hypocretin gene cause familial narcolepsy""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Demonstrates that loss of hypocretin gene function causes narcolepsy."", ""reference"": ""PMID:25728441"", ""snippet"": ""Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."", ""supports"": ""SUPPORT""}], ""name"": ""HCRT"", ""notes"": ""Rare mutations in hypocretin gene cause familial narcolepsy""}"
5410	227	Narcolepsy	Narcolepsy.yaml	genetic	2	HCRTR2									Causative																										Hypocretin receptor 2 mutations (canine model)																						"{""association"": ""Causative"", ""name"": ""HCRTR2"", ""notes"": ""Hypocretin receptor 2 mutations (canine model)""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms that hypocretin receptor mutations cause narcolepsy in animal models."", ""reference"": ""PMID:25728441"", ""snippet"": ""Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."", ""supports"": ""SUPPORT""}], ""name"": ""HCRTR2"", ""notes"": ""Hypocretin receptor 2 mutations (canine model)""}"
5429	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	genetic	0	HLA-A									Susceptibility Alleles																										HLA-A2 and other specific HLA alleles are associated with increased NPC risk in endemic populations. The HLA region shows the strongest genetic association with NPC susceptibility.																						"{""association"": ""Susceptibility Alleles"", ""name"": ""HLA-A"", ""notes"": ""HLA-A2 and other specific HLA alleles are associated with increased NPC risk in endemic populations. The HLA region shows the strongest genetic association with NPC susceptibility.""}"	{}	"{""association"": ""Susceptibility Alleles"", ""name"": ""HLA-A"", ""notes"": ""HLA-A2 and other specific HLA alleles are associated with increased NPC risk in endemic populations. The HLA region shows the strongest genetic association with NPC susceptibility.""}"
5430	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	genetic	1	TP53									Occasionally Mutated																										TP53 mutations are less common in NPC than in HPV-negative HNSCC, occurring in approximately 10% of cases.																						"{""association"": ""Occasionally Mutated"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are less common in NPC than in HPV-negative HNSCC, occurring in approximately 10% of cases.""}"	{}	"{""association"": ""Occasionally Mutated"", ""name"": ""TP53"", ""notes"": ""TP53 mutations are less common in NPC than in HPV-negative HNSCC, occurring in approximately 10% of cases.""}"
5431	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	genetic	2	CDKN2A									Deletion/Methylation																										CDKN2A inactivation through homozygous deletion or promoter methylation occurs in approximately 30-50% of NPC, contributing to cell cycle dysregulation.																						"{""association"": ""Deletion/Methylation"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A inactivation through homozygous deletion or promoter methylation occurs in approximately 30-50% of NPC, contributing to cell cycle dysregulation.""}"	{}	"{""association"": ""Deletion/Methylation"", ""name"": ""CDKN2A"", ""notes"": ""CDKN2A inactivation through homozygous deletion or promoter methylation occurs in approximately 30-50% of NPC, contributing to cell cycle dysregulation.""}"
5432	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	genetic	3	NF-kB Pathway Alterations									Various Mutations																										Mutations in NF-kB pathway genes (TRAF3, CYLD, NFKBIA) occur in approximately 30-40% of NPC, leading to constitutive NF-kB activation independent of LMP1.																						"{""association"": ""Various Mutations"", ""name"": ""NF-kB Pathway Alterations"", ""notes"": ""Mutations in NF-kB pathway genes (TRAF3, CYLD, NFKBIA) occur in approximately 30-40% of NPC, leading to constitutive NF-kB activation independent of LMP1.""}"	{}	"{""association"": ""Various Mutations"", ""name"": ""NF-kB Pathway Alterations"", ""notes"": ""Mutations in NF-kB pathway genes (TRAF3, CYLD, NFKBIA) occur in approximately 30-40% of NPC, leading to constitutive NF-kB activation independent of LMP1.""}"
5455	229	Nephronophthisis	Nephronophthisis.yaml	genetic	0	NPHP1									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""NPHP1""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The NPHP1 gene deletion is associated with juvenile nephronophthisis, confirming the genetic link between NPHP1 and nephronophthisis."", ""reference"": ""PMID:15138899"", ""snippet"": ""Two siblings affected with a mild form of JS were found to have a homozygous deletion of the NPHP1 gene identical, by mapping, to that in subjects with NPHP alone."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the genetic association of nephronophthisis with variants in several genes, highlighting NPHP1 among the genes associated with nephropathy."", ""reference"": ""PMID:36990420"", ""snippet"": ""Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy."", ""supports"": ""SUPPORT""}], ""name"": ""NPHP1""}"
5456	229	Nephronophthisis	Nephronophthisis.yaml	genetic	1	NPHP3									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""NPHP3""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""reference"": ""PMID:34212438"", ""snippet"": ""we detected a homozygous predicted synonymous allele in NPHP3 in two children with hepatorenal fibrocystic disease from a consanguineous family."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:26184788"", ""snippet"": ""Eight of 17 (47.1%) patients detected were identified to have mutations in NPHP3."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:36990420"", ""snippet"": ""Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy."", ""supports"": ""SUPPORT""}], ""name"": ""NPHP3""}"
5457	229	Nephronophthisis	Nephronophthisis.yaml	genetic	2	NPHP4									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""NPHP4""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The literature identifies NPHP4 as one of the genes responsible for different types of Nephronophthisis."", ""reference"": ""PMID:14750102"", ""snippet"": ""Nephronophthisis (NPH) is an autosomal recessive kidney disease... Four genes responsible for different types of NPH have been identified: NPHP1, NPHP2, NPHP3, and NPHP4."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that NPHP4 is associated with end-stage renal disease in Nephronophthisis, highlighting its pathogenic role."", ""reference"": ""PMID:34591160"", ""snippet"": ""Nephronophthisis (NPHP) 4 gene encoding nephrocystin-4... contributes to end-stage renal disease in children and young adults."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature mentions that patients with NPHP4 variants develop nephropathy in the context of Nephronophthisis."", ""reference"": ""PMID:36990420"", ""snippet"": ""Senior-Loken syndrome (SLSN) is an autosomal recessive disorder characterized by retinopathy and nephronophthisis... Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy."", ""supports"": ""SUPPORT""}], ""name"": ""NPHP4""}"
5458	229	Nephronophthisis	Nephronophthisis.yaml	genetic	3	INVS									Pathogenic Variants																										Also known as NPHP2, inversin protein antagonizes canonical WNT signaling																						"{""association"": ""Pathogenic Variants"", ""name"": ""INVS"", ""notes"": ""Also known as NPHP2, inversin protein antagonizes canonical WNT signaling""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The literature identifies NPHP2 (INVS) as one of the genes responsible for different types of Nephronophthisis."", ""reference"": ""PMID:14750102"", ""snippet"": ""Nephronophthisis (NPH) is an autosomal recessive kidney disease... Four genes responsible for different types of NPH have been identified: NPHP1, NPHP2, NPHP3, and NPHP4."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms INVS variants are associated with nephropathy in nephronophthisis."", ""reference"": ""PMID:36990420"", ""snippet"": ""Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy."", ""supports"": ""SUPPORT""}], ""name"": ""INVS"", ""notes"": ""Also known as NPHP2, inversin protein antagonizes canonical WNT signaling""}"
5459	229	Nephronophthisis	Nephronophthisis.yaml	genetic	4	NEK8									Pathogenic Variants																										Also known as NPHP9, a NIMA-family ciliary kinase in the INV complex																						"{""association"": ""Pathogenic Variants"", ""name"": ""NEK8"", ""notes"": ""Also known as NPHP9, a NIMA-family ciliary kinase in the INV complex""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""While this reference doesn't specifically mention NEK8, it establishes the context of genetic heterogeneity in nephronophthisis-related ciliopathies."", ""reference"": ""PMID:36990420"", ""snippet"": ""Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy."", ""supports"": ""SUPPORT""}], ""name"": ""NEK8"", ""notes"": ""Also known as NPHP9, a NIMA-family ciliary kinase in the INV complex""}"
5494	230	Neuroblastoma	Neuroblastoma.yaml	genetic	0	MYCN Amplification									Oncogene Amplification																										MYCN amplification (>10 copies) occurs in approximately 20% of neuroblastomas and is the strongest independent adverse prognostic factor. It drives aggressive biology and is used for risk stratification.																						"{""association"": ""Oncogene Amplification"", ""name"": ""MYCN Amplification"", ""notes"": ""MYCN amplification (>10 copies) occurs in approximately 20% of neuroblastomas and is the strongest independent adverse prognostic factor. It drives aggressive biology and is used for risk stratification.""}"	{}	"{""association"": ""Oncogene Amplification"", ""name"": ""MYCN Amplification"", ""notes"": ""MYCN amplification (>10 copies) occurs in approximately 20% of neuroblastomas and is the strongest independent adverse prognostic factor. It drives aggressive biology and is used for risk stratification.""}"
5495	230	Neuroblastoma	Neuroblastoma.yaml	genetic	1	ALK Mutations									Oncogenic Driver Mutations																										ALK point mutations occur in 8-10% of sporadic and ~50% of familial neuroblastoma. F1174L and R1275Q are the most common mutations. ALK is a therapeutic target for crizotinib and other ALK inhibitors.																						"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""ALK Mutations"", ""notes"": ""ALK point mutations occur in 8-10% of sporadic and ~50% of familial neuroblastoma. F1174L and R1275Q are the most common mutations. ALK is a therapeutic target for crizotinib and other ALK inhibitors.""}"	{}	"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""ALK Mutations"", ""notes"": ""ALK point mutations occur in 8-10% of sporadic and ~50% of familial neuroblastoma. F1174L and R1275Q are the most common mutations. ALK is a therapeutic target for crizotinib and other ALK inhibitors.""}"
5496	230	Neuroblastoma	Neuroblastoma.yaml	genetic	2	Segmental Chromosomal Aberrations									Prognostic Markers																										Segmental chromosomal aberrations including 1p deletion, 11q deletion, and 17q gain are associated with worse prognosis and help define risk stratification.																						"{""association"": ""Prognostic Markers"", ""name"": ""Segmental Chromosomal Aberrations"", ""notes"": ""Segmental chromosomal aberrations including 1p deletion, 11q deletion, and 17q gain are associated with worse prognosis and help define risk stratification.""}"	{}	"{""association"": ""Prognostic Markers"", ""name"": ""Segmental Chromosomal Aberrations"", ""notes"": ""Segmental chromosomal aberrations including 1p deletion, 11q deletion, and 17q gain are associated with worse prognosis and help define risk stratification.""}"
5518	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	genetic	0	NF1									Germline Loss-of-Function Mutations																										NF1 (17q11.2) encodes neurofibromin, a large protein with RAS-GAP domain that negatively regulates RAS signaling. Germline mutations include truncating variants, missense mutations in the GAP domain, splice site variants, and large deletions (5% of cases, associated with more severe phenotype). De novo mutation rate is approximately 50%. Penetrance is essentially complete but expressivity is highly variable, even within families.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""NF1"", ""notes"": ""NF1 (17q11.2) encodes neurofibromin, a large protein with RAS-GAP domain that negatively regulates RAS signaling. Germline mutations include truncating variants, missense mutations in the GAP domain, splice site variants, and large deletions (5% of cases, associated with more severe phenotype). De novo mutation rate is approximately 50%. Penetrance is essentially complete but expressivity is highly variable, even within families.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""NF1"", ""notes"": ""NF1 (17q11.2) encodes neurofibromin, a large protein with RAS-GAP domain that negatively regulates RAS signaling. Germline mutations include truncating variants, missense mutations in the GAP domain, splice site variants, and large deletions (5% of cases, associated with more severe phenotype). De novo mutation rate is approximately 50%. Penetrance is essentially complete but expressivity is highly variable, even within families.""}"
5544	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	genetic	0	HLA-DRB1*03:01									Associated																										"Strong genetic association with HLA class II alleles, particularly HLA-DRB1*03:01, suggesting T cell involvement in disease initiation. This distinguishes NMOSD from MS which is associated with HLA-DRB1*15.
"																						"{""association"": ""Associated"", ""name"": ""HLA-DRB1*03:01"", ""notes"": ""Strong genetic association with HLA class II alleles, particularly HLA-DRB1*03:01, suggesting T cell involvement in disease initiation. This distinguishes NMOSD from MS which is associated with HLA-DRB1*15.\n""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""Meta-analysis confirms HLA-DRB1*03:01 as the primary genetic risk factor for NMO in Western populations, distinct from MS associations."", ""reference"": ""PMID:33420337"", ""snippet"": ""Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03 allelic group than controls. Ethnicity can influence genetic susceptibility. The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele in Western populations and with the DPB1*05:01 allele in Asia."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1*03:01"", ""notes"": ""Strong genetic association with HLA class II alleles, particularly HLA-DRB1*03:01, suggesting T cell involvement in disease initiation. This distinguishes NMOSD from MS which is associated with HLA-DRB1*15.\n""}"
5571	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	0	EGFR			OCCASIONAL						Activating Mutations																																																"{""association"": ""Activating Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""EGFR""}"	{}	"{""association"": ""Activating Mutations"", ""evidence"": [{""explanation"": ""The reference indicates that EGFR mutations, including activating mutations, are a frequent event, which matches the statement that such mutations occur occasionally."", ""reference"": ""PMID:23647298"", ""snippet"": ""EGFR mutations are a relatively frequent event in non-small-cell lung cancer, generally consisting of exon 19 deletion or exon 21 substitution. In adenocarcinoma, additional rare mutations are detectable in the EGFR gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study further supports the association of EGFR activating mutations in NSCLC and the effectiveness of targeted therapies, implying the commonality and impact of these mutations."", ""reference"": ""PMID:27926500"", ""snippet"": ""The results of this study demonstrate that EGFR-TKI therapy results in survival benefits for EGFR-mutant advanced NSCLC patients, regardless of gender, smoking history, pathologic type, type of EGFR mutations, brain metastasis and timing of targeted therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The research recognizes the frequent mutations in EGFR, validating the association stated in the provided statement."", ""reference"": ""PMID:32107398"", ""snippet"": ""EGFR mutation status might be correlated to CT scans imaging phenotypes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The frequency (10-15%) explicitly mentioned aligns well with the occasional occurrence stated in the statement."", ""reference"": ""PMID:30520383"", ""snippet"": ""Moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms that activating mutations in EGFR are significant and frequent enough to impact treatment and response, supporting the statement's claim."", ""reference"": ""PMID:18957054"", ""snippet"": ""Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer."", ""supports"": ""SUPPORT""}, {""explanation"": ""By describing EGFR mutations as a notable factor linked with clinical and demographic attributes of NSCLC patients, it supports the occasional frequency mentioned in the statement."", ""reference"": ""PMID:32657049"", ""snippet"": ""We describe the clinical features, genetic profile, and their correlation in NSCLC patients... The frequency of mutations in EGFR, MET, and RET were significantly higher in nonsmokers than in smokers."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study acknowledges the association of EGFR mutations with clinical outcomes in NSCLC, supporting the idea of their occasional prevalence."", ""reference"": ""PMID:23621221"", ""snippet"": ""Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""EGFR""}"
5572	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	1	ALK			OCCASIONAL						Gene Rearrangements																																																"{""association"": ""Gene Rearrangements"", ""frequency"": ""OCCASIONAL"", ""name"": ""ALK""}"	{}	"{""association"": ""Gene Rearrangements"", ""evidence"": [{""explanation"": ""The literature describes ALK rearrangements occurring in 2-7% of NSCLC cases, supporting the statement that ALK rearrangements are occasional in frequency in NSCLC."", ""reference"": ""PMID:30878128"", ""snippet"": ""The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein rearranged in 2-7% of non-small cell lung cancer (NSCLC) cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mention of ALK rearrangements aligns with the statement indicating that they are a recognised genetic association in NSCLC."", ""reference"": ""PMID:35986977"", ""snippet"": ""the presence of ALK/ROS rearrangements in our study is associated with an approximately threefold to fourfold increase in thrombosis risk in NSCLC patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature identifies ALK rearrangements as part of more commonly recognized alterations/subtypes in NSCLC, supporting their occasional occurrence."", ""reference"": ""PMID:36806787"", ""snippet"": ""more commonly recognized alterations (such as KRAS, BRAF, MET and ERBB family mutations, or ALK, RET and ROS1 fusions)"", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""ALK""}"
5573	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	2	ROS1			OCCASIONAL						Gene Rearrangements																																																"{""association"": ""Gene Rearrangements"", ""frequency"": ""OCCASIONAL"", ""name"": ""ROS1""}"	{}	"{""association"": ""Gene Rearrangements"", ""evidence"": [{""explanation"": ""The literature states that ROS-1 rearrangement occurs in a small percentage of NSCLCs, supporting the statement that ROS1 gene rearrangements are occasional in NSCLC."", ""reference"": ""PMID:35200557"", ""snippet"": ""ROS-1 rearrangement is found in 0.9-2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature mentions ROS1 rearrangements in the context of their association with thromboembolic events, indicating the presence and relevance of these genetic alterations in NSCLC."", ""reference"": ""PMID:35986977"", ""snippet"": ""ROS and ALK rearrangement is highly associated with TE development, with HR of 4.04 ... p = 0.005"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the presence of ROS1 rearrangements in a subgroup of NSCLC patients, which aligns with the statement regarding the occasional frequency of these rearrangements."", ""reference"": ""PMID:34325210"", ""snippet"": ""We investigated the clinical characteristics and gene mutation rate of non-small cell lung cancer patients with osteoblastic bone metastases at the time of the initial diagnosis. ... two were ROS1 rearrangement-positive."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature identifies ROS1 fusions as less common alterations in NSCLC, which supports the occasional occurrence of these gene rearrangements."", ""reference"": ""PMID:36806787"", ""snippet"": ""Less commonly identified alterations (such as...ROS1 fusions)."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""ROS1""}"
5574	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	3	KRAS			OCCASIONAL						Activating Mutations																										Co-mutation with STK11 and/or KEAP1 predicts cold tumor microenvironment and inferior response to immune checkpoint inhibitors																						"{""association"": ""Activating Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""KRAS"", ""notes"": ""Co-mutation with STK11 and/or KEAP1 predicts cold tumor microenvironment and inferior response to immune checkpoint inhibitors""}"	{}	"{""association"": ""Activating Mutations"", ""evidence"": [{""explanation"": ""This reference confirms that KRAS activating mutations are present in non-small cell lung cancer (NSCLC)."", ""reference"": ""PMID:33618059"", ""snippet"": ""Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in advanced non-small cell lung cancer, occurring in approximately 30% of lung adenocarcinomas."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the occurrence of KRAS mutations in NSCLC, indicating they are within a notable frequency and linked to specific subgroups."", ""reference"": ""PMID:23723294"", ""snippet"": ""Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference reiterates the frequent nature of KRAS mutations in NSCLC, aligning with the \""occasional\"" frequency stated."", ""reference"": ""PMID:31862576"", ""snippet"": ""KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""KRAS"", ""notes"": ""Co-mutation with STK11 and/or KEAP1 predicts cold tumor microenvironment and inferior response to immune checkpoint inhibitors""}"
5575	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	4	STK11			OCCASIONAL						Loss-of-function Mutations																										Co-mutation with KRAS creates metabolic dependency on G6PD/PPP pathway; associated with cold tumor microenvironment and poor ICI response; dual PD-L1/CTLA-4 blockade may partially overcome resistance																						"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""STK11"", ""notes"": ""Co-mutation with KRAS creates metabolic dependency on G6PD/PPP pathway; associated with cold tumor microenvironment and poor ICI response; dual PD-L1/CTLA-4 blockade may partially overcome resistance""}"	{}	"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""STK11"", ""notes"": ""Co-mutation with KRAS creates metabolic dependency on G6PD/PPP pathway; associated with cold tumor microenvironment and poor ICI response; dual PD-L1/CTLA-4 blockade may partially overcome resistance""}"
5576	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	5	KEAP1			OCCASIONAL						Loss-of-function Mutations																										Activates NRF2 antioxidant pathway; independent adverse prognostic factor for OS on ICIs (HR 1.890); co-mutation with KRAS predicts ICI resistance; dual PD-L1/CTLA-4 blockade may provide benefit																						"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""KEAP1"", ""notes"": ""Activates NRF2 antioxidant pathway; independent adverse prognostic factor for OS on ICIs (HR 1.890); co-mutation with KRAS predicts ICI resistance; dual PD-L1/CTLA-4 blockade may provide benefit""}"	{}	"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""OCCASIONAL"", ""name"": ""KEAP1"", ""notes"": ""Activates NRF2 antioxidant pathway; independent adverse prognostic factor for OS on ICIs (HR 1.890); co-mutation with KRAS predicts ICI resistance; dual PD-L1/CTLA-4 blockade may provide benefit""}"
5577	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	6	TP53			FREQUENT						Loss-of-function Mutations																										Independent adverse prognostic factor for OS on ICIs (HR 1.735); associated with higher tumor mutational burden; variable impact on ICI outcomes depending on co-mutation context																						"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""FREQUENT"", ""name"": ""TP53"", ""notes"": ""Independent adverse prognostic factor for OS on ICIs (HR 1.735); associated with higher tumor mutational burden; variable impact on ICI outcomes depending on co-mutation context""}"	{}	"{""association"": ""Loss-of-function Mutations"", ""frequency"": ""FREQUENT"", ""name"": ""TP53"", ""notes"": ""Independent adverse prognostic factor for OS on ICIs (HR 1.735); associated with higher tumor mutational burden; variable impact on ICI outcomes depending on co-mutation context""}"
5578	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	genetic	7	G6PD			OCCASIONAL						Metabolic Dependency																										KRAS/LKB1 co-mutant tumors show selective dependency on G6PD for NADPH generation and lipogenesis; genetic ablation activates p53 and suppresses tumorigenesis																						"{""association"": ""Metabolic Dependency"", ""frequency"": ""OCCASIONAL"", ""name"": ""G6PD"", ""notes"": ""KRAS/LKB1 co-mutant tumors show selective dependency on G6PD for NADPH generation and lipogenesis; genetic ablation activates p53 and suppresses tumorigenesis""}"	{}	"{""association"": ""Metabolic Dependency"", ""frequency"": ""OCCASIONAL"", ""name"": ""G6PD"", ""notes"": ""KRAS/LKB1 co-mutant tumors show selective dependency on G6PD for NADPH generation and lipogenesis; genetic ablation activates p53 and suppresses tumorigenesis""}"
5604	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	0	PTPN11			VERY_FREQUENT						Pathogenic Variants																										Most commonly mutated gene, accounting for approximately 50-60% of cases. Encodes SHP2 phosphatase. Gain-of-function mutations destabilize the autoinhibited conformation leading to increased phosphatase activity. Associated with pulmonary stenosis but lower HCM risk.																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""VERY_FREQUENT"", ""name"": ""PTPN11"", ""notes"": ""Most commonly mutated gene, accounting for approximately 50-60% of cases. Encodes SHP2 phosphatase. Gain-of-function mutations destabilize the autoinhibited conformation leading to increased phosphatase activity. Associated with pulmonary stenosis but lower HCM risk.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms PTPN11 mutations account for approximately half of Noonan syndrome cases."", ""reference"": ""PMID:11992261"", ""snippet"": ""Mutations were found in 54 of 119 (45%) unrelated individuals with sporadic or familial NS."", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""gene_term"": {""preferred_term"": ""PTPN11"", ""term"": {""id"": ""hgnc:9644"", ""label"": ""PTPN11""}}, ""name"": ""PTPN11"", ""notes"": ""Most commonly mutated gene, accounting for approximately 50-60% of cases. Encodes SHP2 phosphatase. Gain-of-function mutations destabilize the autoinhibited conformation leading to increased phosphatase activity. Associated with pulmonary stenosis but lower HCM risk.""}"
5605	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	1	SOS1			OCCASIONAL						Pathogenic Variants																										Accounts for 10-20% of PTPN11-negative cases (approximately 10% overall). Encodes a RAS guanine nucleotide exchange factor. Gain-of-function mutations enhance RAS-GTP loading.																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""OCCASIONAL"", ""name"": ""SOS1"", ""notes"": ""Accounts for 10-20% of PTPN11-negative cases (approximately 10% overall). Encodes a RAS guanine nucleotide exchange factor. Gain-of-function mutations enhance RAS-GTP loading.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""SOS1 mutations are a significant cause of PTPN11-negative Noonan syndrome."", ""reference"": ""PMID:17143285"", ""snippet"": ""We identified missense mutations in SOS1, which encodes an essential RAS guanine nucleotide-exchange factor (RAS-GEF), in approximately 20% of cases of Noonan syndrome without PTPN11 mutation."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""gene_term"": {""preferred_term"": ""SOS1"", ""term"": {""id"": ""hgnc:11187"", ""label"": ""SOS1""}}, ""name"": ""SOS1"", ""notes"": ""Accounts for 10-20% of PTPN11-negative cases (approximately 10% overall). Encodes a RAS guanine nucleotide exchange factor. Gain-of-function mutations enhance RAS-GTP loading.""}"
5606	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	2	RAF1			OCCASIONAL						Pathogenic Variants																										Accounts for 3-17% of cases. Strongly associated with hypertrophic cardiomyopathy (up to 95% of patients with RAF1 mutations have HCM).																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""OCCASIONAL"", ""name"": ""RAF1"", ""notes"": ""Accounts for 3-17% of cases. Strongly associated with hypertrophic cardiomyopathy (up to 95% of patients with RAF1 mutations have HCM).""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""RAF1 mutations account for approximately 3% of Noonan syndrome."", ""reference"": ""PMID:17603483"", ""snippet"": ""18 of 231 individuals with Noonan syndrome without known mutations (corresponding to 3% of all affected individuals)...have missense mutations in RAF1"", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""gene_term"": {""preferred_term"": ""RAF1"", ""term"": {""id"": ""hgnc:9829"", ""label"": ""RAF1""}}, ""name"": ""RAF1"", ""notes"": ""Accounts for 3-17% of cases. Strongly associated with hypertrophic cardiomyopathy (up to 95% of patients with RAF1 mutations have HCM).""}"
5607	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	3	RIT1			OCCASIONAL						Pathogenic Variants																										Accounts for approximately 5-10% of cases. Associated with high incidence of hypertrophic cardiomyopathy (70% of mutation-positive individuals).																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""OCCASIONAL"", ""name"": ""RIT1"", ""notes"": ""Accounts for approximately 5-10% of cases. Associated with high incidence of hypertrophic cardiomyopathy (70% of mutation-positive individuals).""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""RIT1 mutations account for approximately 9% of cases without mutations in other known genes."", ""reference"": ""PMID:23791108"", ""snippet"": ""we identified a total of nine missense, nonsynonymous mutations in RIT1...in 17 of 180 individuals (9%) with Noonan syndrome"", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""gene_term"": {""preferred_term"": ""RIT1"", ""term"": {""id"": ""hgnc:10023"", ""label"": ""RIT1""}}, ""name"": ""RIT1"", ""notes"": ""Accounts for approximately 5-10% of cases. Associated with high incidence of hypertrophic cardiomyopathy (70% of mutation-positive individuals).""}"
5608	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	4	KRAS			VERY_RARE						Pathogenic Variants																										Rare cause, less than 2% of cases. Germline activating variants often cause more severe phenotype with significant neurodevelopmental involvement.																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""VERY_RARE"", ""name"": ""KRAS"", ""notes"": ""Rare cause, less than 2% of cases. Germline activating variants often cause more severe phenotype with significant neurodevelopmental involvement.""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""KRAS mutations are a rare cause of Noonan syndrome."", ""reference"": ""PMID:17143285"", ""snippet"": ""KRAS mutations account for <5% of cases of Noonan syndrome"", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_RARE"", ""gene_term"": {""preferred_term"": ""KRAS"", ""term"": {""id"": ""hgnc:6407"", ""label"": ""KRAS""}}, ""name"": ""KRAS"", ""notes"": ""Rare cause, less than 2% of cases. Germline activating variants often cause more severe phenotype with significant neurodevelopmental involvement.""}"
5609	236	Noonan Syndrome	Noonan_Syndrome.yaml	genetic	5	LZTR1			OCCASIONAL						Pathogenic Variants																										Can cause both autosomal dominant and autosomal recessive forms. Acts as a CUL3 adaptor controlling RAS proteostasis through ubiquitination. Dominant mutations act in a dominant-negative manner.																						"{""association"": ""Pathogenic Variants"", ""frequency"": ""OCCASIONAL"", ""name"": ""LZTR1"", ""notes"": ""Can cause both autosomal dominant and autosomal recessive forms. Acts as a CUL3 adaptor controlling RAS proteostasis through ubiquitination. Dominant mutations act in a dominant-negative manner.""}"	{}	"{""association"": ""Pathogenic Variants"", ""frequency"": ""OCCASIONAL"", ""gene_term"": {""preferred_term"": ""LZTR1"", ""term"": {""id"": ""hgnc:6742"", ""label"": ""LZTR1""}}, ""name"": ""LZTR1"", ""notes"": ""Can cause both autosomal dominant and autosomal recessive forms. Acts as a CUL3 adaptor controlling RAS proteostasis through ubiquitination. Dominant mutations act in a dominant-negative manner.""}"
5656	237	Obesity	Obesity.yaml	genetic	0	FTO									Risk Factor																										Strongest common variant association																						"{""association"": ""Risk Factor"", ""name"": ""FTO"", ""notes"": ""Strongest common variant association""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FTO"", ""notes"": ""Strongest common variant association""}"
5657	237	Obesity	Obesity.yaml	genetic	1	MC4R									Risk Factor																										Appetite regulation																						"{""association"": ""Risk Factor"", ""name"": ""MC4R"", ""notes"": ""Appetite regulation""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""MC4R"", ""notes"": ""Appetite regulation""}"
5658	237	Obesity	Obesity.yaml	genetic	2	LEP									Causative																										Rare congenital leptin deficiency																						"{""association"": ""Causative"", ""name"": ""LEP"", ""notes"": ""Rare congenital leptin deficiency""}"	{}	"{""association"": ""Causative"", ""name"": ""LEP"", ""notes"": ""Rare congenital leptin deficiency""}"
5659	237	Obesity	Obesity.yaml	genetic	3	LEPR									Causative																										Rare leptin receptor deficiency																						"{""association"": ""Causative"", ""name"": ""LEPR"", ""notes"": ""Rare leptin receptor deficiency""}"	{}	"{""association"": ""Causative"", ""name"": ""LEPR"", ""notes"": ""Rare leptin receptor deficiency""}"
5660	237	Obesity	Obesity.yaml	genetic	4	POMC									Causative																										Rare, causes severe early-onset obesity																						"{""association"": ""Causative"", ""name"": ""POMC"", ""notes"": ""Rare, causes severe early-onset obesity""}"	{}	"{""association"": ""Causative"", ""name"": ""POMC"", ""notes"": ""Rare, causes severe early-onset obesity""}"
5687	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	genetic	0	PHOX2B									Risk Factor																										Ventilatory control																						"{""association"": ""Risk Factor"", ""name"": ""PHOX2B"", ""notes"": ""Ventilatory control""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PHOX2B"", ""notes"": ""Ventilatory control""}"
5688	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	genetic	1	Craniofacial genes									Risk Factor																										Anatomical predisposition																						"{""association"": ""Risk Factor"", ""name"": ""Craniofacial genes"", ""notes"": ""Anatomical predisposition""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""Craniofacial genes"", ""notes"": ""Anatomical predisposition""}"
5718	240	Osteoarthritis	Osteoarthritis.yaml	genetic	0	GDF5									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""GDF5""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Landmark genetic study establishing GDF5 as a susceptibility gene for osteoarthritis."", ""reference"": ""PMID:17384641"", ""snippet"": ""A SNP in the 5' UTR of GDF5 (+104T/C; rs143383) showed significant association (P = 1.8 x 10(-13)) with hip osteoarthritis in two independent Japanese populations."", ""supports"": ""SUPPORT""}], ""name"": ""GDF5""}"
5719	240	Osteoarthritis	Osteoarthritis.yaml	genetic	1	FRZB									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""FRZB""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FRZB""}"
5720	240	Osteoarthritis	Osteoarthritis.yaml	genetic	2	ASPN									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""ASPN""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ASPN""}"
5721	240	Osteoarthritis	Osteoarthritis.yaml	genetic	3	COL2A1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""COL2A1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""COL2A1""}"
5740	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	genetic	0	COL1A1 Null Mutations									Causative																										"Heterozygous null mutations in COL1A1 account for most OI type I cases. These include nonsense mutations, frameshift mutations, and splice site mutations that lead to nonsense-mediated decay of the mutant transcript. The 50% reduction in collagen quantity produces a milder phenotype than structural mutations.
"																						"{""association"": ""Causative"", ""name"": ""COL1A1 Null Mutations"", ""notes"": ""Heterozygous null mutations in COL1A1 account for most OI type I cases. These include nonsense mutations, frameshift mutations, and splice site mutations that lead to nonsense-mediated decay of the mutant transcript. The 50% reduction in collagen quantity produces a milder phenotype than structural mutations.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study of 23 individuals from 21 families showed null allele-associated mRNA reduction, establishing the molecular basis of COL1A1 haploinsufficiency."", ""reference"": ""PMID:1353940"", ""snippet"": ""In each case there was marked diminution in steady-state mRNA levels from one COL1A1 allele. Loss of an allele through deletion or rearrangement was not the cause of the diminished COL1A1 mRNA levels."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Demonstrates that OI type I is specifically associated with COL1A1 mutations, with common null-allele mutation sequences identified."", ""reference"": ""PMID:9443882"", ""snippet"": ""Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1 Null Mutations"", ""notes"": ""Heterozygous null mutations in COL1A1 account for most OI type I cases. These include nonsense mutations, frameshift mutations, and splice site mutations that lead to nonsense-mediated decay of the mutant transcript. The 50% reduction in collagen quantity produces a milder phenotype than structural mutations.\n""}"
5752	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	genetic	0	COL1A1/COL1A2 Structural Mutations									Causative																										"Glycine substitutions in the Gly-X-Y repeat of COL1A1 or COL1A2 are the most common cause. Mutations closer to the C-terminus of the collagen molecule tend to be more severe due to the C-to-N direction of helix folding. Large deletions and splice mutations that preserve reading frame can also cause type II OI.
"																						"{""association"": ""Causative"", ""name"": ""COL1A1/COL1A2 Structural Mutations"", ""notes"": ""Glycine substitutions in the Gly-X-Y repeat of COL1A1 or COL1A2 are the most common cause. Mutations closer to the C-terminus of the collagen molecule tend to be more severe due to the C-to-N direction of helix folding. Large deletions and splice mutations that preserve reading frame can also cause type II OI.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive review identifying glycine substitutions in Gly-X-Y triplets as the predominant mutation type in perinatal lethal OI."", ""reference"": ""PMID:7643358"", ""snippet"": ""Perinatal lethal osteogenesis imperfecta is the result of heterozygous mutations of the COL1A1 and COL1A2 genes that encode the alpha 1(I) and alpha 2(I) chains of type I collagen, respectively. Point mutations resulting in the substitution of Gly residues in Gly-X-Y amino acid triplets of the triple helical domain of the alpha 1(I) or alpha 2(I) chains are the most frequent mutations."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1/COL1A2 Structural Mutations"", ""notes"": ""Glycine substitutions in the Gly-X-Y repeat of COL1A1 or COL1A2 are the most common cause. Mutations closer to the C-terminus of the collagen molecule tend to be more severe due to the C-to-N direction of helix folding. Large deletions and splice mutations that preserve reading frame can also cause type II OI.\n""}"
5763	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	genetic	0	COL1A1/COL1A2 Mutations									Causative																										"Predominantly glycine substitutions in COL1A1 or COL1A2. Mutations in COL1A1 tend to produce more severe phenotypes than equivalent mutations in COL1A2 because the collagen trimer contains two alpha1 chains and one alpha2 chain. Mutation position along the helix affects severity.
"																						"{""association"": ""Causative"", ""name"": ""COL1A1/COL1A2 Mutations"", ""notes"": ""Predominantly glycine substitutions in COL1A1 or COL1A2. Mutations in COL1A1 tend to produce more severe phenotypes than equivalent mutations in COL1A2 because the collagen trimer contains two alpha1 chains and one alpha2 chain. Mutation position along the helix affects severity.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Explains genotype-phenotype correlation in OI, with mutation location and type determining severity across the OI spectrum."", ""reference"": ""PMID:7643358"", ""snippet"": ""The severity of the clinical phenotype appears to be related to the type of mutation, its location in the alpha chain, the surrounding amino acid sequences, and the level of expression of the mutant allele."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1/COL1A2 Mutations"", ""notes"": ""Predominantly glycine substitutions in COL1A1 or COL1A2. Mutations in COL1A1 tend to produce more severe phenotypes than equivalent mutations in COL1A2 because the collagen trimer contains two alpha1 chains and one alpha2 chain. Mutation position along the helix affects severity.\n""}"
5778	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	genetic	0	COL1A1/COL1A2 Mutations									Causative																										"Structural mutations including glycine substitutions and splice site mutations. Mutations in COL1A2 are more common in type IV than in type III, possibly explaining the milder phenotype given the 2:1 ratio of alpha1 to alpha2 chains in type I collagen.
"																						"{""association"": ""Causative"", ""name"": ""COL1A1/COL1A2 Mutations"", ""notes"": ""Structural mutations including glycine substitutions and splice site mutations. Mutations in COL1A2 are more common in type IV than in type III, possibly explaining the milder phenotype given the 2:1 ratio of alpha1 to alpha2 chains in type I collagen.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Establishes that mutation type and location determine phenotypic severity, explaining the variable expressivity in moderate OI type IV."", ""reference"": ""PMID:7643358"", ""snippet"": ""The severity of the clinical phenotype appears to be related to the type of mutation, its location in the alpha chain, the surrounding amino acid sequences, and the level of expression of the mutant allele."", ""supports"": ""SUPPORT""}], ""name"": ""COL1A1/COL1A2 Mutations"", ""notes"": ""Structural mutations including glycine substitutions and splice site mutations. Mutations in COL1A2 are more common in type IV than in type III, possibly explaining the milder phenotype given the 2:1 ratio of alpha1 to alpha2 chains in type I collagen.\n""}"
5790	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	genetic	0	IFITM5 c.-14C>T Mutation									Causative																										"A single recurrent mutation (c.-14C>T) in the 5'UTR of IFITM5 causes all cases of OI type V. This creates an upstream AUG start codon, resulting in an extended protein with 5 additional N-terminal amino acids (MALEP). This is a gain-of-function mechanism distinct from the collagen defects in classical OI.
"																						"{""association"": ""Causative"", ""name"": ""IFITM5 c.-14C>T Mutation"", ""notes"": ""A single recurrent mutation (c.-14C>T) in the 5'UTR of IFITM5 causes all cases of OI type V. This creates an upstream AUG start codon, resulting in an extended protein with 5 additional N-terminal amino acids (MALEP). This is a gain-of-function mechanism distinct from the collagen defects in classical OI.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Landmark paper identifying the single recurrent IFITM5 c.-14C>T mutation as the cause of all OI type V cases."", ""reference"": ""PMID:22863190"", ""snippet"": ""Using linkage analysis in a four-generation family and whole-exome sequencing, we identified a heterozygous mutation of c.-14C>T in the 5'-untranslated region of a gene encoding interferon-induced transmembrane protein 5 (IFITM5). It completely cosegregated with the disease in three families and occurred de novo in five simplex individuals."", ""supports"": ""SUPPORT""}], ""name"": ""IFITM5 c.-14C>T Mutation"", ""notes"": ""A single recurrent mutation (c.-14C>T) in the 5'UTR of IFITM5 causes all cases of OI type V. This creates an upstream AUG start codon, resulting in an extended protein with 5 additional N-terminal amino acids (MALEP). This is a gain-of-function mechanism distinct from the collagen defects in classical OI.\n""}"
5803	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	genetic	0	CRTAP Mutations									Causative																										"Biallelic loss-of-function mutations in CRTAP cause type VII OI. A common founder mutation (IVS1+1G>A) is found in West African populations. The severity of the phenotype correlates with the residual CRTAP function.
"																						"{""association"": ""Causative"", ""name"": ""CRTAP Mutations"", ""notes"": ""Biallelic loss-of-function mutations in CRTAP cause type VII OI. A common founder mutation (IVS1+1G>A) is found in West African populations. The severity of the phenotype correlates with the residual CRTAP function.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Original paper identifying CRTAP mutations as cause of recessive OI types, establishing a new mechanism for OI distinct from collagen structural mutations."", ""reference"": ""PMID:17055431"", ""snippet"": ""In humans, CRTAP mutations are associated with the clinical spectrum of recessive osteogenesis imperfecta, including the type II and VII forms. Hence, dysregulation of prolyl 3-hydroxylation is a mechanism for connective tissue disease."", ""supports"": ""SUPPORT""}], ""name"": ""CRTAP Mutations"", ""notes"": ""Biallelic loss-of-function mutations in CRTAP cause type VII OI. A common founder mutation (IVS1+1G>A) is found in West African populations. The severity of the phenotype correlates with the residual CRTAP function.\n""}"
5827	247	Osteoporosis	Osteoporosis.yaml	genetic	0	LRP5									Risk Factor																										Wnt signaling pathway																						"{""association"": ""Risk Factor"", ""name"": ""LRP5"", ""notes"": ""Wnt signaling pathway""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""LRP5"", ""notes"": ""Wnt signaling pathway""}"
5828	247	Osteoporosis	Osteoporosis.yaml	genetic	1	SOST									Risk Factor																										Encodes sclerostin																						"{""association"": ""Risk Factor"", ""name"": ""SOST"", ""notes"": ""Encodes sclerostin""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SOST"", ""notes"": ""Encodes sclerostin""}"
5829	247	Osteoporosis	Osteoporosis.yaml	genetic	2	ESR1									Risk Factor																										Estrogen receptor																						"{""association"": ""Risk Factor"", ""name"": ""ESR1"", ""notes"": ""Estrogen receptor""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""ESR1"", ""notes"": ""Estrogen receptor""}"
5830	247	Osteoporosis	Osteoporosis.yaml	genetic	3	VDR									Risk Factor																										Vitamin D receptor																						"{""association"": ""Risk Factor"", ""name"": ""VDR"", ""notes"": ""Vitamin D receptor""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""VDR"", ""notes"": ""Vitamin D receptor""}"
5855	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	genetic	0	PIK3CA									Somatic Activating Mutations																										PIK3CA (3q26.32) encodes p110, the catalytic subunit of class IA PI3K. Activating mutations occur somatically. Hotspot mutations: E542K and E545K in exon 9 (helical domain) disrupt inhibitory interaction with p85 regulatory subunit; H1047R in exon 20 (kinase domain) enhances membrane binding and catalytic activity. Both mechanisms result in constitutive kinase activity.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA (3q26.32) encodes p110, the catalytic subunit of class IA PI3K. Activating mutations occur somatically. Hotspot mutations: E542K and E545K in exon 9 (helical domain) disrupt inhibitory interaction with p85 regulatory subunit; H1047R in exon 20 (kinase domain) enhances membrane binding and catalytic activity. Both mechanisms result in constitutive kinase activity.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Activating Mutations"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""PIK3CA"", ""notes"": ""PIK3CA (3q26.32) encodes p110, the catalytic subunit of class IA PI3K. Activating mutations occur somatically. Hotspot mutations: E542K and E545K in exon 9 (helical domain) disrupt inhibitory interaction with p85 regulatory subunit; H1047R in exon 20 (kinase domain) enhances membrane binding and catalytic activity. Both mechanisms result in constitutive kinase activity.""}"
5880	250	Parkinson's Disease	Parkinsons_Disease.yaml	genetic	0	SNCA									Causative																										Alpha-synuclein gene, autosomal dominant forms																						"{""association"": ""Causative"", ""name"": ""SNCA"", ""notes"": ""Alpha-synuclein gene, autosomal dominant forms""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease."", ""reference"": ""PMID:9197268"", ""snippet"": ""A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."", ""supports"": ""SUPPORT""}], ""name"": ""SNCA"", ""notes"": ""Alpha-synuclein gene, autosomal dominant forms""}"
5881	250	Parkinson's Disease	Parkinsons_Disease.yaml	genetic	1	LRRK2									Risk Factor																										Most common genetic cause of late-onset PD																						"{""association"": ""Risk Factor"", ""name"": ""LRRK2"", ""notes"": ""Most common genetic cause of late-onset PD""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor."", ""reference"": ""PMID:19945904"", ""snippet"": ""The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."", ""supports"": ""SUPPORT""}], ""name"": ""LRRK2"", ""notes"": ""Most common genetic cause of late-onset PD""}"
5882	250	Parkinson's Disease	Parkinsons_Disease.yaml	genetic	2	GBA									Risk Factor																										Glucocerebrosidase, major genetic risk factor																						"{""association"": ""Risk Factor"", ""name"": ""GBA"", ""notes"": ""Glucocerebrosidase, major genetic risk factor""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor."", ""reference"": ""PMID:30097731"", ""snippet"": ""DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."", ""supports"": ""SUPPORT""}], ""name"": ""GBA"", ""notes"": ""Glucocerebrosidase, major genetic risk factor""}"
5883	250	Parkinson's Disease	Parkinsons_Disease.yaml	genetic	3	PARK2									Causative																										Parkin gene, early-onset autosomal recessive																						"{""association"": ""Causative"", ""name"": ""PARK2"", ""notes"": ""Parkin gene, early-onset autosomal recessive""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""This establishes Parkin (PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role."", ""reference"": ""PMID:25611507"", ""snippet"": ""Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."", ""supports"": ""SUPPORT""}], ""name"": ""PARK2"", ""notes"": ""Parkin gene, early-onset autosomal recessive""}"
5884	250	Parkinson's Disease	Parkinsons_Disease.yaml	genetic	4	PINK1									Causative																										Mitochondrial kinase, autosomal recessive																						"{""association"": ""Causative"", ""name"": ""PINK1"", ""notes"": ""Mitochondrial kinase, autosomal recessive""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD."", ""reference"": ""PMID:25611507"", ""snippet"": ""Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."", ""supports"": ""SUPPORT""}], ""name"": ""PINK1"", ""notes"": ""Mitochondrial kinase, autosomal recessive""}"
5923	251	Pars Planitis	Pars_Planitis.yaml	genetic	0	HLA-DR15									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR15""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""HLA-DR15 has been linked to immunogenetic susceptibility in pars planitis."", ""reference"": ""PMID:27051493"", ""snippet"": ""Associations between pars planitis and HLA-DR2, -DR15, -B51 and -DRB1*0802 haplotypes have been described suggesting an immunogenetic predisposition."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DR15""}"
5924	251	Pars Planitis	Pars_Planitis.yaml	genetic	1	HLA-B51									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-B51""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""HLA-B51 is reported among haplotypes associated with pars planitis, supporting a genetic component."", ""reference"": ""PMID:27051493"", ""snippet"": ""Associations between pars planitis and HLA-DR2, -DR15, -B51 and -DRB1*0802 haplotypes have been described suggesting an immunogenetic predisposition."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-B51""}"
5969	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	genetic	0	HLA-DRB1*04									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*04""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""Strong HLA class II associations support the role of autoreactive CD4+ T cells in recognizing desmoglein epitopes and driving autoantibody production."", ""reference"": ""PMID:10878487"", ""snippet"": ""The involvement of CD4+ T lymphocytes in PV has been suggested by the strong association with distinct HLA class II alleles."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1*04""}"
5970	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	genetic	1	HLA-DRB1*14									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*14""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*14""}"
5992	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	genetic	0	9p21.3 locus									Risk Factor																										Same as CAD																						"{""association"": ""Risk Factor"", ""name"": ""9p21.3 locus"", ""notes"": ""Same as CAD""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""9p21.3 locus"", ""notes"": ""Same as CAD""}"
5993	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	genetic	1	PCSK9									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""PCSK9""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PCSK9""}"
5994	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	genetic	2	LPA									Risk Factor																										Lipoprotein(a)																						"{""association"": ""Risk Factor"", ""name"": ""LPA"", ""notes"": ""Lipoprotein(a)""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""LPA"", ""notes"": ""Lipoprotein(a)""}"
6014	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	0	PEX1									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""PEX1""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The statement is supported as it mentions that mutations in the PEX1 gene are among the most prevalent causes of Zellweger syndrome, which is a type of PBD."", ""reference"": ""PMID:33955040"", ""snippet"": ""Zellweger syndrome (ZS) is the foremost common and severe phenotype within the heterogeneous ZSD. However, missense mutations encode proteins with residual functions, which are associated with phenotypes that are milder than ZS. Mutations in the PEX1 gene are among the most prevalent."", ""supports"": ""SUPPORT""}], ""name"": ""PEX1""}"
6015	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	1	PEX6									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""PEX6""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This statement indicates that mutations in PEX genes, including PEX6, are foundational to the development of peroxisome biogenesis disorders."", ""reference"": ""PMID:17055079"", ""snippet"": ""Defects in PEX genes impair peroxisome assembly and multiple metabolic pathways confined to this organelle, thus providing the biochemical and molecular bases of the peroxisome biogenesis disorders (PBD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This paper discusses PEX26 in detail but also underscores the critical function of PEX6 in peroxisome biogenesis."", ""reference"": ""PMID:15858711"", ""snippet"": ""Matsumoto and colleagues recently identified PEX26 as the gene responsible for complementation group 8 of the peroxisome biogenesis disorders... Here, we identify new PEX26 disease alleles, localize the PEX6-binding domain to the N-terminal half of the protein (aa 29-174), and show that, at the cellular level, PEX26 deficiency impairs peroxisomal import of both PTS1- and PTS2-targeted matrix proteins."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report directly links pathogenic variants in PEX6 to a specific case of peroxisome biogenesis disorder."", ""reference"": ""PMID:36980088"", ""snippet"": ""Genetic testing revealed a mutation of the PEX6 (Peroxisomal Biogenesis Factor 6) gene, and the metabolic profile was consistent with the diagnosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""This paper confirms that mutations in PEX6, similar to those in PEX1, are linked to peroxisome biogenesis disorders."", ""reference"": ""PMID:33955040"", ""snippet"": ""Autosomal recessive disorder of the Zellweger spectrum (ZSD) is a major subset of peroxisome biogenesis disorders (PBDs) that can be caused by mutations in any of the 14 PEX genes. ... Mutations in the PEX1 gene are among the most prevalent. PEX1 and PEX6 proteins, belonging to the AAA family of ATPases, form a hexameric complex, which is associated with peroxisome membranes and essential for peroxisome biology."", ""supports"": ""SUPPORT""}, {""explanation"": ""This research clarifies the structure and mutations of PEX6, noting its role in peroxisome biogenesis disorders."", ""reference"": ""PMID:10408779"", ""snippet"": ""The PEX6 (peroxisome assembly factor-2, PAF-2) gene... restores peroxisome assembly in fibroblasts from peroxisome biogenesis disorder patients belonging to complementation group C (group 4 in the United States)."", ""supports"": ""SUPPORT""}], ""name"": ""PEX6""}"
6016	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	2	PEX13									Pathogenic Variants																										PEX13 is part of the docking complex for peroxisomal protein import																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX13"", ""notes"": ""PEX13 is part of the docking complex for peroxisomal protein import""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX13"", ""notes"": ""PEX13 is part of the docking complex for peroxisomal protein import""}"
6017	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	3	PEX26									Pathogenic Variants																										PEX26 anchors the PEX1-PEX6 AAA+ ATPase complex to the peroxisomal membrane																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX26"", ""notes"": ""PEX26 anchors the PEX1-PEX6 AAA+ ATPase complex to the peroxisomal membrane""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX26"", ""notes"": ""PEX26 anchors the PEX1-PEX6 AAA+ ATPase complex to the peroxisomal membrane""}"
6018	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	4	PEX2									Pathogenic Variants																										Part of the RING E3 ubiquitin ligase complex involved in PEX5 ubiquitination																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX2"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex involved in PEX5 ubiquitination""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX2"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex involved in PEX5 ubiquitination""}"
6019	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	5	PEX10									Pathogenic Variants																										Part of the RING E3 ubiquitin ligase complex involved in peroxisomal matrix protein import																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX10"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex involved in peroxisomal matrix protein import""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX10"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex involved in peroxisomal matrix protein import""}"
6020	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	6	PEX12									Pathogenic Variants																										Part of the RING E3 ubiquitin ligase complex																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX12"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX12"", ""notes"": ""Part of the RING E3 ubiquitin ligase complex""}"
6021	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	7	PEX5									Pathogenic Variants																										PTS1 receptor for peroxisomal protein import																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX5"", ""notes"": ""PTS1 receptor for peroxisomal protein import""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX5"", ""notes"": ""PTS1 receptor for peroxisomal protein import""}"
6022	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	8	PEX7									Pathogenic Variants																										PTS2 receptor for peroxisomal protein import																						"{""association"": ""Pathogenic Variants"", ""name"": ""PEX7"", ""notes"": ""PTS2 receptor for peroxisomal protein import""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""PEX7"", ""notes"": ""PTS2 receptor for peroxisomal protein import""}"
6023	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	genetic	9	Other PEX Genes									Pathogenic Variants																										Approximately 14 PEX genes are known to cause peroxisome biogenesis disorders when mutated																						"{""association"": ""Pathogenic Variants"", ""name"": ""Other PEX Genes"", ""notes"": ""Approximately 14 PEX genes are known to cause peroxisome biogenesis disorders when mutated""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This reference indicates that pathogenic variants in other PEX genes are associated with Peroxisome Biogenesis Disorder (PBD)."", ""reference"": ""PMID:10904262"", ""snippet"": ""Recent studies have identified the PEX genes that are mutated in 11 of the 12 known complementation groups of PBD patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference primarily discusses Perrault syndrome, it confirms that variants in PEX genes such as PEX6 are associated with peroxisomal biogenesis disorders."", ""reference"": ""PMID:32399598"", ""snippet"": ""For the first time, we show that pathogenic variants in PEX6 can present clinically as Perrault syndrome... PEX6 encodes a peroxisomal biogenesis factor."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights PEX26 gene variants contributing to peroxisomal disorders which fall under the broader category of peroxisome biogenesis disorders."", ""reference"": ""PMID:34804114"", ""snippet"": ""Pathogenic variants in the PEX26 gene lead to peroxisomal disorders of the full Zellweger spectrum continuum."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports that PEX genes are crucial for peroxisome biogenesis, implying that pathogenic variants can lead to related disorders."", ""reference"": ""PMID:29070486"", ""snippet"": ""The biogenesis of peroxisomes requires a category of proteins named peroxins, which are encoded by the PEX genes."", ""supports"": ""SUPPORT""}], ""name"": ""Other PEX Genes"", ""notes"": ""Approximately 14 PEX genes are known to cause peroxisome biogenesis disorders when mutated""}"
6062	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	genetic	0	STK11 (Serine/threonine kinase 11, also called LKB1)																																			"Germline mutations in STK11 cause autosomal dominant Peutz-Jeghers syndrome. Over 400 different mutations have been identified. The second STK11 allele is somatically inactivated in polyp tissue (two-hit model). Mutation types include nonsense, frameshift, splice site, and missense mutations.
"																						"{""name"": ""STK11 (Serine/threonine kinase 11, also called LKB1)"", ""notes"": ""Germline mutations in STK11 cause autosomal dominant Peutz-Jeghers syndrome. Over 400 different mutations have been identified. The second STK11 allele is somatically inactivated in polyp tissue (two-hit model). Mutation types include nonsense, frameshift, splice site, and missense mutations.\n""}"	{}	"{""evidence"": [{""explanation"": ""Confirms germline STK11 mutations as the causative genetic basis for Peutz-Jeghers syndrome"", ""reference"": ""PMID:37054692"", ""snippet"": ""It is caused by germline pathogenic variants of the STK11 gene, which exhibit an autosomal dominant mode of inheritance"", ""supports"": ""SUPPORT""}], ""name"": ""STK11 (Serine/threonine kinase 11, also called LKB1)"", ""notes"": ""Germline mutations in STK11 cause autosomal dominant Peutz-Jeghers syndrome. Over 400 different mutations have been identified. The second STK11 allele is somatically inactivated in polyp tissue (two-hit model). Mutation types include nonsense, frameshift, splice site, and missense mutations.\n""}"
6063	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	genetic	1	PTEN (Phosphatase and tensin homolog)																																			"Rare STK11-negative Peutz-Jeghers-like cases have PTEN mutations. PTEN loss further enhances mTORC1 pathway activation.
"																						"{""name"": ""PTEN (Phosphatase and tensin homolog)"", ""notes"": ""Rare STK11-negative Peutz-Jeghers-like cases have PTEN mutations. PTEN loss further enhances mTORC1 pathway activation.\n""}"	{}	"{""evidence"": [{""explanation"": ""Alternative genetic mutations including PTEN can account for STK11-negative PJS-like presentations"", ""reference"": ""PMID:37377590"", ""snippet"": ""Among 19 patients with no detectable STK11 mutations, six had no pathogenic germline mutations of other genes, while 13 had other genetic mutations"", ""supports"": ""SUPPORT""}], ""name"": ""PTEN (Phosphatase and tensin homolog)"", ""notes"": ""Rare STK11-negative Peutz-Jeghers-like cases have PTEN mutations. PTEN loss further enhances mTORC1 pathway activation.\n""}"
6076	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	genetic	0	FGFR1 and FGFR2 Mutations									Causative																										"FGFR1 P252R mutation causes only mild Type 1 Pfeiffer syndrome. FGFR2 mutations are more common and can cause all three types. Severe mutations (W290C, Y340C, C342R) in FGFR2 are associated with Types 2 and 3.
"																						"{""association"": ""Causative"", ""name"": ""FGFR1 and FGFR2 Mutations"", ""notes"": ""FGFR1 P252R mutation causes only mild Type 1 Pfeiffer syndrome. FGFR2 mutations are more common and can cause all three types. Severe mutations (W290C, Y340C, C342R) in FGFR2 are associated with Types 2 and 3.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""First identification that FGFR1 mutations cause Pfeiffer syndrome, establishing the genetic basis of the disorder."", ""reference"": ""PMID:7874169"", ""snippet"": ""mutations in the fibroblast growth factor receptor-1 (FGFR1) gene, which maps to 8p, cause one form of familial Pfeiffer syndrome"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms the mutation spectrum in both FGFR1 and FGFR2 genes causing Pfeiffer syndrome."", ""reference"": ""PMID:23348274"", ""snippet"": ""Polymerase chain reaction sequencing of FGFR1 exon 5 and FGFR2 exons 8, 10, 15, 16, and 17 was performed in all PS patients and revealed 9 recurrent mutations in all patients."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Documents that specific FGFR2 mutations are associated with severe forms of Pfeiffer syndrome."", ""reference"": ""PMID:23348274"", ""snippet"": ""The most frequently detected mutation, p.S351C, was associated with the severe form of PS in the Thai population."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms that FGFR1 P252R mutation is associated with milder phenotypic presentations of Pfeiffer syndrome."", ""reference"": ""PMID:23348274"", ""snippet"": ""the p.P252R mutation in FGFR1 was detected in 1 PS patient with unilateral coronal craniosynostosis expanding the phenotypic spectrum of PS with this particular mutation."", ""supports"": ""SUPPORT""}], ""name"": ""FGFR1 and FGFR2 Mutations"", ""notes"": ""FGFR1 P252R mutation causes only mild Type 1 Pfeiffer syndrome. FGFR2 mutations are more common and can cause all three types. Severe mutations (W290C, Y340C, C342R) in FGFR2 are associated with Types 2 and 3.\n""}"
6090	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	genetic	0	BCR-ABL1 Fusion									Defining Genetic Lesion																										The t(9;22)(q34;q11) translocation creates BCR-ABL1 fusion. Ph+ ALL typically expresses p190 BCR-ABL1 (minor breakpoint). The fusion kinase is constitutively active and is the primary driver of leukemia. Targetable with tyrosine kinase inhibitors.																						"{""association"": ""Defining Genetic Lesion"", ""name"": ""BCR-ABL1 Fusion"", ""notes"": ""The t(9;22)(q34;q11) translocation creates BCR-ABL1 fusion. Ph+ ALL typically expresses p190 BCR-ABL1 (minor breakpoint). The fusion kinase is constitutively active and is the primary driver of leukemia. Targetable with tyrosine kinase inhibitors.""}"	{}	"{""association"": ""Defining Genetic Lesion"", ""name"": ""BCR-ABL1 Fusion"", ""notes"": ""The t(9;22)(q34;q11) translocation creates BCR-ABL1 fusion. Ph+ ALL typically expresses p190 BCR-ABL1 (minor breakpoint). The fusion kinase is constitutively active and is the primary driver of leukemia. Targetable with tyrosine kinase inhibitors.""}"
6091	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	genetic	1	IKZF1 Deletion									Cooperating Mutation																										IKZF1 (Ikaros) deletions occur in 70-80% of Ph+ ALL and confer inferior prognosis. Loss of Ikaros removes a brake on proliferation and impairs B-cell development. Defines Ph-like ALL when BCR-ABL1 is absent.																						"{""association"": ""Cooperating Mutation"", ""name"": ""IKZF1 Deletion"", ""notes"": ""IKZF1 (Ikaros) deletions occur in 70-80% of Ph+ ALL and confer inferior prognosis. Loss of Ikaros removes a brake on proliferation and impairs B-cell development. Defines Ph-like ALL when BCR-ABL1 is absent.""}"	{}	"{""association"": ""Cooperating Mutation"", ""name"": ""IKZF1 Deletion"", ""notes"": ""IKZF1 (Ikaros) deletions occur in 70-80% of Ph+ ALL and confer inferior prognosis. Loss of Ikaros removes a brake on proliferation and impairs B-cell development. Defines Ph-like ALL when BCR-ABL1 is absent.""}"
6118	259	Phenylketonuria	Phenylketonuria.yaml	genetic	0	PAH									Causative																										Autosomal recessive, over 1000 mutations described																						"{""association"": ""Causative"", ""name"": ""PAH"", ""notes"": ""Autosomal recessive, over 1000 mutations described""}"	{}	"{""association"": ""Causative"", ""name"": ""PAH"", ""notes"": ""Autosomal recessive, over 1000 mutations described""}"
6139	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	genetic	0	SDHB									Germline Loss-of-Function Mutations																										SDHB mutations are associated with extra-adrenal sympathetic paraganglioma and high malignancy risk (30-40%). Lifelong surveillance required.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""SDHB"", ""notes"": ""SDHB mutations are associated with extra-adrenal sympathetic paraganglioma and high malignancy risk (30-40%). Lifelong surveillance required.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""SDHB"", ""notes"": ""SDHB mutations are associated with extra-adrenal sympathetic paraganglioma and high malignancy risk (30-40%). Lifelong surveillance required.""}"
6140	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	genetic	1	SDHD									Germline Loss-of-Function Mutations																										SDHD mutations cause hereditary paraganglioma syndrome with predisposition to head and neck paragangliomas. Parent-of-origin effect with disease expression only with paternal transmission.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""SDHD"", ""notes"": ""SDHD mutations cause hereditary paraganglioma syndrome with predisposition to head and neck paragangliomas. Parent-of-origin effect with disease expression only with paternal transmission.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""SDHD"", ""notes"": ""SDHD mutations cause hereditary paraganglioma syndrome with predisposition to head and neck paragangliomas. Parent-of-origin effect with disease expression only with paternal transmission.""}"
6141	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	genetic	2	VHL									Germline Loss-of-Function Mutations																										VHL mutations cause von Hippel-Lindau syndrome with pheochromocytoma risk of 10-20%. Associated with clear cell renal cell carcinoma and other tumors.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""VHL"", ""notes"": ""VHL mutations cause von Hippel-Lindau syndrome with pheochromocytoma risk of 10-20%. Associated with clear cell renal cell carcinoma and other tumors.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""VHL"", ""notes"": ""VHL mutations cause von Hippel-Lindau syndrome with pheochromocytoma risk of 10-20%. Associated with clear cell renal cell carcinoma and other tumors.""}"
6142	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	genetic	3	RET									Germline Activating Mutations																										RET mutations in MEN2 syndrome cause pheochromocytoma in approximately 50% of MEN2A and most MEN2B patients. Typically bilateral and benign.																						"{""association"": ""Germline Activating Mutations"", ""name"": ""RET"", ""notes"": ""RET mutations in MEN2 syndrome cause pheochromocytoma in approximately 50% of MEN2A and most MEN2B patients. Typically bilateral and benign.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Activating Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""RET"", ""notes"": ""RET mutations in MEN2 syndrome cause pheochromocytoma in approximately 50% of MEN2A and most MEN2B patients. Typically bilateral and benign.""}"
6143	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	genetic	4	NF1									Germline Loss-of-Function Mutations																										Neurofibromatosis type 1 is associated with pheochromocytoma in approximately 1-5% of patients. Usually unilateral and benign.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""NF1"", ""notes"": ""Neurofibromatosis type 1 is associated with pheochromocytoma in approximately 1-5% of patients. Usually unilateral and benign.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""NF1"", ""notes"": ""Neurofibromatosis type 1 is associated with pheochromocytoma in approximately 1-5% of patients. Usually unilateral and benign.""}"
6164	261	Pick Disease	Pick_Disease.yaml	genetic	0	MAPT						Mendelian			Germline Mutation																										The MAPT gene encodes tau protein. Specific mutations like K281 cause familial Pick's disease with 3R tau inclusions forming Pick bodies. Most cases are sporadic, but rare familial cases demonstrate Mendelian inheritance.																						"{""association"": ""Germline Mutation"", ""name"": ""MAPT"", ""notes"": ""The MAPT gene encodes tau protein. Specific mutations like K281 cause familial Pick's disease with 3R tau inclusions forming Pick bodies. Most cases are sporadic, but rare familial cases demonstrate Mendelian inheritance."", ""subtype"": ""Mendelian""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""This establishes that MAPT K281 mutation causes familial Pick's disease with characteristic 3R tau pathology."", ""reference"": ""PMID:37351604"", ""snippet"": ""Two siblings with deletion mutation K281 in MAPT developed frontotemporal dementia. At autopsy, numerous inclusions of hyperphosphorylated 3R Tau were present in neurons and glial cells of neocortex and some subcortical regions, including hippocampus, caudate/putamen and globus pallidus."", ""supports"": ""SUPPORT""}], ""name"": ""MAPT"", ""notes"": ""The MAPT gene encodes tau protein. Specific mutations like K281 cause familial Pick's disease with 3R tau inclusions forming Pick bodies. Most cases are sporadic, but rare familial cases demonstrate Mendelian inheritance."", ""subtype"": ""Mendelian""}"
6165	261	Pick Disease	Pick_Disease.yaml	genetic	1	MAPT						Haplotype			Risk Factor																										The MAPT H2 haplotype is associated with increased risk of Pick's disease compared to the H1 haplotype in sporadic cases.																						"{""association"": ""Risk Factor"", ""name"": ""MAPT"", ""notes"": ""The MAPT H2 haplotype is associated with increased risk of Pick's disease compared to the H1 haplotype in sporadic cases."", ""subtype"": ""Haplotype""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This demonstrates a genetic risk factor for sporadic Pick's disease through MAPT haplotype variation."", ""reference"": ""PMID:38631765"", ""snippet"": ""The MAPT H2 haplotype was associated with increased risk of Pick's disease compared with the H1 haplotype (OR 135 ... p=00021)"", ""supports"": ""SUPPORT""}], ""name"": ""MAPT"", ""notes"": ""The MAPT H2 haplotype is associated with increased risk of Pick's disease compared to the H1 haplotype in sporadic cases."", ""subtype"": ""Haplotype""}"
6166	261	Pick Disease	Pick_Disease.yaml	genetic	2	GRN						Mendelian			Germline Mutation																										GRN mutations cause frontotemporal lobar degeneration (FTLD), which can present with clinical features overlapping with Pick's disease, though pathologically they are distinct (GRN-FTLD typically shows TDP-43, not tau pathology).																						"{""association"": ""Germline Mutation"", ""name"": ""GRN"", ""notes"": ""GRN mutations cause frontotemporal lobar degeneration (FTLD), which can present with clinical features overlapping with Pick's disease, though pathologically they are distinct (GRN-FTLD typically shows TDP-43, not tau pathology)."", ""subtype"": ""Mendelian""}"	{}	"{""association"": ""Germline Mutation"", ""evidence"": [{""explanation"": ""GRN mutations cause FTLD which can clinically mimic Pick's disease, though the pathology differs (TDP-43 vs tau)."", ""reference"": ""PMID:28890134"", ""snippet"": ""Heterozygous loss-of-function (LOF) mutations in the human progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of haploinsufficiency."", ""supports"": ""PARTIAL""}], ""name"": ""GRN"", ""notes"": ""GRN mutations cause frontotemporal lobar degeneration (FTLD), which can present with clinical features overlapping with Pick's disease, though pathologically they are distinct (GRN-FTLD typically shows TDP-43, not tau pathology)."", ""subtype"": ""Mendelian""}"
6218	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	genetic	0	PKD1 Mutations									Causative																										Accounts for approximately 85% of ADPKD cases; encodes polycystin-1; typically more severe phenotype with earlier onset of ESRD																						"{""association"": ""Causative"", ""name"": ""PKD1 Mutations"", ""notes"": ""Accounts for approximately 85% of ADPKD cases; encodes polycystin-1; typically more severe phenotype with earlier onset of ESRD""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""JAMA review quantifies PKD1 as the predominant cause of ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."", ""supports"": ""SUPPORT""}], ""name"": ""PKD1 Mutations"", ""notes"": ""Accounts for approximately 85% of ADPKD cases; encodes polycystin-1; typically more severe phenotype with earlier onset of ESRD""}"
6219	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	genetic	1	PKD2 Mutations									Causative																										Accounts for approximately 15% of ADPKD cases; encodes polycystin-2; milder phenotype with later onset of ESRD																						"{""association"": ""Causative"", ""name"": ""PKD2 Mutations"", ""notes"": ""Accounts for approximately 15% of ADPKD cases; encodes polycystin-2; milder phenotype with later onset of ESRD""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""JAMA review documents PKD2 as a minority but established cause of ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."", ""supports"": ""SUPPORT""}], ""name"": ""PKD2 Mutations"", ""notes"": ""Accounts for approximately 15% of ADPKD cases; encodes polycystin-2; milder phenotype with later onset of ESRD""}"
6220	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	genetic	2	PKHD1 Mutations									Causative																										Causes autosomal recessive PKD; encodes fibrocystin/polyductin																						"{""association"": ""Causative"", ""name"": ""PKHD1 Mutations"", ""notes"": ""Causes autosomal recessive PKD; encodes fibrocystin/polyductin""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Clin Nephrol study states PKHD1 mutations as the primary cause of ARPKD."", ""reference"": ""PMID:41467628"", ""snippet"": ""Autosomal recessive polycystic kidney disease (ARPKD) is a rare disorder mainly caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene."", ""supports"": ""SUPPORT""}], ""name"": ""PKHD1 Mutations"", ""notes"": ""Causes autosomal recessive PKD; encodes fibrocystin/polyductin""}"
6245	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	genetic	0	DENND1A									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""DENND1A""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""DENND1A""}"
6246	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	genetic	1	THADA									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""THADA""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""THADA""}"
6247	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	genetic	2	LHCGR									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""LHCGR""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""LHCGR""}"
6248	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	genetic	3	FSHR									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""FSHR""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""FSHR""}"
6267	266	Polycythemia Vera	Polycythemia_Vera.yaml	genetic	0	JAK2									Somatic Activating Mutations																										JAK2 V617F occurs in approximately 95% of PV patients. JAK2 exon 12 mutations account for most remaining cases, typically presenting with isolated erythrocytosis. Mutation is acquired in hematopoietic stem cells.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 95% of PV patients. JAK2 exon 12 mutations account for most remaining cases, typically presenting with isolated erythrocytosis. Mutation is acquired in hematopoietic stem cells.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 95% of PV patients. JAK2 exon 12 mutations account for most remaining cases, typically presenting with isolated erythrocytosis. Mutation is acquired in hematopoietic stem cells.""}"
6289	267	Polymyositis	Polymyositis.yaml	genetic	0	HLA-DRB1*0301									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*0301""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*0301""}"
6325	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	genetic	0	HLA-DRB1*08									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*08""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*08""}"
6326	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	genetic	1	IL12A									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL12A""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL12A""}"
6327	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	genetic	2	IL12RB2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL12RB2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL12RB2""}"
6344	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	0	DNAI1									Pathogenic Variants																										Outer dynein arm intermediate chain required for ODA integrity and docking																						"{""association"": ""Pathogenic Variants"", ""name"": ""DNAI1"", ""notes"": ""Outer dynein arm intermediate chain required for ODA integrity and docking""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This study directly links mutations in DNAI1 to the cause of primary ciliary dyskinesia."", ""reference"": ""PMID:11893720"", ""snippet"": ""Mutations in DNAI1 (IC78) cause primary ciliary dyskinesia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies causative variants in DNAI1 associated with primary ciliary dyskinesia."", ""reference"": ""PMID:35869935"", ""snippet"": ""13 rare variants were identified in patients with PCD, among which were three homozygous causative variants (including one splicing variant) in the PCD-associated genes CCDC40 and DNAI1."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study mentions DNAI1 mutations as frequent genetic defects causing primary ciliary dyskinesia."", ""reference"": ""PMID:15750039"", ""snippet"": ""The most frequent genetic defects comprise recessive mutations of DNAH5 and DNAI1, which encode outer dynein arm (ODA) components."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study links compound heterozygous DNAI1 gene defects with primary ciliary dyskinesia."", ""reference"": ""PMID:11231901"", ""snippet"": ""We identified compound heterozygous DNAI1 gene defects in three independent patients and in two of their siblings who presented with PCD and situs solitus."", ""supports"": ""SUPPORT""}], ""name"": ""DNAI1"", ""notes"": ""Outer dynein arm intermediate chain required for ODA integrity and docking""}"
6345	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	1	DNAH5									Pathogenic Variants																										Major axonemal outer dynein arm heavy chain generating motile force																						"{""association"": ""Pathogenic Variants"", ""name"": ""DNAH5"", ""notes"": ""Major axonemal outer dynein arm heavy chain generating motile force""}"	{}	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""The study reports a case of primary ciliary dyskinesia (PCD) with DNAH5 mutations, confirming the association between PCD and pathogenic variants in DNAH5."", ""reference"": ""PMID:31118369"", ""snippet"": ""A genetic examination detected compound heterozygous mutations of DNAH5 that encode ODA components."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that pathogenic variants causing PCD often result in abnormal ODAs, which are associated with DNAH5."", ""reference"": ""PMID:36727596"", ""snippet"": ""Most PCD-causing variants result in abnormal outer dynein arms (ODAs), which provide the generative force for respiratory ciliary beating and proper mucociliary clearance."", ""supports"": ""SUPPORT""}], ""name"": ""DNAH5"", ""notes"": ""Major axonemal outer dynein arm heavy chain generating motile force""}"
6346	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	2	DNAH11									Pathogenic Variants																										Outer dynein arm heavy chain often causing dyskinetic beating with near-normal ultrastructure; associated with milder lung function decline																						"{""association"": ""Pathogenic Variants"", ""name"": ""DNAH11"", ""notes"": ""Outer dynein arm heavy chain often causing dyskinetic beating with near-normal ultrastructure; associated with milder lung function decline""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""DNAH11"", ""notes"": ""Outer dynein arm heavy chain often causing dyskinetic beating with near-normal ultrastructure; associated with milder lung function decline""}"
6347	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	3	CCDC39									Pathogenic Variants																										Nexin-dynein regulatory complex scaffold for inner dynein arms; associated with severe early lung disease and low lung function																						"{""association"": ""Pathogenic Variants"", ""name"": ""CCDC39"", ""notes"": ""Nexin-dynein regulatory complex scaffold for inner dynein arms; associated with severe early lung disease and low lung function""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""CCDC39"", ""notes"": ""Nexin-dynein regulatory complex scaffold for inner dynein arms; associated with severe early lung disease and low lung function""}"
6348	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	4	CCDC40									Pathogenic Variants																										Nexin-dynein regulatory complex scaffold partnering with CCDC39; associated with severe lung function decline and possible congenital heart disease																						"{""association"": ""Pathogenic Variants"", ""name"": ""CCDC40"", ""notes"": ""Nexin-dynein regulatory complex scaffold partnering with CCDC39; associated with severe lung function decline and possible congenital heart disease""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""CCDC40"", ""notes"": ""Nexin-dynein regulatory complex scaffold partnering with CCDC39; associated with severe lung function decline and possible congenital heart disease""}"
6349	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	5	RSPH1									Pathogenic Variants																										Radial spoke head component coordinating central pair-dynein regulation																						"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH1"", ""notes"": ""Radial spoke head component coordinating central pair-dynein regulation""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH1"", ""notes"": ""Radial spoke head component coordinating central pair-dynein regulation""}"
6350	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	6	RSPH4A									Pathogenic Variants																										Radial spoke protein required for radial spoke integrity and coordinated beating																						"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH4A"", ""notes"": ""Radial spoke protein required for radial spoke integrity and coordinated beating""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH4A"", ""notes"": ""Radial spoke protein required for radial spoke integrity and coordinated beating""}"
6351	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	7	RSPH9									Pathogenic Variants																										Radial spoke head subunit impacting central pair-radial spoke interactions																						"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH9"", ""notes"": ""Radial spoke head subunit impacting central pair-radial spoke interactions""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""RSPH9"", ""notes"": ""Radial spoke head subunit impacting central pair-radial spoke interactions""}"
6352	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	8	CCNO									Pathogenic Variants																										Required for centriole amplification and multiciliogenesis; associated with oligocilia and very severe early disease with very low lung function																						"{""association"": ""Pathogenic Variants"", ""name"": ""CCNO"", ""notes"": ""Required for centriole amplification and multiciliogenesis; associated with oligocilia and very severe early disease with very low lung function""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""CCNO"", ""notes"": ""Required for centriole amplification and multiciliogenesis; associated with oligocilia and very severe early disease with very low lung function""}"
6353	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	9	FOXJ1									Pathogenic Variants																										Master transcription factor regulating motile ciliogenesis; can present in autosomal dominant fashion																						"{""association"": ""Pathogenic Variants"", ""name"": ""FOXJ1"", ""notes"": ""Master transcription factor regulating motile ciliogenesis; can present in autosomal dominant fashion""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""FOXJ1"", ""notes"": ""Master transcription factor regulating motile ciliogenesis; can present in autosomal dominant fashion""}"
6354	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	10	MCIDAS									Pathogenic Variants																										Drives multiciliated cell differentiation and centriole biogenesis; associated with reduced cilia number																						"{""association"": ""Pathogenic Variants"", ""name"": ""MCIDAS"", ""notes"": ""Drives multiciliated cell differentiation and centriole biogenesis; associated with reduced cilia number""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""MCIDAS"", ""notes"": ""Drives multiciliated cell differentiation and centriole biogenesis; associated with reduced cilia number""}"
6355	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	genetic	11	ODAD1									Pathogenic Variants																										Outer dynein arm docking/assembly factor; associated with relatively milder lung function impact																						"{""association"": ""Pathogenic Variants"", ""name"": ""ODAD1"", ""notes"": ""Outer dynein arm docking/assembly factor; associated with relatively milder lung function impact""}"	{}	"{""association"": ""Pathogenic Variants"", ""name"": ""ODAD1"", ""notes"": ""Outer dynein arm docking/assembly factor; associated with relatively milder lung function impact""}"
6387	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	genetic	0	JAK2									Somatic Activating Mutations																										JAK2 V617F occurs in approximately 60% of PMF patients. Provides rationale for JAK inhibitor therapy.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 60% of PMF patients. Provides rationale for JAK inhibitor therapy.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""JAK2"", ""notes"": ""JAK2 V617F occurs in approximately 60% of PMF patients. Provides rationale for JAK inhibitor therapy.""}"
6388	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	genetic	1	CALR									Somatic Frameshift Mutations																										CALR exon 9 frameshift mutations occur in approximately 25% of PMF, mostly type 1 (52bp deletion) or type 2 (5bp insertion). Generally associated with better prognosis than JAK2 mutations.																						"{""association"": ""Somatic Frameshift Mutations"", ""name"": ""CALR"", ""notes"": ""CALR exon 9 frameshift mutations occur in approximately 25% of PMF, mostly type 1 (52bp deletion) or type 2 (5bp insertion). Generally associated with better prognosis than JAK2 mutations.""}"	{}	"{""association"": ""Somatic Frameshift Mutations"", ""name"": ""CALR"", ""notes"": ""CALR exon 9 frameshift mutations occur in approximately 25% of PMF, mostly type 1 (52bp deletion) or type 2 (5bp insertion). Generally associated with better prognosis than JAK2 mutations.""}"
6389	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	genetic	2	MPL									Somatic Activating Mutations																										MPL W515L/K mutations occur in approximately 5% of PMF. Activates JAK-STAT signaling through the thrombopoietin receptor.																						"{""association"": ""Somatic Activating Mutations"", ""name"": ""MPL"", ""notes"": ""MPL W515L/K mutations occur in approximately 5% of PMF. Activates JAK-STAT signaling through the thrombopoietin receptor.""}"	{}	"{""association"": ""Somatic Activating Mutations"", ""name"": ""MPL"", ""notes"": ""MPL W515L/K mutations occur in approximately 5% of PMF. Activates JAK-STAT signaling through the thrombopoietin receptor.""}"
6390	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	genetic	3	ASXL1									Somatic Loss-of-Function Mutations																										ASXL1 mutations are adverse prognostic markers independent of driver mutation status. Part of high molecular risk (HMR) category.																						"{""association"": ""Somatic Loss-of-Function Mutations"", ""name"": ""ASXL1"", ""notes"": ""ASXL1 mutations are adverse prognostic markers independent of driver mutation status. Part of high molecular risk (HMR) category.""}"	{}	"{""association"": ""Somatic Loss-of-Function Mutations"", ""name"": ""ASXL1"", ""notes"": ""ASXL1 mutations are adverse prognostic markers independent of driver mutation status. Part of high molecular risk (HMR) category.""}"
6409	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	genetic	0	MAPT									Causative																																																"{""association"": ""Causative"", ""name"": ""MAPT""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""The abstract cites pathogenic mutations in the tau gene (MAPT)."", ""reference"": ""PMID:19300609"", ""snippet"": ""Pathogenic mutations in genes coding for the proteins tau and progranulin have been isolated."", ""supports"": ""SUPPORT""}], ""name"": ""MAPT""}"
6410	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	genetic	1	GRN									Causative																																																"{""association"": ""Causative"", ""name"": ""GRN""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""The abstract cites pathogenic mutations in the progranulin gene (GRN)."", ""reference"": ""PMID:19300609"", ""snippet"": ""Pathogenic mutations in genes coding for the proteins tau and progranulin have been isolated."", ""supports"": ""SUPPORT""}], ""name"": ""GRN""}"
6423	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	genetic	0	HLA-DRB1*03									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*03""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1*03""}"
6424	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	genetic	1	HLA-B8									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-B8""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-B8""}"
6481	276	Proteus syndrome	Proteus_syndrome.yaml	genetic	0	AKT1									Causative																										Somatic activating mosaic variant (c.49G>A, p.Glu17Lys); HGNC:391																						"{""association"": ""Causative"", ""name"": ""AKT1"", ""notes"": ""Somatic activating mosaic variant (c.49G>A, p.Glu17Lys); HGNC:391""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""This identifies the causative somatic AKT1 variant."", ""reference"": ""DOI:10.1038/srep17162"", ""snippet"": ""A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This independently confirms the AKT1 p.E17K mosaic variant as the cause."", ""reference"": ""DOI:10.1093/hmg/ddz116"", ""snippet"": ""Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G>A p.(E17K) in AKT1."", ""supports"": ""SUPPORT""}], ""name"": ""AKT1"", ""notes"": ""Somatic activating mosaic variant (c.49G>A, p.Glu17Lys); HGNC:391""}"
6523	278	Psoriasis	Psoriasis.yaml	genetic	0	HLA-C*06:02									Risk Factor																										Strongest genetic association																						"{""association"": ""Risk Factor"", ""name"": ""HLA-C*06:02"", ""notes"": ""Strongest genetic association""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-C*06:02"", ""notes"": ""Strongest genetic association""}"
6524	278	Psoriasis	Psoriasis.yaml	genetic	1	IL12B									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL12B""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""IL12B encodes the p40 subunit shared by IL-12 and IL-23. Given IL-23's hierarchically dominant role in psoriasis, genetic variants in IL12B that affect IL-23 levels represent important risk factors."", ""reference"": ""PMID:38686385"", ""snippet"": ""Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease."", ""supports"": ""SUPPORT""}], ""name"": ""IL12B""}"
6525	278	Psoriasis	Psoriasis.yaml	genetic	2	IL23R									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL23R""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""IL23R encodes the IL-23 receptor, and genetic variants affecting IL-23 signaling are risk factors for psoriasis given the central role of this pathway."", ""reference"": ""PMID:38686385"", ""snippet"": ""We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases."", ""supports"": ""SUPPORT""}], ""name"": ""IL23R""}"
6526	278	Psoriasis	Psoriasis.yaml	genetic	3	TNFAIP3									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""TNFAIP3""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TNFAIP3""}"
6527	278	Psoriasis	Psoriasis.yaml	genetic	4	CARD14									Causative																										Rare familial psoriasis																						"{""association"": ""Causative"", ""name"": ""CARD14"", ""notes"": ""Rare familial psoriasis""}"	{}	"{""association"": ""Causative"", ""name"": ""CARD14"", ""notes"": ""Rare familial psoriasis""}"
6564	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	0	BMPR2									Loss-of-function variants central in heritable and idiopathic PAH																										BMPR2 encodes bone morphogenetic protein receptor type 2; impaired BMP/SMAD1/5/9 signaling is a core mechanism in PAH pathogenesis																						"{""association"": ""Loss-of-function variants central in heritable and idiopathic PAH"", ""name"": ""BMPR2"", ""notes"": ""BMPR2 encodes bone morphogenetic protein receptor type 2; impaired BMP/SMAD1/5/9 signaling is a core mechanism in PAH pathogenesis""}"	{}	"{""association"": ""Loss-of-function variants central in heritable and idiopathic PAH"", ""name"": ""BMPR2"", ""notes"": ""BMPR2 encodes bone morphogenetic protein receptor type 2; impaired BMP/SMAD1/5/9 signaling is a core mechanism in PAH pathogenesis""}"
6565	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	1	SMAD9									TGF-beta/BMP axis component implicated in PAH																										Downstream transcription factor in BMP signaling pathway																						"{""association"": ""TGF-beta/BMP axis component implicated in PAH"", ""name"": ""SMAD9"", ""notes"": ""Downstream transcription factor in BMP signaling pathway""}"	{}	"{""association"": ""TGF-beta/BMP axis component implicated in PAH"", ""name"": ""SMAD9"", ""notes"": ""Downstream transcription factor in BMP signaling pathway""}"
6566	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	2	ACVRL1									Implicated in PAH, particularly in hereditary hemorrhagic telangiectasia-associated PAH																										Also known as ALK1; encodes activin receptor-like kinase 1, involved in TGF-beta/BMP signaling																						"{""association"": ""Implicated in PAH, particularly in hereditary hemorrhagic telangiectasia-associated PAH"", ""name"": ""ACVRL1"", ""notes"": ""Also known as ALK1; encodes activin receptor-like kinase 1, involved in TGF-beta/BMP signaling""}"	{}	"{""association"": ""Implicated in PAH, particularly in hereditary hemorrhagic telangiectasia-associated PAH"", ""name"": ""ACVRL1"", ""notes"": ""Also known as ALK1; encodes activin receptor-like kinase 1, involved in TGF-beta/BMP signaling""}"
6567	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	3	ENG									Implicated in PAH																										Encodes endoglin, a TGF-beta co-receptor involved in vascular development																						"{""association"": ""Implicated in PAH"", ""name"": ""ENG"", ""notes"": ""Encodes endoglin, a TGF-beta co-receptor involved in vascular development""}"	{}	"{""association"": ""Implicated in PAH"", ""name"": ""ENG"", ""notes"": ""Encodes endoglin, a TGF-beta co-receptor involved in vascular development""}"
6568	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	4	EIF2AK4									Causally linked to pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH)																										Also known as GCN2; encodes eukaryotic translation initiation factor 2 alpha kinase 4																						"{""association"": ""Causally linked to pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH)"", ""name"": ""EIF2AK4"", ""notes"": ""Also known as GCN2; encodes eukaryotic translation initiation factor 2 alpha kinase 4""}"	{}	"{""association"": ""Causally linked to pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH)"", ""name"": ""EIF2AK4"", ""notes"": ""Also known as GCN2; encodes eukaryotic translation initiation factor 2 alpha kinase 4""}"
6569	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	5	KCNK3									Ion channel mutations contribute to vasoconstriction and proliferation																										Also known as TASK-1; encodes potassium two pore domain channel subfamily K member 3																						"{""association"": ""Ion channel mutations contribute to vasoconstriction and proliferation"", ""name"": ""KCNK3"", ""notes"": ""Also known as TASK-1; encodes potassium two pore domain channel subfamily K member 3""}"	{}	"{""association"": ""Ion channel mutations contribute to vasoconstriction and proliferation"", ""name"": ""KCNK3"", ""notes"": ""Also known as TASK-1; encodes potassium two pore domain channel subfamily K member 3""}"
6570	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	6	TBX4									Transcriptional regulator contributing to developmental and adult-onset PAH																										Encodes T-box transcription factor 4																						"{""association"": ""Transcriptional regulator contributing to developmental and adult-onset PAH"", ""name"": ""TBX4"", ""notes"": ""Encodes T-box transcription factor 4""}"	{}	"{""association"": ""Transcriptional regulator contributing to developmental and adult-onset PAH"", ""name"": ""TBX4"", ""notes"": ""Encodes T-box transcription factor 4""}"
6571	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	7	SOX17									Variants associated with severe PAH phenotype																										Encodes SRY-box transcription factor 17; regulates vascular development																						"{""association"": ""Variants associated with severe PAH phenotype"", ""name"": ""SOX17"", ""notes"": ""Encodes SRY-box transcription factor 17; regulates vascular development""}"	{}	"{""association"": ""Variants associated with severe PAH phenotype"", ""name"": ""SOX17"", ""notes"": ""Encodes SRY-box transcription factor 17; regulates vascular development""}"
6572	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	genetic	8	CAV1									Implicated in vascular dysfunction																										Encodes caveolin-1, involved in caveolae formation and endothelial signaling																						"{""association"": ""Implicated in vascular dysfunction"", ""name"": ""CAV1"", ""notes"": ""Encodes caveolin-1, involved in caveolae formation and endothelial signaling""}"	{}	"{""association"": ""Implicated in vascular dysfunction"", ""name"": ""CAV1"", ""notes"": ""Encodes caveolin-1, involved in caveolae formation and endothelial signaling""}"
6599	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	genetic	0	RET									Somatic Gene Fusions																										RET fusions occur in 10-20% of papillary thyroid cancers. Common fusion partners include CCDC6 (RET/PTC1) and NCOA4 (RET/PTC3). Particularly enriched in radiation-induced thyroid cancer. Targetable with selective RET inhibitors.																						"{""association"": ""Somatic Gene Fusions"", ""name"": ""RET"", ""notes"": ""RET fusions occur in 10-20% of papillary thyroid cancers. Common fusion partners include CCDC6 (RET/PTC1) and NCOA4 (RET/PTC3). Particularly enriched in radiation-induced thyroid cancer. Targetable with selective RET inhibitors.""}"	{}	"{""association"": ""Somatic Gene Fusions"", ""evidence"": [{""explanation"": ""Supports RET/PTC rearrangements as common mutations in papillary thyroid carcinoma."", ""reference"": ""PMID:39502057"", ""snippet"": ""The common gene mutations in PTC include BRAF V600E,RET/PTC rearrangement,and RAS mutations."", ""supports"": ""SUPPORT""}], ""name"": ""RET"", ""notes"": ""RET fusions occur in 10-20% of papillary thyroid cancers. Common fusion partners include CCDC6 (RET/PTC1) and NCOA4 (RET/PTC3). Particularly enriched in radiation-induced thyroid cancer. Targetable with selective RET inhibitors.""}"
6616	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	genetic	0	RET									Somatic Rearrangement																										RET (10q11.21) encodes the rearranged during transfection receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners in NSCLC include KIF5B (~70-90%), CCDC6 (~15-20%), and NCOA4. Germline RET mutations cause MEN2 syndrome; somatic RET fusions drive lung and thyroid cancers. Resistance mutations include G810R/S/C (solvent front) and V804L/M (gatekeeper).																						"{""association"": ""Somatic Rearrangement"", ""name"": ""RET"", ""notes"": ""RET (10q11.21) encodes the rearranged during transfection receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners in NSCLC include KIF5B (~70-90%), CCDC6 (~15-20%), and NCOA4. Germline RET mutations cause MEN2 syndrome; somatic RET fusions drive lung and thyroid cancers. Resistance mutations include G810R/S/C (solvent front) and V804L/M (gatekeeper).""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Rearrangement"", ""evidence"": [{""explanation"": ""Abstract reports the frequency of RET fusions in NSCLC."", ""reference"": ""PMID:35220468"", ""snippet"": ""Approximately 1-2% of non-small cell lung cancer (NSCLC) patients harbor RET (rearranged during transfection) fusions."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""RET"", ""notes"": ""RET (10q11.21) encodes the rearranged during transfection receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners in NSCLC include KIF5B (~70-90%), CCDC6 (~15-20%), and NCOA4. Germline RET mutations cause MEN2 syndrome; somatic RET fusions drive lung and thyroid cancers. Resistance mutations include G810R/S/C (solvent front) and V804L/M (gatekeeper).""}"
6617	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	genetic	1	KIF5B									Fusion Partner																										KIF5B (10p11.22) encodes kinesin family member 5B. Most common RET fusion partner in NSCLC. The pericentric inversion on chromosome 10 brings KIF5B coiled-coil domain to RET kinase domain.																						"{""association"": ""Fusion Partner"", ""name"": ""KIF5B"", ""notes"": ""KIF5B (10p11.22) encodes kinesin family member 5B. Most common RET fusion partner in NSCLC. The pericentric inversion on chromosome 10 brings KIF5B coiled-coil domain to RET kinase domain.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Fusion Partner"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""KIF5B"", ""notes"": ""KIF5B (10p11.22) encodes kinesin family member 5B. Most common RET fusion partner in NSCLC. The pericentric inversion on chromosome 10 brings KIF5B coiled-coil domain to RET kinase domain.""}"
6636	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	genetic	0	ROS1									Somatic Rearrangement																										ROS1 (6q22) encodes ROS proto-oncogene 1, a receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners include CD74 (~40%), EZR (~15%), SDC4, SLC34A2, and TPM3. Resistance mutations include G2032R (solvent front), D2033N, and L2026M (gatekeeper).																						"{""association"": ""Somatic Rearrangement"", ""name"": ""ROS1"", ""notes"": ""ROS1 (6q22) encodes ROS proto-oncogene 1, a receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners include CD74 (~40%), EZR (~15%), SDC4, SLC34A2, and TPM3. Resistance mutations include G2032R (solvent front), D2033N, and L2026M (gatekeeper).""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Rearrangement"", ""evidence"": [{""explanation"": ""Abstract reports ROS1-rearranged NSCLC accounts for about 1-2% of cases."", ""reference"": ""PMID:32327173"", ""snippet"": ""ROS1-rearranged non-small cell lung cancer (NSCLC) makes up approximately 1% to 2% of all NSCLC,"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""ROS1"", ""notes"": ""ROS1 (6q22) encodes ROS proto-oncogene 1, a receptor tyrosine kinase. Gene rearrangements occur somatically. Common fusion partners include CD74 (~40%), EZR (~15%), SDC4, SLC34A2, and TPM3. Resistance mutations include G2032R (solvent front), D2033N, and L2026M (gatekeeper).""}"
6637	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	genetic	1	CD74									Fusion Partner																										CD74 (5q33) encodes the MHC class II invariant chain. Most common ROS1 fusion partner, providing dimerization domain for constitutive kinase activation.																						"{""association"": ""Fusion Partner"", ""name"": ""CD74"", ""notes"": ""CD74 (5q33) encodes the MHC class II invariant chain. Most common ROS1 fusion partner, providing dimerization domain for constitutive kinase activation.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Fusion Partner"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""CD74"", ""notes"": ""CD74 (5q33) encodes the MHC class II invariant chain. Most common ROS1 fusion partner, providing dimerization domain for constitutive kinase activation.""}"
6712	287	Retinoblastoma	Retinoblastoma.yaml	genetic	0	RB1									Germline and Somatic Mutations																										RB1 (13q14.2) encodes the retinoblastoma protein, the first tumor suppressor gene identified. Loss-of-function mutations include nonsense, frameshift, splice site, and large deletions. Germline mutations are present in 40% of cases. Hereditary retinoblastoma follows autosomal dominant inheritance with high but incomplete penetrance (approximately 90%).																						"{""association"": ""Germline and Somatic Mutations"", ""name"": ""RB1"", ""notes"": ""RB1 (13q14.2) encodes the retinoblastoma protein, the first tumor suppressor gene identified. Loss-of-function mutations include nonsense, frameshift, splice site, and large deletions. Germline mutations are present in 40% of cases. Hereditary retinoblastoma follows autosomal dominant inheritance with high but incomplete penetrance (approximately 90%).""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline and Somatic Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""RB1"", ""notes"": ""RB1 (13q14.2) encodes the retinoblastoma protein, the first tumor suppressor gene identified. Loss-of-function mutations include nonsense, frameshift, splice site, and large deletions. Germline mutations are present in 40% of cases. Hereditary retinoblastoma follows autosomal dominant inheritance with high but incomplete penetrance (approximately 90%).""}"
6739	289	Rett Syndrome	Rett_Syndrome.yaml	genetic	0	MECP2									Causative																										X-linked dominant, de novo mutations in >99% of cases, almost exclusively affects females																						"{""association"": ""Causative"", ""name"": ""MECP2"", ""notes"": ""X-linked dominant, de novo mutations in >99% of cases, almost exclusively affects females""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Original discovery paper identified MECP2 mutations as the cause of Rett syndrome."", ""reference"": ""PMID:10508514"", ""snippet"": ""we have identified mutations in the gene (MECP2) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"", ""supports"": ""SUPPORT""}], ""name"": ""MECP2"", ""notes"": ""X-linked dominant, de novo mutations in >99% of cases, almost exclusively affects females""}"
6763	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	0	HLA-DRB1									Associated with increased risk																										HLA-DRB1 shared epitope alleles present citrullinated peptides to CD4+ T cells, representing the major genetic risk factor for seropositive RA																						"{""association"": ""Associated with increased risk"", ""name"": ""HLA-DRB1"", ""notes"": ""HLA-DRB1 shared epitope alleles present citrullinated peptides to CD4+ T cells, representing the major genetic risk factor for seropositive RA""}"	{}	"{""association"": ""Associated with increased risk"", ""evidence"": [{""explanation"": ""The study shows an increased frequency of HLA-DRB1*04 and HLA-DRB1*04:05 in the RA group, indicating an association with increased risk."", ""reference"": ""PMID:24447879"", ""snippet"": ""HLA-DRB1*04 was found to have increased frequency in the RA group compared to controls (P < 0.001, OR = 3.14)...HLA-DRB1*04:05 was associated with RA (P = 0.005, OR = 3.41)"", ""supports"": ""SUPPORT""}, {""explanation"": ""The review discusses the significant role of HLA-DRB1 in RA susceptibility."", ""reference"": ""PMID:32638005"", ""snippet"": ""This review identifies the most significant genetic variants associated with RA susceptibility to date, with particular focus on the contribution of the HLA class II genes across different ethnic groups."", ""supports"": ""SUPPORT""}, {""explanation"": ""HLA-DR4, a subtype of HLA-DRB1, is associated with an increased risk of developing RA."", ""reference"": ""PMID:16542468"", ""snippet"": ""HLA-DR alleles such as HLA-DR4 and HLA-DR1 are associated with the risk to develop RA."", ""supports"": ""SUPPORT""}, {""explanation"": ""The review presents the current understanding of HLA-DRB1's role in increasing the risk of RA."", ""reference"": ""PMID:32370106"", ""snippet"": ""Association studies of the HLA-DRB1 gene clearly indicate its importance in RA morbidity."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study reinforces the association of HLA-DRB1 alleles with RA."", ""reference"": ""PMID:24336335"", ""snippet"": ""Certain HLA-DRB1 alleles and single-nucleotide polymorphisms (SNPs) are associated with rheumatoid arthritis (RA)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions the association of HLA-DR4, a subtype of HLA-DRB1, with RA."", ""reference"": ""PMID:3067866"", ""snippet"": ""Part of this genetic predisposition is accounted for by genes within the MHC where there is a well-documented association with HLA-DR4."", ""supports"": ""SUPPORT""}, {""explanation"": ""The meta-analysis highlights the role of HLA-DRB1 alleles in RA-related conditions, such as juvenile idiopathic arthritis."", ""reference"": ""PMID:29037901"", ""snippet"": ""HLA-DRB1*01 and HLA-DRB1*04 may be involved in the genetic predisposition of Rheumatoid Factor (RF) positive forms of JIA."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses the association of HLA-DRB1 SE alleles with RA-ILD."", ""reference"": ""PMID:36155967"", ""snippet"": ""We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1"", ""notes"": ""HLA-DRB1 shared epitope alleles present citrullinated peptides to CD4+ T cells, representing the major genetic risk factor for seropositive RA""}"
6764	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	1	PTPN22									Associated with increased risk																																																"{""association"": ""Associated with increased risk"", ""name"": ""PTPN22""}"	{}	"{""association"": ""Associated with increased risk"", ""evidence"": [{""explanation"": ""The study found significant positive associations between PTPN22 genetic variations and increased risk of rheumatoid arthritis."", ""reference"": ""PMID:30957405"", ""snippet"": ""The overall effect of PTPN22-1123 on RA risk in all genetic random models showed significant positive associations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The variant R620W of PTPN22 is associated with a significantly increased risk of rheumatoid arthritis."", ""reference"": ""PMID:15790351"", ""snippet"": ""A functional variant (R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) has now been conclusively shown to confer approximately two-fold risk for seropositive RA as well as several other autoimmune disorders."", ""supports"": ""SUPPORT""}, {""explanation"": ""The PTPN22 polymorphism has been identified as a genetic risk factor for rheumatoid arthritis."", ""reference"": ""PMID:15838240"", ""snippet"": ""The second risk factor for rheumatoid arthritis, the PTPN22 polymorphism, has been identified."", ""supports"": ""SUPPORT""}], ""name"": ""PTPN22""}"
6765	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	2	STAT4									Associated with increased risk																																																"{""association"": ""Associated with increased risk"", ""name"": ""STAT4""}"	{}	"{""association"": ""Associated with increased risk"", ""evidence"": [{""explanation"": ""The study found a significant positive association between the STAT4 gene rs7574865 SNP and the risk of rheumatoid arthritis (RA)."", ""reference"": ""PMID:30864557"", ""snippet"": ""Herein, we found a significant positive association between minor T allele as well as different genotypes with the risk of RA."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports an association between the STAT4 gene and increased risk of rheumatoid arthritis."", ""reference"": ""PMID:20453440"", ""snippet"": ""We and other investigators also found that IRF5, STAT4 and BLK are associated not only with SLE, but also rheumatoid arthritis and systemic sclerosis."", ""supports"": ""SUPPORT""}], ""name"": ""STAT4""}"
6766	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	3	CTLA4									Associated with increased risk																																																"{""association"": ""Associated with increased risk"", ""name"": ""CTLA4""}"	{}	"{""association"": ""Associated with increased risk"", ""evidence"": [{""explanation"": ""The meta-analysis provides evidence that CTLA-4 gene polymorphisms are associated with an increased risk of rheumatoid arthritis."", ""reference"": ""PMID:34339393"", ""snippet"": ""This meta-analysis confirmed that rs3087243 and rs231775 polymorphism were associated with the risk of RA in both overall population and ethnic-specific analysis, but there was no association between rs5742909 polymorphism and RA risk"", ""supports"": ""SUPPORT""}, {""explanation"": ""The study found significantly higher expression of CTLA-4 in RA patients, supporting the association of CTLA-4 with increased RA risk."", ""reference"": ""PMID:35758965"", ""snippet"": ""There was a significantly higher median (inter-quartile range) expression of CTLA-4 and CCL2 in RA patients in comparison to controls (P < 0.05)"", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses CTLA4 as a candidate gene for susceptibility to autoimmune diseases, including rheumatoid arthritis."", ""reference"": ""PMID:11196709"", ""snippet"": ""For most autoimmune disorders... the gene encoding cytotoxic T lymphocyte-associated antigen 4 (CTLA4) has been suggested as a candidate gene for conferring susceptibility to autoimmunity."", ""supports"": ""SUPPORT""}], ""name"": ""CTLA4""}"
6767	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	4	PADI4									Associated with increased risk																										Encodes peptidylarginine deiminase 4, the enzyme responsible for protein citrullination in neutrophil extracellular traps and immune cells, generating ACPA-target neoepitopes																						"{""association"": ""Associated with increased risk"", ""name"": ""PADI4"", ""notes"": ""Encodes peptidylarginine deiminase 4, the enzyme responsible for protein citrullination in neutrophil extracellular traps and immune cells, generating ACPA-target neoepitopes""}"	{}	"{""association"": ""Associated with increased risk"", ""evidence"": [{""explanation"": ""This review identifies PADI4 as a key non-HLA genetic susceptibility factor for RA, demonstrating the link between citrullination of proteins and generation of autoantigens targeted by anti-citrullinated protein antibodies."", ""reference"": ""PMID:17893996"", ""snippet"": ""peptidylarginine deiminase (gene name abbreviated to PADI, protein name abbreviated to PAD) type 4 is the one of the non-HLA genetic factors involved in RA via citrullination"", ""supports"": ""SUPPORT""}], ""name"": ""PADI4"", ""notes"": ""Encodes peptidylarginine deiminase 4, the enzyme responsible for protein citrullination in neutrophil extracellular traps and immune cells, generating ACPA-target neoepitopes""}"
6768	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	5	PADI2									Associated with increased risk																										Encodes peptidylarginine deiminase 2, contributes to citrullination at mucosal sites and in inflammatory cells																						"{""association"": ""Associated with increased risk"", ""name"": ""PADI2"", ""notes"": ""Encodes peptidylarginine deiminase 2, contributes to citrullination at mucosal sites and in inflammatory cells""}"	{}	"{""association"": ""Associated with increased risk"", ""name"": ""PADI2"", ""notes"": ""Encodes peptidylarginine deiminase 2, contributes to citrullination at mucosal sites and in inflammatory cells""}"
6769	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	6	TNF									Central proinflammatory cytokine																										Master cytokine driving synovitis, fibroblast-like synoviocyte activation, and leukocyte recruitment; therapeutic target of TNF inhibitors																						"{""association"": ""Central proinflammatory cytokine"", ""name"": ""TNF"", ""notes"": ""Master cytokine driving synovitis, fibroblast-like synoviocyte activation, and leukocyte recruitment; therapeutic target of TNF inhibitors""}"	{}	"{""association"": ""Central proinflammatory cytokine"", ""name"": ""TNF"", ""notes"": ""Master cytokine driving synovitis, fibroblast-like synoviocyte activation, and leukocyte recruitment; therapeutic target of TNF inhibitors""}"
6770	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	7	IL6R									Mediates IL-6 signaling																										IL-6 receptor mediates JAK/STAT signaling driving systemic and synovial inflammation; therapeutic target (tocilizumab)																						"{""association"": ""Mediates IL-6 signaling"", ""name"": ""IL6R"", ""notes"": ""IL-6 receptor mediates JAK/STAT signaling driving systemic and synovial inflammation; therapeutic target (tocilizumab)""}"	{}	"{""association"": ""Mediates IL-6 signaling"", ""name"": ""IL6R"", ""notes"": ""IL-6 receptor mediates JAK/STAT signaling driving systemic and synovial inflammation; therapeutic target (tocilizumab)""}"
6771	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	genetic	8	TYK2									Associated with increased risk																										Tyrosine kinase 2, part of JAK/STAT signaling pathway; mediates cytokine signals including IL-6 and interferons																						"{""association"": ""Associated with increased risk"", ""name"": ""TYK2"", ""notes"": ""Tyrosine kinase 2, part of JAK/STAT signaling pathway; mediates cytokine signals including IL-6 and interferons""}"	{}	"{""association"": ""Associated with increased risk"", ""name"": ""TYK2"", ""notes"": ""Tyrosine kinase 2, part of JAK/STAT signaling pathway; mediates cytokine signals including IL-6 and interferons""}"
6810	291	Roifman-syndrome	Roifman-syndrome.yaml	genetic	0	RNU4ATAC									Pathogenic Variants																																																"{""association"": ""Pathogenic Variants"", ""name"": ""RNU4ATAC""}"	"{""inheritance"": [{""name"": ""Autosomal Recessive""}]}"	"{""association"": ""Pathogenic Variants"", ""evidence"": [{""explanation"": ""This study confirms that Roifman Syndrome is associated with compound heterozygous mutations in the RNU4ATAC gene, which is inherited in an autosomal recessive manner."", ""reference"": ""PMID:26522830"", ""snippet"": ""Roifman Syndrome is a rare congenital disorder... Targeted sequencing confirms allele segregation in six cases from four unrelated families."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature explicitly mentions that Roifman syndrome is inherited in an autosomal recessive manner."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study confirms that Roifman syndrome patients have biallelic (autosomal recessive) variants in the RNU4ATAC gene."", ""reference"": ""PMID:37225827"", ""snippet"": ""All patients had biallelic RNU4ATAC variants."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal Recessive""}], ""name"": ""RNU4ATAC""}"
6827	292	SADDAN	SADDAN.yaml	genetic	0	FGFR3 K650M mutation									Causative																										"The c.1949A>T (p.Lys650Met) mutation is the specific cause of SADDAN. This mutation is at the same codon as the K650E mutation (TD2) and K650Q mutation (hypochondroplasia variant), demonstrating how different amino acid substitutions at a single position produce distinct phenotypes. The K650M mutation causes intermediate receptor activation between K650Q and K650E.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 K650M mutation"", ""notes"": ""The c.1949A>T (p.Lys650Met) mutation is the specific cause of SADDAN. This mutation is at the same codon as the K650E mutation (TD2) and K650Q mutation (hypochondroplasia variant), demonstrating how different amino acid substitutions at a single position produce distinct phenotypes. The K650M mutation causes intermediate receptor activation between K650Q and K650E.\n""}"	"{""variants"": [{""description"": ""The specific mutation causing SADDAN."", ""name"": ""c.1949A>T (p.Lys650Met)""}]}"	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""The abstract identifies p.Lys650Met in FGFR3 as the causal mutation."", ""reference"": ""PMID:24352917"", ""snippet"": ""The disorder is the result of a single missense mutation at codon 650 (p.Lys650Met) in the fibroblast growth factor receptor 3 gene (FGFR3)."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""FGFR3"", ""term"": {""id"": ""hgnc:3690"", ""label"": ""FGFR3""}}, ""name"": ""FGFR3 K650M mutation"", ""notes"": ""The c.1949A>T (p.Lys650Met) mutation is the specific cause of SADDAN. This mutation is at the same codon as the K650E mutation (TD2) and K650Q mutation (hypochondroplasia variant), demonstrating how different amino acid substitutions at a single position produce distinct phenotypes. The K650M mutation causes intermediate receptor activation between K650Q and K650E.\n"", ""variants"": [{""description"": ""The specific mutation causing SADDAN."", ""name"": ""c.1949A>T (p.Lys650Met)""}]}"
6848	293	Salla Disease	Salla_Disease.yaml	genetic	0	SLC17A5									Causative																																																"{""association"": ""Causative"", ""name"": ""SLC17A5""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Studies of patient-derived cells demonstrate SLC17A5 biallelic mutations as causative for FSASD including Salla disease."", ""reference"": ""PMID:37727271"", ""snippet"": ""Free sialic acid storage disorders (FSASDs) result from pathogenic variations in the SLC17A5 gene, which encodes the lysosomal transmembrane protein sialin."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report documents a novel homozygous deletion of SLC17A5 exons 8-9 causing infantile-onset FSASD with prenatal hydrops, demonstrating the spectrum of SLC17A5 pathogenic variants extends beyond point mutations to exonic deletions."", ""reference"": ""PMID:34667062"", ""snippet"": ""SLC17A5 gene sequencing was initiated with no sequence variants identified; however, the assay failed to amplify exons 8 and 9, prompting an exon-level copy-number analysis that revealed a novel homozygous deletion of exons 8 and 9, inherited from heterozygous carrier parents."", ""supports"": ""SUPPORT""}], ""gene_term"": {""preferred_term"": ""SLC17A5"", ""term"": {""id"": ""hgnc:10933"", ""label"": ""SLC17A5""}}, ""name"": ""SLC17A5""}"
6879	294	Sarcoidosis	Sarcoidosis.yaml	genetic	0	HLA-DRB1 Variants									Susceptibility																										HLA-DRB1*03 associated with acute, self-limited disease; HLA-DRB1*15 with chronic disease																						"{""association"": ""Susceptibility"", ""name"": ""HLA-DRB1 Variants"", ""notes"": ""HLA-DRB1*03 associated with acute, self-limited disease; HLA-DRB1*15 with chronic disease""}"	{}	"{""association"": ""Susceptibility"", ""name"": ""HLA-DRB1 Variants"", ""notes"": ""HLA-DRB1*03 associated with acute, self-limited disease; HLA-DRB1*15 with chronic disease""}"
6880	294	Sarcoidosis	Sarcoidosis.yaml	genetic	1	BTNL2 Variants									Susceptibility																										Butyrophilin-like 2 gene variants increase sarcoidosis risk																						"{""association"": ""Susceptibility"", ""name"": ""BTNL2 Variants"", ""notes"": ""Butyrophilin-like 2 gene variants increase sarcoidosis risk""}"	{}	"{""association"": ""Susceptibility"", ""name"": ""BTNL2 Variants"", ""notes"": ""Butyrophilin-like 2 gene variants increase sarcoidosis risk""}"
6916	297	Schizophrenia	Schizophrenia.yaml	genetic	0	DRD2									Risk Factor																										Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining >20% liability in aggregate with other common variants.																						"{""association"": ""Risk Factor"", ""name"": ""DRD2"", ""notes"": ""Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining >20% liability in aggregate with other common variants.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""DRD2"", ""notes"": ""Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining >20% liability in aggregate with other common variants.""}"
6917	297	Schizophrenia	Schizophrenia.yaml	genetic	1	GRIN1									Risk Factor																										NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.																						"{""association"": ""Risk Factor"", ""name"": ""GRIN1"", ""notes"": ""NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""GRIN1"", ""notes"": ""NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.""}"
6918	297	Schizophrenia	Schizophrenia.yaml	genetic	2	GRIN2A									Risk Factor																										NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.																						"{""association"": ""Risk Factor"", ""name"": ""GRIN2A"", ""notes"": ""NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""GRIN2A"", ""notes"": ""NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.""}"
6919	297	Schizophrenia	Schizophrenia.yaml	genetic	3	GAD1									Risk Factor																										GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.																						"{""association"": ""Risk Factor"", ""name"": ""GAD1"", ""notes"": ""GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""GAD1"", ""notes"": ""GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.""}"
6920	297	Schizophrenia	Schizophrenia.yaml	genetic	4	RELN									Risk Factor																										Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.																						"{""association"": ""Risk Factor"", ""name"": ""RELN"", ""notes"": ""Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""RELN"", ""notes"": ""Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.""}"
6921	297	Schizophrenia	Schizophrenia.yaml	genetic	5	C4A									Risk Factor																										Complement component 4A; drives excessive microglial synaptic pruning during adolescence.																						"{""association"": ""Risk Factor"", ""name"": ""C4A"", ""notes"": ""Complement component 4A; drives excessive microglial synaptic pruning during adolescence.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""C4A"", ""notes"": ""Complement component 4A; drives excessive microglial synaptic pruning during adolescence.""}"
6922	297	Schizophrenia	Schizophrenia.yaml	genetic	6	C3									Risk Factor																										Complement component 3; works with C4A in complement-mediated synaptic elimination.																						"{""association"": ""Risk Factor"", ""name"": ""C3"", ""notes"": ""Complement component 3; works with C4A in complement-mediated synaptic elimination.""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""C3"", ""notes"": ""Complement component 3; works with C4A in complement-mediated synaptic elimination.""}"
6923	297	Schizophrenia	Schizophrenia.yaml	genetic	7	DISC1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""DISC1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk."", ""reference"": ""PMID:30286368"", ""snippet"": ""DISC1 gene has been shown as a risk factor for schizophrenia in some reports."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus."", ""reference"": ""PMID:24056909"", ""snippet"": ""Questions about DISC1 as a genetic risk factor for schizophrenia."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor."", ""reference"": ""PMID:30285728"", ""snippet"": ""The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review highlights the relevance of studying DISC1 functions in the context of schizophrenia."", ""reference"": ""PMID:20302823"", ""snippet"": ""Modeling the disease in genetically tractable animals is thus a challenging but increasingly important task. In this review, I discuss the potential problems and perspectives associated with modeling schizophrenia in fruit flies, and briefly review the recent studies analyzing the molecular and cellular functions of Disrupted-In-Schizophrenia-1 (DISC1) in transgenic flies."", ""supports"": ""SUPPORT""}], ""name"": ""DISC1""}"
6924	297	Schizophrenia	Schizophrenia.yaml	genetic	8	COMT									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""COMT""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies."", ""reference"": ""PMID:23573605"", ""snippet"": ""COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme activity. In people with schizophrenia, in their healthy siblings, and also in normal controls, the COMT genotype predicts 4% of the variation in human executive cognition and working memory. We have thus identified a genetic mechanism in the human species that affects the efficiency and efficacy of information-processing in the prefrontal cortex. It is, also, a weak genetic risk factor for schizophrenia: in family studies, it increases the risk of schizophrenia by 50-80%."", ""supports"": ""SUPPORT""}], ""name"": ""COMT""}"
6925	297	Schizophrenia	Schizophrenia.yaml	genetic	9	NRG1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""NRG1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role."", ""reference"": ""PMID:16520822"", ""snippet"": ""Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association."", ""reference"": ""PMID:15162166"", ""snippet"": ""Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review points to NRG1 as a gene potentially related to the risk of schizophrenia."", ""reference"": ""PMID:20600464"", ""snippet"": ""We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia."", ""supports"": ""SUPPORT""}, {""explanation"": ""This paper focuses on NRG1 as one of the risk genes associated with schizophrenia."", ""reference"": ""PMID:24968777"", ""snippet"": ""...It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1..."", ""supports"": ""SUPPORT""}], ""name"": ""NRG1""}"
6926	297	Schizophrenia	Schizophrenia.yaml	genetic	10	DTNBP1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""DTNBP1""}"	{}	"{""association"": ""Risk Factor"", ""evidence"": [{""explanation"": ""This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans."", ""reference"": ""PMID:19862852"", ""snippet"": ""This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor."", ""reference"": ""PMID:18474210"", ""snippet"": ""To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions."", ""reference"": ""PMID:24968777"", ""snippet"": ""It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis)."", ""supports"": ""SUPPORT""}], ""name"": ""DTNBP1""}"
6961	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	genetic	0	Genetic underpinnings																																			"The genetic basis of scimitar syndrome remains largely unknown. It is typically sporadic. In one cohort study, genetic testing revealed an underlying diagnosis in roughly 40% of those tested by chromosomal microarray or whole-exome sequencing. STRC and CATSPER2 have been tentatively suggested as possible contributors but causal roles are unconfirmed. Extracardiac anomalies are present in 96% of cases, and chromosomal microarray plus whole-exome sequencing is recommended for patients with extracardiac defects.
"																						"{""name"": ""Genetic underpinnings"", ""notes"": ""The genetic basis of scimitar syndrome remains largely unknown. It is typically sporadic. In one cohort study, genetic testing revealed an underlying diagnosis in roughly 40% of those tested by chromosomal microarray or whole-exome sequencing. STRC and CATSPER2 have been tentatively suggested as possible contributors but causal roles are unconfirmed. Extracardiac anomalies are present in 96% of cases, and chromosomal microarray plus whole-exome sequencing is recommended for patients with extracardiac defects.\n""}"	{}	"{""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Texas Children's Hospital cohort of 89 patients showing 39% diagnostic yield from genetic testing and high prevalence of extracardiac findings."", ""reference"": ""PMID:34210367"", ""snippet"": ""A molecular genetic diagnosis was made in 7 of 18 cases (39% of those tested). Ninety-six per cent of the cohort had some type of extracardiac finding, with 43% having asthma and 20% having a gastrointestinal pathology."", ""supports"": ""SUPPORT""}], ""name"": ""Genetic underpinnings"", ""notes"": ""The genetic basis of scimitar syndrome remains largely unknown. It is typically sporadic. In one cohort study, genetic testing revealed an underlying diagnosis in roughly 40% of those tested by chromosomal microarray or whole-exome sequencing. STRC and CATSPER2 have been tentatively suggested as possible contributors but causal roles are unconfirmed. Extracardiac anomalies are present in 96% of cases, and chromosomal microarray plus whole-exome sequencing is recommended for patients with extracardiac defects.\n""}"
7028	303	Sengers syndrome	Sengers_syndrome.yaml	genetic	0	AGK									Causative																										Autosomal recessive; HGNC:21869																						"{""association"": ""Causative"", ""name"": ""AGK"", ""notes"": ""Autosomal recessive; HGNC:21869""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""This statement identifies AGK mutations as the cause of Sengers syndrome with autosomal recessive inheritance."", ""reference"": ""DOI:10.3389/fped.2021.639687"", ""snippet"": ""Sengers syndrome (OMIM #212350) is a rare autosomal recessive disorder due to mutations in acylglycerol kinase (AGK) gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report provides direct genetic evidence of a pathogenic AGK variant in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""After genetic analysis, a novel homozygous (c.1131+2T>C) variant of AGK gene was identified in the proband."", ""supports"": ""SUPPORT""}], ""name"": ""AGK"", ""notes"": ""Autosomal recessive; HGNC:21869""}"
7061	304	Shigellosis	Shigellosis.yaml	genetic	0	NLRC4 (NOD-like receptor family CARD domain-containing 4)																																			"NLRC4 is a core component of the NAIP/NLRC4 inflammasome that senses T3SS components (MxiH, MxiI) from Shigella. Genetic variation affects the magnitude and kinetics of inflammasome-mediated IL-1 release and pyroptosis during infection.
"																						"{""name"": ""NLRC4 (NOD-like receptor family CARD domain-containing 4)"", ""notes"": ""NLRC4 is a core component of the NAIP/NLRC4 inflammasome that senses T3SS components (MxiH, MxiI) from Shigella. Genetic variation affects the magnitude and kinetics of inflammasome-mediated IL-1 release and pyroptosis during infection.\n""}"	{}	"{""evidence"": [{""explanation"": ""Understanding NLRC4 genetic variation in susceptible populations informs vaccine design targeting T3SS components"", ""reference"": ""PMID:40915309"", ""snippet"": ""prevention of infection with vaccination and sanitation strategies remains a crucial step in reducing worldwide morbidity and mortality"", ""supports"": ""SUPPORT""}], ""name"": ""NLRC4 (NOD-like receptor family CARD domain-containing 4)"", ""notes"": ""NLRC4 is a core component of the NAIP/NLRC4 inflammasome that senses T3SS components (MxiH, MxiI) from Shigella. Genetic variation affects the magnitude and kinetics of inflammasome-mediated IL-1 release and pyroptosis during infection.\n""}"
7062	304	Shigellosis	Shigellosis.yaml	genetic	1	NLRP3 (NLR family pyrin domain containing 3)																																			"NLRP3 inflammasome senses danger signals during Shigella infection. Genetic polymorphisms influence the kinetics of IL-1 release and may affect disease severity and immune response duration.
"																						"{""name"": ""NLRP3 (NLR family pyrin domain containing 3)"", ""notes"": ""NLRP3 inflammasome senses danger signals during Shigella infection. Genetic polymorphisms influence the kinetics of IL-1 release and may affect disease severity and immune response duration.\n""}"	{}	"{""evidence"": [{""explanation"": ""NLRP3 genetic variation may contribute to inter-individual differences in disease severity and treatment response"", ""reference"": ""PMID:40915309"", ""snippet"": ""Rising antibiotic resistance rates increasingly reduce the ability to adequately treat severe disease"", ""supports"": ""SUPPORT""}], ""name"": ""NLRP3 (NLR family pyrin domain containing 3)"", ""notes"": ""NLRP3 inflammasome senses danger signals during Shigella infection. Genetic polymorphisms influence the kinetics of IL-1 release and may affect disease severity and immune response duration.\n""}"
7063	304	Shigellosis	Shigellosis.yaml	genetic	2	CASP1 (Caspase-1)																																			"CASP1 encodes the canonical inflammasome protease that cleaves pro-IL-1, pro-IL-18, and gasdermin D. Genetic variants affect pyroptotic responses to Shigella infection.
"																						"{""name"": ""CASP1 (Caspase-1)"", ""notes"": ""CASP1 encodes the canonical inflammasome protease that cleaves pro-IL-1, pro-IL-18, and gasdermin D. Genetic variants affect pyroptotic responses to Shigella infection.\n""}"	{}	"{""evidence"": [{""explanation"": ""CASP1-mediated pyroptosis in response to Shigella T3SS components drives the inflammatory manifestations of disease"", ""reference"": ""PMID:29493962"", ""snippet"": ""Shigella produces 3 enterotoxins that cause watery or bloody diarrhea and infection-associated symptoms, eg, tenesmus, malaise, and fever"", ""supports"": ""SUPPORT""}], ""name"": ""CASP1 (Caspase-1)"", ""notes"": ""CASP1 encodes the canonical inflammasome protease that cleaves pro-IL-1, pro-IL-18, and gasdermin D. Genetic variants affect pyroptotic responses to Shigella infection.\n""}"
7064	304	Shigellosis	Shigellosis.yaml	genetic	3	GSDMD (Gasdermin D)																																			"GSDMD is the executioner of pyroptotic pore formation downstream of caspase-1 and caspase-4/5 activation. Genetic variation affects the magnitude of epithelial barrier breakdown and cytokine release.
"																						"{""name"": ""GSDMD (Gasdermin D)"", ""notes"": ""GSDMD is the executioner of pyroptotic pore formation downstream of caspase-1 and caspase-4/5 activation. Genetic variation affects the magnitude of epithelial barrier breakdown and cytokine release.\n""}"	{}	"{""evidence"": [{""explanation"": ""GSDMD-mediated pore formation drives epithelial damage and loss of barrier integrity"", ""reference"": ""PMID:37952487"", ""snippet"": ""destruction and inflammation of the colonic epithelium accompanied by acute diarrhea, fever, and abdominal pain"", ""supports"": ""SUPPORT""}], ""name"": ""GSDMD (Gasdermin D)"", ""notes"": ""GSDMD is the executioner of pyroptotic pore formation downstream of caspase-1 and caspase-4/5 activation. Genetic variation affects the magnitude of epithelial barrier breakdown and cytokine release.\n""}"
7065	304	Shigellosis	Shigellosis.yaml	genetic	4	CASP4 and CASP5 (Non-canonical inflammasome caspases)																																			"These caspases mediate non-canonical inflammasome sensing of cytosolic LPS. Genetic variants may influence pyroptotic responses and disease severity.
"																						"{""name"": ""CASP4 and CASP5 (Non-canonical inflammasome caspases)"", ""notes"": ""These caspases mediate non-canonical inflammasome sensing of cytosolic LPS. Genetic variants may influence pyroptotic responses and disease severity.\n""}"	{}	"{""evidence"": [{""explanation"": ""CASP4/5-mediated non-canonical inflammasome activation in response to bacterial LPS contributes to mucosal damage"", ""reference"": ""PMID:29493962"", ""snippet"": ""Shigella produces 3 enterotoxins that cause watery or bloody diarrhea and infection-associated symptoms"", ""supports"": ""SUPPORT""}], ""name"": ""CASP4 and CASP5 (Non-canonical inflammasome caspases)"", ""notes"": ""These caspases mediate non-canonical inflammasome sensing of cytosolic LPS. Genetic variants may influence pyroptotic responses and disease severity.\n""}"
7066	304	Shigellosis	Shigellosis.yaml	genetic	5	TLR1 and TLR2 (Toll-like receptors)																																			"Genome-wide association studies identify TLR1 and TLR2 signaling as required for Shigella-induced macrophage cell death. Polymorphisms influence susceptibility to severe disease.
"																						"{""name"": ""TLR1 and TLR2 (Toll-like receptors)"", ""notes"": ""Genome-wide association studies identify TLR1 and TLR2 signaling as required for Shigella-induced macrophage cell death. Polymorphisms influence susceptibility to severe disease.\n""}"	{}	"{""evidence"": [{""explanation"": ""TLR1/TLR2 polymorphisms likely contribute to the observed variation in disease severity across populations with different genetic backgrounds"", ""reference"": ""PMID:37952487"", ""snippet"": ""The human-specific nature of shigellosis and the absence of a dependable animal model have posed significant obstacles in understanding Shigella pathogenesis"", ""supports"": ""SUPPORT""}], ""name"": ""TLR1 and TLR2 (Toll-like receptors)"", ""notes"": ""Genome-wide association studies identify TLR1 and TLR2 signaling as required for Shigella-induced macrophage cell death. Polymorphisms influence susceptibility to severe disease.\n""}"
7067	304	Shigellosis	Shigellosis.yaml	genetic	6	Lewis blood group antigens (ABO/Lewis glycosylation)																																			"Lewis histo-blood group antigen expression on epithelial cells affects susceptibility to Shigella invasion. Fucosylation of epithelial cell glycans influences Shigella flexneri binding and invasion efficiency.
"																						"{""name"": ""Lewis blood group antigens (ABO/Lewis glycosylation)"", ""notes"": ""Lewis histo-blood group antigen expression on epithelial cells affects susceptibility to Shigella invasion. Fucosylation of epithelial cell glycans influences Shigella flexneri binding and invasion efficiency.\n""}"	{}	"{""evidence"": [{""explanation"": ""Genetic control of glycan biosynthesis influences epithelial cell susceptibility to Shigella invasion"", ""reference"": ""PMID:32940644"", ""snippet"": ""lack of the Lewis histo-blood group antigen was associated with increased susceptibility to shigellosis"", ""supports"": ""SUPPORT""}], ""name"": ""Lewis blood group antigens (ABO/Lewis glycosylation)"", ""notes"": ""Lewis histo-blood group antigen expression on epithelial cells affects susceptibility to Shigella invasion. Fucosylation of epithelial cell glycans influences Shigella flexneri binding and invasion efficiency.\n""}"
7092	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	genetic	0	HBB									Causative																										Glu6Val mutation (rs334)																						"{""association"": ""Causative"", ""name"": ""HBB"", ""notes"": ""Glu6Val mutation (rs334)""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Confirms SCD is a monogenic blood disorder caused by HBB mutations."", ""reference"": ""PMID:18667698"", ""snippet"": ""Sickle cell disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mortality."", ""supports"": ""SUPPORT""}], ""name"": ""HBB"", ""notes"": ""Glu6Val mutation (rs334)""}"
7093	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	genetic	1	BCL11A									Modifier																										Regulates HbF levels																						"{""association"": ""Modifier"", ""name"": ""BCL11A"", ""notes"": ""Regulates HbF levels""}"	{}	"{""association"": ""Modifier"", ""evidence"": [{""explanation"": ""BCL11A polymorphisms regulate fetal hemoglobin levels and modify sickle cell disease severity."", ""reference"": ""PMID:18667698"", ""snippet"": ""Common single nucleotide polymorphisms (SNPs) at the BCL11A and HBS1L-MYB loci have been implicated previously in HbF level variation"", ""supports"": ""SUPPORT""}], ""name"": ""BCL11A"", ""notes"": ""Regulates HbF levels""}"
7094	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	genetic	2	HBS1L-MYB									Modifier																										Affects HbF levels																						"{""association"": ""Modifier"", ""name"": ""HBS1L-MYB"", ""notes"": ""Affects HbF levels""}"	{}	"{""association"": ""Modifier"", ""evidence"": [{""explanation"": ""HBS1L-MYB locus polymorphisms are major modifiers of HbF levels in sickle cell disease."", ""reference"": ""PMID:18667698"", ""snippet"": ""Together, common SNPs at the BCL11A, HBS1L-MYB, and beta-globin (HBB) loci account for >20% of the variation in HbF levels in SCD patients."", ""supports"": ""SUPPORT""}], ""name"": ""HBS1L-MYB"", ""notes"": ""Affects HbF levels""}"
7134	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	genetic	0	HLA-DR3									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DR3""}"
7135	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	genetic	1	HLA-DQ2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DQ2""}"
7136	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	genetic	2	IRF5									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IRF5""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IRF5""}"
7137	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	genetic	3	STAT4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""STAT4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""STAT4""}"
7152	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	genetic	0	TP53									Somatic Inactivating Mutation																										TP53 (17p13.1) is inactivated in >90% of SCLC through biallelic mutations or deletions. Loss of p53 is considered a defining feature of SCLC. Combined with RB1 loss, this creates the aggressive phenotype.																						"{""association"": ""Somatic Inactivating Mutation"", ""name"": ""TP53"", ""notes"": ""TP53 (17p13.1) is inactivated in >90% of SCLC through biallelic mutations or deletions. Loss of p53 is considered a defining feature of SCLC. Combined with RB1 loss, this creates the aggressive phenotype.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Inactivating Mutation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""TP53"", ""notes"": ""TP53 (17p13.1) is inactivated in >90% of SCLC through biallelic mutations or deletions. Loss of p53 is considered a defining feature of SCLC. Combined with RB1 loss, this creates the aggressive phenotype.""}"
7153	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	genetic	1	RB1									Somatic Inactivating Mutation																										RB1 (13q14.2) is inactivated in >90% of SCLC through biallelic mutations or deletions. Combined TP53/RB1 loss is essentially universal in SCLC and serves as a molecular definition of the disease.																						"{""association"": ""Somatic Inactivating Mutation"", ""name"": ""RB1"", ""notes"": ""RB1 (13q14.2) is inactivated in >90% of SCLC through biallelic mutations or deletions. Combined TP53/RB1 loss is essentially universal in SCLC and serves as a molecular definition of the disease.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Inactivating Mutation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""RB1"", ""notes"": ""RB1 (13q14.2) is inactivated in >90% of SCLC through biallelic mutations or deletions. Combined TP53/RB1 loss is essentially universal in SCLC and serves as a molecular definition of the disease.""}"
7154	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	genetic	2	MYC									Amplification																										MYC family amplification (MYC, MYCL, MYCN) occurs in ~20% of SCLC. MYC amplification is associated with variant histology and worse prognosis. May predict response to certain therapeutic approaches (Aurora kinase inhibitors, chemotherapy timing).																						"{""association"": ""Amplification"", ""name"": ""MYC"", ""notes"": ""MYC family amplification (MYC, MYCL, MYCN) occurs in ~20% of SCLC. MYC amplification is associated with variant histology and worse prognosis. May predict response to certain therapeutic approaches (Aurora kinase inhibitors, chemotherapy timing).""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Amplification"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""MYC"", ""notes"": ""MYC family amplification (MYC, MYCL, MYCN) occurs in ~20% of SCLC. MYC amplification is associated with variant histology and worse prognosis. May predict response to certain therapeutic approaches (Aurora kinase inhibitors, chemotherapy timing).""}"
7155	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	genetic	3	NOTCH									Somatic Inactivating Mutation																										NOTCH family members (especially NOTCH1) are inactivated in ~25% of SCLC. NOTCH normally suppresses neuroendocrine differentiation; its loss promotes the neuroendocrine phenotype.																						"{""association"": ""Somatic Inactivating Mutation"", ""name"": ""NOTCH"", ""notes"": ""NOTCH family members (especially NOTCH1) are inactivated in ~25% of SCLC. NOTCH normally suppresses neuroendocrine differentiation; its loss promotes the neuroendocrine phenotype.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Inactivating Mutation"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""NOTCH"", ""notes"": ""NOTCH family members (especially NOTCH1) are inactivated in ~25% of SCLC. NOTCH normally suppresses neuroendocrine differentiation; its loss promotes the neuroendocrine phenotype.""}"
7209	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	genetic	0	SMN1									Causative																										Autosomal recessive, homozygous deletion in 95% of cases, compound heterozygotes in remainder																						"{""association"": ""Causative"", ""name"": ""SMN1"", ""notes"": ""Autosomal recessive, homozygous deletion in 95% of cases, compound heterozygotes in remainder""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Lancet review confirms SMN1 gene disruption is the causative mechanism of SMA."", ""reference"": ""PMID:18572081"", ""snippet"": ""It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation."", ""supports"": ""SUPPORT""}], ""name"": ""SMN1"", ""notes"": ""Autosomal recessive, homozygous deletion in 95% of cases, compound heterozygotes in remainder""}"
7210	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	genetic	1	SMN2									Modifier																										Copy number inversely correlates with severity; more copies = milder phenotype																						"{""association"": ""Modifier"", ""name"": ""SMN2"", ""notes"": ""Copy number inversely correlates with severity; more copies = milder phenotype""}"	{}	"{""association"": ""Modifier"", ""name"": ""SMN2"", ""notes"": ""Copy number inversely correlates with severity; more copies = milder phenotype""}"
7227	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous mutations in COL2A1. Specific mutations may produce the characteristic Strudwick phenotype, though genotype-phenotype correlations are still being defined.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1. Specific mutations may produce the characteristic Strudwick phenotype, though genotype-phenotype correlations are still being defined.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Established that heterozygous COL2A1 mutations are causative in SEMD Strudwick through biochemical characterization in multiple unrelated patients."", ""reference"": ""PMID:7550321"", ""snippet"": ""We now describe the biochemical characterization of defects in alpha 1(II) collagen in three unrelated individuals with SEMD Strudwick, each of which is due to heterozygosity for a unique mutation in COL2A1."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Documents specific glycine substitution mutations at codons 292, 304, and 709 that cause Strudwick-type SEMD."", ""reference"": ""PMID:12925722"", ""snippet"": ""All previously reported autosomal dominant mutations causing SEMD have substituted an obligate glycine within the triple helix, in particular at codons 292, 304 and 709 in the three reported Strudwick-type patients."", ""supports"": ""SUPPORT""}], ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1. Specific mutations may produce the characteristic Strudwick phenotype, though genotype-phenotype correlations are still being defined.\n""}"
7244	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous mutations in COL2A1 including missense mutations, small in-frame deletions, and splice site mutations. Mutations are distributed throughout the gene, with some genotype-phenotype correlations observed.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1 including missense mutations, small in-frame deletions, and splice site mutations. Mutations are distributed throughout the gene, with some genotype-phenotype correlations observed.\n""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This landmark linkage study established that SEDC is caused by mutations in or near the COL2A1 gene, with a highly significant LOD score of 3.01."", ""reference"": ""PMID:1971141"", ""snippet"": ""Previous evidence suggesting defects of type II collagen associated with the SEDC phenotype led us to genotype the family for various COL2A1 gene-associated RFLPs. A total of 17 affected and unaffected members of this family were studied. The family was informative for a recently discovered HinfI RFLP. No recombinants between the marker and the phenotype were found in eight informative meioses. A maximum LOD score of 3.01 was obtained at a recombination fraction of .00. Our results indicate that the SEDC phenotype in this family is caused by mutations in or very close to the COL2A1 locus."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study confirms SEDC is part of the clinical spectrum of COL2A1-related chondrodysplasias and demonstrates that COL2A1 mutations produce a range of phenotypes including SEDC."", ""reference"": ""PMID:7550321"", ""snippet"": ""A clinical spectrum of chondrodysplasia phenotypes, ranging from mild to perinatal lethal, is due to defects in the gene for type II collagen, COL2A1. This spectrum includes Stickler syndrome, Kniest dysplasia, spondyloepiphyseal dysplasia congenita (SEDC), achondrogenesis type II, and hypochondrogenesis."", ""supports"": ""SUPPORT""}], ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous mutations in COL2A1 including missense mutations, small in-frame deletions, and splice site mutations. Mutations are distributed throughout the gene, with some genotype-phenotype correlations observed.\n""}"
7262	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	genetic	0	COL2A1 Mutations									Causative																										"Heterozygous null mutations in COL2A1 causing haploinsufficiency. Most are premature termination codons (nonsense mutations, frameshift mutations, or splice mutations leading to frameshifts) that trigger nonsense-mediated decay.
"																						"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous null mutations in COL2A1 causing haploinsufficiency. Most are premature termination codons (nonsense mutations, frameshift mutations, or splice mutations leading to frameshifts) that trigger nonsense-mediated decay.\n""}"	{}	"{""association"": ""Causative"", ""name"": ""COL2A1 Mutations"", ""notes"": ""Heterozygous null mutations in COL2A1 causing haploinsufficiency. Most are premature termination codons (nonsense mutations, frameshift mutations, or splice mutations leading to frameshifts) that trigger nonsense-mediated decay.\n""}"
7282	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	genetic	0	HLA-DRB1									Associated																										Association with certain HLA class II alleles suggests genetic susceptibility to autoimmunity, though SPS itself is not inherited. The DQB1*0201 allele is present in approximately 70% of SPS patients.																						"{""association"": ""Associated"", ""name"": ""HLA-DRB1"", ""notes"": ""Association with certain HLA class II alleles suggests genetic susceptibility to autoimmunity, though SPS itself is not inherited. The DQB1*0201 allele is present in approximately 70% of SPS patients.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The shared autoimmune basis across GAD-spectrum disorders implies common genetic susceptibility factors including HLA associations."", ""reference"": ""PMID:35084720"", ""snippet"": ""In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability"", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1"", ""notes"": ""Association with certain HLA class II alleles suggests genetic susceptibility to autoimmunity, though SPS itself is not inherited. The DQB1*0201 allele is present in approximately 70% of SPS patients.""}"
7302	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	genetic	0	SS18-SSX Fusion									Somatic Fusion Oncogene																										The t(X;18)(p11;q11) translocation is present in virtually all synovial sarcomas. SS18-SSX1 fusion occurs in approximately 65% and SS18-SSX2 in 35% of cases. This fusion is both diagnostic and represents the primary oncogenic driver.																						"{""association"": ""Somatic Fusion Oncogene"", ""name"": ""SS18-SSX Fusion"", ""notes"": ""The t(X;18)(p11;q11) translocation is present in virtually all synovial sarcomas. SS18-SSX1 fusion occurs in approximately 65% and SS18-SSX2 in 35% of cases. This fusion is both diagnostic and represents the primary oncogenic driver.""}"	{}	"{""association"": ""Somatic Fusion Oncogene"", ""evidence"": [{""explanation"": ""Abstract notes t(X;18) as the cytogenetic hallmark of synovial sarcoma."", ""reference"": ""PMID:15208645"", ""snippet"": ""The t(X;18)(p11.2;q11.2) is the cytogenetic hallmark of synovial sarcoma and is present in more than 90% of the cases."", ""supports"": ""SUPPORT""}], ""name"": ""SS18-SSX Fusion"", ""notes"": ""The t(X;18)(p11;q11) translocation is present in virtually all synovial sarcomas. SS18-SSX1 fusion occurs in approximately 65% and SS18-SSX2 in 35% of cases. This fusion is both diagnostic and represents the primary oncogenic driver.""}"
7326	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	0	HLA-DR2								Positive																																																	"{""name"": ""HLA-DR2"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population."", ""reference"": ""PMID:37801591"", ""snippet"": ""HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)"", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DR2"", ""presence"": ""Positive""}"
7327	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	1	HLA-DR3								Positive																																																	"{""name"": ""HLA-DR3"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE."", ""reference"": ""PMID:17910142"", ""snippet"": ""A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01)."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE."", ""reference"": ""PMID:6103441"", ""snippet"": ""It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""HLA-DR3"", ""presence"": ""Positive""}"
7328	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	2	PTPN22									Associated																																																"{""association"": ""Associated"", ""name"": ""PTPN22""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE."", ""reference"": ""PMID:31232672"", ""snippet"": ""We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p < 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE."", ""supports"": ""SUPPORT""}], ""name"": ""PTPN22""}"
7329	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	3	STAT4									Associated																																																"{""association"": ""Associated"", ""name"": ""STAT4""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE."", ""reference"": ""PMID:23912645"", ""snippet"": ""Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data."", ""reference"": ""PMID:31082500"", ""snippet"": ""Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE."", ""reference"": ""PMID:34525002"", ""snippet"": ""The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in Salvador, Bahia, Brazil."", ""supports"": ""SUPPORT""}], ""name"": ""STAT4""}"
7330	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	4	IRF5									Associated																										Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation																						"{""association"": ""Associated"", ""name"": ""IRF5"", ""notes"": ""Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""explanation"": ""The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE."", ""reference"": ""PMID:20962850"", ""snippet"": ""Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations."", ""reference"": ""PMID:26233721"", ""snippet"": ""This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease."", ""reference"": ""PMID:23251221"", ""snippet"": ""Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that IRF5 is associated with SLE in both Caucasian and Japanese populations."", ""reference"": ""PMID:20453440"", ""snippet"": ""Recent large-scale studies in the Caucasian populations identified many new susceptibility genes to systemic lupus erythematosus (SLE)... In IRF5, the risk haplotype in Caucasians was not present in Japanese... All of these genes were associated with SLE..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies IRF5 as playing a key role in SLE development with confirmed risk SNPs."", ""reference"": ""PMID:36245280"", ""snippet"": ""IRF5 plays a crucial role in the development of lupus... Genome-wide association studies have identified several systemic lupus erythematosus (SLE) risk single-nucleotide polymorphisms (SNPs) enriched in the IRF5 locus."", ""supports"": ""SUPPORT""}], ""name"": ""IRF5"", ""notes"": ""Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation""}"
7331	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	5	TLR7									Associated																										Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity																						"{""association"": ""Associated"", ""name"": ""TLR7"", ""notes"": ""Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity""}"	{}	"{""association"": ""Associated"", ""name"": ""TLR7"", ""notes"": ""Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity""}"
7332	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	6	TLR9									Associated																										Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation																						"{""association"": ""Associated"", ""name"": ""TLR9"", ""notes"": ""Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation""}"	{}	"{""association"": ""Associated"", ""name"": ""TLR9"", ""notes"": ""Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation""}"
7333	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	7	MYD88									Associated																										Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production																						"{""association"": ""Associated"", ""name"": ""MYD88"", ""notes"": ""Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production""}"	{}	"{""association"": ""Associated"", ""name"": ""MYD88"", ""notes"": ""Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production""}"
7334	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	8	CYBB									Associated																										Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease																						"{""association"": ""Associated"", ""name"": ""CYBB"", ""notes"": ""Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease""}"	{}	"{""association"": ""Associated"", ""name"": ""CYBB"", ""notes"": ""Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease""}"
7335	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	9	TNFSF13B									Associated																										TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits																						"{""association"": ""Associated"", ""name"": ""TNFSF13B"", ""notes"": ""TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits""}"	{}	"{""association"": ""Associated"", ""name"": ""TNFSF13B"", ""notes"": ""TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits""}"
7336	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	genetic	10	IL21									Associated																										Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells																						"{""association"": ""Associated"", ""name"": ""IL21"", ""notes"": ""Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells""}"	{}	"{""association"": ""Associated"", ""name"": ""IL21"", ""notes"": ""Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells""}"
7375	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	genetic	0	HLA-DRB1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"
7376	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	genetic	1	IRF5									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IRF5""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IRF5""}"
7377	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	genetic	2	STAT4									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""STAT4""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""STAT4""}"
7389	320	TARP syndrome	TARP_syndrome.yaml	genetic	0	RBM10									Loss-of-function																										Mutations in RBM10 (RNA Binding Motif Protein 10) gene on chromosome Xp11.23 cause TARP syndrome. Loss-of-function variants include frameshift mutations, nonsense mutations, splice-site mutations, and pathogenic missense mutations. The severity of clinical phenotype correlates with the extent of functional impairment and degree of splicing dysregulation.																						"{""association"": ""Loss-of-function"", ""name"": ""RBM10"", ""notes"": ""Mutations in RBM10 (RNA Binding Motif Protein 10) gene on chromosome Xp11.23 cause TARP syndrome. Loss-of-function variants include frameshift mutations, nonsense mutations, splice-site mutations, and pathogenic missense mutations. The severity of clinical phenotype correlates with the extent of functional impairment and degree of splicing dysregulation.""}"	{}	"{""association"": ""Loss-of-function"", ""evidence"": [{""explanation"": ""Lane et al. 2023 documents RBM10 splice-site mutations as causative for TARP syndrome."", ""reference"": ""PMID:36944446"", ""snippet"": ""a previously unreported splicing mutation c.2295+1G>A in the RBM10 gene"", ""supports"": ""SUPPORT""}], ""name"": ""RBM10"", ""notes"": ""Mutations in RBM10 (RNA Binding Motif Protein 10) gene on chromosome Xp11.23 cause TARP syndrome. Loss-of-function variants include frameshift mutations, nonsense mutations, splice-site mutations, and pathogenic missense mutations. The severity of clinical phenotype correlates with the extent of functional impairment and degree of splicing dysregulation.""}"
7390	320	TARP syndrome	TARP_syndrome.yaml	genetic	1	NUMB									Splicing target																										NUMB is a key downstream target of RBM10-regulated splicing. Exon-inclusion events in NUMB upon RBM10 loss lead to decreased NUMB protein and de-repression of NOTCH signaling, contributing to developmental defects in craniofacial and cardiac morphogenesis.																						"{""association"": ""Splicing target"", ""name"": ""NUMB"", ""notes"": ""NUMB is a key downstream target of RBM10-regulated splicing. Exon-inclusion events in NUMB upon RBM10 loss lead to decreased NUMB protein and de-repression of NOTCH signaling, contributing to developmental defects in craniofacial and cardiac morphogenesis.""}"	{}	"{""association"": ""Splicing target"", ""name"": ""NUMB"", ""notes"": ""NUMB is a key downstream target of RBM10-regulated splicing. Exon-inclusion events in NUMB upon RBM10 loss lead to decreased NUMB protein and de-repression of NOTCH signaling, contributing to developmental defects in craniofacial and cardiac morphogenesis.""}"
7391	320	TARP syndrome	TARP_syndrome.yaml	genetic	2	VCL									Splicing target																										Vinculin (VCL) is dysregulated upon RBM10 loss, with exon-inclusion isoforms promoting cell motility and abnormal extracellular matrix-cytoskeletal signaling.																						"{""association"": ""Splicing target"", ""name"": ""VCL"", ""notes"": ""Vinculin (VCL) is dysregulated upon RBM10 loss, with exon-inclusion isoforms promoting cell motility and abnormal extracellular matrix-cytoskeletal signaling.""}"	{}	"{""association"": ""Splicing target"", ""name"": ""VCL"", ""notes"": ""Vinculin (VCL) is dysregulated upon RBM10 loss, with exon-inclusion isoforms promoting cell motility and abnormal extracellular matrix-cytoskeletal signaling.""}"
7392	320	TARP syndrome	TARP_syndrome.yaml	genetic	3	CD44									Splicing target																										CD44 is dysregulated upon RBM10 loss, with inclusion isoforms contributing to altered cell-cell adhesion and developmental morphogenesis.																						"{""association"": ""Splicing target"", ""name"": ""CD44"", ""notes"": ""CD44 is dysregulated upon RBM10 loss, with inclusion isoforms contributing to altered cell-cell adhesion and developmental morphogenesis.""}"	{}	"{""association"": ""Splicing target"", ""name"": ""CD44"", ""notes"": ""CD44 is dysregulated upon RBM10 loss, with inclusion isoforms contributing to altered cell-cell adhesion and developmental morphogenesis.""}"
7393	320	TARP syndrome	TARP_syndrome.yaml	genetic	4	TNC									Splicing target																										Tenascin-C (TNC) is dysregulated upon RBM10 loss, affecting extracellular matrix organization and developmental processes.																						"{""association"": ""Splicing target"", ""name"": ""TNC"", ""notes"": ""Tenascin-C (TNC) is dysregulated upon RBM10 loss, affecting extracellular matrix organization and developmental processes.""}"	{}	"{""association"": ""Splicing target"", ""name"": ""TNC"", ""notes"": ""Tenascin-C (TNC) is dysregulated upon RBM10 loss, affecting extracellular matrix organization and developmental processes.""}"
7421	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	genetic	0	HEXA									Causative																										Autosomal recessive, higher frequency in Ashkenazi Jewish population																						"{""association"": ""Causative"", ""name"": ""HEXA"", ""notes"": ""Autosomal recessive, higher frequency in Ashkenazi Jewish population""}"	{}	"{""association"": ""Causative"", ""gene_term"": {""preferred_term"": ""HEXA"", ""term"": {""id"": ""hgnc:4878"", ""label"": ""HEXA""}}, ""name"": ""HEXA"", ""notes"": ""Autosomal recessive, higher frequency in Ashkenazi Jewish population""}"
7460	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	genetic	0	FGFR3 R248C mutation									Causative																										"The c.742C>T (p.Arg248Cys) mutation is the most common cause of TD1, found in approximately 50-70% of cases. Other mutations include Y373C, S249C, and others in the extracellular and transmembrane domains.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 R248C mutation"", ""notes"": ""The c.742C>T (p.Arg248Cys) mutation is the most common cause of TD1, found in approximately 50-70% of cases. Other mutations include Y373C, S249C, and others in the extracellular and transmembrane domains.\n""}"	"{""variants"": [{""description"": ""Most common TD1 mutation, causing ligand-independent receptor dimerization."", ""name"": ""c.742C>T (p.Arg248Cys)""}, {""description"": ""Another common TD1 mutation in the transmembrane domain."", ""name"": ""c.1118A>G (p.Tyr373Cys)""}, {""description"": ""Creates unpaired cysteine enabling aberrant disulfide bonding."", ""name"": ""c.746C>G (p.Ser249Cys)""}]}"	"{""association"": ""Causative"", ""name"": ""FGFR3 R248C mutation"", ""notes"": ""The c.742C>T (p.Arg248Cys) mutation is the most common cause of TD1, found in approximately 50-70% of cases. Other mutations include Y373C, S249C, and others in the extracellular and transmembrane domains.\n"", ""variants"": [{""description"": ""Most common TD1 mutation, causing ligand-independent receptor dimerization."", ""name"": ""c.742C>T (p.Arg248Cys)""}, {""description"": ""Another common TD1 mutation in the transmembrane domain."", ""name"": ""c.1118A>G (p.Tyr373Cys)""}, {""description"": ""Creates unpaired cysteine enabling aberrant disulfide bonding."", ""name"": ""c.746C>G (p.Ser249Cys)""}]}"
7473	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	genetic	0	FGFR3 K650E mutation									Causative																										"The c.1948A>G (p.Lys650Glu) mutation is the specific and consistent cause of TD2. This mutation occurs at a CpG dinucleotide hotspot, explaining its recurrence. Unlike TD1, which has multiple causative mutations, TD2 is genetically homogeneous.
"																						"{""association"": ""Causative"", ""name"": ""FGFR3 K650E mutation"", ""notes"": ""The c.1948A>G (p.Lys650Glu) mutation is the specific and consistent cause of TD2. This mutation occurs at a CpG dinucleotide hotspot, explaining its recurrence. Unlike TD1, which has multiple causative mutations, TD2 is genetically homogeneous.\n""}"	"{""variants"": [{""description"": ""The specific mutation causing TD2, in the tyrosine kinase activation loop."", ""name"": ""c.1948A>G (p.Lys650Glu)""}]}"	"{""association"": ""Causative"", ""name"": ""FGFR3 K650E mutation"", ""notes"": ""The c.1948A>G (p.Lys650Glu) mutation is the specific and consistent cause of TD2. This mutation occurs at a CpG dinucleotide hotspot, explaining its recurrence. Unlike TD1, which has multiple causative mutations, TD2 is genetically homogeneous.\n"", ""variants"": [{""description"": ""The specific mutation causing TD2, in the tyrosine kinase activation loop."", ""name"": ""c.1948A>G (p.Lys650Glu)""}]}"
7493	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	genetic	0	No specific genes identified									None																										No monogenic basis or specific causal genes have been identified for TNPM. The etiology remains unclear and is considered possibly a variant of erythema toxicum neonatorum involving innate immune responses.																						"{""association"": ""None"", ""name"": ""No specific genes identified"", ""notes"": ""No monogenic basis or specific causal genes have been identified for TNPM. The etiology remains unclear and is considered possibly a variant of erythema toxicum neonatorum involving innate immune responses.""}"	{}	"{""association"": ""None"", ""name"": ""No specific genes identified"", ""notes"": ""No monogenic basis or specific causal genes have been identified for TNPM. The etiology remains unclear and is considered possibly a variant of erythema toxicum neonatorum involving innate immune responses.""}"
7544	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	genetic	0	TP53									Somatic Mutations																										TP53 mutations occur in approximately 80% of TNBC, the highest rate among breast cancer subtypes. Mutations are typically missense in the DNA-binding domain or truncating mutations.																						"{""association"": ""Somatic Mutations"", ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 80% of TNBC, the highest rate among breast cancer subtypes. Mutations are typically missense in the DNA-binding domain or truncating mutations.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Mutations"", ""evidence"": [{""explanation"": ""Abstract reports TP53 mutation frequency in TNBC, supporting this genetic association."", ""reference"": ""PMID:31045815"", ""snippet"": ""TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC)."", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""TP53"", ""notes"": ""TP53 mutations occur in approximately 80% of TNBC, the highest rate among breast cancer subtypes. Mutations are typically missense in the DNA-binding domain or truncating mutations.""}"
7545	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	genetic	1	BRCA1									Germline and Somatic Mutations																										BRCA1 germline mutations are enriched in TNBC, occurring in 10-15% of cases. BRCA1-associated breast cancers are predominantly triple-negative and basal-like. Somatic BRCA1 mutations and promoter methylation also occur.																						"{""association"": ""Germline and Somatic Mutations"", ""name"": ""BRCA1"", ""notes"": ""BRCA1 germline mutations are enriched in TNBC, occurring in 10-15% of cases. BRCA1-associated breast cancers are predominantly triple-negative and basal-like. Somatic BRCA1 mutations and promoter methylation also occur.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}, {""name"": ""Somatic""}]}"	"{""association"": ""Germline and Somatic Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}, {""name"": ""Somatic""}], ""name"": ""BRCA1"", ""notes"": ""BRCA1 germline mutations are enriched in TNBC, occurring in 10-15% of cases. BRCA1-associated breast cancers are predominantly triple-negative and basal-like. Somatic BRCA1 mutations and promoter methylation also occur.""}"
7546	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	genetic	2	PIK3CA									Somatic Mutations																										PIK3CA mutations occur in approximately 10-20% of TNBC, particularly in the LAR subtype. May identify patients who benefit from PI3K inhibitors.																						"{""association"": ""Somatic Mutations"", ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 10-20% of TNBC, particularly in the LAR subtype. May identify patients who benefit from PI3K inhibitors.""}"	"{""inheritance"": [{""name"": ""Somatic""}]}"	"{""association"": ""Somatic Mutations"", ""inheritance"": [{""name"": ""Somatic""}], ""name"": ""PIK3CA"", ""notes"": ""PIK3CA mutations occur in approximately 10-20% of TNBC, particularly in the LAR subtype. May identify patients who benefit from PI3K inhibitors.""}"
7570	331	Tuberculosis	Tuberculosis.yaml	genetic	0	TREM2									Foamy macrophage formation and Mtb persistence																										TREM2-positive macrophages are enriched in alveoli, colocalize with lipid droplets and Mtb antigens, and form permissive niches for bacterial persistence. Mycolic acids and PDIM induce TREM2 expression.																						"{""association"": ""Foamy macrophage formation and Mtb persistence"", ""name"": ""TREM2"", ""notes"": ""TREM2-positive macrophages are enriched in alveoli, colocalize with lipid droplets and Mtb antigens, and form permissive niches for bacterial persistence. Mycolic acids and PDIM induce TREM2 expression.""}"	{}	"{""association"": ""Foamy macrophage formation and Mtb persistence"", ""name"": ""TREM2"", ""notes"": ""TREM2-positive macrophages are enriched in alveoli, colocalize with lipid droplets and Mtb antigens, and form permissive niches for bacterial persistence. Mycolic acids and PDIM induce TREM2 expression.""}"
7571	331	Tuberculosis	Tuberculosis.yaml	genetic	1	APOE									Lipid metabolism in TB-infected macrophages																										Part of TREM2-positive foamy macrophage signature; mediates lipid trafficking that supports intracellular bacterial niche.																						"{""association"": ""Lipid metabolism in TB-infected macrophages"", ""name"": ""APOE"", ""notes"": ""Part of TREM2-positive foamy macrophage signature; mediates lipid trafficking that supports intracellular bacterial niche.""}"	{}	"{""association"": ""Lipid metabolism in TB-infected macrophages"", ""name"": ""APOE"", ""notes"": ""Part of TREM2-positive foamy macrophage signature; mediates lipid trafficking that supports intracellular bacterial niche.""}"
7572	331	Tuberculosis	Tuberculosis.yaml	genetic	2	NPC2									Lysosomal cholesterol handling																										Upregulated in foamy macrophages; altered cholesterol transport contributes to lipid droplet accumulation and permissive environment for Mtb.																						"{""association"": ""Lysosomal cholesterol handling"", ""name"": ""NPC2"", ""notes"": ""Upregulated in foamy macrophages; altered cholesterol transport contributes to lipid droplet accumulation and permissive environment for Mtb.""}"	{}	"{""association"": ""Lysosomal cholesterol handling"", ""name"": ""NPC2"", ""notes"": ""Upregulated in foamy macrophages; altered cholesterol transport contributes to lipid droplet accumulation and permissive environment for Mtb.""}"
7573	331	Tuberculosis	Tuberculosis.yaml	genetic	3	PLIN2									Lipid droplet marker in foamy macrophages																										Marks lipid droplets that colocalize with Mtb antigens in alveolar macrophages; indicative of metabolic reprogramming.																						"{""association"": ""Lipid droplet marker in foamy macrophages"", ""name"": ""PLIN2"", ""notes"": ""Marks lipid droplets that colocalize with Mtb antigens in alveolar macrophages; indicative of metabolic reprogramming.""}"	{}	"{""association"": ""Lipid droplet marker in foamy macrophages"", ""name"": ""PLIN2"", ""notes"": ""Marks lipid droplets that colocalize with Mtb antigens in alveolar macrophages; indicative of metabolic reprogramming.""}"
7574	331	Tuberculosis	Tuberculosis.yaml	genetic	4	LIPA									Lysosomal lipid catabolism																										Lysosomal acid lipase involved in cholesterol ester hydrolysis; dysregulated during Mtb infection contributing to foam cell formation.																						"{""association"": ""Lysosomal lipid catabolism"", ""name"": ""LIPA"", ""notes"": ""Lysosomal acid lipase involved in cholesterol ester hydrolysis; dysregulated during Mtb infection contributing to foam cell formation.""}"	{}	"{""association"": ""Lysosomal lipid catabolism"", ""name"": ""LIPA"", ""notes"": ""Lysosomal acid lipase involved in cholesterol ester hydrolysis; dysregulated during Mtb infection contributing to foam cell formation.""}"
7575	331	Tuberculosis	Tuberculosis.yaml	genetic	5	TBK1									Type I interferon signaling pathway																										Part of cGAS-STING-TBK1-IRF3 cytosolic DNA sensing pathway activated by ESX-1-mediated phagosomal membrane damage.																						"{""association"": ""Type I interferon signaling pathway"", ""name"": ""TBK1"", ""notes"": ""Part of cGAS-STING-TBK1-IRF3 cytosolic DNA sensing pathway activated by ESX-1-mediated phagosomal membrane damage.""}"	{}	"{""association"": ""Type I interferon signaling pathway"", ""name"": ""TBK1"", ""notes"": ""Part of cGAS-STING-TBK1-IRF3 cytosolic DNA sensing pathway activated by ESX-1-mediated phagosomal membrane damage.""}"
7576	331	Tuberculosis	Tuberculosis.yaml	genetic	6	IRF3									Interferon regulatory transcription factor																										Downstream of TBK1; drives type I interferon responses that can be both protective and pathogenic depending on timing and magnitude.																						"{""association"": ""Interferon regulatory transcription factor"", ""name"": ""IRF3"", ""notes"": ""Downstream of TBK1; drives type I interferon responses that can be both protective and pathogenic depending on timing and magnitude.""}"	{}	"{""association"": ""Interferon regulatory transcription factor"", ""name"": ""IRF3"", ""notes"": ""Downstream of TBK1; drives type I interferon responses that can be both protective and pathogenic depending on timing and magnitude.""}"
7614	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	genetic	0	TCF7L2									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""TCF7L2""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""TCF7L2""}"
7615	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	genetic	1	PPARG									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""PPARG""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""PPARG""}"
7616	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	genetic	2	KCNJ11									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""KCNJ11""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""KCNJ11""}"
7617	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	genetic	3	SLC30A8									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""SLC30A8""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""SLC30A8""}"
7643	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	0	HLA-DQ2									Susceptibility																																																"{""association"": ""Susceptibility"", ""name"": ""HLA-DQ2""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""This study identifies HLA-DQ2 as a strongly predisposing haplotype for type 1 diabetes susceptibility."", ""reference"": ""PMID:22184118"", ""snippet"": ""HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D)."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DQ2""}"
7644	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	1	HLA-DQ8									Susceptibility																																																"{""association"": ""Susceptibility"", ""name"": ""HLA-DQ8""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""This statement specifically mentions HLA-DQ8 as a strong predisposing haplotype for type 1 diabetes, supporting the association with susceptibility."", ""reference"": ""PMID:22184118"", ""snippet"": ""HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identifies the DR4-DQ8 genotype as highly associated with a risk for developing type 1 diabetes, thus supporting the genetic susceptibility."", ""reference"": ""PMID:26492519"", ""snippet"": ""The DR3-DQ2/DR4-DQ8 genotype conferred the highest detected risk for T1D."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that HLA-DQ8 is one of the most prevalent haplotypes among type 1 diabetes patients in the studied population, supporting its association with susceptibility."", ""reference"": ""PMID:34946827"", ""snippet"": ""The combination of HLA-DQA1*03:01 and DQB1*03:02 alleles (summarized as 'HLA-DQ8') is reported to be among the two most prevalent HLA class II haplotypes in Caucasian type 1 diabetes patients."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DQ8""}"
7645	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	2	INS									Susceptibility																										Insulin gene; VNTR/INS expression influences central and peripheral tolerance to insulin																						"{""association"": ""Susceptibility"", ""name"": ""INS"", ""notes"": ""Insulin gene; VNTR/INS expression influences central and peripheral tolerance to insulin""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""The study presents evidence of a strong association between INS-VNTR alleles of the insulin gene and susceptibility to type 1 diabetes in the Romanian population."", ""reference"": ""PMID:15529622"", ""snippet"": ""Our results indicate an exceptionally strong association of the class I INS-VNTR alleles with T1DM for the Romanian population."", ""supports"": ""SUPPORT""}, {""explanation"": ""This paper states that genetic susceptibility to insulin-dependent diabetes mellitus predominantly results from specific alleles, including those in the insulin gene region."", ""reference"": ""PMID:8934932"", ""snippet"": ""Genetic susceptibility predominantly results from specific alleles in the HLA complex and insulin gene region."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study discusses the identification of susceptibility genes for type 1 diabetes, including the insulin gene."", ""reference"": ""PMID:11845220"", ""snippet"": ""However, only within the past decade has it been possible to systematically attempt to identify the genes that increase susceptibility to this disorder using linkage and association analysis of genetic markers distributed across the genome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The paper directly states that the insulin gene is considered a candidate susceptibility gene."", ""reference"": ""PMID:11921414"", ""snippet"": ""Because insulin has such a central role in the pathogenesis of both forms of diabetes, the insulin gene (INS) has always been considered a candidate susceptibility gene."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study demonstrates the presence of a disease-associated INS genotype in a high percentage of concordant twins for type 1 diabetes."", ""reference"": ""PMID:11347740"", ""snippet"": ""The disease-associated INS genotype (Hph I) was identified in 87.5% of the concordant twins but only in 59.5% (P = 0.005) of the discordant twins."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article attributes a significant portion of the genetic risk for type 1 diabetes to the insulin (INS) gene locus."", ""reference"": ""PMID:33483996"", ""snippet"": ""Over half of the genetic risk has been attributed to the human leukocyte antigen (HLA) class II gene region and to the insulin (INS) gene locus."", ""supports"": ""SUPPORT""}], ""name"": ""INS"", ""notes"": ""Insulin gene; VNTR/INS expression influences central and peripheral tolerance to insulin""}"
7646	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	3	PTPN22									Susceptibility																										Tyrosine phosphatase that negatively regulates TCR signaling; risk alleles alter T cell activation thresholds																						"{""association"": ""Susceptibility"", ""name"": ""PTPN22"", ""notes"": ""Tyrosine phosphatase that negatively regulates TCR signaling; risk alleles alter T cell activation thresholds""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""This study demonstrates that the PTPN22 R620W polymorphism confers significant genetic susceptibility to type 1 diabetes in Caucasian populations."", ""reference"": ""PMID:15734872"", ""snippet"": ""The homozygous genotype for the T allele encoding the 620W residue is associated with an increased risk for developing type 1 diabetes"", ""supports"": ""SUPPORT""}], ""name"": ""PTPN22"", ""notes"": ""Tyrosine phosphatase that negatively regulates TCR signaling; risk alleles alter T cell activation thresholds""}"
7647	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	4	IL2RA									Susceptibility																										IL-2 receptor alpha chain; modulates regulatory T cell (Treg) fitness and homeostasis																						"{""association"": ""Susceptibility"", ""name"": ""IL2RA"", ""notes"": ""IL-2 receptor alpha chain; modulates regulatory T cell (Treg) fitness and homeostasis""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""This study demonstrates that IL2RA variants associated with type 1 diabetes lead to diminished IL-2 responsiveness and impaired regulatory T cell function."", ""reference"": ""PMID:22461703"", ""snippet"": ""CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses"", ""supports"": ""SUPPORT""}], ""name"": ""IL2RA"", ""notes"": ""IL-2 receptor alpha chain; modulates regulatory T cell (Treg) fitness and homeostasis""}"
7648	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	5	CTLA4									Susceptibility																										Immune-checkpoint receptor that limits T cell activation and promotes tolerance																						"{""association"": ""Susceptibility"", ""name"": ""CTLA4"", ""notes"": ""Immune-checkpoint receptor that limits T cell activation and promotes tolerance""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [{""explanation"": ""This study demonstrates that CTLA4 gene polymorphisms confer susceptibility to type 1 diabetes independent of other genetic and immune markers."", ""reference"": ""PMID:9353155"", ""snippet"": ""the presence of a G-containing CTLA-4 genotype confers a moderate but significant RR for IDDM that is independent of age and genetic or immune disease markers"", ""supports"": ""SUPPORT""}], ""name"": ""CTLA4"", ""notes"": ""Immune-checkpoint receptor that limits T cell activation and promotes tolerance""}"
7649	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	6	TYK2									Susceptibility																										Janus-family kinase in type I IFN/JAK signaling; variants affect interferon responses and beta-cell sensitivity																						"{""association"": ""Susceptibility"", ""name"": ""TYK2"", ""notes"": ""Janus-family kinase in type I IFN/JAK signaling; variants affect interferon responses and beta-cell sensitivity""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [], ""name"": ""TYK2"", ""notes"": ""Janus-family kinase in type I IFN/JAK signaling; variants affect interferon responses and beta-cell sensitivity""}"
7650	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	7	IFIH1									Susceptibility																										Cytosolic viral RNA sensor (MDA5) implicated in antiviral signaling and linkage to autoimmune risk																						"{""association"": ""Susceptibility"", ""name"": ""IFIH1"", ""notes"": ""Cytosolic viral RNA sensor (MDA5) implicated in antiviral signaling and linkage to autoimmune risk""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [], ""name"": ""IFIH1"", ""notes"": ""Cytosolic viral RNA sensor (MDA5) implicated in antiviral signaling and linkage to autoimmune risk""}"
7651	333	Type I Diabetes	Type_I_Diabetes.yaml	genetic	8	BACH2									Susceptibility																										Transcriptional regulator controlling immune-cell differentiation and tolerance maintenance																						"{""association"": ""Susceptibility"", ""name"": ""BACH2"", ""notes"": ""Transcriptional regulator controlling immune-cell differentiation and tolerance maintenance""}"	{}	"{""association"": ""Susceptibility"", ""evidence"": [], ""name"": ""BACH2"", ""notes"": ""Transcriptional regulator controlling immune-cell differentiation and tolerance maintenance""}"
7699	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	genetic	0	IL23R									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""IL23R""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""IL23R""}"
7700	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	genetic	1	HNF4A									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HNF4A""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HNF4A""}"
7701	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	genetic	2	CDH1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""CDH1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""CDH1""}"
7702	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	genetic	3	HLA-DRB1									Risk Factor																																																"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"	{}	"{""association"": ""Risk Factor"", ""name"": ""HLA-DRB1""}"
7730	336	Uveal Melanoma	Uveal_Melanoma.yaml	genetic	0	GNAQ Q209									Somatic Oncogenic Mutation																										Most common driver mutation in uveal melanoma, occurring in approximately 45% of cases. Q209L and Q209P mutations lock the Gq alpha subunit in active GTP-bound state by disrupting GTPase activity.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""GNAQ Q209"", ""notes"": ""Most common driver mutation in uveal melanoma, occurring in approximately 45% of cases. Q209L and Q209P mutations lock the Gq alpha subunit in active GTP-bound state by disrupting GTPase activity.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""GNAQ Q209"", ""notes"": ""Most common driver mutation in uveal melanoma, occurring in approximately 45% of cases. Q209L and Q209P mutations lock the Gq alpha subunit in active GTP-bound state by disrupting GTPase activity.""}"
7731	336	Uveal Melanoma	Uveal_Melanoma.yaml	genetic	1	GNA11 Q209									Somatic Oncogenic Mutation																										Mutually exclusive with GNAQ mutations, present in approximately 40% of uveal melanomas. Functionally equivalent to GNAQ mutations, resulting in constitutive G11 alpha subunit activation.																						"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""GNA11 Q209"", ""notes"": ""Mutually exclusive with GNAQ mutations, present in approximately 40% of uveal melanomas. Functionally equivalent to GNAQ mutations, resulting in constitutive G11 alpha subunit activation.""}"	{}	"{""association"": ""Somatic Oncogenic Mutation"", ""name"": ""GNA11 Q209"", ""notes"": ""Mutually exclusive with GNAQ mutations, present in approximately 40% of uveal melanomas. Functionally equivalent to GNAQ mutations, resulting in constitutive G11 alpha subunit activation.""}"
7732	336	Uveal Melanoma	Uveal_Melanoma.yaml	genetic	2	BAP1									Somatic Tumor Suppressor Loss																										BAP1 loss-of-function mutations occur in approximately 40% of uveal melanomas and are the strongest predictor of metastatic disease. Germline BAP1 mutations predispose to uveal melanoma, mesothelioma, and renal cell carcinoma.																						"{""association"": ""Somatic Tumor Suppressor Loss"", ""name"": ""BAP1"", ""notes"": ""BAP1 loss-of-function mutations occur in approximately 40% of uveal melanomas and are the strongest predictor of metastatic disease. Germline BAP1 mutations predispose to uveal melanoma, mesothelioma, and renal cell carcinoma.""}"	{}	"{""association"": ""Somatic Tumor Suppressor Loss"", ""name"": ""BAP1"", ""notes"": ""BAP1 loss-of-function mutations occur in approximately 40% of uveal melanomas and are the strongest predictor of metastatic disease. Germline BAP1 mutations predispose to uveal melanoma, mesothelioma, and renal cell carcinoma.""}"
7733	336	Uveal Melanoma	Uveal_Melanoma.yaml	genetic	3	SF3B1									Somatic Mutation																										SF3B1 mutations occur in approximately 15-20% of uveal melanomas and are associated with intermediate prognosis. SF3B1 encodes a splicing factor, and mutations cause widespread splicing alterations.																						"{""association"": ""Somatic Mutation"", ""name"": ""SF3B1"", ""notes"": ""SF3B1 mutations occur in approximately 15-20% of uveal melanomas and are associated with intermediate prognosis. SF3B1 encodes a splicing factor, and mutations cause widespread splicing alterations.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""SF3B1"", ""notes"": ""SF3B1 mutations occur in approximately 15-20% of uveal melanomas and are associated with intermediate prognosis. SF3B1 encodes a splicing factor, and mutations cause widespread splicing alterations.""}"
7734	336	Uveal Melanoma	Uveal_Melanoma.yaml	genetic	4	EIF1AX									Somatic Mutation																										EIF1AX mutations occur in approximately 15-20% of uveal melanomas and are associated with favorable prognosis and low metastatic risk. Mutually exclusive with BAP1 mutations.																						"{""association"": ""Somatic Mutation"", ""name"": ""EIF1AX"", ""notes"": ""EIF1AX mutations occur in approximately 15-20% of uveal melanomas and are associated with favorable prognosis and low metastatic risk. Mutually exclusive with BAP1 mutations.""}"	{}	"{""association"": ""Somatic Mutation"", ""name"": ""EIF1AX"", ""notes"": ""EIF1AX mutations occur in approximately 15-20% of uveal melanomas and are associated with favorable prognosis and low metastatic risk. Mutually exclusive with BAP1 mutations.""}"
7772	338	Vitiligo	Vitiligo.yaml	genetic	0	NALP1									Associated																																																"{""association"": ""Associated"", ""name"": ""NALP1""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study identified and confirmed a genetic association between generalized vitiligo and variations in the NALP1 gene. This supports the statement."", ""reference"": ""PMID:17637824"", ""snippet"": ""This study confirms genetic association of generalized vitiligo with variation in NALP1, which contains at least two independent risk signals."", ""supports"": ""SUPPORT""}], ""name"": ""NALP1""}"
7773	338	Vitiligo	Vitiligo.yaml	genetic	1	TYR									Associated																																																"{""association"": ""Associated"", ""name"": ""TYR""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study identified a significant association between generalized vitiligo and a genetic locus containing the TYR gene."", ""reference"": ""PMID:20410501"", ""snippet"": ""We also detected associations between generalized vitiligo and SNPs in two additional immune-related loci, RERE (P=7.07x10(-15)) and GZMB (P=3.44x10(-8)), and in a locus containing TYR (P=1.60x10(-18)), encoding tyrosinase."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Elevated serum tyrosinase levels in vitiligo patients suggest a genetic association involving the TYR gene with vitiligo."", ""reference"": ""PMID:32838589"", ""snippet"": ""The tyrosinase levels were significantly elevated in patients. The TT genotype was the most prevalent one in the patients... MiRNA 196a-2 C/T (11614913) gene polymorphism and the elevated serum tyrosinase levels might be related to the pathogenesis of vitiligo and may affect its therapeutic response."", ""supports"": ""SUPPORT""}], ""name"": ""TYR""}"
7774	338	Vitiligo	Vitiligo.yaml	genetic	2	PTPN22									Associated																																																"{""association"": ""Associated"", ""name"": ""PTPN22""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature specifically mentions that PTPN22 is associated with vitiligo as part of its association with several autoimmune diseases."", ""reference"": ""PMID:21515266"", ""snippet"": ""The PTPN22 locus is one of the strongest risk factors outside of the major histocompatability complex that associates with autoimmune diseases...vitiligo"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This source confirms the association but notes that the genetic association is specific to the European population and not found in the Asian population, suggesting partial support."", ""reference"": ""PMID:28164884"", ""snippet"": ""Several studies have demonstrated the association of protein tyrosine phosphatase, non-receptor type 22 +1858C-->T polymorphism with vitiligo... limited ethnic-based studies... In conclusion, protein tyrosine phosphatase, non-receptor type 22 +1858 T allele predisposes European individuals to vitiligo."", ""supports"": ""PARTIAL""}], ""name"": ""PTPN22""}"
7775	338	Vitiligo	Vitiligo.yaml	genetic	3	MC1R									Associated																																																"{""association"": ""Associated"", ""name"": ""MC1R""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference provides evidence of an association between the MC1R gene and vitiligo."", ""reference"": ""PMID:20197744"", ""snippet"": ""Genome-wide association studies (GWAS) have unveiled single nucleotide polymorphisms (SNPs) or genetic variants in MC1R, TPCN2, ASIP, KITLG, NCKX5, TYR, IRF4, OCA2, and TYRP1 pigmentation genes."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference identifies MC1R as a key gene involved in vitiligo, providing further support for its genetic association."", ""reference"": ""PMID:33757175"", ""snippet"": ""MC1R was found as a key gene in vitiligo and involved in the melanogenesis."", ""supports"": ""SUPPORT""}], ""name"": ""MC1R""}"
7776	338	Vitiligo	Vitiligo.yaml	genetic	4	HLA-A									Associated																																																"{""association"": ""Associated"", ""name"": ""HLA-A""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The meta-analysis strongly suggests an association between HLA-A2, a specific allele of HLA-A, and vitiligo."", ""reference"": ""PMID:17243956"", ""snippet"": ""Meta-analysis showed a significantly increased frequency of HLA-A2 in vitiligo among cases [OR = 2.07, 95% confidence interval (CI) 1.67-2.58]."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-A""}"
7777	338	Vitiligo	Vitiligo.yaml	genetic	5	HLA-DRB1									Associated																																																"{""association"": ""Associated"", ""name"": ""HLA-DRB1""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study discusses the association of different HLA-DRB1 allelic genes, including HLA-DRB1, with vitiligo."", ""reference"": ""PMID:34686989"", ""snippet"": ""In this study, we have evaluated the association and role of HLA-DRB4*01:01, -DRB1*07:01, and -DQB1*03:03:2 genes in different clinical subtypes of Vitiligo in the Iranian population."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The findings of the genome-wide association study indicate an association of HLA-DRB1 alleles with vitiligo."", ""reference"": ""PMID:20526339"", ""snippet"": ""Further analyses suggested that the strong association at rs11966200 might reflect the reported association of the HLA-A*3001, HLA-B*1302, HLA-C*0602 and HLA-DRB1*0701 alleles..."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Although this specifically mentions HLA-DR4, it generally supports the connection between HLA class II genes and vitiligo, which includes HLA-DRB1."", ""reference"": ""PMID:6600753"", ""snippet"": ""Association of HLA-DR4 with vitiligo."", ""supports"": ""SUPPORT""}], ""name"": ""HLA-DRB1""}"
7778	338	Vitiligo	Vitiligo.yaml	genetic	6	IFIH1									Associated																										MDA5 (melanoma differentiation-associated gene 5), involved in innate immune sensing and type I interferon signaling. Associated with vitiligo susceptibility in GWAS studies.																						"{""association"": ""Associated"", ""name"": ""IFIH1"", ""notes"": ""MDA5 (melanoma differentiation-associated gene 5), involved in innate immune sensing and type I interferon signaling. Associated with vitiligo susceptibility in GWAS studies.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large-scale GWAS meta-analysis identified IFIH1 as a vitiligo susceptibility locus at genome-wide significance, encoding an immunoregulatory protein involved in innate immune sensing."", ""reference"": ""PMID:22561518"", ""snippet"": ""IFIH1 (P = 4.91  10(-15))"", ""supports"": ""SUPPORT""}], ""name"": ""IFIH1"", ""notes"": ""MDA5 (melanoma differentiation-associated gene 5), involved in innate immune sensing and type I interferon signaling. Associated with vitiligo susceptibility in GWAS studies.""}"
7779	338	Vitiligo	Vitiligo.yaml	genetic	7	BACH2									Associated																										BTB and CNC homology 2, transcription regulator involved in immune cell development and function. GWAS-identified risk locus for vitiligo and other autoimmune diseases.																						"{""association"": ""Associated"", ""name"": ""BACH2"", ""notes"": ""BTB and CNC homology 2, transcription regulator involved in immune cell development and function. GWAS-identified risk locus for vitiligo and other autoimmune diseases.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GWAS meta-analysis identified BACH2 as a vitiligo susceptibility locus at genome-wide significance. BACH2 encodes an immunoregulatory transcription factor involved in immune cell development."", ""reference"": ""PMID:22561518"", ""snippet"": ""BACH2 (P = 2.53  10(-8))"", ""supports"": ""SUPPORT""}], ""name"": ""BACH2"", ""notes"": ""BTB and CNC homology 2, transcription regulator involved in immune cell development and function. GWAS-identified risk locus for vitiligo and other autoimmune diseases.""}"
7780	338	Vitiligo	Vitiligo.yaml	genetic	8	IRF4									Associated																										Interferon regulatory factor 4, involved in immune regulation and pigmentation. Associated with vitiligo susceptibility.																						"{""association"": ""Associated"", ""name"": ""IRF4"", ""notes"": ""Interferon regulatory factor 4, involved in immune regulation and pigmentation. Associated with vitiligo susceptibility.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GWAS meta-analysis identified IRF4 as one of the 23 new vitiligo susceptibility loci at genome-wide significance (P = 8.86  10-16). IRF4 is a key transcription factor for both immune cells and melanocytes."", ""reference"": ""PMID:27723757"", ""snippet"": ""identified 23 new significantly associated loci and 7 suggestive loci. Most encode immune and apoptotic regulators, with some also associated with other autoimmune diseases, as well as several melanocyte regulators."", ""supports"": ""SUPPORT""}], ""name"": ""IRF4"", ""notes"": ""Interferon regulatory factor 4, involved in immune regulation and pigmentation. Associated with vitiligo susceptibility.""}"
7781	338	Vitiligo	Vitiligo.yaml	genetic	9	FOXP3									Associated																										Forkhead box P3, master regulator of regulatory T cells. Implicated in vitiligo pathogenesis through impaired immune regulation.																						"{""association"": ""Associated"", ""name"": ""FOXP3"", ""notes"": ""Forkhead box P3, master regulator of regulatory T cells. Implicated in vitiligo pathogenesis through impaired immune regulation.""}"	{}	"{""association"": ""Associated"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study found that FOXP3 expression is significantly reduced in regulatory T cells of vitiligo patients, and identified FOXP3 promoter polymorphisms associated with disease susceptibility."", ""reference"": ""PMID:33181260"", ""snippet"": ""FOXP3 mRNA and protein levels were significantly decreased (p < 0.001) in GV Tregs compared to controls"", ""supports"": ""SUPPORT""}], ""name"": ""FOXP3"", ""notes"": ""Forkhead box P3, master regulator of regulatory T cells. Implicated in vitiligo pathogenesis through impaired immune regulation.""}"
7806	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	genetic	0	VHL									Germline Loss-of-Function Mutations																										VHL (3p25.3) encodes the VHL protein, a substrate recognition subunit of an E3 ubiquitin ligase complex that targets HIF-alpha for degradation. Germline mutations include missense (particularly in Type 2), nonsense, frameshift, splice site, and large deletions. De novo mutations account for approximately 20% of cases. Penetrance is nearly complete by age 65.																						"{""association"": ""Germline Loss-of-Function Mutations"", ""name"": ""VHL"", ""notes"": ""VHL (3p25.3) encodes the VHL protein, a substrate recognition subunit of an E3 ubiquitin ligase complex that targets HIF-alpha for degradation. Germline mutations include missense (particularly in Type 2), nonsense, frameshift, splice site, and large deletions. De novo mutations account for approximately 20% of cases. Penetrance is nearly complete by age 65.""}"	"{""inheritance"": [{""name"": ""Autosomal Dominant""}]}"	"{""association"": ""Germline Loss-of-Function Mutations"", ""inheritance"": [{""name"": ""Autosomal Dominant""}], ""name"": ""VHL"", ""notes"": ""VHL (3p25.3) encodes the VHL protein, a substrate recognition subunit of an E3 ubiquitin ligase complex that targets HIF-alpha for degradation. Germline mutations include missense (particularly in Type 2), nonsense, frameshift, splice site, and large deletions. De novo mutations account for approximately 20% of cases. Penetrance is nearly complete by age 65.""}"
7851	341	Wilms Tumor	Wilms_Tumor.yaml	genetic	0	WT1 Mutations									Tumor Suppressor Loss																										WT1 mutations occur in 10-20% of sporadic Wilms tumors. Germline WT1 mutations cause predisposition syndromes (WAGR, Denys-Drash). WT1 is a transcription factor essential for kidney development.																						"{""association"": ""Tumor Suppressor Loss"", ""name"": ""WT1 Mutations"", ""notes"": ""WT1 mutations occur in 10-20% of sporadic Wilms tumors. Germline WT1 mutations cause predisposition syndromes (WAGR, Denys-Drash). WT1 is a transcription factor essential for kidney development.""}"	{}	"{""association"": ""Tumor Suppressor Loss"", ""name"": ""WT1 Mutations"", ""notes"": ""WT1 mutations occur in 10-20% of sporadic Wilms tumors. Germline WT1 mutations cause predisposition syndromes (WAGR, Denys-Drash). WT1 is a transcription factor essential for kidney development.""}"
7852	341	Wilms Tumor	Wilms_Tumor.yaml	genetic	1	CTNNB1 Mutations									Oncogenic Driver Mutations																										Activating mutations in CTNNB1 (beta-catenin) occur in approximately 15% of Wilms tumors, leading to constitutive Wnt pathway activation.																						"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""CTNNB1 Mutations"", ""notes"": ""Activating mutations in CTNNB1 (beta-catenin) occur in approximately 15% of Wilms tumors, leading to constitutive Wnt pathway activation.""}"	{}	"{""association"": ""Oncogenic Driver Mutations"", ""name"": ""CTNNB1 Mutations"", ""notes"": ""Activating mutations in CTNNB1 (beta-catenin) occur in approximately 15% of Wilms tumors, leading to constitutive Wnt pathway activation.""}"
7853	341	Wilms Tumor	Wilms_Tumor.yaml	genetic	2	WTX (AMER1) Mutations									Tumor Suppressor Loss																										WTX inactivation occurs in 15-20% of Wilms tumors. WTX negatively regulates Wnt signaling, and its loss leads to pathway activation.																						"{""association"": ""Tumor Suppressor Loss"", ""name"": ""WTX (AMER1) Mutations"", ""notes"": ""WTX inactivation occurs in 15-20% of Wilms tumors. WTX negatively regulates Wnt signaling, and its loss leads to pathway activation.""}"	{}	"{""association"": ""Tumor Suppressor Loss"", ""name"": ""WTX (AMER1) Mutations"", ""notes"": ""WTX inactivation occurs in 15-20% of Wilms tumors. WTX negatively regulates Wnt signaling, and its loss leads to pathway activation.""}"
7854	341	Wilms Tumor	Wilms_Tumor.yaml	genetic	3	Loss of 11p15 Imprinting									Epigenetic Alteration																										Loss of imprinting at 11p15, leading to biallelic IGF2 expression, occurs in approximately 70% of Wilms tumors. This is also the mechanism in Beckwith-Wiedemann syndrome.																						"{""association"": ""Epigenetic Alteration"", ""name"": ""Loss of 11p15 Imprinting"", ""notes"": ""Loss of imprinting at 11p15, leading to biallelic IGF2 expression, occurs in approximately 70% of Wilms tumors. This is also the mechanism in Beckwith-Wiedemann syndrome.""}"	{}	"{""association"": ""Epigenetic Alteration"", ""name"": ""Loss of 11p15 Imprinting"", ""notes"": ""Loss of imprinting at 11p15, leading to biallelic IGF2 expression, occurs in approximately 70% of Wilms tumors. This is also the mechanism in Beckwith-Wiedemann syndrome.""}"
7878	342	Wilson Disease	Wilsons_Disease.yaml	genetic	0	ATP7B									Causative																										Autosomal recessive, over 500 mutations described																						"{""association"": ""Causative"", ""name"": ""ATP7B"", ""notes"": ""Autosomal recessive, over 500 mutations described""}"	{}	"{""association"": ""Causative"", ""evidence"": [{""explanation"": ""Establishes ATP7B mutations as the causative genetic defect in Wilson's disease."", ""reference"": ""PMID:37741465"", ""snippet"": ""Inactivating mutations of the copper-transporting P-type ATPase, ATP7B, result in Wilson's disease, an autosomal recessive disorder"", ""supports"": ""SUPPORT""}], ""name"": ""ATP7B"", ""notes"": ""Autosomal recessive, over 500 mutations described""}"
7928	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	genetic	0	Chromosome 4p16.3 Deletion									Causal																										Most cases are sporadic, but an unbalanced translocation may be inherited from a parent with a balanced rearrangement. The deletion involves the terminal 4p16.3 region. Less than half of patients can be identified by conventional cytogenetics; molecular cytogenetic testing should be offered for diagnosis.																						"{""association"": ""Causal"", ""name"": ""Chromosome 4p16.3 Deletion"", ""notes"": ""Most cases are sporadic, but an unbalanced translocation may be inherited from a parent with a balanced rearrangement. The deletion involves the terminal 4p16.3 region. Less than half of patients can be identified by conventional cytogenetics; molecular cytogenetic testing should be offered for diagnosis.""}"	{}	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""This provides important diagnostic guidance regarding the need for molecular cytogenetic testing and parental karyotyping."", ""reference"": ""PMID:32914558"", ""snippet"": ""Less than half of the patients can be identified by conventional cytogenetics and molecular cytogenetic testing should be offered for diagnosis. Karyotyping of the parents should always be offered in a child with WHS."", ""supports"": ""SUPPORT""}], ""name"": ""Chromosome 4p16.3 Deletion"", ""notes"": ""Most cases are sporadic, but an unbalanced translocation may be inherited from a parent with a balanced rearrangement. The deletion involves the terminal 4p16.3 region. Less than half of patients can be identified by conventional cytogenetics; molecular cytogenetic testing should be offered for diagnosis.""}"
7955	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	genetic	0	TELO2 mutations									Causal																										"Compound heterozygous or homozygous mutations in TELO2 gene on chromosome 16p13. Mutations lead to unstable TELO2 protein and destabilization of the TTT complex. Both truncating and missense variants have been reported.
"																						"{""association"": ""Causal"", ""name"": ""TELO2 mutations"", ""notes"": ""Compound heterozygous or homozygous mutations in TELO2 gene on chromosome 16p13. Mutations lead to unstable TELO2 protein and destabilization of the TTT complex. Both truncating and missense variants have been reported.\n""}"	"{""inheritance"": [{""name"": ""Autosomal recessive""}]}"	"{""association"": ""Causal"", ""evidence"": [{""explanation"": ""Documents novel compound heterozygous TELO2 variants causing YHFS."", ""reference"": ""PMID:37215500"", ""snippet"": ""two compound heterozygous mutations, including a likely pathogenic TELO2 variant, c.2245A > T (p.K749X) from her mother and an uncertain variant, c.2299C > T (p.R767C) from her father"", ""supports"": ""SUPPORT""}], ""inheritance"": [{""name"": ""Autosomal recessive""}], ""name"": ""TELO2 mutations"", ""notes"": ""Compound heterozygous or homozygous mutations in TELO2 gene on chromosome 16p13. Mutations lead to unstable TELO2 protein and destabilization of the TTT complex. Both truncating and missense variants have been reported.\n""}"
